

## Final addendum to the

# Draft Assessment Report (DAR)

- public version -

Initial risk assessment provided by the rapporteur Member State Sweden for the existing active substance

### DIFLUBENZURON

of the third stage Part A of the review programme referred to in Article 8(2) of Council Directive 91/414/EEC

**March 2009** 

#### Table of contents

Corrigendum to Volume 3	December 2008 <u>3</u> B.2 Physical and Chemical Properties
Addendum to Volume 3	December 2008 <u>8</u> B.5 Methods of analysis
Addendum to Volume 3	December 2008
Addendum to Volume 3	December 2008 <u>106</u> B.7 Residue data
Corrigendum to Volume 3	December 2008 <u>112</u> B.7 Residue data
Addendum to Volume 3	December 2008
Addendum to Volume 3	February 2009 <u>172</u> B.6 Toxicology and metabolism
Addendum to Volume 3	February 2009 <u>210</u> B.8 Environmental fate and behaviour B.9 Ecotoxicology

# 

Rapporteur Member State: Sweden

December 2008

#### Volume 1

Level 1: Statement of subject matter and purpose for which the monograph was prepared

- Level 2: Reasoned statement of the overall conclusions drawn by the Rapporteur Member State Appendix 1: Standard terms and abbreviations Appendix 2: Specific terms and abbreviations Appendix 3: List of endpoints
- Level 3: Proposed decision with respect to the application for inclusion of the active substance in Annex I
- Level 4: Further information to permit a decision to be made, or to support a review of the conditions and restrictions associated with the proposed inclusion in Annex 1

#### Volume 2

Annex A: List of the tests and studies submitted and of information available

#### Volume 3

#### Annex B: RMS summary, evaluation and assessment of the data and information

Annex B.1: Identity

#### Annex B.2: Phys/chem.

Annex B.3: Data application and further information.

- Annex B.4: Proposal for classification and labelling
- Annex B.5: Analytical method
- Annex B.6: Toxicology and metabolism
- Annex B.7: Residues in crop
- Annex B.8: Fate and behaviour
- Annex B.9: Ecotoxicology
  - Appendix 1: Standard terms and abbreviations
  - Appendix 2: Specific terms and abbreviations

#### Volume 4

Annex C: Confidential information and summary and assessment of information relating to the collective submission of dossiers

#### Table of contents

0
6
6
6
7
··· / 7

#### Introduction

This corrigendum was prepared in response to the requirements of the Reporting table rev. 1-0 (20.12.2007). Included herein are also the results on the log  $P_{ow}$  of the metabolites which were omitted in the original Annex B.2.

#### **B.2** Physical and chemical properties

#### **B.2.1** Physical and chemical properties of the active substance (IIA 2)

#### B.2.1.8 Partition coefficient, log Pow

#### Thus, J. L. G. 1988

Test Material:	Diflubenzuron technical, batch id. Fun80D21D, purity 97.6 %, 4-chlorophenylurea, 2,6-
	difluorobenzoic acid
Method:	A modified version of OECD 117 HPLC method (a draft method at the time of the study),
	where a phenyl modified silica column and a highly salt containing mobile phase buffered
	at pH 3, were utilized.
Results:	At pH=3.0 and 22 $^{\circ}C \pm 0.1 ^{\circ}C$ :
	diflubenzuron: log Pow=3.89 <mark>at pH=3.0 and 22 °C ± 0.1 °C</mark>
	4-chlorophenylurea: $\log P_{ow} = 1.14$
	2,6-difluorobenzoic acid: $\log P_{ow} = -0.02$
Comments:	The measurement was performed with technical grade substance instead of pure substance.
	However, since the HPLC-method is less sensitive to impurities than the "shake-flask"-
	method, this should not have affected the result. The measurement was only done at pH 3
	and the pH-effect was not examined. Moreover the measurement was not performed in
	accordance with GLP. Nevertheless, the results from the study show a good relationship
	between the log Pow-values (literature data) for reference compounds, and the retention data.
	Moreover the solubility of diflubenzuron in water (see B.2.1.6) was proven to be virtually
	the same at pH 4 and pH 7, which means that the low pH utilized in this study should not
	have affected the result significantly. Consequently, the method and the result are
	acceptable.

6

## **B.2.2** Physical, chemical and technical properties of the plant protection product –Water dispersible granules (WG)

Product trade name	Product code number	Concentration of active substance
Dimilin WG-80	-	800 g/kg

#### B.2.2.8.5.1 Dry sieve test

#### Reporting table point 1 (21).

Results on dry sieving are available from the shelf-life study and could be presented in B.2.2.8.5.1 even though it is not required for a WG-formulation. RMS to consider a corrigendum.

Not applicable required, since Dimilin WG-80 is not a dustable powder formulation. However a dry sieve test was performed in the shelf-life study and is thus also presented here:

<i>Poel, E. N.</i> <b>1998</b>		
Test Material:	Dimilin WG-80, batch	id. FUN93I21C/FUX024000, concentration of active substance:
	<mark>79.4% w/w</mark>	
Method:	Sieve test (eq. to CIPA	<mark>C MT 170)</mark>
Results:	<u>Sieve size (mm)</u>	<u>r<sub>x</sub> (%)</u>
	> 1	0.03
	0.5-1	30.7
	0.25-0.5	57.5
	0.1-0.25	11.4
	< 0.1 (dust)	0.20
Comments:	The method and the res	ult are acceptable

Addendum to Draft Assessment Report



## DIFLUBENZURON

## Volume 3 Annex B.5 Analytical method

Rapporteur Member State: Sweden

December 2008



#### Volume 1

Level 1: Statement of subject matter and purpose for which the monograph was prepared

- Level 2: Reasoned statement of the overall conclusions drawn by the Rapporteur Member State Appendix 1: Standard terms and abbreviations Appendix 2: Specific terms and abbreviations Appendix 3: List of endpoints
- Level 3: Proposed decision with respect to the application for inclusion of the active substance in Annex I

Level 4: Further information to permit a decision to be made, or to support a review of the conditions and restrictions associated with the proposed inclusion in Annex 1

#### Volume 2

Annex A: List of the tests and studies submitted and of information available

#### Volume 3

#### Annex B: RMS summary, evaluation and assessment of the data and information

Annex B.1: Identity

Annex B.2: Phys/chem.

Annex B.3: Data application and further information.

Annex B.4: Proposal for classification and labelling

#### Annex B.5: Analytical method

Annex B.6: Toxicology and metabolism

Annex B.7: Residues in crop

Annex B.8: Fate and behaviour

Annex B.9: Ecotoxicology

Appendix 1: Standard terms and abbreviations

Appendix 2: Specific terms and abbreviations

#### Volume 4

Annex C: Confidential information and summary and assessment of information relating to the collective submission of dossiers

#### Table of contents

Introduction		11
B.5	Methods of Analysis	11
B.5.1	Analytical methods for formulation analysis (Annex IIA, 4.1, Annex IIIA, 5.1)	11
B.5.1.1	Analytical methods for the determination of the active substance in the active substance as manufactured	11
B.5.1.2	Analytical methods for the determination of the impurities in the active substance as manufactur	ed12
B.5.2	Analytical methods (residue) for plants, plant products, foodstuff of plant and animal origin,	
	feedingstuffs (Annex IIA 4.2.1; Annex IIIA 5.2)	13
B.5.2.1	Analytical methods for analysis of residues in food of plant origin	13
B.5.3	Analytical methods (residue) soil, water, air (Annex IIA 4.2.2 to 4.2.4)	21
B.5.3.1	Analytical method for the determination of residues in soil (Annex IIA 4.2.2)	22
B.5.3.2	Analytical method for the determination of residues in water (Annex IIA 4.2.3)	22
B.5.3.4	Analytical method for the determination of residues in air (Annex IIA 4.2.4)	23
B.5.6	References relied on	25

#### Introduction

The Draft Assessment Report on diflubenzuron was finalised and submitted to EFSA in May 2005.

In September 2007 the applicant submitted a new batch analysis and the active ingredient assay method employed in that study was not the same as presented in the original DAR. The method is thus presented in this Addendum.

In addition to this, presented herein are the study aimed to show the applicability of multi-residue methods for analysis of diflubenzuron in plant materials (point of clarification 1.2 in the evaluation table) and the new method for analysis of residues in air (data gap). Addressed herein is also the type of soil used in the validation of the soil method presented in the DAR (open point 1.14). The characteristics of the water used in the validation of the water method (see the original DAR) were provided as supplementary information in January 2007 to address open point 1.14 and it is also presented in this Addendum. Finally, the situation for the analytical method(s) for residues in plant material is clarified in this Addendum as a background for discussions at a meeting of experts (open points 1.13 and 1.16).

#### **B.5** Methods of Analysis

#### B.5.1 Analytical methods for formulation analysis (Annex IIA, 4.1, Annex IIIA, 5.1)

## **B.5.1.1** Analytical methods for the determination of the active substance in the active substance as manufactured

In the peer-review a new batch analysis derived from fully validated methods was requested (data gap in the Evaluation table). New batch data was provided in September 2007 and the method used for the analysis of the active substance was not the same as presented in the original DAR. The new method was not specifically requested in the peer-review but as it is a part of the requested batch analysis it is presented below.

Reference: Goebel, N. (2007). Determin	ation of diflubenzuron in technical and formulated
materials by high performance	e liquid chromatography with internal standardization.
Method Number GRL-GM-1	066 given as Appendix VI in:
Riggs, A.S. (2007) Prelimina	ry analysis of diflubenzuron technical. Final Report
Chemtura Canada Co./Cie, G	uelph Technology Centre. PO Box 1120, 120 Huron
Street Guelph, Ontario, Cana	da N1H 6N3. Test Facility Study Number: GRL-12508.
GLP, Not Published, CONFI	DENTIAL
GLP: Yes (the method GRL-GM-1	066 contains a summary of the validation data which is
stated to have been derived a	ccording to GLP in studies GRL-10796, GRL-11113,
GR-12060, GRL-12242 and	GRL-12483 which were not submitted to the RMS)

Principle of the method:	The technical material is dissolved in dioxane (~90 mL) under heating (70-80°C) and
	occasional swirling. 10 mL internal standard solution (linuron in acetonitrile) is added
	and the solution is diluted 1:9 with the eluent (acetonitrile:water:dioxane, 550:550:25).
	The content of diflubenzuron is determined by HPLC fitted with a Bondapak C18
	column employing gradient elution (acetontrile:water:dioxane, $45:45:10 \rightarrow 100:0:0$ )
	and UV-detection at 254 nm using external calibration relative to the internal standard.
Validation Data:	
Specificity:	The specificity was checked by means of HPLC-DAD and there was no evidence of
	peak interference with diflubenzuron or the internal standard from the known
	impurities in technical diflubenzuron.
Linearity:	The linearity was assessed using 5 calibration points in the range 19.2-80.1 mg/1000
	ml, corresponding to an actual content of ~40-160% diflubenzuron in the technical
	material. The curve was found to be linear with a correlation coefficient of 1.000.
Accuracy:	The accuracy was assayed as %recovery of added diflubenzuron to technical
	diflubenzuron. The results are given table B.5.1.1-1
Precision (Repeatability):	The method precision was determined by the analysis of six weights of the technical
	diflubenzuron. The results are given in table B.5.1.1-2

#### Table B.5.1.1-1: Accuracy data for method GRL-GM-1066 (Riggs, 2007)

Recovery (%)	N	%RSD	F test	Critical F (95% conf.)	t-test	Critical t (99.5% conf.)
101.4%	4	0.17	2.82	9.28	3.83	7.45

 Table B.5.1.1-2: Precision data for the analysis of six replicates

 using method GRL-GM-1066 (Riggs, 2007)

Mean (%w/w)	SD	%RSD	Acceptable %RSD (Horwitz)
96.9	1.01	1.04	1.35

#### **RMS conclusion:**

The validation data provided in the method description is considered sufficient even though the primary validation study was not provided. The validation data is in compliance with the criteria in SANCO/3030/99 rev.4 and the batch data derived using the method is thus acceptable. It should be noted that the used method is very similar to the CIPAC method 339/TK/M/-.

## **B.5.1.2** Analytical methods for the determination of the impurities in the active substance as manufactured

The fully validated method for the impurities, used in the new batch analysis, is considered to be confidential-see Addendum to Annex C

## **B.5.2** Analytical methods (residue) for plants, plant products, foodstuff of plant and animal origin, feedingstuffs (Annex IIA 4.2.1; Annex IIIA 5.2)

#### B.5.2.1 Analytical methods for analysis of residues in food of plant origin

#### Applicability of multiresidue method

In the peer-review it was concluded that the applicability of a multi-residue method for the analysis of diflubenzuron in food of plant origin must be addressed (1.2 point of clarification in the Evaluation table). In January 2007 the applicant submitted a study aiming to analyse diflubenzuron according to the US FDA's multi-residue method. The study is presented below:

Reference:	Allan, E. and Pouwelse, A. V. (1993) Determination of diflubenzuron residues
	according to multiresidue methods described in FDA's pesticide analytical manuals.
	Solvay Duphar B.V., Analytical Development Department, C.J. van Houtenlaan 36,
	1381 CP Weesp, The Netherlands, Laboratory Project ID: C.303.50.019, GLP, Not
	Published
GLP:	Yes
Principle of the method:	The procedures for multi-residue methods laid down in FDA's Pesticide Analytical
	Manual Vol. 1 were followed (available at <u>http://www.cfsan.fda.gov/~frf/pami1.html</u> ).
	The guideline describes procedures for GC and HPLC, but the latter seems only to be
	described for specific classes of substances (i.e. N-methyl carbamates). GC conditions
	were therefore used for diflubenzuron employing the mildest chromatographic
	conditions, as diflubenzuron was known to decompose under normal GC-conditions
	(i.e. hot injection devices).
	Diflubenzuron calibration solutions with concentrations of 0.107, 1.07, 107 $\mu$ g/l and
	$0.107$ and $1.07\mu$ g/l in acetone and n-hexane respectively were used. Calibration
	solutions of teradifon, a pesticide usually analysed by GC, with roughly the same
	concentrations were used as reference check of the performance of the analytical
	system.
	A GC-chromatograph fitted with a fused silica 30 m x 0.32 mm capillary column
	coated with 0.25 $\mu$ m DB-17, ECD and FID-detectors was used employing cold on-
	column injection and a column heating programme of $75^{\circ}C \rightarrow 250^{\circ}C (30^{\circ}C/min)$ .
	HPLC-UV was also used for verification of the concentration of the injected
	calibration solutions.
Results:	For all injected solutions, tetradifon was found as a single chromatographic signal,
	whereas no diflubenzuron was found. When the highest concentrated diflubenzuron
	solution was analysed a multiple signal was found, probably due to decomposition.
	Hereby, the full testing of the multi-residue method was not performed.

**RMS comments:** The study proved that diflubenzuron is not amenable to GC-analysis. Given that the multiresidue method DFG S19 is based on GC, it is also not considered applicable to diflubenzuron. However there are examples in the open literature of multi-residue methods for diflubenzuron using LC-MS/MS (Pihlstrom, T., *et al.*, 2007, Anal. Bioanal. Chem. DOI 10.1007/s00216-007-1425-6; Klein and Alder, 2003, Journal of AOAC International, Vol. 86, No. 5.).

#### Clarification of the situation of the available method for analysis of residues in apple, pomace and juice

In the peer-review the validation data for the primary validation study for the method in apples, pomace and juice presented in the DAR (Thus and Allan, 1995) was not considered acceptable and not in support of the claimed LOQ of 0.01 mg/kg (reporting table 1(31)).

In addition to this it was questioned if there was any confirmatory method available and if the presented ILV of the method (Rose, 2001) was a ILV or a different method as it appeared that a different detector was used (reporting table 1(41)). These comments resulted in open point 1.13 in the evaluation table stating that "The acceptability of the validation data for the plant residue methods should be discussed by a meeting of experts". As a background for the proposed discussion the RMS has tried to clarify the situation below, by making revisions of the original data presented in the DAR.

Reference:	<ol> <li>Thus, J.L.G. and Allan, E. (1995). Diflubenzuron residues in apple, pomace and juice. Report Solvay Duphar B.V., The Netherlands, No. 56835/49/1994, DI – 9320.</li> <li>Thus, J.L.G. and Allan, E. (1996). Addendum to report diflubenzuron residues in apples, pomes and juice. Report Solvay Dupher B.V., The</li> </ol>		
	residues in apples, pointe and juice. Report Solvay Duphar B.v., The		
Method:	Apple matrix		
	Diflubenzuron is extracted from apple homogenates with dichloromethane		
	and the extract is purified on a Florisil cartridge. The amount of		
	diflubenzuron is determined by HPLC using a C8-column and a mixture of		
	tetrehydrofuran/acetonitrile/water (10/40/50, v/v/v) as mobile phase.		
	Diflubenzuron is detected by UV spectrometry at 254 nm. The content of		
	diflubenzuron is determined by comparing the peak height of the sample		
	with that of standard solutions of diflubenzuron (calibration line).		
GLP:	Yes		
Validation Data			
valuation Data:	Control complex of untrooted apples (Idered Elster, James Crieve variaties)		
specificity:	Control samples of untreated apples (Idared, Elstar, James Grieve varieties)		
	contained no or low traces of diffubenzuron ( $< 0.003 \text{ mg/kg}$ ). Jonagold		

variety contained diflubenzuron in the range 0.004 - 0.011 mg/kg, which

was still less than 10% of the residue found in treated samples. No

	interfering co-extractive compounds were observed.			
Linearity:	Analytes in mobile phase (six concentrations in the range 0-1.11 $\mu$ g/ml)			
	were analysed to determine linearity. The calibration curve was obviously			
	linear to the naked eye, with the linear equation reported (i.e. based on peak			
	heights not peak areas using 6 calibration points each for apples and			
	pommace and juice) <del>(however, the coefficient of correlation or</del>			
	determination was not presented). The correlation coefficient was not			
	reported in the study, but using the calibration data the RMS calculated			
	correlation coefficients of 1.0000 and 0.9997 for whole apples and pomace			
	and juice respectively. This calibration curve corresponded to apple analysis,			
	and a calibration curve of very similar performance was presented when			
	juice/pomace matrices was used in the validation			
Accuracy:	Determined as recovery (see table B.5.2.1-1 below). Mean recoveries,			
	globally and for each fortification level, were within the range 80-110%.			
	More detailed accuracy data is available in the report and it is presented in			
	table B.5.2.1-2 below (also given as supplementary information by the			
	applicant in February 2007).			
Precision (Repeatability):	Not calculated (se table below) but obviously well ≤ 20% (rsd)			
	Not explicitly reported in the study. However, using the raw data presented			
	the %RSD for each level is calculated by RMS and presented in table			
	B.5.2.1-2 below (also given as supplementary information by the applicant			
	in February 2007).			
LOQ:	Reported as 0.01 mg/kg in the study. However, the applicant stated during			
	the peer-review that using statistical analysis of the recoveries for the 0.1			
	mg/kg spikes a LOQ of 0.1 mg/kg is confirmed, which is in line with the			
	lowest fortification level used.			
	The LOQ is thus 0.1 mg/kg.			
LOD:	Not reported in the study. However, during the peer-review the applicant			
	submitted a statistical analysis of the recoveries from the 0.1 mg/kg spikes			
	(t-statistics x std deviation), which gives a LOD of 0.038 mg/kg.			

#### <mark>Results:</mark>

Table B.5.2.1-1: Validation data as presented in original DAR (Thus and Allan, 1995)						
Matrix	Fortification level (mg/kg)	Recovery (%)	Global mean recovery (%)	Coefficient of variation (%)		
Apples	0.1	70-102 (n=8)	01	Not reported		
	1	94-103 (n=8)	91	Not reported		
Apple pomace	0.1	67-88 (n=4)	88	Not reported		
	1	95-102 (n=4)	00	Not reported		
Apple juice	0.1	97-103 (n=4)	100	Not reported		
	1	97-108 (n=4)	100	Not reported		

Table B.5.2.1-2: ]	Table B.5.2.1-2: More detailed accuracy and precision data (Thus and Allan, 1995)						
<mark>Matrix</mark>	Fortification level (mg/kg)	Individual Recovery (%)	Mean recovery (%)	<mark>%RSD</mark>			
Apples:							
<mark>Blank</mark>	<mark>0</mark>	<loq, <loq,="" <loq<="" td=""><td>-</td><td>-</td></loq,>	-	-			
Idared		<mark>79, 70</mark>					
Elstar	-01	<mark>93, 102</mark>	82	14			
Jonagold		<mark>86, 86</mark>	<u>-</u>	<b>-</b> •			
James Grieve		<mark>70, 71</mark>					
Idared		<u>101, 102</u>					
<mark>Elstar</mark>	- 1.0	<u>98, 98</u>	<mark>99</mark>	3.2			
Jonagold		<mark>96, 94</mark>	<u> </u>				
James Grieve		103, 101					
Pomace:							
Blank	<mark>0</mark>	<loq, <loq<="" td=""><td>-</td><td>-</td></loq,>	-	-			
Jonagold	$-\frac{01}{01}$	<u>84, 88</u>	77	13			
James Grieve	<b>···</b>	<mark>67, 70</mark>	· · ·	10			
Jonagold	10	<u>102, 95</u>	98	$\frac{23}{23}$			
James Grieve	<b>*··</b>	<mark>98, 98</mark>	<mark>/                                    </mark>				
Juice:							
Blank	<mark>0</mark>	<loq, <loq<="" td=""><td>-</td><td>-</td></loq,>	-	-			
Jonagold	0.1	<mark>98, 98</mark>	07	<mark>77</mark>			
James Grieve	<b>V.1</b>	<mark>97, 103</mark>	<mark>//</mark>	<u> </u>			
Jonagold	1.0	108, 100	102	16			
James Grieve	<b>1.0</b>	<mark>97, 101</mark>	102	<mark>4.0</mark>			

**RMS comments (re-evaluation):** The validation data is in compliance with the requirements in SANCO/825/00 rev.7, except that only four samples instead of five were used for each fortification level for pomace and juice. However, given the total number of samples used for each fortification level the method is considered sufficiently validated for a LOQ of 0.1 mg/kg. No confirmatory method is presented, but further information is available in the ILV-study (see below).

#### Independent Laboratory Validation

Reference:	Rose, J.E. (2001). Independent laboratory validation (ILV) of an analytical method
	for analysis of diflubenzuron in apple and processed apple matrices. Report PTRL
	west INC., U.S.A. No.971 W-1 (Uniroyal Chemical Company No. RP-0009), D-11641.
Method:	Same as above (but supplemented with negative APCI LC-MS confirmation, using a
	slightly modified mobile phase to increase ionisation). However, the validation data was
	generated using the exact same method as for the primary validation study (i.e. HPLC-
	UV).
GLP:	Yes.

#### Validation Data:

Specificity:

The method is specific, which is supported by LC-MS at 0.10 mg/kg (using the [M-H] of m/z 309 and the [M+formic acid] of m/z 355 but also the [M-H]-HF of m/z 289 is visible).

Linearity:	The calibration curve was based on nine concentrations (0.01, 0.02, 0.05, 0.10, 0.20, 0.30,					
	0.50, 0.75 and 1.00 $\mu$ g/ml). The linear equation was reported (r <sup>2</sup> =0.9995) and the curve					
	appeared nicely linear to the naked eye. The linear range corresponds to 25% (apples) of					
	LOQ to ~90% of 10 x LOQ (juice).					
Accuracy:	Determined as recovery (see table B.5.2.1-3 below). Mean recoveries were all within the					
	range $80 - 110\%$ (all matrices and all fortification levels).					
Precision (Repeatability):	Determined as RSD (see table B.5.2.1-3 below). All RSD were < 20%.					
LOQ:	0.01 mg/kg.					
LOD:	Calculated to be 0.005 mg/kg for apples and 0.002 mg/kg for apple juice and pomace.					

#### Results:

#### Table B.5.2.1-3: Validation data for ILV for apple, pomace and juice (Rose, 2001)

Matrix	Fortification level (mg/kg)	Recovery (%)	Mean recovery (%) (n=5)	RSD (%)
Apples	Blank	<l00, <l00<="" th=""><th></th><th></th></l00,>		
(McIntosh)	0.01	75.0 - 106.0	91.6	15.0
	0.1	94.5 - 101.7	97.8	2.7
Apple inice	Blank	<mark><loq, loq<="" mark=""></loq,></mark>	<mark>-</mark>	-
Apple Juice	0.01	86.7 - 96.9	91.2	5.2
	0.1	79.5 - 84.6	81.9	2.8
Appla pomoco	Blank	<loq, <loq<="" td=""><td>-</td><td>-</td></loq,>	-	-
Apple pomace	0.01	75.0 - 86.0	79.8	6.2
	0.1	75.8 - 105.6	89.2	12.2

**RMS comments (re-evaluation):** The validation data is in compliance with the requirements in SANCO/825/00 rev.7.

**RMS conclusion on the method for residues in apple, pomace and juice:** The primary validation is considered acceptable with only a slight deviation in the number of samples for fortification for pomace and juice. However, no confirmatory method was presented. The primary validation indicated a LOQ of 0.1 mg/kg.

The ILV-study was also acceptable and it included a LC-MS procedure for confirmation. The ILV-study was conducted at 0.01 mg/kg and 0.1 mg/kg which gave acceptable accuracy and precision data, whereby this study indicates a LOQ of 0.01 mg/kg. However, in conclusion as the primary validation gives a LOQ of 0.1 mg/kg only this level could be seen to be sufficiently validated by primary validation and ILV. If the LOQ thus is set at 0.1 mg/kg, no ILV is available for >LOQ, so this issue might need to be discussed at a meeting of experts.

It should be noted that the available MRLs for diflubenzuron in pome fruit is 5 mg/kg according to Regulation (EC) No 396/2005. This means that according to SANCO/825/00 rev.7 the validation should have been performed at 0.1 mg/kg (LOQ) and 5 mg/kg (MRL).

#### Clarification of the situation of the available method for analysis of residues in mushrooms

In the peer-review the validation data for the primary validation study for the method for residues in mushrooms presented in the DAR (Gaydosh, 1998) was not considered acceptable (reporting table 1(32), (43) and (44)).

These comments resulted in open point 1.13 in the Evaluation table stating that "The acceptability of the validation data for the plant residue methods should be discussed by a meeting of experts". As a background for the proposed discussion the RMS has tried to clarify the situation below, by making revisions of the original data presented in the DAR.

Reference:	Gaydosh, K.A. (1998). Dimilin 25 W and Dimilin 4 L in mushrooms: Magnitude of			
	the residue study. Report Uniroyal Chemical INC., U.S.A. No. RP-97004, DI-11455.			
Method:	Mushroom matrix			
	Diflubenzuron			
	Diflubenzuron is extracted with ethyl acetate (2x), evaporated to dryness and re-dissolved			
	in dichloromethane and purified on a Florisil cartridge. The amount of diflubenzuron is			
	determined by reversed phase HPLC (Zorbax C8 column) using gradient elution			
	(acetonitrile:water:1,4-dioxane, $45:45:10 \rightarrow 85:5:10$ ) with UV spectrometric detection at			
	254 nm. The content of diflubenzuron is determined by comparing the peak height area of			
	the sample with that of standard solutions of diflubenzuron (calibration line).			
	4-chlrorophenyl urea (CPU)			
	CPU is extracted with ethyl acetate (2x), evaporated to dryness and re-dissolved in			
	acetone:petroleum ether (5:25) and purified on a deactivated silica column. The residue is			
	evaporated to dryness and re-dissolved in acetontrile. The CPU is derivatised using			
	heptafluorobutyric acid anhydride (HFBA) and the derivative is analysed on GC fitted			
	with a DB 5 capillary column and electron capture detector (ECD). The content of CPU is			
	determined by comparing the peak area of the sample with that of derivatised standard			
	solutions of CPU (calibration line).			
	4-chloroaniline (PCA)			
	PCA is extracted with 0.1 N aqueous HCl and the extract is adjusted to $pH > 12$ using			
	50% aqueous NaOH and the PCA is extracted with hexane. The combined hexane			
	extracts are purified on a Florsil column and the eluant is derivatised using			
	heptafluorobutyric acid anhydride (HFBA) and the derivative is analysed on GC fitted			
	with a Supelco SPB 1701 capillary column and MS-detector (SIM mode). The PCA is			
	identified by coincidence of its retention time with the internal standard ( <sup>13</sup> C-PCA), and			
	quantified by integration of the peak areas for $^{12}$ C-PCA relative to peak areas for $^{13}$ C-			
	PCA. Additionally, quantitation was achieved by peak area of the <sup>12</sup> C-PCA relative to the			
	external standard linearity curve (derivatised PCA). The following fragments are used for			
	quantification and identification m/z 323 (derivatised PCA), 329 (derivatised <sup>13</sup> C-PCA),			

	126 (PCA) and 132 ( <sup>13</sup> C-PCA).
GLP:	Yes (with documented exceptions)
Validation Data:	
Specificity:	Diflubenzuron and CPU
	The analyte was identified by the coincidence of its retention time with the reference
	standards and quantitated by integration of the peak area. Control samples showed no
	peak areas >LOD. No confirmatory procedure is presented.
	PCA
	The analyte was identified by the coincidence of its retention time with the internal
	reference standard and the external reference standards. Control samples showed no peak
	areas >LOD. Given that quantification/confirmation was based on retention time
	matching with both internal <sup>13</sup> C-standard and external PCA standard as well as the use of
	two fragments each for the <sup>12</sup> C-PCA and the <sup>13</sup> C-PCA, the method is considered highly
	specific.
Linearity:	Diflubenzuron
	The calibration curve was based on injections of diflubenzuron standards of the
	concentrations 0.025, 0.05, 0.1, 0.25, and 0.5 $\mu$ g/ml. The linear equation of the calibration
	line was reported ( $r^2=1.000$ ).
	<u>CPU</u>
	The calibration curve was based on injections of derivatised CPU standards of the
	concentrations 0.005, 0.01, 0.05 and 0.1 $\mu$ g/ml. The linear equation of the calibration line
	was reported ( $r^2=0.993$ ).
	PCA
	The external calibration curve was based on injections of derivatised PCA standards of
	the concentrations 0.025, 0.05, 0.1 and 0.5 $\mu$ g/ml. The linear equation of the calibration
	line was reported (r <sup>2</sup> =0.996).
	The internal standard calibration curve was based on injections of <sup>12</sup> C-PCA: <sup>13</sup> C-PCA
	mass ratios of 0.5:1.0, 1.0:1.0, 5.0:1.0 and 10.0:1.0. The linear equation of the calibration
	line was reported ( $r^2=1.000$ ).
Accuracy:	Determined as recovery (se table B.5.2.1-4 below). Global mean recovery was within the
	range 80-100%.
	More detailed accuracy data is available in the report and is presented in table B.5.2.1-5
	below (also given as supplementary information by the applicant in February 2007). In
	addition to the duplicate fortifications performed at two levels, a duplicate determination
	of two fortified samples were performed for each residue trial (QC-sample) meaning a
	total of 16 fortifications and 32 determinations.

Precision (Repeatability):	Not calculated (se table below) but obviously well ≤ 20% (rsd)
	Not reported in detail in the study. However, using the raw data presented the %RSD for
	each level is calculated by RMS and presented in table B.5.2.1-5 below.
LOQ:	0.01 mg/kg
LOD:	Not reported

Results:

Matrix	Fortification level (mg/kg)	Recovery (%)	Mean recovery (%)	Coefficient of variation (%)
Mushroom	0.01	not reported		
	0.1 (QC samples)	not reported	88	SD=11
	0.20	not reported		

#### Table B.5.2.1-5: More detailed accuracy and precision data (Gaydosh, 1998)

<mark>Matrix</mark>	<mark>Analyte</mark>	Fortification level (mg/kg)	Recovery range (%)	N	<mark>Mean recovery</mark> (%)	<mark>%RSD</mark>
<mark>Mushroom</mark>	<b>Diflubenzuron</b>	<mark>0.01</mark>	<mark>72-82</mark>	<mark>2</mark>	<mark>77</mark>	<mark>9.2</mark>
		<mark>0.2</mark>	<mark>92-97</mark>	<mark>2</mark>	<mark>95</mark>	<mark>3.7</mark>
		<mark>0.1</mark>	<mark>80-111</mark>	<mark>16</mark>	<mark>97</mark>	<mark>8.0</mark>
	CPU	<mark>0.01</mark>	<mark>88-106</mark>	<mark>2</mark>	<mark>97</mark>	<mark>13</mark>
		<mark>0.1</mark>	<mark>86-104</mark>	<mark>2</mark>	<mark>95</mark>	<mark>13</mark>
		0.02	<mark>70-125</mark>	<mark>16</mark>	<mark>97</mark>	<mark>16</mark>
	PCA	<mark>5.0 μg/kg</mark>	<u>106-117</u>	<mark>2</mark>	<mark>112</mark>	<mark>7.0</mark>
		<mark>10 µg/kg</mark>	<u>113</u>	<mark>2</mark>	<u>113</u>	
		<mark>10 µg/kg</mark>	<mark>89-160</mark>	<mark>16</mark>	<mark>106</mark>	<mark>12</mark>

**RMS comments (re-evaluation):** As the residue definition for mushrooms is under discussion the RMS has presented the available data also for the metabolites. However, no ILV is available for the analysis of the metabolites.

The validation data presented for diflubenzuron and the metabolites CPU and PCA is in compliance with SANCO/825/00 rev.7 with respect to recovery and %RSD. However, the sample set deviates from the requirements as only two samples were used at each fortification level for the normal validation. Further data is available from the control fortification performed for each residue trial so one can argue that the overall number of samples used is acceptable.

Nevertheless, for diflubenzuron the LOQ level has too few samples whereas the 10 x LOQ is acceptable. For CPU the samples at both LOQ and 10 x LOQ is too few whereas the 2 x LOQ is sufficient, whereby it can be argued that LOQ should be set at 0.02 mg/kg. For PCA the situation is similar to that for CPU with too few samples at LOQ and 2 x LOQ in the normal validation (i.e. 2 x LOQ is used instead of 10 x LOQ), but with sufficient samples at 2 x LOQ (i.e. 10  $\mu$ g/kg) in the additional validation. See further discussion in the overall evaluation below the ILV-study.

Finally, no confirmation method was presented for diflubenzuron and CPU, whereas the method presented for PCA could bee seen as highly specific. Further information is also available in the ILV-study (see below).

Reference:	Class, T. (2001). Independent laboratory validation (ILV) of an HPLC/UV based				
	analytical method for the determination of diflubenzuron in plant material.				
	Report PTRL Europe GMBH, Germany No.B 451 G (Uniroyal Chemical Company				
	No.RP-00013), DI-11640.				
Method:	Same as above for generating validation data (with documented minor changes), but up-				
	graded with a LC-MS/MS method for confirmation (C18-column, acetonitrile: 0.1%				
	aqueous formic acid, $50:50 \rightarrow 95:5$ , negative APCI monitoring the transition m/z $309/311$				
	([M-H] <sup>-</sup> , Cl <sub>1</sub> isotopic pattern) $\rightarrow$ m/z 289 [M-H <sub>2</sub> F])				
GLP:	Yes				
Validation Data:					
Specificity:	The method is specific, which is supported by LC-MS/MS. LC-MS/MS chromatograms				
	of calibration solutions, blank controls and a sample fortified at LOQ indicated that the				
	confirmatory method is acceptable. Residues of 35% of LOQ were found in the blanks				
	using the HPLC-UV method (see also accuracy below).				
Linearity:	The calibration curve was based on injections of diflubenzuron standards of eight				
	concentrations ( $0.010 - 1.5 \ \mu g/mL$ ). The curve appeared nicely linear to the naked eye				
	and the linear equation was reported ( $r^2=0.999865$ ). The linear range corresponds to 15%				
	of LOQ to 140% of 10 x LOQ.				
Accuracy:	Determined as recovery (see table B.5.3.1-6 below). Mean recoveries, globally and for				
	each fortification level, were within the range 80 -110%. In control sample (blank) 0.0034				
	mg diflubenzuron/kg was found (ca 35% of LOQ), a value which was used for corrections				
	of the recoveries (below).				
Precision (Repeatability):	Determined as RSD (se table B.5.3.1-6 below). All RSD were < 20%.				
LOQ:	0.010 mg/kg.				
LOD:	Estimated to be 0.005 mg/kg.				

#### Independent Laboratory Validation

Table B.5.2.1-6: Validation data for ILV for mushrooms as presented in the original DAR (Class, 2001)							
Matrix	Fortification level (mg/kg)	Recovery (%)	Mean recovery (%) (n=5)	RSD (%)			
Mushrooms	0.01	77-109 (corr) 111-143 (uncorr)	92 (cor) 126 (uncorr)	16 (corr) 12 (uncorr)			
	0.1	95-104 (corr) 98-107 (uncorr)	99 (corr) 102 (uncorr)	4 (corr) 4 (uncorr)			

**RMS comments (re-evaluation):** The generated validation data corrected for the levels found in the blanks are in compliance with the criteria in SANCO/825/00 rev.7. However, it should be noted that blank levels above 30% is not accepted according to SANCO/825/00 rev.7 whereas levels as high as 38% were found in this study.

**RMS conclusion on the method for residues in mushrooms:** The validation data generated in the primary validation (Gaydosh, 1998) indicates that the method is acceptable. However, the used sample set was too small (i.e. only two samples per fortification level with additional samples at one more level). Moreover, no confirmatory method was presented for diflubenzuron and the metabolite CPU.

In the ILV-study (Class, 2001) a sufficient sample set was used and the data was in compliance with the criteria in SANCO/825/00 rev.7. However levels of >30% LOQ were found in the blanks, which is not acceptable according to SANCO/825/00 rev.7. Finally an acceptable confirmatory method based on LC-MS/MS was presented for diflubenzuron in the ILV-study.

In conclusion therefore the acceptance of the available data needs to be discussed at a meeting of experts as the primary validation was performed using a too small sample set and as levels >30% of LOQ were found in the blanks in the ILV-study.

It should be noted that the available MRLs for diflubenzuron in cultivated mushrooms is 2 mg/kg according to Regulation (EC) No 396/2005. This means that according to SANCO/825/00 rev.7 the validation should have been performed at 0.1 mg/kg (LOQ) and 2 mg/kg (MRL).

#### B.5.3 Analytical methods (residue) soil, water, air (Annex IIA 4.2.2 to 4.2.4)

#### **B.5.3.1** Analytical method for the determination of residues in soil (Annex IIA 4.2.2)

In the peer-review it was concluded that details of the type of soil used in the validation of the analytical method for soil is needed (open point 1.14 in the Evaluation table). In the study presented in the original DAR (Faltzynski, 2003a) the used soil was reported as a sandy loam type and no further characteristics were given. However, this information is considered to be sufficient to address the open point 1.14.

#### **B.5.3.2** Analytical method for the determination of residues in water (Annex IIA 4.2.3)

In the peer-review it was concluded that the source and characteristics of the water used in the validation of the water method should be given (open point 1.15 in the Evaluation table). In the study included in the DAR (Faltzynski, 2003b) it is stated that the water used was obtained from a local pond (Winston-Salem, NC, U.S.A.). Furthermore it stated that the water was characterized by Agvise Laboratories and the sample was given the EN-CAS (the company performing the validation) id ES0537.

In January 2007, the applicant submitted a one page document, signed by Robert Deutsch 21.03.2003, which appears to be the characterization report of sample ES0537 performed by Agvise laboratories (see table B.5.3.2-1 below). The open point 1.15 is therefore considered addressed.

рН	6.8
Sodium	6 ppm
Calcium	4 ppm

Table B.5.3.2-1: Characteristics of the water sample ES0537

Magnesium	2 ppm
Hardness mg equivalent CaCO <sub>3</sub> /L	16 ppm
Conductivity	0.18 mmhos/cm
Sodium Adsorption Ratio (SAR)	0.66
Total Dissolved Solids	52 ppm
Total Suspended Solids	10 ppm
Turbidity	12.5 NTU
Dissolved Organic Carbon	4.4 ppm
Total Organic Carbon	5.0 ppm

#### B.5.3.4 Analytical method for the determination of residues in air (Annex IIA 4.2.4)

Already in the DAR it was highlighted that the available method for analysis of diflubenzuron in air was not sufficient as it was not highly specific. In May 2006 the RMS received a new method for air and it was proposed in the peer-review that it should be evaluated in an Addendum (reporting table 1(53)), which resulted in the data gap "Analytical method for air" in the Evaluation table. The new method is presented below.

Reference:	Bacher, R. (2006). Validation of an analytical confirmatory method for the
	determination of diflubenzuron in air. Report PTRL Europe GmbH, Germany, No. B
	1000 G (Chemtura 2006-001), DI – 11817., GLP, Not Published
GLP:	Yes
Principle of the method:	Air is drawn through XAD adsorption tubes (i.e. stated to retain both particles and
	aerosols) at about 1.4 L/min for approximately 6 hours (total air sampling volume $\approx$
	$0.5\ m^3)$ . Subsequently, the adsorption material is extracted with methanol. The extract
	is chromatographed on HPLC fitted with a $C_{18}$ -column using gradient elution (0.1%
	aqueous formic acid: 0.1% methanolic formic acid, 70:30 $\rightarrow$ 5:95) and tandem mass
	spectometry for detection. The method was validated for two transitions: $309 \rightarrow 289$
	(primary) and $309 \rightarrow 156$ (qualifier).
Validation Data:	
Specificity:	The LC/MS/MS chromatograms of the blank control specimens showed no signals
	(< $0.12 \ \mu g/m^3$ ) at the retention time of diflubenzuron. The method used is highly
	specific.
Linearity:	Linearity was established over the range 0.50 to 50 ng/mL (20% of LOQ to 200% of
	10 x LOQ) using seven calibration points. The correlation coefficient was $r^2 = >0.995$
	for both transitions using a 1/x weighing.
Accuracy:	Determined as recovery (see table B.5.3.4-1 below). The extraction efficiency and
	storage stability was demonstrated with acceptable average recoveries of 87 % to
	109%. The average recoveries for the analyte, for both fortification levels and both

	MS/MS transitions after air sampling ranged between 102% to 108% with relative standard deviations $\leq 6\%$
	No breakthrough above 5% was observed in the second chamber of the air sampling
	units.
Precision (Repeatability):	Determined as %RSD (se table B.5.3.4-1 below). All RSD were < 20%.
LOQ:	The limit of quantification (LOQ) was 0.6 $\mu$ g/m <sup>3</sup> . This is in compliance with the
	criterion in SANCO/825/00 rev.7 since the LOQ is lower than C, which using an
	AOEL of 0.0066 mg/kg bw/day, is equal to 1.98 $\mu$ g/m <sup>3</sup> air.
LOD:	Estimated to be $\leq 0.12 \ \mu g/m^3$ .

Table B.5.3.4-1: Validation data for the air method (Bacher, 2006)

	Fortified	Average	309 m	/z →289 m/z	5	309 m	/z →156 m/	Z	n
Specimen type	diflubenzuron (µg)	C <sub>Air</sub> (µg/m <sup>3</sup> )	Range recovery	Average recovery	RSD	Range recovery	Average recovery	RSD	
Extraction	0.30		108-109%	109%		107-108%	107%	i i	2
efficiency	3.0		83-93%	87%		82-91%	87%		2
ernerer,	Overall	1	83-109%	98%	13%	82-108%	97%	13%	4
Storage stability: overnight, RT	3.0		95-102%	99%		94-101% 96-99%	97%		2
Storage stability: 5 days, RT	3.0		97-98%	97%		96-99%	98%		2
Ambient air 21 °C, 22%	0.30	0.63	104-112%	108%	3%	106-111%	108%	2%	5
relative humidity	3.0	6.1	100-108%	102%	3%	100-107%	102%	3%	5
Warm, humid air 35°C, 99%	0.30	0.62	99-114%	107%	5%	97-116%	107%	6%	5
relative humidity	3.0	5.9	104-110%	107%	2%	105-108%	107%	1%	5
RSD = relative stan	dard deviation								
n = number of specimens included in calculation									

Average  $C_{Air}$  = Average fortified concentration of diflubenzuron in air

RT = room temperature

RMS comments: The method was fully validated and the data generated is in compliance with the criteria in

SANCO/825/00 rev.7. The data requirement for a method for air is therefore considered met.

#### B.5.6 References relied on

Only references not presented in the original DAR included here.

			Title	Data	
Annex point /	Author(s)	Year	Source (where different from company)	Protection	Owner
reference			Company, Report No	Claimed*	
number			GLP or GEP status (where relevant)		
			Published or not	Y/N	
IIA, 4.1.1/01	Riggs, A. S.	2003	Validation of an analytical method for the determination of organic impurities in technical diflubenzuron using HPLC. Final Report Chemtura Canada Co./Cie, Guelph Technology Centre. PO Box 1120, 120 Huron Street Guelph, Ontario, Canada N1H 6N3. Test Facility Study Number: GRL- 12064, Sponsor Project Number: 2003-048 GLP, Not Published	Y	CRO
			CONFIDENTIAL		
IIA 4.2.1/01	Allan, E Pouwelse, A.V.	1993	Determination of diflubenzuron residues according to multiresidue methods described in FDA's pesticide analytical manuals. Solvay Duphar B.V., Analytical Development Department, C.J. van Houtenlaan 36, 1381 CP Weesp, The Netherlands, Laboratory Project ID: C.303.50.019, GLP, Not Published	Y	CRO
IIA 4.2.4/01	Bacher, R.	2006	Validation of an analytical confirmatory method for the determination of diflubenzuron in air. Report PTRL Europe GmbH, Germany, No. B 1000 G (Chemtura 2006-001), DI – 11817., GLP, Not Published	Y	CRO

\* Protection for 5 years claimed from date of decision concerning listing in Annex I - the study report has not been submitted in any of the Member States in support of an application for authorization, or (though the study report has been submitted) has not been used in any of the Member States as the basis for decision on the initial authorization, or to maintain a given authorization, of a plant protection product before the date of submission of the dossier to Rapporteur Member State.

\*\* Owners' code identifications and names (Code identification: CRO,, Name: Chemtura Europe Limited previously Crompton Europe B.V)





## DIFLUBENZURON

Volume 3 Annex B.6 Toxicology

Rapporteur Member State: Sweden

December 2008



Volume 1

Level 1: Statement of subject matter and purpose for which the monograph was prepared

- Level 2: Reasoned statement of the overall conclusions drawn by the Rapporteur Member State Appendix 1: Standard terms and abbreviations Appendix 2: Specific terms and abbreviations Appendix 3: List of endpoints
- Level 3: Proposed decision with respect to the application for inclusion of the active substance in Annex I
- Level 4: Further information to permit a decision to be made, or to support a review of the conditions and restrictions associated with the proposed inclusion in Annex 1

#### Volume 2

Annex A: List of the tests and studies submitted and of information available

#### Volume 3

#### Annex B: RMS summary, evaluation and assessment of the data and information

Annex B.1: Identity

Annex B.2: Phys/chem.

Annex B.3: Data application and further information.

Annex B.4: Proposal for classification and labelling

Annex B.5: Analytical method

#### Annex B.6: Toxicology and metabolism

Annex B.7: Residues in crop

Annex B.8: Fate and behaviour

Annex B.9: Ecotoxicology

Appendix 1: Standard terms and abbreviations

Appendix 2: Specific terms and abbreviations

#### Volume 4

Annex C: Confidential information and summary and assessment of information relating to the collective submission of dossiers

#### Table of contents

B.6.2	Acute toxicity (Annex IIA 5.2) 29	
B.6.3	Short-term toxicity (Annex IIA 5.3)	30
B.6.10	Summary of mammalian toxicology a (Annex IIA 5.10) 45	nd proposed ADI, AOEL, ARfD and drinking water limit
B.6.12	Dermal absorption (Annex IIIA 7.3)	75
B.6.14	Exposure data (Annex IIIA 7.2)	75
Appendix 1	88	

#### **B.6.2** Acute toxicity (Annex IIA 5.2)

#### Reporting table, mammalian toxicity, 2(2)

EFSA: for some studies the purity level is not mentioned or batches with much lower purity than recommended one have been used. RMS to provide an explanation on the reliability of conclusions drawn.

16 Jan 2007 the RMS received, by e-mail, a document with the purity of the technical diflubenzuron used for the acute toxicity studies. As seen in the table below, all batches had a high purity of Diflubenzuron.

In the skin irritation study by Taylor there are no purity information, however the other skin irritation study by Koopman are prepared with VC-90 which contains 90 % diflubenzuron and in neither of the studies there are any signs of irritation to the skin.

Study Name	Author	Study Date	Study Number	Batch Number	Purity %
Acute Oral Studies with DU 112307 in Mice and Rats	Eldik	1973	56645/14/73	309181	>99.6
Acute Toxicity in Rats of DU 112307 Technical After Dermal Application	Keet	1976	56645/2/76	405093	>99.6
Acute Dermal Toxicity Study with DU 112307 Technical in Rats	Koopman	1977	56645/7/77	405093	>99.6
Acute Percutaneous Toxicity to Rabbit of DU112307 Technical	Davies	1974	2171/D175/73	309181	>99.6
Acute Inhalation Toxicity to the Rat of DU 112307 Technical Grade Powder	Berczy	1973	PDR 74/73849	309181	>99.6
Acute Inhalation Toxicity to the Rabbit of DU 112307 Technical Grade Powder	Berczy	1975	PDR 198/74988	405093	>99.6
Primary Skin Irritation Study TH-6040 Technical (Albino Rat)	Taylor	1973			
Irritant Effects of DU 112307 Technical on Rabbit Eye Mucosa	Davies	1973	2170/176D/73	309181	>99.6
Sensitization Study with Diflubenzuron Technical in Guinea Pigs	Prinsen	1992	56645/26/1992	FUN91A10A/ FUX021000	95.6

#### Purity for the diflubenzuron used in the different acute toxicity studies.

#### **B.6.3** Short-term toxicity (Annex IIA 5.3)

#### Reporting table, mammalian toxicity, 2(5)

UK: Derivation of a NOAEL versus NOEL in the 90 day dog study of Greenbough et al, 1985 Justification is required for the assumption that increases in methaemoglobin at 10 mg/kg bw/day, which are statistically significant, are not toxicologically significant.

#### Chemtura's comments of List of Endpoints and the proposed classification with R48

The 24th of September the RMS received the following e-mail from Chemtura. It contains the Notifier's comments on the changes in the List of Endpoints. The RMS has gone through the List of Endpoint again and some corrections have been made. However we disagree with the notifier and consider increased methaemoglobin as an adverse effect see the section "Toxicological relevance of increased methaemoglobin", after the two papers from Chemtura.

#### Dear Lena,

Sorry for my late response, but I had other important projects with deadlines to work on. We were quite surprised by the change in your opinion about methaemoglobin and have to react on it, because we really disagree.

We kindly ask you to send our comments (the attached documents) to EFSA and the members of the expert panel dealing with human toxicology too, so that they are informed of our opinion on the recent changes in the List of Endpoints. In the reporting table send to us by the EFSA recently we didn't had the opportunity to comment on the changes in the List of Endpoints. After asking the EFSA why we couldn't comment on the changes in the list of Endpoints, the EFSA said that this wasn't possible in the current procedure and recommended us to send our comment to you, being the rapporteur.

**R48 classification**: You are probably referring to the report from Blom (2001, \* see reference in red below), but we do not understand why you didn't use the, of more recent date, document

0703a11\_NL\_haemolytic\_anaemia\_finalreport. This report is from August 2004, it's the final report from the Working Group on Haemolytic Anaemia, based on the comments from Belgium, Denmark, Germany, Industry, Ireland, The Netherlands and The United Kingdom. This report reflects the opinion of the EU, the Blom-report (2001) is referenced several times in this document and has been used as a source. The report from Blom is the opinion of only 1 Member State and is of an earlier date.

We have assessed the severity of the haemolytic anaemia caused by diflubenzuron using the 2004-document and came to the following conclusion:

Administration of diflubenzuron to laboratory animals does not demonstrate severe anaemia or severe hemolytic anaemic effects. The effects demonstrated are sub-clinical and reversible. Based on the entire toxicological database and especially the long term studies, the

classification of R48 is not warranted. (See the attached file called "R48 Danger of serious damage to health by prolonged exposure" for more details).

**Updated list of Endpoints**: Not only are we disagreeing with your opinion on the severity of the haemolytic anaemia, but also in the choice of NOEL/NOAEL values from reports that weren't even considered acceptable (for several reasons, mostly old non-GLP-studies) and in one case even not evaluated (present on a list of studies not evaluated, but only mentioned in a list because they had been submitted in the past to the authorities), totally ignoring the results from the acceptable GLP-conform studies. What's the point in doing these GLP-studies then? There are several issues that I want to point out to you, also included is the comment (in black) I've made in the reporting table send lately to the EFSA. I've also attached the updated list of endpoints with my comments on the section Toxicology:

• Short term toxicity (Annex IIA, 5.3): You mention as target/critical effect **chronic hepatitus**, although this wasn't caused by diflubenzuron.

There were 2 experiments in which chronic hepatitis was seen, both in the control & treatment groups and therefore the hepatitis was not caused by the treatment with diflubenzuron, see below.

- Burdock (1980) subchronic (13 weeks) tox in rat: the majority of rats showed chronic hepatitis, also in the control group, but the severity was generally higher at  $\geq$  2000 ppm (139.1/164.5 mg/kg bw/day M/F).

- Burdock (1980) 90 day –mice: The hepatitis was of variable incidence and also occurred in control animals and this effect was considered to be unrelated to DFB.

• Short term toxicity (Annex IIA, 5.3), relevant oral NOAEL/NOEL: 2-week mouse: the only 2 week mouse study I could find was Keet (1977), this study hasn't been evaluated by you and furthermore the NOEL value was misinterpretated.

The 2 week mouse study (Keet, 1977) is not evaluated by the RMS, but only mentioned as a reference in the DAR because it had been submitted in the past to local authorities The NOEL was established at **40 mg/kg bw/day**. The rapporteur has made a mistake in the NOEL-value, for in the updated list of end-points 2 mg/kg bw/day is mentioned in stead of 40 mg/kg bw/day. This non-GLP study, which hasn't even been evaluated by the rapporteur shouldn't be used for determining end-points.

• Short term toxicity (Annex IIA, 5.3), relevant oral NOAEL/NOEL: oral 90-day and 1 year toxicity - Dog:

We do not agree with the proposed NOEAL of 2 mg/kg bw/day: the study of Greenough (1985) is referring to the 1-year dog study <u>not</u> the 90-day study. An exposure of 1 year in dogs is not a short term exposure (short term: 28 - 90 days), the duration of this study is approximately <u>4 times</u> the 90-day study. The effects seen in both the 90-day and 1-year dog study are not biologically relevant and certainly not adverse.

In the 90-day study (Versendaal, 1983) the NOEL is 4 mg/kg bw/day and the NOAEL is 50 mg/kg bw/day! The effects at 50 mg/kg bw/day are minor and not adverse: The value of MetHb was < 1% at 50 mg/kg bw/day which is the standard value presented in ECB's document (ECBI/07/03 Add.11).</p>

- In the 1-year dog study (Greenough, 1985) the level of MetHb was < 1% at the NOAEL of 10 mg/kg bw/day. The 2 mg/kg is equal to the NOEL but is not relevant for the NOAEL. The NOAEL should be 10 mg/kg bw/day based on the increase in spleen weight, which is a secondary effect.</p>
- Short term toxicity (Annex IIA, 5.3), relevant inhalation NOAEL/NOEL: An unacceptable 28-day rabbit study of restricted quality was used for chosing NOAEL/NOEL values.

Value of 1.9 mg DFB/L air is based on Berczy *et al* 1975, 28d rabbit: "Study is of restricted quality". The conclusion of this study was: The dust of technical diflubenzuron has no appreciable sub-acute inhalation toxicity in the rabbit under the conditions described. No NOAEL or NOEL could be established from this study, except that the NOAEL and NOEL were greater than 1.99 mg/L. This study shouldn't be used for determining end-points. The NOAEL/NOEL of the 28 days rat (acceptable study, GLP-compliant) is: **30 mg/L**.

- Long term toxicity and carcinogenicity (Annex IIA, point 5.5): Target/critical effect: You mention "other signs of anemia like haemosiderosis of spleen and liver, marrow, erythroid and thyroid hyperplasia, discoluration of extremites and Heinz body formation", but these are all <u>secondary effects</u> caused by the haemolytic anaemia. Thus no reason to add them as separate effects to the critical effects.
- R48 classification: see also attached file called "R48 Danger of serious damage to health by prolonged exposure", in this document each criterium of the document ECBI/07/03 Add.11 has been adressed.

The toxicology package for diflubenzuron was assessed in association with ECBI/07/03 Add. 11 (Proposal for criteria to be used in the classification of R48 for hemolytic anemia in repeated dose toxicity studies). The treatment related effects seen in the toxicity studies with diflubenzuron are not indicative of serious adverse effects. The assessment concluded that the classification of R48 is not warranted for diflubenzuron. A separate document with our detailed assessment will be sent to the rapporteur (see attached file called.

No serious systemic effects were demonstrated in any toxicity studies with diflubenzuron. Repeated dose studies with diflubenzuron in the diet, by oral bolus dose in the form of a capsule, by inhalation or by dermal exposure, have not resulted in any deaths related to treatment. Dietary treatment levels were up to 100,000 ppm for 9 weeks in rats (corresponding to 7801 & 8539 mg/kg bw/day fors males & females, respectively) (Hunter 1979). Clinical signs were not observed during dosing in any study. No decrease in life span for any animal species was noted in any repeated dose study. This demonstrates that the haematological effects as a result of diflubenzuron treatment do not result in a decrease in overall health of the treated animal.

Repeated dose administration of diflubenzuron resulted in sub-clinical expression of anaemia, which was most likely due to extracellular hemolysis. The level of anaemia can be classified as sub-clinical because of the lack of clinical symptoms associated with treatment. The decrease in haemoglobin (Hb) levels was not below the designated adverse level of 10% of in any of the studies. Methemoglobin (MetHb) levels were only above the level of concern (4% in rats, 2% in mice) at extremely high doses (400 ppm in mice and 100,000 ppm in rats). Furthermore, chronic administration of diflubenzuron resulted in a reduction in the expression of anaemia compared to those evident upon sub-chronic treatment.

The increase in liver and spleen weight is a secondary effect which is attributable to the deposition of pigment from damaged erythrocytes. Diflubenzuron affects the circulatory system through mild, subclinical extravascular hemolytic anemia. The effects seen are reversible and compensatable as demonstrated by the toxicological database of diflubenzuron.

- Reproduction target/critical effect: "increase in liver and spleen weight and methaemoglobin" is mentioned again, but these aren't effects on reproduction and should be removed
- Derivation of ADI and AOEL: We do not agree with the NOAEL of 2 mg/kg bw/days as proposed by the RMS for use in the derivation of the ADI and AOEL. The NOAEL used for the ADI & AOEL should be **10 mg/kg bw/day** based on the increase in spleen weight, which is a secondary and certainly not an adverse effect. The effects seen at 10 mg/kg bw/day are minor and not biologically relevant, the values of MetHb are below the 1% value that is mentioned as a standard value in the ECB document (ECBI/07/03 Add.11).
- ARfD: See attached file called "R48 Danger of serious damage to health by prolonged exposure" for the details of the assessment: Methaemoglobinemia is not an acute effect for diflubenzuron, since this effect isn't observed in the acute studies. Only in the short term and chronic studies the levels of methaemoglobinemia are increased. However these effects are <u>mild</u> and are <u>reversible</u> and compensatable, therefore there are certainly no <u>scientifically sound</u> reasons to establish an ARfD!
- Dermal absorption: We do not agree with the 6 % dermal absorption, the Diflubenzuron present in the skin (stratum corneum) is not biologically available and as the skin is renewed every 20 days, it will not be a depot for possible release afterwards.
- All exposure senarios (operator/worker/bystander) have been recalculated by the rapporteur with a new AOEL-value we do not agree with (see above). The NOAEL used for the AOEL should be **10 mg/kg bw/day** and <u>not 2 mg/kg bw/day</u>.

\* Blom, M. in RIVM Rapport 601516007 Luttik R ; Raaij MTM van (eds) 2001 Factsheets for the (eco)toxicological risk assessment strategy of the National Institute of Public Health and the Environment (RIVM)



#### **DIFLUBENZURON** Addendum to Annex B.6: Toxicology





#### Chemtura's Response to the List of Endpoints for Diflubenzur<u>on Toxicity and Risk Assessment</u>

27 August 2007

#### Short-term toxicity

#### Target/Critical Effect:

Critical effects are the main effects seen upon increasing the dose. For diflubenzuron, the critical effect in most studies is the increase in methemoglobin and sulfhemoglobin in the blood and the liver and spleen weight, the other hematological effects mentioned in the updated list of endpoints are not biologically relevant/adverse.

 The increase in methemoglobin and sulfhemoglobin in the blood is statistically significant, but non-biologically relevant. The increase in liver and spleen weight is a secondary effect which is attributable to the deposition of pigment from damaged erythrocytes.

 Other signs of anaemia include effects which are secondary and often compensatory.

- Chronic hepatitis is not an effect that is attributable to diflubenzuron treatment.
  - Chronic hepatitis was reported to result in a dose-related increase in the severity of chronic hepatitis in a subchronic dietary rat study conducted in 1980 (Burdock, 1980). Similar findings were not found in a previous subchronic (90 day) studies in rats (Kemp, 1973a), in the 28 day study in rats (Palmer, 1977), in the 9 week study with 4 week withdrawal period in rats (Hunter 1979), in any of the subchronic inhalation or percutaneous absorption studies, or in either of the chronic toxicity/oncogenicity studies in rats (Burdock, 1984 and Hunter, 1976). Doses used in the other studies were comparable or substantially higher than the study in which chronic hepatitis was found. In addition, the study in which chronic hepatitis was found had instances of chronic hepatitis in all animals including controls.
  - Chronic hepatitis was also reported in only one subchronic dietary mouse study (Burdock, 1980). The effect was not demonstrated in a 6 week dietary study in male mice (Hunter, 1974), in the 14 week dietary study in mice (Colley, 1981), or in either of the mouse oncogenicity studies (Hunter, 1975 and Colley, 1976). If this was a true treatment related effect, then it would be seen in other studies, especially ones of chronic duration. Furthermore the hepatitis was of variable incidence and also occurred in control animals, this effect was considered to be unrelated to DFB.

35

Chronic hepatitis was not reported in any of the dog studies.

- Mild crythroid hyperplasia in bone marrow is not an adverse effect. The
  hyperplasia is secondary and in response to the anemia. It does not result
  in irreversible damage. The bone marrow hyperplasia is a regenerative
  measure. This effect is not demonstrated in every study, but it occurrence
  can be attributed secondarily to treatment with diflubenzuron.
- Congestion of the spleen is also secondary to the hemolytic anemia. It has been demonstrated to be reversible upon withdrawal in subchronic studies and compensatable in chronic studies (effect is not present upon chronic treatment).
- Liver haemosiderosis is also secondary to the hemolytic effect. It has been demonstrated to be reversible and does not result in permanent damage.
- Heinz bodies are found in a subchronic mouse study (Colley, 1981) as well as in the mouse chronic toxicity / oncogenicity study by Colley et al, 1984. Otherwise, the identification of heinz bodies was not common finding in the diflubenzuron toxicity database.

#### Relevant Oral NOAEL/NOEL

NOAEL: 10 mg/kg bw/day; NOEL: 2 mg/kg bw/day (Greenough, 1985)

- The 14 day oral gavage study in male mice demonstrated a NOEL of 40 mg/kg bw/day based on increase in sulfhemoglobin levels. (Keet 1977). NOAEL is > 5000 mg/kg bw/day.
- Short term toxicity should be subchronic (28 90 days). An exposure of
  1 year in dogs is not a short term exposure. If the endpoint were
  intermediate exposure, the 1 year dog study would be applicable. The
  effects seen in the 1 year dog study are not biologically relevant. The 2
  mg/kg is equal to the NOEL but is not relevant for the NOAEL. The
  NOAEL should be 10 mg/kg based on the increase in spleen weight.
- The NOEL in the two week mouse study (Keets, 1977) was 40 mg/kg/day or 5000 ppm and not 2 mg/kg/day.

#### Relevant Dermal NOAEL/NOEL

NOAEL: > 322 mg/kg bw/day (21.5%); NOEL: 150 mg/kg bw/day (10%) (Davies, 1975)

- Biologically non-relevant changes in MetHb levels. Changes in MetHb levels were not associated with changes in Hb or Hematocrit.
- MetHb levels were not dose related. Statistical Power is low (low number of samples, low statistical significance). If an ANOVA was run with this data, it is highly unlikely that there would be a real difference.

Group	Sex	Met Hb individual	Met Hb
		values	Average
1) Control, intact	Male	0.1,0.1,0.1,0.1,0.1	0.1
	Female	0.1,0.1,0.1,0.1,0.1	0.1
2) Control abraded	Mala	0101010101	01
-----------------------	--------	---------------------	------
2) Condon, abraded	Male	0.1,0.1,0.1,0.1,0.1	0.1
	Female	0.1,0.1,0.1,0.1,0.1	0.1
3) 69.6 mg/kg bw/day	Male	0.4,0.5,0.1,0.1,0.3	0.3*
(4 64%); intact	Female	0 1,0 1,0 2,0 1,0 1	0.1
4) 69.6 mg/kg bw/day	Male	0.1,0.1,0.2,0.2,0.1	0.1
(4 64%); abraded	Female	0.3,0.2,0.1,0.2,0.2	0.2
5) 150 mg/kg bw/day	Male	0.1,0.1,0.2,0.2,0.1	0.1
(10%); intact	Female	0.4,0.2,0.1,0.2,0.1	0.2
6) 150 mg/kg bw/day	Male	0.3,0.2,0.1,0.2,0.7	0.3*
(10%); abraded	Female	0 2,0 1,0 3,0 3,0 1	0.2
7) 322.5 mg/kg bw/day	Male	0.3,0.5,0.2,0.4,0.2	0.3*
(21 5%); intact	Female	0.1,0.3,0.3,0.1,0.4	0.2*
8) 322.5 mg/kg bw/day	Male	0.3,0.2,0.1,0.2,0.1	0.2
(21.5%); abraded	Female	0.3,0.1,0.2,0.4,0.1	0.2*

\* Significance at 5%

#### Relevant Inhalation NOAEL/NOEL

NOAEL: > 30 mg/m3; NOEL: = 30 mg/m3 (Newton 1999). NOEL is based on slightly statistical significant decreases in Hb and Hematocrit.

• The study the NOEL of 1.99 was derived from is an unacceptable non-GLP study (Berczy et al 1975, 28d rabbit). In this study, rabbits were dosed 1 hour a day, 5 days a week for 3 weeks. In addition, the 1.99 mg/m3 was the highest dose tested and no observed effects were demonstrated at this level. No NOAEL or NOEL could be established from this study, except that the NOAEL and NOEL were greater than 1.99 mg/L. This is not an appropriate study for the derivation of an endpoint for inhalation. The Newton 1999 study (rat, 4 weeks) was conducted in accordance with current testing guidelines and is the most appropriate study for the derivation of the inhalation endpoint.

## Long-term toxicity

Target/Critical Effect:

1) Blood/increased in methemoglobin and sulfhemoglobin are statistically significant but non-biologically relevant

2) Other signs of anaemia include effects which are secondary and often compensatory. These effects include increased liver and spleen weight which is attributable to the deposition of pigment from damaged erythrocytes.

 Heinz bodies are found in a subchronic mouse study (Colley, 1981) as well as in the mouse chronic toxicity / oncogenicity study by Colley et al, 1984. Otherwise, the identification of heinz bodies was not common finding in the diflubenzuron toxicity database.

- Congestion of the spleen is also secondary to the hemolytic anemia. It has been demonstrated to be reversible upon withdrawal in subchronic studies and compensatable in chronic studies (effect is not present upon chronic treatment).
- Liver haemosiderosis is also secondary to the hemolytic effect It has been demonstrated to be reversible and does not result in permanent damage.
- Marrow, erythroid and thyroid hyperplasia are not common effects related to treatment with diflubenzuron (erythroid and thyroid hyperplasia) or are compensatory, reversible mechanisms (marrow hyperplasia).
- Discolouration of extremeties is also not a common effect of treatment with diflubenzuron even at treatment levels as high as 1% of the diet. This is not an effect that should be regarded as a critical effect as its occurrence is not typical of the treatment related effects of diflubenzuron.

#### Lowest relevant NOAEL/NOEL

NOAEL: 6.4 mg/kg/day based on the Mouse 91 week carcinogenicity study.

- Mouse 91 week study: NOAEL: 6.4 mg/kg/day in male mice. NOEL: 1.2 mg/kg/day male mice. The NOEL is based on non-biologically relevant (not adverse) changes in hemaetology.
- Dog 1 year study: The 2 mg/kg is equal to the NOEL but is not relevant for the NOAEL. The NOAEL should be 10 mg/kg based on the increase in spleen weight.

#### ADI

	Value: 0.064	Study: 91 week mouse	Safety Factor: 100
AOEL			1
	Value: 0.033	Study: 1 year dog, 90 day rat, 90 day mouse	Safety Factor: 100 33% oral absorption

Chemtura

#### Applicability of the R48 Classification to Diflubenzuron

#### August 21, 2007

The toxicology package for diflubenzuron was assessed in association with ECBJ/07/03 Add. 11 (Proposal for criteria to be used in the classification of R48 for hemolytic anemia in repeated dose toxicity studies). The treatment related effects seen in the toxicity studies with diflubenzuron are not indicative of serious adverse effects. The assessment concluded that the classification of R48 is not warranted for diflubenzuron.

No serious systemic effects were demonstrated in any toxicity study with diflubenzuron. Repeated dose studies with diflubenzuron in the diet, by oral bolus dose in the form of a capsule, by inhalation or by dermal exposure, have not resulted in any deaths related to treatment. Dietary treatment levels were up to 100,000 ppm for 9 weeks in rats (7801/8539 mg/kg bw/day male and female respectively) (Hunter 1979). Clinical signs were not observed during dosing in any study. No decrease in life span for any animal species was noted in any repeated dose study. This demonstrates that the hematological effects of diflubenzuron treatment do not result in a decrease in overall health of the treated animal.

Repeated dose administration of diflubenzuron resulted in sub-clinical expression of anaemia, which was most likely due to extracellular hemolysis. The level of anaemia can be classified as sub-clinical because of the lack of clinical symptoms associated with treatment. The decrease in hemoglobin(Hb) levels was not below the designated adverse level of 10% of in any of the studies. Methemoglobin (MetHb) levels were only above the level of concern (4% in rats, 2% in mice) at extremely high doses (400 ppm in mice and 100,000 ppm in rats). Furthermore, chronic administration of diflubenzuron resulted in a reduction in the expression of anaemia compared to those evident upon sub-chronic treatment. This negates the need for classification based on chronic sub-clinical methemoglobinemia.

ECBI/07/03 Add 11 (Proposal for criteria to be used in the classification of R48 for hemolytic anemia in repeated dose toxicity studies) states that the decision for classification should be based on longest duration study. The longest duration studies in terms of time and percentage of lifespan covered are the combined chronic / carcinogenicity studies in rats and mice. In the rat studies, methaemoglobin levels do not exceed the >4% level of concern. The high dose level in the rat chronic study was 10,000 ppm (1% of the diet). The effects on hematology parameters are decreased or absent at 104 weeks when compared to the 52 week measurement. No clinical effects, deaths or decrease in life span was detected in the rat studies. The percent Hb levels in the chronic rat study were not-dose related. The decreases at 52 weeks of treated ranged from 7 - 8% at the high dose to 12% in females at 2500 ppm and males at 650 ppm at 52 weeks The percent Hb increased at 104 weeks to 16% in the high dose males. The improvement in Hb levels along with improvements in erythrocyte levels, MCV and reticulocytes demonstrate a successful compensatory mechanism or an alleviation of the hemolytic effect. The increases in relative and absolute liver and spleen weights can be accounted for by the deposition of hemosiderin-like pigment. These are not direct adverse effects but are effects secondary to the hemolytic anaemia The organs are not irreversibly damaged as shown by the recovery period after 7 weeks of treatment and 4 weeks of nontreatment. The pigment deposition is not accompanied by indications of severe anaemia. The results of the rat chronic/oncogenicity study demonstrate that the classification of R48 is not appropriate.

The chronic/carcinogenicity study in mice was also considered in this assessment. There was no affect on survival. Males in the 10000 ppm treatment group had statistically lower body weight at week 52. The Hb level in the same high dose males was significantly higher than controls at week 78 but were similar among all group at weeks 52 and 91 (termination). The MetHb levels were above the noted 2% of the total Hb level of concern in the male and female treatment groups at 400 ppm. However, as the DAR states, the statistically significant alterations are still within the normal range. Increases in spleen weight that were evident at the interim (52 weeks) were not present at terminal sacrifice. The results of the chronic toxicity/carcinogenicity mouse study furthers the determination that diflubenzuron does not warrant an R48 classification

Administration of diflubenzuron to laboratory animals does not demonstrate severe anaemia or severe hemolytic anaemic effects. The effects demonstrated are subclinical and reversible. Based on the entire toxicological database and especially the long term studies, the classification of R48 is not warranted.

R48 Danger of serious damage to health by prolonged exposure; *Clear functional disturbance or morphological change which has toxicological significance.* 

- Particularly important when changes are irreversible
  - Not the case with Diffubenzuron (DFB dietary treatment with recovery period demonstrated a recovery or decrease in severity of all symptoms. Furthermore, chronic studies demonstrated a recovery upon prolonged treatment
- Classification depends on dose level, exposure period and dose route
   Even at extreme dose levels of DFB (1% of the diet), no
  - clinical signs of anaemia were present
- If studies of multiple durations are available, the study of the longest duration should normally be used
  - For DFB those studies would be the rat
  - chronic/carcinogenicity and mouse oncogenicity studies
- 1. Substance related death
  - For DFB, no substance related deaths were reported in any study
    - For DFB, no substance related reproductive / developmental toxicity
- 2 Major Functional Changes in Organ System
  - For DFB, no clinical signs of hypoxia were seen during treatment

3. Changes in clinical biochem/hematology/urinalysis parameters which indicate severe organ dysfunction. Hematological changes are considered to be of particular importance if the evidence suggests that they are due to decreased bone marrow production

- DFB did not result in a decreased bone marrow production
- There was no reduction of Hemoglobin at ≥ 20% in any study with DFB at any dose level
- There was no reduction of functional hemoglobin at ≥ 20% due to a combination of hemoglobin reduction and metHb formation in any study with DFB
- Hemoglobinuria or hemosiderinuria was not detected in any study with DFB

- Severe organ damage noted on microscopic examination following autopsy: 4.1 Widespread or severe necrosis fibrosis etc in organs with
  - regenerative capacity
    - No widespread or severe fibrosis in the spleen, liver or kidney was detected in any study with DFB
  - 4.2 Severe morphological changes that are potentially reversible but are clear evidence of marked organ dysfunction
    - No severe tubular nephrosis was detected in any study with DFB
  - 4.3 Evidence of appreciable cell death in vital organs incapable of regeneration or in a stem cell population
    - No appreciable cell death in organs incapable of regeneration or in a stem cell population.

The guidance document also mentions that it is important to consider not only specific severe changes in a single organ or biological system but also generalized changes of a less severe nature involving several organs or severe changes in general health status.

- DFB does not result in any severe changes to the general health status of the treated animals at any dose level or route of administration
- DFB affects the circulatory system through mild, subclinical extravascular hemolytic anemia. The effects seen are reversible and compensatable as demonstrated by the toxicological data.

These effects are relevant when attempting to determine a no-effect level for a chemical substance – irrespective of stat significance.

- Clinical observations or changes in bodyweight gain, food consumption or water intake, which may have some toxicological significance but which do not, by themselves, indicate 'serious damage'
  - DFB does not result in clinical symptoms or significant changes in bodyweight gain, food consumption or water intake. This is relevant when considering the statistically significant but not biologically relevant changes which are not indicative of serious damage.
- Small changes in clinical biochemistry, hematology or urinalysis which are of doubtful or minimal toxicological importance
  - DFB treatment results in sub-clinical expression of anaemia. The changes in hemoglobin levels are less than 10% for the majority of tested doses. MetHb levels are within the 0-4% for rats and usually in the range of 0-2% for the mice. Full recovery was noted after 4 weeks of withdrawal in rats treated for 7 weeks in feed. Compensatory mechanisms begin within 28 days of treatment and chronic treatment demonstrates improvement if not complete reversal of effects.
- Changes in organ weights without evidence of organ dysfunction
  - No or minimal severe histopathology effects were noted in the spleen and liver
- Adaptive responses

Are present and compensatory. No clinical effects.
 Species specific mechanism of toxicity has been demonstrated
 All animals responded similarly to DFB. There is no indication that humans would respond any differently to treatment.

# Toxicological relevance of increased methaemoglobin (written by the RMS)

## Background information of methaemoglobin (MetHb) formation and following reactions

Normally, methaemoglobin levels are <1% of the total haemoglobin. MetHb binds oxygen more strongly than haemoglobin (Hb) and therefore does not effectively deliver oxygen to tissue.

Spontaneous formation of methaemoglobin is normally counteracted by protective enzyme systems: NADH methaemoglobin reductase (cytochrome-b5 reductase) and NADPH methaemoglobin reductase. The pentose phosphate pathway is a metabolic pathway that supplies energy to the cells and glucose-6-phosphate dehydrogenase (G6PD) is an enzyme in the pentose phosphate pathway that generates NADPH which is thought to be a main source of reducing power. NADPH is primarily used to convert the oxidized glutathione (GSSG) into its reduced form (GSH) in a reaction catalyzed by glutathione reductase. GSH is necessary for avoiding the irreversible oxidation of intracellular proteins, including membrane proteins and enzymes, while the accumulation of GSSG cause protein dysfunction, by creating disulfide bonds between the –SH groups of cysteine and methionine residues. Extended erythrocytic oxidative stress promotes depletion of the antioxidant capacity of the cell, causing dysfunction by reversible interaction between protein thiols and glutathione.

Rat and rabbit (guinea pig and monkey) are less sensitive to MetHb formation and generally show a more effective reduction of MetHb than man and dog (cat) do. Extra sensitive groups are e.g. foetuses and newborns characterized by low NADH and more fluctuating Hb, elderly people with more fluctuating Hb, which is more susceptible to oxidation and people with glucose-6 phosphate dehydrogenase deficiency, with defective NADPH production.

If an effect on MetHb concentration is observed, it is considered an adverse effect because an increase in MetHb levels is possible only when the capacity of the reducing mechanisms is exceeded, the exposure has then already reached such a level that considerable energy will be spent on reduction of MetHb and production of reticulocytes. Any significant increase in MetHb concentration compared to control level is in principle considered an adverse effect if a dose-response relationship is present. An increase in MetHb concentration which is not significant is still considered adverse if dose-response relationship is observed at the consecutive dosage.

Heinz bodies are associated with oxidative damage to the red blood cells and are more persistent than MetHb and therefore their presence may be a more robust indicator of MetHb formation than measurements of blood MetHb concentration. When a macrophage in the spleen "sees" a red blood cell with a Heinz Body, it is removed from the circulation. Prolonged exposure to MetHb-inducing compounds may bring about several effects, such as the presence of Heinz bodies in red blood cells and changes in the different cell count indicative of anaemia: RBC $\downarrow$ , Hb $\downarrow$ , MCV $\uparrow$ , and reticulocytes $\uparrow$ . In addition, haematopoiesis in liver and spleen, hemosiderins (insoluble iron precipitates) in the liver, and possible (in the beginning of the study) bluing of the skin and/or nose. Increased LDH activity may be an indication of haemolysis.

Howell-Jolly bodies are a histological sign comprising clusters of DNA remaining in red blood cells indicating abnormal mitosis and have been observed in relation to haemolytic anaemia. They have a reduced amount of cell membrane and a hyperchromatic colour. In normal individuals they are removed by the spleen, so that they are not seen in the blood. When the spleen has been removed, or is not functioning properly Howell-Jolly bodies appear in the peripheral blood.

Haemosiderosis is defined as a marked increase in hemosiderin accumulation in organs compared to the normal status, and thereby is a hallmark of secondary iron overload. Haemosiderosis is the deposition of haemosiderin bound iron in several organs, usually the liver, spleen, kidney and bone marrow. Macrophages with dense dark brown (haemosiderin) pigment may occur. Since a low extent of haemosiderosis is a normal age related lesion that may show some degree of individual variation, only clear increases in haemosiderin deposition compared to the internal control group should be considered as treatment-related effects. Marked haemosiderosis in multiple organs is clearly an adverse effect.

Increased spleen weight and enlarged spleen could be indicative of increased degradation of erythrocytes including haemosiderin accumulation, extramedullary haematopoiesis or both.

Increased liver weight could be indicative of extramedullary haematopoiesis or uptake of residues from haemolysed erythrocytes (haemosiderosis). Kupffer cell (macrophage in the liver) activation, increased accumulation of haemosiderin in endothelial (Kupffer) cells may occur in response to haemolytic anaemia. A prominent accumulation of haemosiderin pigment in sinusoidal Kupffer cells and hepatocytes gives an indication of intravascular haemolysis.

Haemosiderin deposition in the liver is a pathological condition.

Normally new blood cells are produced in the bone marrow in adults. However, in foster the haematopoiesis also occurs in the spleen and liver and the splenic and hepatic erythropoiesis can be reactivated in attempt to meet the demand for increased oxygen transport.

Free iron catalyzes autooxidation by Fenton and Haber-Weiss reactions, resulting in the production of reactive oxygen species.

## Conclusions

The primary adverse effect caused by diflubenzuron is the formation of methemoglobinemia (caused by oxidative stress) and associated dysfunctions of erythrocytes. The other abnormalities observed could be explained as secondary to this type of hematotoxicity with increased erythrocyte damage and turnover, including red blood cell morphological alterations (e.g. Heinz bodies, Howell-Jolly bodies), discolouration of extremities, effect on the spleen and liver (increased weight, congestion, hemosiderin accumulation and increased hematopoietic cell proliferation) and increased erythroid hyperplasia in the bone marrow.

Main sources of information Information from RIVM report 601516 007 April 2001 Regular Toxicology and Pharmacology 45 (2006) 299-241

# **B.6.10** Summary of mammalian toxicology and proposed ADI, AOEL, ARfD and drinking water limit (Annex IIA 5.10)

## Reporting table, mammalian toxicity, 2 (5), (9), (10)

Several of the comments in the reporting table are dealing with the effect of increased methaemoglobin and sulfhaemoglobin, seen in almost all studies with diflubenzuron. The question is if the effect should be regarded as adverse or not. When the DAR was first prepared the RMS regarded the effect as not adverse, however after having received the comments from other MS and consulting the literature the RMS now consider increase in methaemoglobin and sulfhaemoglobin as an adverse effect. Even if this is reversible effects it has to be taken seriously when the exposure is repeated many times and signs of anaemia is seen. The changed attitude to these effects has influenced the risk assessment of many of the studies in the Dossier and many NOAELs have been lowered. Therefore this section with the summary of toxicity and the proposed ADI, AOEL and ARfD, has been included to the addendum.

#### Absorption, distribution, excretion and metabolism (toxicokinetics)

Diflubenzuron is poorly absorbed from the gastro-intestinal tract and, at a dose range of 5-100 mg kg<sup>-1</sup> used absorption decreases with increased dose level in the rat. High level of non-absorbed diflubenzuron was found in the faeces. The oral absorption was approx. 33 %. Absorbed radioactivity was removed almost completely in 24-48 hours, with the exception of low residues in liver and erythrocytes. In no other part of the rat body do the compound and/or its metabolites accumulate. Excretion takes place *via* bile and urine. The major metabolites of diflubenzuron identified in rat urine were 4-chloroaniline-2-sulfate (45% of urine TTR), and n-(4-chlorophenyl)oxamic acid (13% of urine TRR). About 3% of urine TRR was 2'-hydroxy-diflubenzuron. Other 18 metabolites were accounted and none for more than 2% urine TRR. Diflubenzuron was the only residue found in the faeces. Neither 4-chloroaniline (PCA), 4-chlorophenylurea (CPU) nor their n-hydroxyl derivatives were found in rat urine at a limit of detection of 0.4 ppb. It is suggested that 4-chloroanilin-2-sulfate, an aromatic amine, is responsible for the methaemoglobin formation seen in many studies.

#### Acute studies

Diflubenzuron had a very low acute mammalian toxicity *via* oral, dermal, inhalation administration. Diflubenzuron was neither irritant nor sensitizer in the animals tested.

The acute oral  $LD_{50}$  of diflubenzuron was > 5000 mg kg<sup>-1</sup> bw in rats and mice. No classification is required in accordance with the provisions of Council Directive 67/548/EEC. The acute dermal  $LD_{50}$  of diflubenzuron was > 10000 mg kg<sup>-1</sup> bw in rats. No classification is required in accordance with the provisions of Council Directive 67/548/EEC.

#### Short-term toxicity

## Oral

The oral short-term toxicity for diflubenzuron has been study in rat, mouse and dog. One 28-day study and three 90-day studies on the rat, two 90-day studies on the mouse, and one 90-day study and one 1-year study on the dog were presented with acceptable quality. The major detected adverse effects were increase of metheamoglobin and sulfhaemoglobin (as % of Hb), variations in organ weights (liver and spleen) and changes in haematological parameters.

In rat, the NOAEL after a 90-day exposure with diflubenzuron was less than less than 160 ppm (M/F < 11/14 mg kg<sup>-1</sup>day<sup>-1</sup>) based on increase in methaemoglobin, sulfhaemoglobin and spleen weight. In mouse, the lowest NOAEL was 80 ppm (M/F: 7.1 mg kg<sup>-1</sup>day<sup>-1</sup>), based on increase in methaemoglobin effects on liver, spleen and adrenal weights and changes haematological parameters. In dog, after 90-day of treatment with diflubenzuron the established NOAEL in males was 2 mg kg<sup>-1</sup>day<sup>-1</sup> based on increase methaemoglobin (%Hb) in the blood. At higher dose levels an increased liver weight was observed. Therefore, the NOAEL for this study was established to 2 mg kg<sup>-1</sup>day<sup>-1</sup> and the value has been considered relevant for the setting of ADI.

In most of the studies there are indications that Diflubenzuron causes anaemia. The RMS therefore suggests that Diflubenzuron should be labelled with R48 "Danger of serious damage to health by prolonged exposure".

In all studies where, it has been measured, it is an increase in sulfhaemoglobin and methhaemoglobin. There is a RIVM report dealing with Methaemoglobin/Heinz bodies an in summary they conclude that rat/mouse/rabbit/guinea pig/monkey are less sensitive to methhaemoglobin formation and generally show more effective reduction of induced MetHb than do man/dog/cat. If an effect on MetHb concentration is observed, it is by definition considered an adverse effect because an increase in MetHb levels is possible only when the capacity of the reducing mechanisms is exceeded. The exposure in question has then already reached such a level that considerable energy will be spent on reduction of MetHb and production of reticulocytes. This is certainly considered an adverse effect on a long term basis. RIVM (report 601516 007) 2001.

Formation of sulfhaemoglobin, unlike methaemoglobin, is not reversible and therefore considered to be of great toxic significance.

Changes in the blood parameters are seen in most studies:  $Hb\downarrow$ , PCV or  $Hct\downarrow$ , Erythrocyte counts $\downarrow$  and RBC  $\downarrow$  or $\uparrow$  and also increase in liver and spleen weights which all are indicative of anaemia.

Additional signs of anaemia on top of the ones mentioned above that occurred during exposure of 50 mg/kg bw/ day or less:

6.3.1.2(1) Oral 90-day rat study by Burdock

Dose dependent increased in grading of chronic hepatitis and liver haemosiderosis (incidence: zero for control, 50 % of the animals exposed to 27/34 mg/kg bw (M/F) and 100% of the animals exposed to the highest dose), congestion of the spleen and mild erythroid hyperplasia of the bone marrow.

6.3.1.3(1) Oral 6 week mouse study by Hunter (study used as complementary)Live necrosis in 3 out of 8 mice exposed to 6 mg/kg bw/day with or without inflammatory cells.

6.3.1.3(2) Oral 90-day mouse study by BurdockLiver necrosis, haemosiderosis and chronic hepatitis. The severity increased with dose.

6.3.1.3(3) Oral 90-day mouse study by Colley

Heinz bodies, increase in plasma glutamic pyruvic transaminase (indicating liver damage), discolouration and enlargement of the spleen, haemosiderosis in the spleen, liver areas of focal necrosis and /or fibrosis in the parenchyma with or without associated inflammatory cells, dose related increase in grey/blue discolouration of extremities.

6.3.1.4(1) Oral 90-day dog study by ChestermanIncrease in alkaline phosphatise and serum glutamic pyruvic transaminase.

6.3.1.4(3) Oral 90-day dog study by Greenough

Dose related increase in incidence and severity of macrophage and Kupffer cell siderosis, Heinz bodies, increase in LDH (indicating liver damage), and haemosiderosis in the liver.

The effects on haematological parameters were evaluated on the basis of the document presented by ECBI (ECBI/07/03 add.11). Considering the change in blood parameters, increased methaemoglobin and sulfhaemoglobin together with pathological effects like haemosiderosis and necrosis in the liver, enlargement and congestion of the spleen and effect of the boon marrow the RMS suggest R48 to be an appropriate classification.

#### Inhalation short-term toxicity

One 28-day inhalation study on rat and one on rabbit have been preformed with acceptable quality. In the rat study the NOAEL was 0.1 mg/L based on change in haematological parameters. In the rabbit study no adverse effects was observed up to a dose of 1.9 mg diflubenzuron/L air. RMS consider that since diflubenzuron has a low vapour pressure (<  $1.2 \times 10-7$  Pa at 25°C) and the exposure to operators during normal agricultural use is anticipated to be very low, the toxicity of diflubenzuron *via* inhalation doesn't need to be further investigated.

#### Dermal short-term toxicity

One 21-day and one 28-day in both rat and rabbit dermal studies, with acceptable quality, have been preformed. In rat, the NOAEL was established to 500 mg kg<sup>-1</sup>day<sup>-1</sup> based on increase in methaemoglobin and in rabbit the NOAEL was 150 mg kg<sup>-1</sup>day<sup>-1</sup> based on increased sulfhaemoglobin

#### Genotoxicity

Four *in vitro* studies were presented to predict the genotoxic potential of diflubenzuron. The systems used were: Ames Salmonella/microsome assay, malignant transformation in BAL/3T3 cells, cytogenetic assay for measuring chromosome aberration in Chinese hamster and primary culture of rat hepatocytes. All the assays were negative under the study conditions.

One *in vivo* micronucleus test in mice treated with diflubenzuron was presented with acceptable quality. Diflubenzuron was not mutagenic under the study conditions. One *in vivo* dominat lethal test in albino mice was presented and concluded as negative, however no positive control was presented and concluded as negative, however no positive control was presented and concluded as negative, however no positive control was presented and concluded as negative,

#### Long-term toxicity and carcinogenicity

Three studies (one in rat, mouse and dog) with acceptable quality have been evaluated. No tumour induction related to diflubenzuron was observed in these three studies.

In rat, the NOAEL was 156 ppm (7.8 mg kg<sup>-1</sup> day<sup>-1</sup>) based on increased methaemoglobin and sulfhaemoglobin at 625 followed by increased spleen weight (absolute and relative) in both sexes and increased liver weight (relative) in females at 2 500 ppm. In mouse, a NOAEL of 16 ppm (1.24/1.44 mg kg<sup>-1</sup> day<sup>-1</sup> M/F) can be derived from this study based on increased Methaemoglobin and sulfhaemoglobin seen in both sexes at 80 ppm. After 1-year treatment the NOAEL in dog was 2 mg kg<sup>-1</sup>day<sup>-1</sup> in both sexes, based on increased Methaemoglobin at 10 mg kg<sup>-1</sup>day<sup>-1</sup> followed by changes on liver, spleen and brain weights changes in and blood parameters. The NOAEL established for the mouse, 1.2 mg kg<sup>-1</sup>day<sup>-1</sup> was considered relevant for the setting of ADI.

In most of the studies there are indications that Diflubenzuron causes anaemia. The RMS therefore suggests that Diflubenzuron should be labelled with R48 "Danger of serious damage to health by prolonged exposure".

In all studies, where it has been measured, it is an increase in sulfhaemoglobin and methaemoglobin. There is a RIVM report dealing with Methaemoglobin/Heinz bodies an in summary they conclude that rat/mouse/rabbit/guinea pig/monkey are less sensitive to methaemoglobin formation and generally show more effective reduction of induced MetHb than do man/dog/cat. If an effect on MetHb concentration is observed, it is by definition considered an adverse effect because an increase in MetHb levels is possible only when the capacity of the reducing mechanisms is exceeded. The exposure in question has then already reached such a level that considerable energy will be spent on reduction of MetHb and production of reticulocytes. This is certainly considered an adverse effect on a long term basis. RIVM (report 601516 007) 2001.

Formation of sulfhaemoglobin, unlike methaemoglobin, is not reversible and therefore considered to be of great toxic significance.

Changes in the blood parameters are seen in most studies:  $Hb\downarrow$ , PCV or  $Hct\downarrow$ , Erythrocyte counts $\downarrow$  and RBC  $\downarrow$  or $\uparrow$  and also increase in liver and spleen weights which all are indicative of anaemia.

Additional signs of anaemia on top of the ones mentioned above that occurred during exposure of 50 mg/kg bw/ day or less:

#### 6.5.2(1) Carcinogenicity study in rat by Burdock

Compound-related increase in haemosiderosis of spleen and liver, marrow hyperplasia, erythroid hyperplasia and distended marrow spaces (males) and thyroid hyperplasia (female) at al dose levels.

6.5.4(1) Chronic toxicity and carcinogenicity study on mouse by Colley

Discolouration of extremities, Heinz bodies, increased extra medullary haemopoesis in spleen, siderocytosis in spleen and hepatocytes enlargement.

The effects on haematological parameters were evaluated on the basis of the document presented by ECBI (ECBI/07/03 add.11). Considering the change in blood parameters, increased methaemoglobin and sulfhaemoglobin together with pathological effects like haemosiderosis in liver and spleen, and effect of the boon marrow the RMS suggest R48 to be an appropriate classification.

## **Reproduction toxicity**

#### *Multigeneration*

One two-generation study in rat of acceptable quality was presented. The LOAEL was established to 30 mg kg<sup>-1</sup>day<sup>-1</sup> based on increased of liver and spleen weight in correlation with histopatological changes and variations in blood parameters. No NOAEL could be established in the study. However, no treatment related reprotoxic effects were observed.

In most of the studies there are indications that Diflubenzuron causes anaemia. The RMS therefore suggests that Diflubenzuron should be labelled with R48 "Danger of serious damage to health by prolonged exposure".

In all studies, where it has been measured, it is an increase in sulfhaemoglobin and methaemoglobin. There is a RIVM report dealing with Methaemoglobin/Heinz bodies an in summary they conclude that rat/mouse/rabbit/guinea pig/monkey are less sensitive to methaemoglobin formation and generally show more effective reduction of induced MetHb than do man/dog/cat. If an effect on MetHb concentration is observed, it is by definition considered an adverse effect because an increase in MetHb levels is possible only when the capacity of the reducing mechanisms is exceeded. The exposure in question has then already reached such a level that considerable energy will be spent on reduction of MetHb and production of reticulocytes. This is certainly considered an adverse effect on a long term basis. RIVM (report 601516 007) 2001.

Formation of sulfhaemoglobin, unlike methaemoglobin, is not reversible and therefore considered to be of great toxic significance.

Changes in the blood parameters are seen in most studies:  $Hb\downarrow$ , PCV or  $Hct\downarrow$ , Erythrocyte counts $\downarrow$  and RBC  $\downarrow$  or $\uparrow$  and also increase in liver and spleen weights which all are indicative of anaemia.

Additional signs of anaemia on top of the ones mentioned above that occurred during exposure of 50 mg/kg bw/ day or less:

#### 6.6.1.3(1) Two-generation reproductive toxicity in rat by Brooker

Polychromasia, Howell-Jolly bodies, macroscopic changes in the spleen (enlargement, congestion, increased fluid-filled cysts), haemosiderosis in the spleen, centrilobular hepatocytes enlargement, pigmented Kuppfer cells.

The effects on haematological parameters were evaluated on the basis of the document presented by ECBI (ECBI/07/03 add.11). Considering the change in blood parameters, increased methaemoglobin and sulfhaemoglobin together with pathological effects like haemosiderosis in liver and spleen, and effect of the boon marrow the RMS suggest R48 to be an appropriate classification.

#### Teratogenicity

Two teratogenicity studies of acceptable quality, one in rat and one in rabbit, were presented. The NOAELs were  $\geq 1000 \text{ mg kg}^{-1} \text{ day}^{-1}$ . No maternal toxicity or any evidence of embryo toxicity was found.

#### **Delayed neurotoxicity**

Diflubenzuron is neither an organophosphorous nor a carbamate compound. Therefore, specific neurotoxicity testing is not deemed necessary. In all acute, sub-acute, semi-chronic and chronic toxicity studies no effect whatsoever indicative for or related to neurotoxic properties was found.

Table B.6.10-1: Summary of diflubenzuron repeated dose toxicity studies with acceptable quality

Study	Dose levels	Adminis-	NOAEL/	LOAEL/	Target organ and effects
		tration way	NOEL	LOEL	

Study	Dose levels	Adminis-	NOAEL/	LOAEL/	Target organ and effects
Study		tration	NOEL	LOEL	inger organ and eneets
		way			
ORAL:					
28-day in rat					
Palmer <i>et al</i> .	0, 81/87,	Oral via dietary	M/F:81/87	M/F:430/420 mg	↑ MetHb
1977	430/420, 2 000/2 100 and	mixture	тд кд аау	kg day	↑ SulfHb
	10 500		800 nnm		↑ Spleen weight
	mg kg <sup>-1</sup> day <sup>-1</sup> (M/F)		ooo hhuu	4 000 ppm	↑ Liver weight (100 000 ppm)
					Haematological changes
	0, 800, 4 000, 20 000 and 100 000 ppm				(100 000 ppm)
90-day in rat					
Kemp, <i>et al</i>	0, 0.3/0.4,	Oral via	NOAEL:	LOAEL:	
1977; Offringa, 1977	1.1/1.6, 4.2/6.3 and $17/26$	mixture	M/F:≥ 17/26 mg kg <sup>-1</sup> day <sup>-1</sup>	M/F:≥ 17/26 mg kg <sup>-1</sup> day <sup>-1</sup>	
	(M/F)		≥ 200 ppm	≥ 200 ppm	
			NOEL:	LOEL:	Organ weights of testis and
	0, 3.125, 12, 50 and 200 ppm		$M/F:\ge 4.2/6.3$ mg kg <sup>-1</sup> day <sup>-1</sup>	M/F: 17/26 mg kg <sup>-1</sup> day <sup>-1</sup>	adrenals Haemological parameters
			50 ppm	200 ppm	
Burdock <i>et al</i>	0, 11/14, 27/34,	Oral via	NOAEL:	LOAEL:	↑ MetHb
1980; Goodman 1980	and 3 700/4 400 $\text{mg kg}^{-1}$ day <sup>-1</sup>	mixture	M/F:<11/14 mg kg <sup>-1</sup> day <sup>-1</sup>	M/F:27/34 mg kg <sup>-1</sup> day <sup>-1</sup>	↑SulfHb
	(M/F)		160 ppm	400 ppm	<b>↑Spleen weight</b>
	0, 160, 400, 2 000, 10 000 and 50 000 ppm				
Hunter <i>et al</i>	0, 1 000 and 10	Oral via	<1 000 mg kg <sup>-1</sup> day <sup>-1</sup>	<1 000	↑ MetHb
1979	$mg kg^{-1} dav^{-1}$	mixture	<pre></pre>	10 000 nnm	<b>↑Spleen weight</b>
	ing ng - uuy		i ooo ppm	i o ooo ppin	Histophatological changes in spleen
	0, 10 000 and 100 000 ppm				Changes in haematological parameters
90-day in mouse					
Burdock et al	0, 2.3, 7.1, 57,	Oral via	NOAEL	LOAEL	↑ MetHb in both sexes
1980	290, 1400  and 7 100	mixture	M/F:7.1 mg kg <sup>-1</sup> day <sup>-1</sup>	M/F:290/1 400 mg kg <sup>-1</sup> day <sup>-1</sup>	↑ Organ weights: liver, spleen and adrenals
	шуку цау		M/F: 50 ppm	M/F: 2 000/10 000	Histophatological changes in liver
	0, 16, 50, 400,			ррш	

G4 J	Developeda	A 1			The sector sector is the first sector
Study	Dose levels	tration	NOAEL/	LOAEL/	l arget organ and effects
		way	NOEL	LOEL	
	2 000, 10 000 and				
	50 000 ppm				
Colley <i>et al</i> 1981	0/0, 9.7/11, 51/55, 240/290,	Oral via dietary	NOAEL M/F: 9.7/11	LOAEL M/F: 51/55	↑Increase in MetHb (%Hb)
	1 200/1 400, 6 000/7 500 mg kg <sup>-1</sup> day <sup>-1</sup>	mixture	$mg kg^{-1} day^{-1}$	$mg kg^{-1} day^{-1}$	↑Increase in SulfHb (%Hb
	(M/F)		oo pp	Pp	↑ Organ weights: liver and spleen (2 000 ppm)
	0, 80, 400, 2 000, 10 000 and 50 000 ppm				Histophatological changes in liver and spleen (2 000 ppm)
					↑ spleen weights (80 ppm)
90-day in dog					
Versendaal <i>et al</i> 1983	0, 2, 4, 50 and 250 mg kg <sup>-1</sup> day <sup>-1</sup>	Oral <i>via</i> gavage/	NOAEL 4 mg kg <sup>-1</sup> day <sup>-1</sup>	LOAEL 50 mg kg <sup>-1</sup> day <sup>-1</sup>	↑Increase in MetHb (%Hb)
		gelatine capsules	→ mg kg uay	50 mg kg uay	↑ M: liver weight (250 mg kg <sup>-1</sup> day <sup>-1</sup> )
1-year in dog					
Greenough <i>et</i> <i>al</i> 1985	0, 2, 10, 50 and 250 mg kg <sup>-1</sup> day <sup>-1</sup>	Oral via gavage/	NOAEL	LOAEL	↑Increase in MetHb (%Hb)
		gelatine capsules	2 mg kg uay	to mg kg day	Changes on organ weights and
					Histopatological changes (50 mg kg <sup>-1</sup> day <sup>-1</sup> )
INHALATION:					
28-day in rat					
Newton <i>et al</i>	0, 11.6, 34 and	Inhalation	NOAEL	LOAEL	Changes in haematological
1999	109 mg/L air		109 mg/L air	≥ 109 mg/L air	parameters
28-day in rabbit					
Berczy et al	0, 015, 0.75 and	Inhalation	NOAEL	LOAEL	
1975	1.9 mg/L air		≥ 1.9 mg/L air	≥ 1.9 mg/L air	
"Study used of restricted quality"					

Stud-	Dece less la	A d	NOAEL /	LOAFL /	Tongot or an 1 . ee (
Study	Dose levels	Adminis- tration way	NOAEL/ NOEL	LOEL	rarget organ and effects
DERMAL:			-		
21-day in rat					
Goldenthal, E.I (1996)	0, 20, 500, 1 000 kg <sup>-1</sup> bw day <sup>-1</sup>	Dermal	NOAEL	LOAEL	Increased methaemoglobin
21-day dermal toxicity study in rats			500 kg <sup>-1</sup> bw day <sup>-1</sup>	1 000 kg <sup>-1</sup> bw day <sup>-1</sup>	Increased sulfhaemoglobin
28-day in rabbit					
Davies <i>et al.</i> (1975b)	0, 70, 150 and 322 mg kg <sup>-1</sup> bw day <sup>-1</sup>	Dermal	NOAEL 150 mg kg <sup>-1</sup> day <sup>-1</sup>	LOAEL 322 mg kg <sup>-1</sup> day <sup>-1</sup>	Increased sulfhaemoglobin
ORAL					
Rat 1-year					
104 weeks	0, 7.8, 31, 120 and	Oral via	NOAEL/NOEL;	LOAEL/LOEL:	Increased
(2 years) in rat	500 mg kg <sup>-1</sup> day <sup>-1</sup>	the diet	7.8 mg kg <sup>-1</sup> day <sup>-1</sup>	120 mg kg <sup>-1</sup> day <sup>-</sup>	methaemoglobin
Burdock <i>et al.</i> 1984	0, 156, 625, 2 500		156 ppm	2 500 ppm	Increased sulfhaemoglobin
	and 10 000 ppm				Increased spleen weight (30-61%) at 2 500 ppm, both sexes
					Increased adjusted liver weight (28%) at 2500 ppm, females
					No tumour induction related to diflubenzuron was observed.
Mouse					
<b>91 weeks</b> Colley, et al. 1984	0, 1.2/1.4, 6.4/7.2, 32/35, 160/190 and 835/958 mg kg <sup>-1</sup> day <sup>-1</sup> (M/F) 0, 16, 80, 400, 2 000 and 10 000 ppm	Oral <i>via</i> the diet	NOAEL M/F:1.24/1.44 mg kg <sup>-1</sup> day <sup>-1</sup> 16 ppm	LOAEL M/F:6.4/7.2 mg kg <sup>-1</sup> day <sup>-1</sup> 80 ppm	Increased methaemoglobin Increased sulfhaemoglobin Methaemoglobinemia >2% associated with Heinz bodies at 400 ppm, both sexes
D					No tumour induction related to diflubenzuron was observed.
Dog					

Study	Dose levels	Adminis-	NOAEL/	LOAEL/	Target organ and effects
		tration way	NOEL	LOEL	
1-year	0, 2, 10, 50 and $250 \text{ mg } \text{kg}^{-1} \text{day}^{-1}$	Oral via	NOAEL	LOAEL	Increased
Greenough et	2.50 mg kg day	gelatine	2 mg kg <sup>-1</sup> day <sup>-1</sup>	10 mg kg <sup>-1</sup> day <sup>-1</sup>	methaemoglobin
104 weeks	$500 \text{ mg kg}^{-1} \text{ day}^{-1}$	capsules			Changes on organ weights
(2 years) in rat		the diet			Histopatological
Burdock <i>et al.</i> 1984	0, 156, 625, 2 500 and 10 000 ppm				changes at 50 mg kg <sup>-1</sup> <sup>1</sup> day <sup>-1</sup>
MULTI-GENERA	TION:				
Two generation/ra	t				
Brooker 1995	0, 30, 300 and 3 200	Oral via dietary	<30 mg kg <sup>-1</sup> day <sup>-1</sup>	≤ 30 mg kg <sup>-1</sup> day <sup>-1</sup>	Increased methaemoglobin
	mg kg <sup>-1</sup> day <sup>-1</sup> 0, 500, 5 000 and 50 000 ppm	mixture	500 ppm	500 ppm	Increase of liver and spleen weights and histopatological changes
					Non effect on reproduction was observed in this study.
TERATOGENICI	TY:				
Rat					
Kavanagh <i>et al</i> .	0, 1 000	Orally by	NOAEL/NOEL	LOAEL/LOEL	No maternal or any
1987	mg kg <sup>-1</sup> day <sup>-1</sup>	gavage	≥ 1 000 mg kg <sup>-1</sup> day <sup>-1</sup>	≥ 1 000 mg kg <sup>-1</sup> day <sup>-1</sup>	evidence of embryotoxicity
Rabbit					
Kavanagh <i>et al</i> .	0, 1000	Orally by	NOAEL/NOEL	LOAEL/LOEL	No maternal toxicity
19870	mg kg <sup>-</sup> ' day <sup>-</sup> '	gavage	≥ 1 000 mg kg <sup>-1</sup> day <sup>-1</sup>	≥ 1 000 mg kg <sup>-1</sup> day <sup>-1</sup>	or any evidence of embryo toxicity
M = male; F = fem	ale				

## **B.6.10.8** Acceptable daily intake (ADI)

The chronic studies in rat, mice, and dog were considered appropriate studies to use as a basis for the ADI. See Table B.6.10.8-1 for a summary of the NOAEL/NOELs observed in these studies.

The observed effects after diflubenzuron treatment in rats, mouse and dogs were increase in methaemoglobin and sulfhaemoglobin, changes in other blood parameters, increased organ weights (liver and spleen in rat and dog and brain in dog). The most sensitive species was the male mouse showing increased met- and sulfhaemoglobin at a dose of 1.2 mg kg<sup>-1</sup> day<sup>-1</sup> (Colley *et al.*, 1984) followed by changes in other blood parameters, formation of Heinz bodies, increased siderocytosis and extramedullary haemopoesis in spleen, hepatocytes enlargement and pigmented Kupffer cell pigmentation in higer concentrations. **The NOEL was established to 1.2 mg kg<sup>-1</sup>day<sup>-1</sup> from the mouse 91 weeks study. Therefore, by applying a 100-fold safety factor to 1.2 mg kg<sup>-1</sup>day<sup>-1</sup>, the proposed ADI is 0.012 mg kg<sup>-1</sup>day<sup>-1</sup>.** 

The notifier disagreed with the setting of ADI and had the opinion that the NOAEL of 2 mg/kg bw/day, from the dog study, should be used.

Study	Dose levels	Adminis-	NOAEL/	LOAEL/	Target organ and effects
	way	way	NOEL	LOEL	
Rat					
104 weeks	$0, 7.8, 31, 120$ and $500 \text{ mg kg}^{-1} \text{ dav}^{-1}$	Oral <i>via</i> the diet	NOAEL/NOEL: 7.8 mg kg <sup>-1</sup> day <sup>-1</sup>	LOAEL/LOEL: 120 mg kg <sup>-1</sup> dav <sup>-1</sup>	Increased methaemoglobin
(2 years) in rat	500 mg kg day		156 ppm	2 500 ppm	Increased sulfhaemoglobin
Burdock et al. 1984	0, 156, 625, 2 500 and 10 000 ppm				Increased spleen weight (30-61%) at 2 500 ppm, both sexes
					Increased adjusted liver weight (28%) at 2500 ppm, females
					No tumour induction related to diflubenzuron was observed.
Mouse					
91 weeks	0, 1.2/1.4, 6.4/7.2,	Oral via	NOAEL	LOAEL	Increased methaemoglobin
al. 1984	32/35, 160/190 and 835/958 mg kg <sup>-1</sup> day <sup>-1</sup> (M/E)	the diet	M/F:1.24/1.44 mg kg <sup>-1</sup> day <sup>-1</sup>	M/F:6.4/7.2 mg kg <sup>-1</sup> day <sup>-1</sup>	Increased sulfhaemoglobin
	0, 16, 80, 400, 2		16 ppm	80 ppm	Methaemoglobinemia >2% associated with Heinz bodies at 400 ppm, both

#### B.6.10.8-1. Summary of the NOAEL/NOEL observed in the chronic studies

Study	Dose levels	Adminis- tration way	NOAEL/ NOEL	LOAEL/ LOEL	Target organ and effects
	000 and 10 000 ppm				sexes No tumour induction related to diflubenzuron was observed
Dog					was observed
1-year	0, 2, 10, 50 and 250	Oral via	NOAEL	LOAEL	Increased methaemoglobin
<b>Greenoug</b> mg kg <sup>-1</sup> day <sup>-1</sup>	mg kg <sup>-1</sup> day <sup>-1</sup>	gavage/ gelatine	2 mg kg <sup>-1</sup> day <sup>-1</sup>	10 mg kg <sup>-1</sup> day <sup>-1</sup>	Changes on organ weights
1985		capsules			Histopatological changes at 50 mg kg <sup>-1</sup> day <sup>-1</sup>
M = male; F	= female				

# B.6.10.9 Acceptable operator exposure level (AOEL).

Table B.6.10.9-1 Summary of repeated toxicity studies suitable for setting AOEL

Study	Dose levels	Adminis- tration	NOAEL/	LOAEL/	Target organ and effects	
		way	NOEL	LOEL		
ORAL:	-	-	-		-	
28-day in rat						
Palmer <i>et al.</i>	0, 81/87,	Oral via	M/F:81/87	M/F:430/420 mg	↑ MetHb	
1977	430/420, 2 000/2 100 and	mixture	mg kg <sup>-1</sup> day <sup>-1</sup>	kg <sup>-1</sup> day <sup>-1</sup>	↑ SulfHb	
	10 500		800		↑ Spleen weight	
	mg kg <sup>-1</sup> day <sup>-1</sup> (M/F)	mg kg <sup>-1</sup> day <sup>-1</sup> 800 ppm 4 000 ppm (M/F)	4 000 ppm	↑ Liver weight (100 000 ppm)		
	0, 800, 4 000, 20 000 and 100 000 ppm				Haematological changes (100 000 ppm)	
90-day in rat						
Kemp, <i>et al</i>	0, 0.3/0.4,	Oral via	NOAEL:	LOAEL:		
1977; Offringa, 1977	1.1/1.6, 4.2/6.3 and 17/26	mixture	mixture	M/F:≥ 17/26 mg kg⁻¹ day⁻¹	M/F:≥ 17/26 mg kg <sup>-1</sup> day <sup>-1</sup>	
	mg kg <sup>+</sup> day <sup>+</sup> (M/F)		≥ 200 ppm	≥ 200 ppm		
			NOEL:	LOEL:	Organ weights of testis and	
	0, 3.125, 12, 50 and 200 ppm		$M/F:\ge 4.2/6.3$ mg kg <sup>-1</sup> day <sup>-1</sup>	M/F: 17/26 mg kg <sup>-1</sup> day <sup>-1</sup>	Haemological parameters	
			50 ppm	200 ppm		

Study	Dose levels	Adminis-	NOAEL/	LOAEL/	Target organ and effects		
		tration way	NOEL	LOEL			
Burdock et al	0, 11/14, 27/34,	Oral via	NOAEL:	LOAEL:	↑ MetHb		
1980; Goodman 1980	140/160, 690/890 and 3 700/4 400	dietary mixture	dietary mixture	dietary mixture M/F:<11/14	M/F:<11/14	M/F:27/34	↑SulfHb
	mg kg <sup>-1</sup> day <sup>-1</sup> (M/F)		mg kg <sup>2</sup> day <sup>2</sup>	mg kg <sup>2</sup> day <sup>2</sup>	<b>↑Spleen weight</b>		
	((()))		100 ppm	400 ppm			
	0, 160, 400, 2 000, 10 000 and 50 000 ppm						
Hunter <i>et al</i>	0, 1 000 and 10	Oral via	<1 000 mg kg <sup>-1</sup> day <sup>-1</sup>	<1 000 mg kg <sup>-1</sup> day <sup>-1</sup>	↑ MetHb		
1979	mg kg <sup>-1</sup> dav <sup>-1</sup>	mixture	<pre></pre>	<pre>/// // // // // // // // // // // // //</pre>	<b>↑Spleen weight</b>		
	ing kg duy		i ooo ppm	40 000 ppm	Histophatological changes in spleen		
	0, 10 000 and 100 000 ppm				Changes in haematological parameters		
90-day in mouse							
Burdock <i>et al</i>	0, 2.3, 7.1, 57,	Oral via	NOAEL	LOAEL	↑ MetHb in both sexes		
1900	<b>980</b> 290, 1400 and 7 100	mixture	M/F:7.1 mg kg <sup>-1</sup> day <sup>-1</sup>	M/F:290/1 400 mg kg <sup>-1</sup> day <sup>-1</sup>	↑ Organ weights: liver, spleen and adrenals		
	mg kg <sup>+</sup> day <sup>+</sup>		M/F: 50 ppm	M/F: 2 000/10 000	Histophatological changes in liver		
	0, 16, 50, 400, 2 000, 10 000 and 50 000 ppm			ppm			
Colley <i>et al</i> 1981	0/0, 9.7/11, 51/55, 240/290,	Oral via dietary	NOAEL M/F: 9.7/11	LOAEL M/F: 51/55	↑Increase in MetHb (%Hb)		
	1 200/1 400, 6 000/7 500 mg kg <sup>-1</sup> dav <sup>-1</sup>	mixture	$mg kg^{-1} day^{-1}$	$mg kg^{-1} day^{-1}$	↑Increase in SulfHb (%Hb		
	(M/F)		oo ppm	400 ppm	↑ Organ weights: liver and spleen (2 000 ppm)		
	0, 80, 400, 2 000, 10 000 and 50 000 ppm				Histophatological changes in liver and spleen (2 000 ppm)		
					↑ spleen weights (80 ppm)		
90-day in dog							
Versendaal <i>et</i> <i>al</i> 1983	0, 2, 4, 50 and 250 mg kg <sup>-1</sup> day <sup>-1</sup>	Oral <i>via</i> gavage/	NOAEL	LOAEL	↑Increase in MetHb (%Hb)		
		gelatine capsules	<b>⊣</b> шg кg uay	JU MY KY UAY	↑ M: liver weight (250 mg kg <sup>-1</sup> day <sup>-1</sup> )		
1-year in dog							
Greenough et	0, 2, 10, 50 and	Oral via	NOAEL	LOAEL	↑Increase in MetHb		
al 1985	250 mg kg 'day '	gavage/ gelatine	2 mg kg <sup>-1</sup> day <sup>-1</sup>	10 mg kg <sup>-1</sup> day <sup>-1</sup>	(%HD)		
		-			Cnanges on organ		

Study	Doso lovala	Adminia	NOAEL /	I A FI /	Targat angan and affasts
Sludy	Dose levels	tration	NOEL	LUALL/	rarget organ and effects
		way	NUEL	LUEL	
		capsules			weights and
					Histopatological changes (50 mg kg <sup>-1</sup> day <sup>-1</sup> )
INHALATION:					
28-day in rat					
Newton <i>et al</i>	0, 11.6, 34 and	Inhalation	NOAEL	LOAEL	Changes in haematological
1999	109 mg/L air		109 mg/L air	≥ 109 mg/L air	parameters
28-day in rabbit					
Berczy <i>et al</i> 1975	0, 015, 0.75 and 1.9 mg/L air	Inhalation	NOAEL	LOAEL	
"Study used of restricted quality"	C		≥ 1.9 mg/L air	≥ 1.9 mg/L air	
DERMAL:					
21-day in rat					
Goldenthal,	0, 20, 500, 1 000 mg $kg^{-1}$ by $day^{-1}$	Dermal	NOAEL	LOAEL	↑Increase in MetHb and
E.I (1996)	ing kg low day		500 mg kg <sup>-1</sup> bw day <sup>-1</sup>	1 000 mg kg <sup>-1</sup> bw day <sup>-1</sup>	Sumi (70115)
28-day in rabbit					
Davies <i>et al.</i>	0, 70, 150 and	Dermal	NOAEL	LOAEL	
(19750)	322 mg kg <sup>-1</sup> bw day <sup>-1</sup>		150	322	
			mg kg <sup>-1</sup> day <sup>-1</sup>	mg kg <sup>-1</sup> day <sup>-1</sup>	
MULTI-GENERA	ATION:				
Two generation/rd	at				
Brooker 1995	0, 30, 300 and 3 200	Oral via dietary mixture	<30 mg kg <sup>-1</sup> day <sup>-1</sup>	≤ 30 mg kg <sup>-1</sup> day <sup>-1</sup>	Increased methaemoglobin
	0, 500, 5 000 and 50 000 ppm		500 ppm	500 ppm	Increase of liver and spleen weights and histopatological changes Non effect on
					reproduction was observed in this study.

December 2008

Study	Dose levels	Adminis- tration way	NOAEL/ NOEL	LOAEL/ LOEL	Target organ and effects	
TERATOGENICITY:						
Rat						
Kavanagh <i>et al</i> .	0, 1 000	Orally by	NOAEL/NOEL	LOAEL/LOEL	No maternal or any	
1987	mg kg <sup>-1</sup> day <sup>-1</sup>	gavage	≥ 1 000 mg kg <sup>-1</sup> day <sup>-1</sup>	≥ 1 000 mg kg <sup>-1</sup> day <sup>-1</sup>	evidence of embryotoxicity	
Rabbit						
Kavanagh <i>et al</i> .	0, 1 000	Orally by	NOAEL/NOEL	LOAEL/LOEL	No maternal toxicity	
1987b	mg kg <sup>-1</sup> day <sup>-1</sup>	gavage	≥ 1 000 mg kg <sup>-1</sup> day <sup>-1</sup>	≥ 1 000 mg kg <sup>-1</sup> day <sup>-1</sup>	or any evidence of embryo toxicity	
M = male; F = female						

According to the guideline of setting the AOEL<sup>1</sup>, the NOAEL for effects in the long-term studies (including 1 year dog) should be considered in AOEL setting if there are indicators that effects only become evident in chronic studies but might be initiated by shorter term exposure. Metabolism studies demonstrated that diflubenzuron is poorly absorbed from the intestinal tract, high levels of non-absorbed diflubenzuron was found in the faeces. The oral absorption was approx. 33%. In the subchronic studies, the lowest relevant NOAEL was 2 mg kg<sup>-1</sup>day<sup>-1</sup> in dog after an oral administration of diflubenzuron. The proposed AOEL is 2 mg kg<sup>-1</sup>day<sup>-1</sup>, applying a 100-fold safety factor to the relevant dose and an oral absorption of 33%.

$$AOEL = \frac{NOAEL \text{ x oral absoption}}{Safety \text{ factor}} \frac{2 \text{ mg kg}^{-1} \text{day}^{-1} \times 33\%}{100} = 0.0066 \text{ mg kg}^{-1} \text{day}^{-1}$$

# The major effect observed at the Lowest Observed Adverse Effect Level (LOAEL) was increase in methaemoglobin and sulfhaemoglobin.

The notifier disagreed with the setting of AOEL and had the opinion that the NOAEL of 20 mg/kg bw/day, from the dermal rat study (Goldenthal 1996), should be used, as operators will not be exposed to diflubenzuron every day of the year. The notifier expect fewer than 28 exposures per year for operators and in most situations fewer than 5 exposures per day.

<sup>&</sup>lt;sup>1</sup> AOEL Guideline for setting of acceptable operator exposure levels (AOELs). Draft. Sanco/xxx/2005 rev.8, 27 January 2005

## **B.6.10.10** Acute reference dose (ARfD)

## Reporting table, mammalian toxicity, 2(11)

Methaemoglobin can be an acute effect. However, Diflubenzurone has very low acute toxicity when given by various routs (oral, dermal, inhalation). There are recovery systems for increase in methaemoglobin so most likely one single acute dose is not critical but it is the repeated doses that overwhelm the reducing system and affects the whole body that is critical. Thus according to the toxicological profile of Diflubenzuron the RMS suggest that establishing an ARfD is unnecessary.

However, if an ARfD have to be set; the most striking effect of Diflubenzuron is increase in methaemoglobin and sulfhaemoglobin. In the 28-day study in rat by Palmer et al 1977 these effects were seen in both sexes at around 80 mg kg<sup>-1</sup> day<sup>-1</sup> = LOAEL. Applying a safety factor for inter- and intraspecies differences of 100 and a factor 2 for extrapolation from LOAEL to NOAEL results in an ARfD of 0.4 mg kg<sup>-1</sup> day<sup>-1</sup>.

The Notifier's opinion is that no ARfD has to be set and the 24<sup>th</sup> of February 2007 RMS received a document by e-mail from Chemtura with the title "Rationale in Support of the Removal of the Acute Reference Dose (ARfD)", see below.



## PRODUCT Diflubenzuron

## STUDY TITLE Rationale in Support of the Removal of the Acute Reference Dose (ARfD)

## **AUTHOR**

PERFORMING INSTITUTION Chemtura Corporation

> STUDY NUMBER EF002

DATE 05 February 2007

Chemtura Corporation 199 Benson Road Middlebury, CT 06749 USA T: 203-573-2000 F: 203-573-4531 www.chemtura.com

Page 1 of 8

;



Company:

#### STATEMENT OF NO DATA CONFIDENTIALITY CLAIMS

No claim of confidentiality is made for any information contained in this study on the basis of its falling within the scope of FIFRA 10 (d) (1) (A), (B) or (C).

CHEMTURA CORPORATION

These data are the property of the Chemtura Corporation, and as such, are considered to be confidential for all purposes other than compliance with FIFRA Section 10. Submission of these data in compliance with FIFRA does not constitute a waiver of any right to confidentiality that may exist under any statue or in any other country.

Page 2 of 8

÷



## GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT

The information complied herein is not a study as defined in FR 54 (158): 34068, and therefore a Good Laboratory Practice Compliance Statement is not required.

Submitter/Sponsor/Approver



Page 3 of 8

1



## TABLE OF CONTENTS

Statement of No Data Confidentiality Claims		
Compliance with Good Laboratory Practices		
Table of Contents		
Purpose	5	
Summary	5	
<ul> <li>Rationale for the Removal of the Acute Reference Dose (ARfD)</li> <li>I. The decision of the US EPA FIFRA in regards to the ARfD for diflubenzuron</li> <li>II. The decision of the FAO/WHO in regards to the ARfD for diflubenzuron</li> <li>III. General Considerations on the derivation of an ARfD IV. Sensitive populations discussion</li> </ul>	5	
Conclusion	7	
References	8	

Page 4 of 8

:



#### PURPOSE

To provide rationale in support of the removal of the acute reference dose (ARfD) for diflubenzuron.

#### SUMMARY

Chemtura contends that an Acute Reference Dose (ARfD) is not warranted for diflubenzuron. This position is supported by both the US EPA and the FAO/WHO. Diflubenzuron is not acutely toxic. Exposure to diflubenzuron via food or water will not result in any biological relevant change in methaemoglobinemia (MetHb) levels, even in sensitive populations. There should not be an ARfD for diflubenzuron.

## **RATIONALE FOR THE REMOVAL OF THE ACUTE REFERENCE DOSE (ARfD) FOR DIFLUBENZURON**

I. The Decision of the US EPA FIFRA in regards to the ARfD for diflubenzuron.

Diflubenzuron is not acutely toxic (LD50s > 4640 mg/kg orally, >10000 mg/kg dermally, > 3.7 mg/L inhalation). According to the US EPA RED document, one day single dose oral studies in rats and mice indicated only marginal effects on methaemoglobinemia (MetHb) levels at a dose level of 10000 mg/kg of a 25% wettable powder formulation (2500 mg/kg bw of diflubenzuron).<sup>1,2</sup> Sulfhaemoglobin levels and Heinz bodies were not affected. Therefore according to the EPA assessment, there is no acute dietary endpoint and a risk assessment for acute dietary exposure is not necessary.<sup>3</sup>

II. The Decision of the FAO/WHO in regards to the ARfD for diflubenzuron.

FAO/WHO has also concluded that the ARfD is not necessary. The Meeting concluded that, although MetHb is potentially an acute effect, the overall

Page 5 of 8



toxicological profile of diflubenzuron indicates that establishment of an ARfD is unnecessary. The absorption of diflubenzuron declined with increasing doses, and its excretion was relatively rapid, which would tend to limit systemic concentrations after high acute doses. The meeting also concluded that MetHb and sulfhaemoglobinemia occurred only after saturation of reduction processes in the toxicological database.

Diflubenzuron has very low acute toxicity when given by various routes (oral, dermal and inhalation). The results of acute toxicity studies show that diflubenzuron (purity, 99.6%) has little acute toxicity when given by the oral, inhalation or dermal route. The LD50 in mice and rats given diflubenzuron in 1% tragacanth by gavage was > 4600 mg/kg bw (van Eldik, 1973). In rats treated dermally for 24 h, the  $LD_{50}$  was > 10,000 mg/kg bw (Koopman, 1977), and in rats treated by whole-body inhalation of a preparation with a mass median aerodynamic diameter  $< 5 \mu m$ , the LC<sub>50</sub> was > 2.9 mg/l of air (Berczy et al., 1973). No clinical signs were seen in these studies. Only marginal increases (less than doubling) in MetHb concentrations were seen in mice and rats given 10,000 mg/kg bw of a formulation of diflubenzuron, equivalent to 2500 mg/kg bw, which is above the limit doses used in toxicological tests.<sup>1,2</sup> No developmental toxicity was seen when diflubenzuron was given at up to a limit dose of 1000 mg/kg bw per day. There was no evidence of neurotoxicity in routine studies of toxicity.4

#### III. General Considerations on the derivation of an ARfD

Chemtura's position is that humans will not be exposed via food and water in one day to the amounts of diflubenzuron required to produce the minimal effects seen in the rat and mouse acute studies.<sup>1,2</sup> In addition to the extremely high levels of diflubenzuron required to be consumed to make even a non-relevant change in MetHb levels, the metabolism of diflubenzuron must also be considered in the evaluation for the need of an ARfD. Diflubenzuron is poorly absorbed from the gastrointestinal tract and, at a dose range of 5-100 mg/kg, absorption decreased with increased dose in the rat. High level of non-absorbed diflubenzuron was found in the faeces. The oral absorption was approximately 0.33% and absorbed radioactivity was almost completely removed by 24-48 hours. Taking the

Page 6 of 8



absorption, distribution, metabolism and excretion of diflubenzuron into consideration along with the toxicological database, there is no need for an ARfD. The doses required to result in even non-significant changes of MetHb will not be achieved upon acute exposure.

#### IV. Sensitive Populations

There are increased levels of MetHb over background levels (normal background levels are 1-2%) that do not clicit any clinical effects. Clinical symptoms are proportional to the level of MetHb; less than 10% MetHb is associated with no clinical symptoms.<sup>6</sup> This is in accordance with the JMPR Guideline for setting an ARfD which states that increased levels of MetHb in humans will not produce a biologically significant effect until over 6% MetHb, which is the threshold for the occurrence of clinical signs due to MetHb formation in sensitive individuals.<sup>7</sup> Understandably, the concern that the most sensitive population, those deficient in enzyme responsible for the reformation of haemoglobin from MetHb, should be protected. This is not a concern with diflubenzuron because the levels of MetHb produced by diflubenzuron will never be of clinical significance, even in a sensitive population.

#### CONCLUSION

In conclusion, Chemtura Corporation is in agreement with both US EPA and the FAO/WHO in that the assignment of an ARfD is not warranted for diflubenzuron. This is based on the lack of effects seen in toxicological testing, the non-biological relevance of the change in MetHb levels, as well as the metabolism and the limited potential exposure to diflubenzuron via food and water.

Page 7 of 8



#### REFERENCES

1. EPA Reregistration Elegibility Decision (RED) Diflubenzuron (1997). EPA 738-R-97-008. August 1997. <u>http://www.epa.gov/REDs/0144red.pdf</u>

2. Keet, C.M.J.F. (1977a) The effect of DU112307 WP 25% on the methaemoglobin, sulph-haemoglobin levels and Heinz body formation after a single oral administration in male mice Unpublished report No. 56645/12/77 from Philips Duphar, Netherlands. Submitted to WHO by Uniroyal Chemical Co. Inc., Bethany, CT, USA.

3. Keet, C.M.J.F. (1977b) The effect of DU112307 WP 25% on the methaemoglobin, sulph-haemoglobin and Heinz body formation after a single oral administration in rats. Unpublished report No. 56645/32/77 from Philips Duphar, Netherlands. Submitted to WHO by Uniroyal Chemical Co. Inc., Bethany, CT, USA.

4. Joint Meeting on Pesticide Residues (2001). Diflubenzuron Monograph. http://www.inchem.org/documents/jmpr/jmpmono/2001pr04.htm

5. European Commission (2001). Draft Guidance Document. Guidance for the Setting of an Acute Reference Dose (ARfD). 7199/VI/99 rev.5. http://ec.europa.eu/food/plant/protection/resources/7199\_vi\_99.pdf.

6. <u>Denshaw-Burke, M</u>. (2006) Methaemoglobinemia. http://www.emedicine.com/med/topic1466.htm

7. Solecki, R. (2005). <u>Guidance for Setting Acute Reference Doses (ARfD)</u> for pesticides. Food and Chemical Toxicology. 43. 1569-1593.

Page 8 of 8

## **B.6.10.11** Drinking water limit

Assuming that exposure through drinking water should not account for more than 10% of the ADI, an average consumption of 2 L of water per person per day and a body weight of 60 kg, the proposed drinking water limit for diflubenzuron is:

 $0.012 \text{ mg kg}^{-1}\text{day}^{-1} \ge 0.1 \ge 60 \text{ kg} \div 2 \text{ L} = 0.06 \text{ mg/L} = 36 \text{ }\mu\text{g/L}$ 

The maximum permissible concentration laid down by Council Directive 80/778/EEC is 0.1µg/L for pesticide active substances.

#### **Classification with R48**

As stated in section 6.10, diflubenzuron should be classified with R48 according to the RMS. The Notifier does not agree with this classification and RMS has received the following document from Chemtura called "Applicabillity of the R48 Classification to diflubenzuron".

Chemtura

#### Applicability of the R48 Classification to Diflubenzuron

August 21, 2007

The toxicology package for diflubenzuron was assessed in association with ECBI/07/03 Add. 11 (Proposal for criteria to be used in the classification of R48 for hemolytic anemia in repeated dose toxicity studies) The treatment related effects seen in the toxicity studies with diflubenzuron are not indicative of serious adverse effects. The assessment concluded that the classification of R48 is not warranted for diflubenzuron.

No serious systemic effects were demonstrated in any toxicity study with diflubenzuron. Repeated dose studies with diflubenzuron in the diet, by oral bolus dose in the form of a capsule, by inhalation or by dermal exposure, have not resulted in any deaths related to treatment. Dietary treatment levels were up to 100,000 ppm for 9 weeks in rats (7801/8539 mg/kg bw/day male and female respectively) (Hunter 1979). Clinical signs were not observed during dosing in any study. No decrease in life span for any animal species was noted in any repeated dose study. This demonstrates that the hematological effects of diflubenzuron treatment do not result in a decrease in overall health of the treated animal.

Repeated dose administration of diflubenzuron resulted in sub-clinical expression of anaemia, which was most likely due to extracellular hemolysis. The level of anaemia can be classified as sub-clinical because of the lack of clinical symptoms associated with treatment The decrease in hemoglobin(Hb) levels was not below the designated adverse level of 10% of in any of the studies. Methemoglobin (MetHb) levels were only above the level of concern (4% in rats, 2% in mice) at extremely high doses (400 ppm in mice and 100,000 ppm in rats). Furthermore, chronic administration of diflubenzuron resulted in a reduction in the expression of anaemia compared to those evident upon sub-chronic treatment. This negates the need for classification based on chronic sub-clinical methemoglobinemia.

ECBI/07/03 Add. 11 (Proposal for criteria to be used in the classification of R48 for hemolytic anemia in repeated dose toxicity studies) states that the decision for classification should be based on longest duration study. The longest duration studies in terms of time and percentage of lifespan covered are the combined chronic / carcinogenicity studies in rats and mice. In the rat studies, methaemoglobin levels do not exceed the >4% level of concern. The high dose level in the rat chronic study was 10,000 ppm (1% of the diet). The effects on hematology parameters are decreased or absent at 104 weeks when compared to the 52 week measurement. No clinical effects, deaths or decrease in life span was detected in the rat studies. The percent Hb levels in the chronic rat study were not-dose related. The decreases at 52 weeks of treated ranged from 7 - 8% at the high dose to 12% in females at 2500 ppm and males at 650 ppm at 52 weeks. The percent Hb increased at 104 weeks to 16% in the high dose males. The improvement in Hb levels along with improvements in erythrocyte levels, MCV and reticulocytes demonstrate a successful compensatory mechanism or an alleviation of the hemolytic effect. The increases in relative and absolute liver and spleen weights can be accounted for by the deposition of hemosiderin-like pigment. These are not direct adverse effects but are effects secondary to the hemolytic anaemia. The organs are not irreversibly damaged as shown by the recovery period after 7 weeks of treatment and 4 weeks of nontreatment. The pigment deposition is not accompanied by indications of severe anaemia. The results of the rat chronic/oncogenicity study demonstrate that the classification of R48 is not appropriate.

The chronic/carcinogenicity study in mice was also considered in this assessment. There was no affect on survival. Males in the 10000 ppm treatment group had statistically lower body weight at week 52. The Hb level in the same high dose males was significantly higher than controls at week 78 but were similar among all group at weeks 52 and 91 (termination). The MetHb levels were above the noted 2% of the total Hb level of concern in the male and female treatment groups at 400 ppm. However, as the DAR states, the statistically significant alterations are still within the normal range. Increases in spleen weight that were evident at the interim (52 weeks) were not present at terminal sacrifice. The results of the chronic toxicity/carcinogenicity mouse study furthers the determination that diflubenzuron does not warrant an R48 classification.

Administration of diflubenzuron to laboratory animals does not demonstrate severe anaemia or severe hemolytic anaemic effects. The effects demonstrated are subclinical and reversible. Based on the entire toxicological database and especially the long term studies, the classification of R48 is not warranted.

**R48** Danger of serious damage to health by prolonged exposure; *Clear functional disturbance or morphological change which has toxicological significance.* 

- Particularly important when changes are irreversible
  - Not the case with Diflubenzuron (DFB dietary treatment with recovery period demonstrated a recovery or decrease in severity of all symptoms. Furthermore, chronic studies demonstrated a recovery upon prolonged treatment
- Classification depends on dose level, exposure period and dose route
  Even at extreme dose levels of DFB (1% of the diet), no
  - clinical signs of anaemia were present
- If studies of multiple durations are available, the study of the longest duration should normally be used
  - For DFB those studies would be the rat
  - chronic/carcinogenicity and mouse oncogenicity studies
- 1. Substance related death
  - For DFB, no substance related deaths were reported in any study
    - For DFB, no substance related reproductive / developmental toxicity
- 2. Major Functional Changes in Organ System
  - For DFB, no clinical signs of hypoxia were seen during treatment

3. Changes in clinical biochem/hematology/urinalysis parameters which indicate severe organ dysfunction. Hematological changes are considered to be of particular importance if the evidence suggests that they are due to decreased bone marrow production

- DFB did not result in a decreased bone marrow production
- There was no reduction of Hemoglobin at ≥ 20% in any study with DFB at any dose level
- There was no reduction of functional hemoglobin at ≥ 20% due to a combination of hemoglobin reduction and metHb formation in any study with DFB
- Hemoglobinuria or hemosiderinuria was not detected in any study with DFB

71

- Severe organ damage noted on microscopic examination following autopsy: 4.1 Widespread or severe necrosis fibrosis etc in organs with
  - regenerative capacity
    - No widespread or severe fibrosis in the spleen, liver or kidney was detected in any study with DFB
  - 4.2 Severe morphological changes that are potentially reversible but are clear evidence of marked organ dysfunction
    - No severe tubular nephrosis was detected in any study with DFB
  - 4.3 Evidence of appreciable cell death in vital organs incapable of regeneration or in a stem cell population
    - No appreciable cell death in organs incapable of regeneration or in a stem cell population.

The guidance document also mentions that it is important to consider not only specific severe changes in a single organ or biological system but also generalized changes of a less severe nature involving several organs or severe changes in general health status.

- DFB does not result in any severe changes to the general health status of the treated animals at any dose level or route of administration
- DFB affects the circulatory system through mild, subclinical extravascular hemolytic anemia. The effects seen are reversible and compensatable as demonstrated by the toxicological data.

These effects are relevant when attempting to determine a no-effect level for a chemical substance – irrespective of stat significance.

- Clinical observations or changes in bodyweight gain, food consumption or water intake, which may have some toxicological significance but which do not, by themselves, indicate 'serious damage'
  - DFB does not result in clinical symptoms or significant changes in bodyweight gain, food consumption or water intake. This is relevant when considering the statistically significant but not biologically relevant changes which are not indicative of serious damage.
- Small changes in clinical biochemistry, hematology or urinalysis which are of doubtful or minimal toxicological importance
  - DFB treatment results in sub-clinical expression of anaemia. The changes in hemoglobin levels are less than 10% for the majority of tested doses. MetHb levels are within the 0-4% for rats and usually in the range of 0-2% for the mice. Full recovery was noted after 4 weeks of withdrawal in rats treated for 7 weeks in feed. Compensatory mechanisms begin within 28 days of treatment and chronic treatment demonstrates improvement if not complete reversal of effects.
- Changes in organ weights without evidence of organ dysfunction
  - No or minimal severe histopathology effects were noted in the spleen and liver
- Adaptive responses
;

Are present and compensatory No clinical effects.
 Species specific mechanism of toxicity has been demonstrated
 All animals responded similarly to DFB. There is no indication that humans would respond any differently to treatment.

The RMS has read the paper by Freeman E and still has the opinion that diflubenzuron should be classified as R48 "Danger of serious damage to health by prolonged exposure".

Diflubenzuron oxidises haemoglobin to methaemoglobin. This is seen in most of the studies with diflubenzuron together with formation of sulfhaemoglobin.

Normally methaemoglobin is rapidly reduced back to haemoglobin and if an increase in methaemoglobin can be measured it is because the reducing capacity has been exceeded. The exposure has then already reached such a level that considerable energy will be spent on reduction of methaemoglobin and production of new reticulocytes. This is considered an adverse toxicological effect on a long term basis (RIVM report 061516 007, 2001). In the same report it is stated that rat, mouse, rabbit, guinea pig and monkey are less sensitive to methaemoglobin formation and generally show more effective reduction of methaemoglobin than man and dog do.

Unlike methaemoglobin the formation of sulfhaemoglobin is not reversible and is therefore also considered to be of toxic significance.

The increased formation of methaemoglobin and sulfhaemoglobin seems to cause an increased turn over of erythrocytes. Normally the blood cells are produced in the bone marrow but under extreme conditions the blood cells can also be produced in the liver and spleen, as during the foetal period, and this is observed during diflubenzuron exposure. The increased turnover of erythrocytes also causes an increased accumulation of iron. In healthy individuals small amounts of haemosiderin can occur in the spleen (and it increases with age) but haemosiderin present in liver and kidney is a pathologic condition and can cause damage to the organs. In several studies with diflubenzuron damage to the liver has also been observed.

The RMS has listed the studies with the above-mentioned effects indicative of anaemia that was seen during diflubenzuron exposure and that occurred during repeated exposure of 50 mg/kg bw/day or less. Other effects observed in most studies with diflubenzuron were changes in blood parameters: Hb $\downarrow$ , PCV or Hct $\downarrow$ , erythrocyte counts $\downarrow$  and RBC $\downarrow$  o r $\uparrow$  and also increase in liver and spleen weights which all are indicative of anaemia.

6.3.1(3) Oral 6 week mouse study by Hunter (study used as complementary)Live necrosis in 3 out of 8 mice exposed to 6 mg/kg bw/day with or without inflammatory cells.

#### 6.3.1 (3) Oral 90-day mouse study by Colley (study of restricted quality)

Heinz bodies (sine of methaemoglobin formation but more stable), increase in plasma glutamic pyruvic transaminase (indicating liver damage). Discolouration and enlargement of spleen, haemosiderosis in the spleen, liver areas of focal necrosis and/or fibrosis in the parenchyma with or without associated inflammatory cells, dose related increase in grey/blue discolouration of extremities.

6.4.1(3) Oral 90-day mouse study by Burdock

Liver necrosis, haemosiderosis and chronic hepatitis. The severity increased with dose.

6.4.1(2) Oral 90-day rat study by Burdock

Dose dependent increased in grading of chronic hepatitis and liver haemosiderosis (incidence: zero for control, 50 % of the animals exposed to 27/34 mg/kg bw (M/F) and 100% of the animals exposed to the highest dose), congestion of the spleen and mild erythroid hyperplasia of the bone marrow.

6.4.1(5) Oral 90-day dog study by Chesterman (study of restricted quality) Increase in alkaline phosphatise and serum glutamic transaminase.

6.4.1(6) Oral 90-day dog study by Greenough

Dose related increase in incidence and severity of macrophage and Kupffer cell siderosis, Heinz bodies, increase in LDH (indicating liver damage), and haemosiderosis in the liver.

The effects on haematological parameters were evaluated on the basis of the document presented by ECBI (ECBI/07/03 add.11). Considering the change in blood parameters, increased methaemoglobin and sulfhaemoglobin together with pathological effects like haemosiderosis and necrosis in the liver, enlargement and congestion of the spleen and the effect on the boon marrow RMS suggest R48 to be an appropriate classification.

# **B.6.12** Dermal absorption (Annex IIIA 7.3)

#### **Reporting table 2(14)**

In the dermal absorption study the animals were killed immediately after 1, 4 or 10 h of exposure. At these time points a significant amount of label was still present in the exposed skin. Furthermore, for the low dose label was still excreted in urine at the end of the 10 h exposure period.

Based on this study the dermal absorption should be about 6% as the amount remaining in the skin after 10 hours could be absorbed.

# **B.6.14** Exposure data (Annex IIIA 7.2)

Dimilin WG-80 is a water-dispersible granular (WG) formulation containing 800 g diflubenzuron/kg recommended for use in pome fruit, mushrooms and forestry. Dimilin WG-80 is applied to pome fruit by tractor-mounted or hand-held spray equipment, to mushrooms by hand-held spray equipment or automatic sprayer, and to forestry by aerial application. A summary of the application methods and the recommended "worst case" application rates are provided in the following table:

Field of use	Method of application	Max. application rate	Spray volume	Max. application concentration
Pome fruit	Tractor-mounted sprayer; spray directed upwards and sideways	180 g a s /ha	1 500 L/ha	0.12 g a.s./L
	Hand-held sprayer; spray directed upwards and sideways	100 g u.s./11u		
Forestry	Aerial application - ultra low volume (ULV)	48 g a s /ha	3 - 5 L/ha in oil	16 g a.s./L
	Aerial application - low volume (LV)	10 g u.s./nu	30 - 50 L/ha in water	1.6 g a.s./L
Mushrooms	Automatic sprayer	$1 \text{ g a.s./m}^2$	1 - 1.5 L/m <sup>2</sup>	
	Hand-held sprayer; high volume spray directed downwards	(=10 000 g a.s./ha)		1 g a.s./L

Table B.6.14-1: Summary of application methods and rates of Dimilin WG-80 relevant for the operator exposure assessment

## **B.6.14.1** Operator exposure

## **B.6.14.1.1** Estimation of operator exposure in orchards

#### Estimation of operator exposure in orchards using UK POEM and the German model

The estimates of total diflubenzuron exposure predicted by UK POEM<sup>2</sup>(Predictive operator exposure model) and the German model<sup>3</sup> were calculated as a proportion of the proposed AOEL for the active ingredient. Two different application techniques are used: Tractor-mounted sprayer (spray directed upwards and sideways) and hand-held sprayer (spray directed upwards and sideways).

Additional assumptions/data utilised in the models are as follows:

8 ha/day for tractor-mounted sprayer
1 ha for hand-held treatment
180 g as./ha
0.01 ml/hr
1 500 l/ha
100%
6 %

#### Tractor-mounted and hand-held sprayer in orchards

The estimated operator exposure values for tractor-mounted sprayer and hand-held sprayer in orchards,

determined on the basis of the model scenarios without or with minimum acceptable protective clothing, were set

<sup>&</sup>lt;sup>2</sup> Scientific Subcommittee on Pesticides and British Agrochemicals Joint Medical Panel., Estimation of Exposure and Absorption of Pesticides by Spray Operators (UK MAFF) 1986 and the Predictive Operator Exposure Model (POEM – UK MAFF) 1992

<sup>&</sup>lt;sup>3</sup> Uniform Principles for Safeguarding the Health of Applicators of Plant Protection Products (Uniform Principles for Operator Protection); Mitteilungen aus der Biologischen Bundesanstalt für Land- und Forstwirtschaft, Berlin-Dahlem, no. 277, 1992

out in Table B.6.14.1.1-1. Systemic exposure was taken into consideration in relation to the AOELsystemic.

Total systemic exposure was calculated from the addition of dermal and inhalation exposure (see also calculation in Appendix 1, A-J).

Tractor-mounted sprayer				
PPE	<b>Operator total exposure</b> (mg kg <sup>-1</sup> bw day <sup>-1</sup> )	% of AOEL <sup>1)</sup>		
	UK POEM			
Without	0.0292	442 %		
With gloves and PRE	0.0112	170 %		
(FFP3) during mixing				
and loading and gloves				
during spraying				
*****.4	German model			
Without	0.0201	304 %		
With gloves during	0.00308	47 %		
mixing and loading and				
sturdy footwear during				
spraving				
Hand-held spraver				
fiund nota sprayer	<b>Operator total exposure</b> (mg kg <sup>-1</sup> bw day <sup>-1</sup> )	% of AOEL <sup>1)</sup>		
PPE	UK POEM	/		
Without	0.0400	607 %		
With gloves during	0.00629	95 %		
mixing and loading and				
gloves during spraying				
With gloves during	0.00260	39 %		
mixing and loading and				
gloves and impermeable				
coverall during spraying	Cormon model			
Without		182 %		
With gloves during	0.0120	97 %		
mixing and loading and	0.00050	<i><i><i></i></i></i>		
gloves during spraying				
With gloves during	0.00211	32 %		
mixing and loading and				
gloves, coverall and				
sturdy footwear during				
spraying				

 Table B.6.14.1.1-1: Estimations of operator exposure to Dimilin WG-80 and comparison in relation to the systemic AOEL in orchards

 DIMILIN WG-80

AOELsys=0.0066 mg kg<sup>-1</sup> bw day<sup>-1</sup>; Dermal exposure 6%

#### **Conclusion:**

The modelling data based on UK POEM and the German model for tractor-mounted and hand-held spraying in orchards showed that exposure to diflubenzuron does involve a significant risk to the health of the operators concerned. Using tractor-mounted sprayer, the German model predicted a value of 47 % of the AOEL when maximum PPE was used. However, with the same conditions in the UK POEM 170 % of AOEL was reached. Using hand-held sprayer 95 and 97 % of AOEL was reached using gloves during mixing, loading and spraying.

#### **B.6.14.1.2 Estimation of operator exposure in forestry**

The scenario for application Dimilin WG-80 in forestry is either by aerial application using fixed-wing aircraft or helicopters with enclosed cockpits or by ground application by tractor-mounted or hand –held spray. All the applications are done by specialist companies who are licensed by local government bodies. The intended use of Dimilin WG-80 in forestry is dependent on the biological cycle of the pest but no more than one application per crop and year. The applications are made in spring or autumn. Treatments are not sprayed routinely but if an infestation of the pest is present. For aerial application separate operators do the mixing/loading and the applications.

# Aerial application by aircraft or helicopter

Mixing and loading is done in the same way as for applications by tractor-mounted equipment. The appropriate weight of product is mixed with the required volume of water for low volume (LV) applications or with water plus mineral oil or crop oil for ultra-low volume (ULV) applications. Sufficient product is mixed to apply up to 200 ha per flight.

Applications by air are generally made in early morning (four to five hours spraying time) and/or late afternoon (two to three hours spraying time) to reduce drift and evaporation of the droplets during windy or hot weather conditions. For ULV applications, the nozzles are designed to apply droplets of between 80 and 120  $\mu$ m to give good crop coverage and to reduce drift. Each flight takes approximately one hour for application to 200 ha. Based on a working day of 8 hours, assuming 0.5 hours for mixing/loading and 4 times taking off and landing the airplane (5 x 0.5 hour = 2.5 hours), the maximum flying time would be 5 hours per day. Therefore, the maximum area that could be treated in a day is 1 000 ha. This can be considered to represent the worst-case use for the assessment of operator exposure.

'Ground markers' or 'flaggers', i.e. persons on the ground who direct the pilots to the correct location for spraying, are not used in forestry. The crop canopy is high and such persons would not be visible from the air. Modern forest plantations are set out in separate blocks allowing the pilot to locate the correct target area. The potential exposure of operators during aerial application is therefore limited to persons involved in mixing/loading and to the pilots of the aircraft or helicopters.

#### Ground application by tractor-mounted or hand-held spray

The application of Dimilin WG-80 could be done by tractor-mounted spray or hand –held spry equipment, "high" crop application.

*Estimation of mixing/loading and application based on the German model during aerial and ground application* Exposure during mixing prior to application by air can be estimated using the German model as the product is prepared in the same way as for application by tractor-mounted equipment. The exposure was 1.024 mg kg<sup>-1</sup> bw day<sup>-1</sup> without PPE and 0.0104 mg kg<sup>-1</sup> bw day<sup>-1</sup> with gloves and A1P2, corresponding to 15515 % respective 157 % of the AOEL already during the mixing and loading step, indicating a risk during forest treatment by aircraft. No further calculations on the application from aircraft were therefore done. (For calculations se Appendix 1 K-L)

Total systemic exposure was calculated for Dimilin WG-80: application to forest with tractor-mounted or hand – held spray equipment, from the addition of dermal and inhalation exposure (see also calculation in Appendix 1). Without the use of PPE the exposure was 0.00535 and 0.00320 mg kg<sup>-1</sup> bw day<sup>-1</sup> respectively which corresponds to 81 and 49 % of the AOEL. (For calculations se Appendix 1 M-N)

Additional assumptions/data utilised in the models are as follows:

	Application from air	Ground application	Ground application
		Tractor-mounted spray	Hand-held spray
Area Treated in One Day:	1 000 ha	8 ha	1 ha
Application Rate:	48 g as./ha	48 g as./ha	48 g as./ha
Inhalation absorption	100%	100%	100%
Dermal absorption	6 %	6 %	6 %

 Table B.6.14.1.2-1: Estimations of operator exposure during mixing/loading and application to Dimilin WG-80 with and without PPE and comparison in relation to the systemic AOEL in aerial and ground application

 DIMULY WC-80

DIMILIN WG-00		
<b>Application-Forest</b>		
PPE		% of AOEL <sup>1)</sup>
	Aerial application	
	<b>Exposure during mixing and loading (</b> mg kg <sup>-1</sup> bw day <sup>-1</sup> )	
	German model mixing and loading	
Without	1.024	15515 %
With gloves and A1P2	0.0104	157 %
	Cround application	
PPE	<b>Operator total exposure</b> (mg kg <sup>-1</sup> bw dav <sup>-1</sup> )	
	operator total exposure (ing kg bit duy )	
	Tractor-mounted sprayer (German model)	
Without	0.00535	81 %
	Hand-held sprayer(German model)	
Without	0.00320	49 %

<sup>1</sup>AOELsys=0.0066 mg kg<sup>-1</sup> bw day<sup>-1</sup>; Dermal exposure 6%

## Conclusion

The exposure of the operators to diflubenzuron during mixing/loading in the scenario of aircraft application has been calculated from the German model; the exposure already during mixing and loading, using PPE was 157% of the AOEL and it is not acceptable. However, ground application using either tractor-mounted or hand-held sprayer resulted in exposure 81 % and 49 % of the AOEL respectively, without the use of PPE. This application is considered acceptable use.

#### B.6.14.1.3 Estimation of operator exposure in greenhouse using mushrooms grower

Mushrooms are grown in insulated houses and planted in compost in wooden trays or aluminium shelves stacked in tiers on either side of a central aisle. The compost consists of peat and is pasteurised prior to use. Mushroom spawn (mycelium culture) is incorporated into the compost and this is subsequently covered with casing medi, which is typically a mixture of peat and sugar beet lime. Mushroom farms vary in size and an average area of production would be approximately 300 to 400 m<sup>2</sup> with the largest farms growing a total of up to 1 500 m<sup>2</sup>, i.e. 0.15 ha, in three to four mushroom houses. Applications are made routinely to the casing media as a high volume low pressure sprays drench. There is one application of Dimilin WG-80 per cropping cycle (which takes 6 to 8 weeks) and up to five cycles per year. Cycles start at different times within a mushroom house to provide continuous cropping and so an application of Dimilin WG-80 could be made once a week with each application taking approximately one hour. The same operators do the mixing/loading and the applications. Product is prepared and used by each mushroom grower and applications are not made at several mushroom farms by spray contractors.

Applications are made automatically through the irrigation system in many modern houses. Alternatively, applications are made using hand-held equipment. The product is mixed and loaded prior to application by both methods but application by hand-held equipment involves the higher potential for exposure of operators. Sprays are applied at high volume (up to  $1.5 \text{ L/m}^2$ , equivalent to  $15\ 000\ \text{L/ha}$ ) and the spray is directed downwards to the casing media. The water volume incorporates the active substance into the casing media.

Additional assumptions/data utilised in the models are as follows:

Area Treated in One Day:	1 ha
Application Rate:	10 kg a.s./ha
Application volume:	15 000 L/ha
Inhalation absorption	100 %
Dermal absorption	6 %

#### Estimation of operator exposure in greenhouse for growing mushrooms during mixing and loading

The operator exposure during mixing and loading is estimated using the German model. It is assumed that a maximum of 0.15 ha/day can be treated as the farmers are not bigger (see above). Based on a maximum use rate of 1 g a.s./m<sup>2</sup> (10 kg a.s./ha), this will result in the following estimated exposure of spray operators to diflubenzuron without or with personal protective equipments (see also Appendix 1, O-R):

DIMILIN WG-80			
Aerial application-mushroom			
PPE	<b>Operator total exposure</b> (mg kg <sup>-1</sup> bw day <sup>-1</sup> )	% of AOEL <sup>1)</sup>	
	German model automatic spraying (only mixing and load	ing)	
Without	0.032	484%	
With gloves	0.000815	12 %	
-	German model hand-held spraying		
Without	0.1001	1571 %	
With gloves and A1P2	0.0102	155 %	
during mixing and			
loading and Hood,			
visor, gloves, coverall			
and sturdy footwear			
during spraying			

Table B.6.14.1.3-1: Estimations of operator exposure during mixing/loading to Dimilin WG-80 with and without PPE
and comparison in relation to the systemic AOEL in greenhouse using mushrooms grower

<sup>1</sup>AOELsys=0.0066 mg kg<sup>-1</sup> bw day<sup>-1</sup>; Dermal exposure 6%

No calculations have been presented by the notifier on the operator exposure during spraying in greenhouse. The arguments are that the application in greenhouse is comparable to "high" crops in orchards. RMS doesn't agree with this argument since the greenhouses are closed rooms and the operator exposure could be higher than outside. However, the operator exposure during spraying automatically is consider as acceptable, the exposure during mixing/loading is low when gloves is used (12 % of AOEL) and since the operator doesn't need to be in the greenhouse during spraying and the exposure during spraying should be negligible. The operator exposure with hand-held sprayer is not acceptable even if maximum PPE is used (155 %). In conclusion, the operator exposure to diflubenzuron in greenhouse using mushrooms grower is considered as acceptable using automatic sprayer with gloves during mixing and loading. Hand–held spraying is not acceptable-

#### **B.6.14.1.4 Summary of operator exposure**

The proposed AOEL for diflubenzuron is  $0.0066 \text{ mg kg}^{-1} \text{ day}^{-1}$  using 100 as safety factor and correlated with an oral absorption of 33%. Skin absorption value of 6 % for the concentrated product and the spray solution is used.

The operator exposure of diflubenzuron for pome fruit using tractor-mounted sprayer and hand-held sprayer was calculated using the German model and the UK POEM. The outcome exposure was below the systemic AOEL when maximum PPE was used according to the German model, but according to the UK POEM it was above AOEL and not acceptable. In forestry and greenhouse, the operator exposure during mixing/loading was also calculated using the German model. Furthermore, no appropriate calculations were presented by the notifier for the exposure during spraying in forestry and mushrooms. However, during the forest application the exposure was too high already in the mixing and loading step even when maximum PPE was used. Thus the forest application is not accepted. In greenhouse, the operator exposure during automatic spraying was considered as negligible and accepted if gloves were used during mixing and loading. During hand-held sprayer the operator exposure was considered as not acceptable, not even when all possible PPE was worn.

The overall exposure modelling assessments is presented in Table below:

Field of use	Method of application	Dose (kg a.s./ha) Work rate (ha/day)	Exposure mg kg <sup>-1</sup> day <sup>-1</sup>	% AOEL <sup>1</sup>	PPE
Pome fruit	Tractor-mounted sprayer; spray directed upwards and sideways	0.18 8	$0.0031^{2}$ $0.0112^{3}$	47 % >100 %	yes <sup>4</sup> yes
<u>r one nut</u>	Hand-held sprayer; spray directed upwards and sideways	0.18 1	$0.0063^{3}$ $0.0064^{2}$	95 % 97 %	yes yes
Forestry	Aerial application - ultra low volume (ULV) Aerial application - low volume (LV)	0.048 1000	Mix/loading: 0.014 <sup>2</sup>	>100 %	yes
	Ground application Tractor-mounted sprayer Hand-held sprayer		$0.00535^2$ $0.00320^2$	81 % 49 %	no no
	Automatic sprayer	10	Mix/loading: 0.00082 <sup>2</sup> Spraying: negligible	12 %	yes
<u>Mushrooms</u>	Hand-held sprayer; high volume	1	Mix/loading: 0.00082 <sup>2</sup>	12 %	no
	spray directed downwards		Spraying: not calculated	>100%	yes <sup>4</sup>
<sup>1</sup> AOEL= 0.0066 mg kg <sup>-1</sup> day <sup>-1</sup> ; <sup>2</sup> German model; <sup>3</sup> UK POEM; <sup>4</sup> gloves and overall during spraying					

Table B.6.14.1.4-1: Summary of the predicted operator exposure using Dimilin WG-80 in pome fruit, forestry and mushrooms

In conclusion, the operator exposure of diflubenzuron in pome fruit with tractor mounted and hand-held application is acceptable when PPE are used. The forest aerial application with aircraft or helicopters is not accepted but the ground application with tractor-mounted or hand-held sprayer is accepted without PPE. Fore mushroom grower the application with automatic sprayer is accepted when PPE is used. The hand-held sprayer is not accepted.

#### **B.6.14.2** Bystander exposure

Bystanders are not expected to be present in mushroom houses during application. Bystanders will not be present in forests during application as specific precautions are taken to exclude the public from forests that are being sprayed.

Bystanders could be exposed to spray drift if they were walking next to an orchard being treated with Dimilin WG-80. However, the bystander can always be expected to be several metres away from the spray boom. At 10 m from the sprayer, estimates that for pome fruit the maximum drift estimate (90th percentile data, single application; late application for pome fruit) is  $3.60\%^4$ .

<sup>&</sup>lt;sup>4</sup>Rautmann, D., Streloke, M., Winkler, R. (2001) New basic drift values in the authorisation procedure for plant protection products. In: Workshop on risk assessment and risk mitigation measures in the context of the authorisation of plant protection products (WORMM; Forster, R., Streloke, M. Eds.), 27-29 September, 1999, Heft 383, Biologischen Bundesanstalt für Land - und Fortwirtschaft, Berlin and Braunschweig, Germany.

Based on the maximum application rate for diflubenzuron to pome fruit of 0.18 kg/ha and assuming a bystander is located 10 m from the sprayer, they could receive 3.6% drift, i.e. 0.65 mg diflubenzuron/m<sup>2</sup>. Assuming that 50% of a body surface, assumed to be 2 m<sup>2</sup> in total (US EPA<sup>5</sup>), is covered with clothing and that dermal exposure is reduced to 50 % with long shirt and trousers, direct deposition on the skin could be 0.975 mg diflubenzuron. Using 6 % skin absorption, the absorbed dose of diflubenzuron would be 0.0585 mg.

As a worst case scenario the inhalation value can be assumed to be the same as for the operator and can be taken from the German model, tractor-mounted sprayer which is 0.01152 mg/day.

Taken together the dermal and inhalation exposure is 0.07 mg and assuming a 60 kg body weight (as appropriate for adult men and women), the systemic exposure would be  $0.001167 \text{ mg kg}^{-1} \text{ day}^{-1}$ .

Compared with the AOEL for diflubenzuron of 0.066 mg kg<sup>-1</sup> day<sup>-1</sup>, the potential exposure of bystanders is 18 % of systemic AOEL. Therefore, the bystander exposure during the use of Dimilin WG-80 is considered as acceptable.

## B.6.14.3 Worker exposure

#### **B.6.14.3.1** Estimation of worker exposure in orchards

Worker exposure to diflubenzuron during re-entering the application area in orchards has been estimated using the coefficients from EUROPOEM<sup>6</sup>. Table below shows the calculation of the potential dermal exposure:

#### Table B.6.14.3.1-1: Worker exposure of Dimilin 80WG in orchards

Dimilin 80WG in orchards

Worker exposure=	(AR/LAI)*T	TF*T) * DA	/bw	
Application rate (AR) Leaf area index (LAI)	180 1	g a.s./ha µg/cm2	(pome fruit)	•
Transfer Factor (TF) Exposure duration (T)	4500 8	cm2/h h		
Dermal abs (DA): Body weight (bw)	6 60	% kg		
Worker exposure of <i>Dimilin 80 WG</i> Pome fruit = 0			0.0648	mg kg-1 day-1
%AOEL (0.0066 mg kg <sup>-1</sup> day <sup>-1</sup> )	)	982 %		

<sup>&</sup>lt;sup>5</sup> Central estimate for adults. The EPA Exposure Factors Handbook (1997)

<sup>&</sup>lt;sup>6</sup> EUROPOEM-the developmenta, maintenance and dissemination of generic european databases and predictive exposure models to plant protection products. Final report December 2002

The systemic exposure for workers harvesting pome fruit or carrying out maintenance operations such as pruning without PPE is 0.0648 mg kg<sup>-1</sup> day<sup>-1</sup>, equivalent to 982 % of the AOEL of 0.0066 mg kg<sup>-1</sup> day<sup>-1</sup>. If the workers wear gloves, the dermal absorption could be reduced to 0.6 % and give an exposure of 0.00648 mg kg<sup>-1</sup> day<sup>-1</sup>, equivalent to 98 % of the AOEL. In conclusion, the worker exposure of Dimilin WG-80 is acceptable in orchards for pome fruit under the conditions that PPE is used. This assumption assume that the trees only are sprayed once as the concentrations on the fruits and leafs other vice could be built up to a concentration that gloves can not reduce to an acceptable level.

#### **B.6.14.3.2** Estimation of worker exposure in forestry

Workers are not expected to handle treated trees and so exposure following use of Dimilin WG-80 in forests is not considered further.

#### B.6.14.3.3 Estimation of worker exposure in greenhouse using mushrooms grower

A study to measure the exposure of workers handling treated compost, which is relevant to harvesting mushrooms treated with Dimilin WG-80 is summarised below.

<b>R</b> EFERENCE <b>01</b> :	BELCHER,T. (1997). GREENHOUSE WORKER REENTRY EXPOSURE TO ETRIDIAZOLE
Formulation/a.s. Guideline/GLP:	Terrazole 35%WP/ Etridiazole or Truban 5g Granular fungicide/4.58%etridiazole OPPTS Harmonised Test Guideline Series 875 (875.2200, 875.1200 and 875.1400)/yes
Acceptability:	Yes
Test system:	The exposure of workers to etridiazole residues when handling soil media treated with 'Terrazole 35% Wettable Powder' (a WP formulation containing 33.39% etridiazole) or 'Truban 5G Granular Fungicide' (a G formulation containing 4.58% etridiazole) was measured under greenhouse conditions in California, USA. The results with 'Terrazole 35% Wettable Powder' are considered to be applicable to Dimilin WG-80 as a WP formulation type is similar to a WG, whereas a G formulation is designed to release active substance more slowly over time. The results with 'Truban 5G Granular Fungicide' are therefore not considered further. Soil media consisting of bark, peat moss and sand was treated evenly with 'Terrazole 35% Wettable Powder' at a nominal rate of 37.2 g a.s./m3. At 4 hours, 12 hours and 24 hours after application (re-entry times), four workers each filled 12 plastic pots (10 cm diameter) by scooping them into the treated soil media with their bare hands. They then brushed off excess soil media so that the media was level with the top of the pot, and placed the full pot in a pot holder. All workers were observed and actions such as brushing their faces with their hands noted. Dermal exposure was measured using whole body dosimeters (worn over workers underwear and under cotton trousers and shirt), facial and neck swabs of cotton gauze and hand washings. Inhalation exposure was measured using pump on the workers belt. Monitoring took place over approximately a 4-hour period at each interval. Samples of treated and untreated soil media were also collected and 'dislodged' 0, 4, 8, 12, 24, 48 and 72 hours after treatment for measurement of residue decline. Samples were analysed for etridiazole after extraction from the matrices using gas chromatography with electron capture detection. Field fortifications were made for all matrices.

#### **Findings:**

Etridiazole residues in the soil media declined from 14.4  $\mu$ g/g immediately after application to 11.3 4  $\mu$ g/g after 72 hours (Table B.6.14.3.3-1). The data were used to construct a decline curve using linear regression. The dislodgeable soil residues at 4, 12 and 24 hours were calculated from the regression line.

Sampling interval (hours)	Dislodgeable etridiazole residues in soil media (µg/g)
0	14.3
4	14.6
8	9.83
12	9.57
24	9.05
48	10.8
72	11.3

Table B.6.14.3.3-1: Dislodgeable residues of etridiazole in soil following application of 'Terrazol	e 35% WP'
---	-----------

Etridiazole residues were found in sections of the cotton whole body dosimeters and all inhalation tubes at all reentry times. Residues in facial swabs were absent with the exception of one worker at the 12-hour re-entry time. Residues in hand washings were found in the 4-hour re-entry time but not in other samplings. The residues found were used to calculate total dermal and inhalation exposure. From these values, total exposure for an 8hour working day and the total exposure rate were calculated. Transfer factors were calculated by dividing the exposure rate by the dislodgeable soil residues at each re-entry time. Transfer factors for the 4, 12 and 24-hour time intervals were 9.15, 5.45 and 8.62 g/hour, respectively (Table B.6.14.3.3-2). The worst case value for the transfer factor was 9.15 g/hour and was found after 4 hours. The mean transfer factor was 7.74 g/hour.

Table B.6.14.3.3-2:	Measured	exposure of	' etridiazole	residues	and	calculated	transfer	factors f	from soil	dislodg	eable
residues		_								_	

Parameter	4 hours	12 hours	24 hours	
Dermal exposure over 8 hours (µg)	249.6	143.3	177.9	
Inhalation exposure over 8 hours (µg)	595.5	352.8	591.2	
Dermal plus inhalation exposure over 8 hours (µg)	845.1	496.1	769.1	
Total exposure rate (μg/hour)	105.6	62.0	96.1	
Dislodgeable soil residues (µg/g)*	11.54	11.38	11.15	
Transfer factor (g/hour)	9.15	5.45	8.62	
Worst case/Mean transfer factor (g/hour)	9.15/7.74			
* Calculated from regression line from decline curve.				

For workers handling soil media treated with etridiazole, a mean soil transfer factor of 7.74 g/hour from dislodgeable soil residues to human exposure was calculated.

Dimilin WG-80 is recommended for application to the casing media at 1 g diflubenzuron/ $m^2$ . The active substance is incorporated into the casing media by the high volume of water applied. Assuming the active substance is incorporated evenly to a depth of 15 cm, the concentration of diflubenzuron in the casing media would be 6.67 g a.s./ $m^3$ .

In the study with 'Terrazole 35% Wettable Powder', etridiazole was applied to soil media at 37.2 g a.s./m<sup>3</sup>. Assuming that the density of the soil media in the study and the casing media used in mushroom growing in the EU are the same, the concentration of etridiazole was approximately 5.6 times the expected concentration of diflubenzuron. Dislodgeable residues of etridiazole in soil media 0 and 4 hours after application were 14.3 and 14.6  $\mu$ g/g (mean 14.5  $\mu$ g/g). The mean of the values at 0 and 4 hours can be used as surrogates for diflubenzuron. Residues of etridiazole at later samplings are not applicable as levels declined and this decline is likely to be specific to etridiazole. Thus, the application of 'Terrazole 35% Wettable Powder' at a rate of active substance 5.6 times higher than Dimilin WG-80 led to dislodgeable residues in soil media of 14.5  $\mu$ g/g. Therefore, at the recommended rate of Dimilin WG-80, dislodgeable residues of diflubenzuron can be expected to be 2.6  $\mu$ g/g a.s.

In the worker exposure study, workers scooped treated soil media into plastic pots and brushed off the excess with their hands. These tasks are considered to be a suitable surrogate for workers harvesting mushrooms by hand. Harvesting involves leaning over the mushroom beds to pick the ripe crop and this would involve contact with diflubenzuron treated casing media. In the study with etridiazole, a worst case soil transfer factor of 9.15 g/hour was calculated.

Therefore, the daily exposure to diflubenzuron for an 8-hour working day and a worker of body weight 60 kg is calculated as follows:

Exposure without PPE =  $0.0026 \text{ mg/g x } 9.15 \text{ g/hour x } 8 \text{ hours/day} \div 60 \text{ kg} = 0.0032 \text{ mg kg}^{-1} \text{ day}^{-1}$ 

The systemic exposure for workers harvesting mushrooms without PPE and without taking the dermal absorption into consideration was 48 % of the AOEL. The exposure of workers carrying out other tasks in mushroom houses is likely to be lower than during harvesting as contact with the casing media would be lower. Therefore, the risk to workers is considered to be acceptable and it is not necessary to set a re-entry period before workers can re-enter mushroom houses to harvest the crop or handle the treated casing media after applications of Dimilin WG-80, and it is not necessary for workers to wear personal protective equipment.

86

# **B.6.14.3.4** Summary of worker exposure

The worker exposure of Dimilin WG-80 in pome fruits, forestry and mushrooms are considered as acceptable under the conditions studied. PPE are needed for the workers using Dimilin WG-80 in the orchards.

# Appendix 1

# A. UK POEM: tractor-mounted, orchard without PPE using Dimilin WG-80

Application method	Tractor-mounted/trailed broadcast air-assis	ted sprayer: 500 l/ha				
Product	Dimilin WG80		Active substance		diflubenzuron	
Formulation type	WG or SG 🛛 🔻		a.s. concentration		<b>800</b> mg/g	
Dermal absorption from product	6	%	Dermal absorption from spray	7	<mark>6</mark> %	
PPE during mix/loading	None 📃 🗸 🔻		PPE during application		None	-
Dose	0,225	kg product/ha	Work rate/day		8 <mark>ha</mark>	
Application volume	1500	l/ha	Duration of spraying		6 <mark>h</mark>	
AOEL	0,0066	mg/kg bw/day				
DERMAL EXPOSURE DURING	MIXING AND LOADING					
Hand contamination/kg a.s.	5,72	mg/kg a.s.				
Hand contamination/day	8,2368	mg/day				
Protective clothing	None					
Transmission to skin	100	%				
Dermal exposure to a.s.	8,2368	mg/day				
INHALATION EXPOSURE DUR	ING MIXING AND LOADING					
Inhalation exposure/kg a.s.	0,242	mg/kg a.s.				
Inhalation exposure/day	0,34848	mg/day				
RPE	None					
Transmission through RPE	100	%				
Inhalation exposure to a.s.	0,34848	mg/day				
DERMAL EXPOSURE DURING	SPRAY APPLICATION		500.14			
Application technique	Tractor-mounted/trailed broadca	ist air-assisted spra	ayer: 500 l/ha			
Application volume	1500	spray/ha				
Volume of surface contamination	400	ml/h				
Distribution	Hands	Trunk	Legs			
	10%	65%	25%	)		
Clothing	None	Permeable	Permeable	;		
Penetration	100%	2%	5%	)		
Dermal exposure	10	5,2	5	ml/h		
Duration of exposure	6	h				
l otal dermal exposure to spray	121,2	ml/day				
Concentration of a.s. in spray solut	0,12	mg/ml				
Dermal exposure to a.s.	14,544	mg/day				
INITAL ATION EXPOSURE DUR	INC SDD A VINC					
INHALATION EXPOSURE DUR	IING SPRATING					
Duration of our own	0,03	1111/11				
Concentration of a g in anray	0 12	n ma/ml				
Inhelation exposure to a s	0,12	mg/day				
Dereent cheerbad	0,030					
Absorbed dose	100	70 mg/day				
Absorbed dose	0,030	iiig/uay				
ABSORBED DOSE						
	Mix/load		Application			
Dermal exposure to a s	8 2368	mg/day	14 544	mg/dav		
Percent absorbed	6,2500	%	6	%		
Absorbed dose (dermal route)	0 494208	mg/day	0 87264	mg/dav		
Inhalation exposure to a s	0 34848	mg/day	0,07204	mg/day		
Absorbed dose	0.842688	mg/day	0.90864	mg/dav		
	0,042000		0,70004			
PREDICTED EXPOSURE						
Total absorbed dose	1.751328	mg/day				
Operator body weight	60	kg				
Operator exposure	0,0291888	mg/kg bw/day				
<b>Operator exposure % of AOEL</b>	442,2545455	%				

# B. UK POEM: tractor-mounted, orchard with PPE using Dimilin WG-80

Application method	Tractor-mounted/trailed broadcast air-assis	ted sprayer: 500 l/ha		▼			
Product	Dimilin WG80		Active substance			diflubenzuron	
Formulation type	WG or SG 🛛 🔻		a.s. concentration			800 mg/g	
Dermal absorption from product	6	%	Dermal absorption fr	om spray		<mark>6</mark> %	
PPE during mix/loading	Gloves and RPE (FFP3)	_	PPE during application	on		Gloves	-
Dose	0,225	kg product/ha	Work rate/day			8 <mark>ha</mark>	
Application volume	1500	l/ha	Duration of spraying			6 <mark>h</mark>	
AOEL	0,0066	mg/kg bw/day					
DERMAL EXPOSURE DURING	MIXING AND LOADING						
Hand contamination/kg a.s.	5,72	mg/kg a.s.					
Hand contamination/day	8,2368	mg/day					
Protective clothing	Gloves	5					
Transmission to skin	1	%					
Dermal exposure to a.s.	0,082368	mg/day					
INHALATION EXPOSURE DUR	ING MIXING AND LOADING						
Inhalation exposure/kg a.s.	0,242	mg/kg a.s.					
Inhalation exposure/day	0,34848	mg/day					
RPE	RPE (FFP3)						
Transmission through RPE	5	%					
Inhalation exposure to a.s.	0,017424	mg/day					
Amiliation taskaina	SPRAY APPLICATION		500 1/h -				
Application technique	I ractor-mounted/trailed broadca	ast air-assisted s	prayer: 500 I/na				
Application volume	1500	spray/na					
Volume of surface contamination	400	mi/n	.1				
Distribution	Hands	i i ru	1K 0/	Legs			
Clothing	Claves	Dormook	70 la D	2370			
Penetration	10%		0/.	50/			
Dermal experies	1070	) <u> </u>	70 <b>1</b>	570	m1/h		
Duration of our acture	4	J.	2	3	1111/11		
Total darmal avecure to array	0 95 2	II m1/day					
Concentration of a g in enroy colu	65,2	ma/m1					
Dermal experience to a s	10 224	mg/day					
Definal exposure to a.s.	10,224	ilig/uay					
INHALATION EXPOSURE DUR	ING SPRAYING						
Inhalation exposure to spray	0.05	ml/h					
Duration of exposure	6	h					
Concentration of a.s. in spray	0,12	mg/ml					
Inhalation exposure to a.s.	0,036	mg/day					
Percent absorbed	100	%					
Absorbed dose	0,036	mg/day					
ABSORBED DOSE							
	Mix/load	1	Application	10.55			
Dermal exposure to a.s.	0,082368	mg/day		10,224	mg/day		
Percent absorbed	6	%		6	%		
Absorbed dose (dermal route)	0,00494208	mg/day		0,61344	mg/day		
Inhalation exposure to a.s.	0,017424	mg/day		0,036	mg/day		
Absorbed dose	0,02236608	mg/day		0,64944	mg/day		
PREDICTED EVPOSUDE							
Total absorbed dose	0 67100200	mg/day					
Operator body weight	0,07100008	hg uay					
Operator exposure	0.011196768	mg/kg hw/da	v				
Operator exposure % of AOEL	169.648	%	,				
		-					

# C. German model: tractor-mounted, orchard without PPE using Dimilin WG-80

Application method	Tractor-mounted/trailed broadcast air-assis	ed sprayer		-			
Product	Dimilin WG-80		Active substance	e		diflubenzuron	
Formulation type	WG 🔻		a.s. concentration	on		800 g/kg	
Dermal absorption from product	6	%	Dermal absorpt	ion from spray		<mark>6</mark> %	
RPE during mix/loading	None 🗸 🗸		RPE during app	olication		None	-
PPE during mix/loading	None 💌		0.11				
PPE during application: Head	None 🗸 🗸	Hands	None	-	Body	None	-
Dose	0,225	kg product/ha	Work rate/day			8 ha	
AOEL	0,0066	mg/kg bw/day					
DERMAL EXPOSURE DURING	MIXING AND LOADING						
Hand contamination/kg a.s.	2	mg/kg a.s.					
Hand contamination/day	2,88	mg/day					
Protective clothing	none						
Transmission to skin	100	%					
Dermal exposure to a.s.	2,88	mg/day					
INHALATION EXPOSURE DUR	ING MIXING AND LOADING						
Inhalation exposure/kg a s		ma/ka a s					
Inhalation exposure/day	0,008	mg/day					
ninalation exposure/day	0,01132	ilig/uay					
KPE Transmission through DDE	100	0/					
I ransmission inrough RPE	100	<sup>%</sup> 0					
innalation exposure to a.s.	0,01152	mg/day					
DERMAL EXPOSURE DURING	SPRAY APPLICATION						
Application technique	Tractor-mounted/trailed broadca	st air-assisted spi	aver				
** *	Head	Hands	5	Rest of body			
Dermal contamination/kg a.s.	1.2	0.7	,	9.6			
Dermal contamination/day	1.728	1.008	:	13.824			
Protective clothing	none	none		none			
Transmission to skin	100	100		100	%		
Total dermal exposure to a s	16.56	mg/day		100	/0		
Fotal definal exposure to a.s.	10,50	ing/day					
INHALATION EXPOSURE DUR	ING SPRAYING						
Inhalation exposure/kg a.s.	0,018	mg/kg a.s.					
Inhalation exposure/day	0,02592	mg/day					
RPE	none						
Transmission through RPE	100	%					
Inhalation exposure to a.s.	0,02592	mg/day					
ABSORBED DOSE	Mix/load		Application				
Dermal exposure to a s	2.88	ma/day	ripplication	16.56	ma/day	7	
Percent absorbed	2,00	0/2		10,50	0%		
Abasehad dasa (damaal maata)	0 1728	/0		0.0026	/0		
Absorbed dose (dermai route)	0,1728	mg/day		0,9930	mg/day		
The last of the second se	0,01152	mg/day		0,02592	mg/day		
i otai systemic exposure	0,18432	mg/day		1,01952	mg/day	T	
PREDICTED EXPOSURE							
Total systemic exposure	1,20384	mg/day					
Operator body weight	60	kg					
Operator exposure	0,020064	mg/kg bw/day					
<b>Operator exposure % of AOEL</b>	304	%					
- •							

# D. German model: tractor-mounted, orchard with PPE using Dimilin WG-80

Application method	Tractor-mounted/trailed broadcast air-assist	ed sprayer	-			
Product	Dimilin WG-80		Active substance		diflubenzuron	
Formulation type	WG 🔻		a.s. concentration		800 g/kg	
Dermal absorption from product	6	%	Dermal absorption from spray	,	<mark>6</mark> %	
RPE during mix/loading	None 💌		RPE during application		None	-
PPE during mix/loading	Gloves 🔻					
PPE during application: Head	None 💌	Hands	Gloves	Body	Coverall and sturdy footwear	-
Dose	0.225	kg product/ha	Work rate/day		8 ha	
AOEL	0,0066	mg/kg bw/day				
		00				
DERMAL EXPOSURE DURING	MIXING AND LOADING					
Hand contamination/kg a s	2	mo/ko a s				
Hand contamination/day	2.88	mg/day				
Protective clothing	2,00 gloves	iiig/day				
Transmission to skin	gioves	0/				
	0.0288	70 				
Dermai exposure to a.s.	0,0288	mg/day				
INHALATION EXPOSURE DUR	ING MIXING AND LOADING					
Inhalation exposure/kg a.s.	0,008	mg/kg a.s.				
Inhalation exposure/day	0,01152	mg/day				
RPE	none					
Transmission through RPE	100	%				
Inhalation exposure to a.s.	0,01152	mg/day				
DERMAL EXPOSURE DURING	SPRAY APPLICATION					
Application technique	Tractor-mounted/trailed broadca	st air-assisted spr	ayer			
** *	Head	Hands	Rest of body			
Dermal contamination/kg a.s.	1.2	0.7	9.6			
Dermal contamination/day	1 728	1 008	13 824			
Protective clothing	none	gloves	coverall and sturdy footwear			
Transmission to skin	100	1	5	0/0		
Total dermal exposure to a s	2 /2028	ma/day	5	/0		
Total definal exposure to a.s.	2,42928	iiig/day				
INITAL ATION EXPOSTIBE DUD						
INHALATION EAFOSURE DUR	ING SPRATING					
Innalation exposure/kg a.s.	0,018	mg/kg a.s.				
Inhalation exposure/day	0,02592	mg/day				
RPE	none					
Transmission through RPE	100	%				
Inhalation exposure to a.s.	0,02592	mg/day				
ABSORBED DOSE						
	Mix/load		Application			
Dermal exposure to a.s.	0,0288	mg/day	2,42928	mg/day	7	
Percent absorbed	6	%	6	%		
Absorbed dose (dermal route)	0,001728	mg/day	0,1457568	mg/day	7	
Inhalation exposure to a.s.	0,01152	mg/day	0,02592	mg/dav	t	
Total systemic exposure	0.013248	mg/day	0.1716768	mg/dav	7	
	.,010210	<i></i> ,	-,-/10/00			
PREDICTED EXPOSURE						
Total systemic exposure	0 1849248	mg/day				
Operator body weight	60	kg				
Operator exposure	0 00308208					
Operator exposure % of AOFL	47	%				
operator exposure /0 of AOEL	47	/ •				

# E. UK POEM: hand-held, orchard without PPE using Dimilin WG-80

Application method	Hand-held rotary atomiser equipment (2.5	I tank). Outdoor, high lev	el target 💌	
Product	Dimilin WG80		Active substance	diflubenzuron
Formulation type	WG or SG	_	a.s. concentration	<b>800</b> mg/g
Dermal absorption from product	6	%	Dermal absorption from spray	<b>6</b> %
PPE during mix/loading	None	<b>.</b>	PPE during application	None
Application volume	0,223	kg product/na	Work rate/day	l na
	0.0066	1/na mg/kg bw/day	Duration of spraying	<u> </u>
AOLL	0,000	mg/kg 0w/day		
DERMAL EXPOSURE DURING	MIXING AND LOADING			
Hand contamination/kg a.s.	171,4	mg/kg a.s.		
Hand contamination/day	30,852	mg/day		
Protective clothing	None			
Transmission to skin	100	%		
Dermal exposure to a.s.	30,852	mg/day		
NULAL ATION EVPOSIBE DUD				
Infial ATION EXPOSURE DUR		ma/ka a c		
Inhalation exposure/kg a.s.	0,0628	mg/kg a.s.		
RPE	0,011304 None	ilig/uay		
Transmission through RPE	100	0/2		
Inhalation exposure to a s	0.011304	mg/day		
initiation exposure to u.s.	0,011501	ing duy		
DERMAL EXPOSURE DURING	SPRAY APPLICATION			
Application technique	Hand-held rotary atomiser equip	oment (2.5 l tank).	Outdoor, high level target	
Application volume	1500	spray/ha		
Volume of surface contamination	50	ml/h		
Distribution	Hands	Trunk	Legs	
	10%	65%	25%	
Clothing	None	Permeable	Permeable	
Penetration	100%	15%	20%	
Dermal exposure	5	4,875	2,5	ml/h
Duration of exposure	6	h		
I otal dermal exposure to spray	/4,25	ml/day		
Concentration of a.s. in spray solut	t: 0,12	mg/mi		
Dermai exposure to a.s.	8,91	mg/day		
INHALATION EXPOSURE DUR	ING SPRAYING			
Inhalation exposure to spray	0,01	ml/h		
Duration of exposure	6	h		
Concentration of a.s. in spray	0,12	mg/ml		
Inhalation exposure to a.s.	0,0072	mg/day		
Percent absorbed	100	%		
Absorbed dose	0,0072	mg/day		
ABSORBED DOSE	Mix/load		Application	
Dermal exposure to a s	30.852	mø/dav	2 of	mg/dav
Percent absorbed	50,852	%	6,51	%
Absorbed dose (dermal route)	1 85112	mg/day	0 5346	mg/day
Inhalation exposure to a s	0.011304	mg/day	0.0072	mg/dav
Absorbed dose	1,862424	mg/day	0,5418	mg/day
PREDICTED EXPOSURE				
Total absorbed dose	2,404224	mg/day		
Operator body weight	60	kg		
Operator exposure % of AOEI	0,0400/04	mg/kg bw/day		
operator exposure /0 of AOEE	007,1272727	/0		

# F. UK POEM: hand-held, orchard with PPE using Dimilin WG-80

Application method	Hand-held rotary atomiser equipment (2.5	I tank). Outdoor, high lev	vel target 🔹 💌	
Product	Dimilin WG80		Active substance	diflubenzuron
Formulation type	WG or SG		a.s. concentration	<b>800</b> mg/g
Dermal absorption from product	6	%	Dermal absorption from spray	<mark>6</mark> %
PPE during mix/loading	Gloves		PPE during application	Gloves
Dose	0,225	kg product/ha	Work rate/day	l ha
Application volume	1500	l/ha	Duration of spraying	6 h
AUEL	0,0066	mg/kg bw/day		
DERMAL EXPOSURE DURING	MIXING AND LOADING			
Hand contamination/kg a s	171 4	mø/kø a s		
Hand contamination/day	30.852	mg/day		
Protective clothing	Gloves	ing/day		
Transmission to skin	1	0/_		
Dermal exposure to a s	0 30852	70 mg/day		
Definal exposure to a.s.	0,50852	ilig/day		
INHALATION EXPOSURE DUR	ING MIXING AND LOADING			
Inhalation exposure/kg a s	0.0628	mø/kø a s		
Inhalation exposure/day	0.011304	mg/day		
RPE	None	ing/day		
Transmission through RPE	100	%		
Inhalation exposure to a s	0.011304	mg/day		
initiation enposare to u.s.	0,011201	ing au		
DERMAL EXPOSURE DURING	SPRAY APPLICATION			
Application technique	Hand-held rotary atomiser equir	oment (2.5 l tank).	Outdoor, high level target	
Application volume	1500	spray/ha	, , , , , , , , , , , , , , , , , , , ,	
Volume of surface contamination	50	ml/h		
Distribution	Hands	Trunk	Legs	
	10%	65%	25%	
Clothing	Gloves	Permeable	Permeable	
Penetration	10%	15%	20%	
Dermal exposure	0,5	4,875	2,5	ml/h
Duration of exposure	6	h		
Total dermal exposure to spray	47,25	ml/day		
Concentration of a.s. in spray solut	t 0,12	mg/ml		
Dermal exposure to a.s.	5,67	mg/day		
INHALATION EXPOSURE DUR	ING SPRAYING			
Inhalation exposure to spray	0,01	ml/h		
Duration of exposure	6	h		
Concentration of a.s. in spray	0,12	mg/ml		
Inhalation exposure to a.s.	0,0072	mg/day		
Percent absorbed	100	%		
Absorbed dose	0,0072	mg/day		
ADSODDED DOSE				
ABSORBED DOSE	N.C. (1 1		A	
Dormal exposure to a a	MIX/load	ma/day	Application	ma/day
Dermai exposure to a.s.	0,30832	mg/day	5,07	mg/day
Absorbed dose (dormal route)	0.0185112	∕0 ma/dav	0 2402	/0 mg/day
Inhalation exposure to a s	0,0103112	mg/uay	0,5402	mg/day
Absorbed dose	0,011504	mg/day	0,0072	mg/day
	0,0298132	mg/uay	0,5474	ing/uay
PREDICTED EXPOSURE				
Total absorbed dose	0.3772152	mg/day		
Operator body weight	60	kg		
Operator exposure	0,00628692	mg/kg bw/day		
<b>Operator exposure % of AOEL</b>	95,25636364	%		

# G. UK POEM: hand-held, orchard with PPE using Dimilin WG-80

Application method	Hand-held rotary atomiser equipment (2.5	I tank). Outdoor, high le	vel target 🛛 🔻	
Product	Dimilin WG80		Active substance	diflubenzuron
Formulation type	WG or SG 🛛 💌		a.s. concentration	<mark>800</mark> mg/g
Dermal absorption from product	6	<mark>i</mark> %	Dermal absorption from spray	7 6 <mark>%</mark>
PPE during mix/loading	Gloves	_	PPE during application	Gloves and impermeable coveralls
Dose	0,225	kg product/ha	Work rate/day	1 ha
Application volume	1500	l/ha	Duration of spraying	6 h
AOEL	0,0066	mg/kg bw/day		
DERMAL EXPOSURE DURING	MIXING AND LOADING			
Hand contamination/kg a.s.	171,4	mg/kg a.s.		
Hand contamination/day	30,852	mg/day		
Protective clothing	Gloves	5		
Transmission to skin	1	%		
Dermal exposure to a.s.	0,30852	mg/day		
BULLI ATION EVPOCUDE DUD				
INHALATION EXPOSURE DUR	ING MIXING AND LOADING			
Innalation exposure/kg a.s.	0,0628	mg/kg a.s.		
Inhalation exposure/day	0,011304	mg/day		
RPE	None	e 0/		
Iransmission through RPE	100	%		
Inhalation exposure to a.s.	0,011304	mg/day		
DERMAL EXPOSURE DURING	SPRAY APPLICATION			
Application technique	Hand-held rotary atomiser equit	oment (2.5.1 tank)	Outdoor high level target	
Application volume	1500	sprav/ha		
Volume of surface contamination	50	ml/h		
Distribution	Hands	Trunk	Leg	
	10%	65%	25%	
Clothing	Gloves	Impermeable	Impermeable	
Penetration	10%	5%	5%	
Dermal exposure	0,5	1,625	0,625	ml/h
Duration of exposure	6	h	,	
Total dermal exposure to spray	16,5	ml/day		
Concentration of a.s. in spray solut	t 0,12	mg/ml		
Dermal exposure to a.s.	1,98	mg/day		
INHALATION EXPOSURE DUR	ING SPRAYING	1/1		
Inhalation exposure to spray	0,01	ml/h		
Duration of exposure	6	h		
Concentration of a.s. in spray	0,12	mg/ml		
Inhalation exposure to a.s.	0,0072	mg/day		
Percent absorbed	100	%		
Absorbed dose	0,0072	mg/day		
ABSORBED DOSE				
	Mix/load	1	Application	
Dermal exposure to a.s.	0,30852	mg/day	1.98	mg/day
Percent absorbed	6	%	6	%
Absorbed dose (dermal route)	0,0185112	mg/day	0,1188	mg/day
Inhalation exposure to a.s.	0.011304	mg/day	0.0072	mg/day
Absorbed dose	0,0298152	mg/day	0,126	mg/day
PREDICTED EXPOSURE		(1		
I otal absorbed dose	0,1558152	mg/day		
Operator body weight	60	Kg		
Operator exposure	0,00259092	mg/kg dw/day		
Operator exposure % of AOEL	39,34/2/2/3	/0		

# H. German model: hand-held, orchard without PPE using Dimilin WG-80

Application method	Hand-held sprayer: hydraulic nozzles. Outdo	oor, high level target		-			
Product	Dimilin WG-80		Active substance	e		diflubenzuron	
Formulation type	WG 🔻		a.s. concentratio	'n		800 g/kg	
Dermal absorption from product	6	%	Dermal absorpti	on from spray		6 %	
RPE during mix/loading	None 💌		RPE during app	lication		None	-
PPE during mix/loading	None		0.11				
PPE during application: Head	None 🗸 🗸	Hands	None	-	Body	None	
Dose	0.225	kg product/ha	Work rate/day		1	1 ha	_
AOEL	0,0066	mg/kg bw/day					
		00					
DERMAL EXPOSURE DURING	MIXING AND LOADING						
Hand contamination/kg a s	21	mø/kø a s					
Hand contamination/day	3 78	mg/day					
Protective clothing	5,76	ing/day					
Transmission to skin	100	0/					
	100	70					
Dermal exposure to a.s.	3,78	mg/day					
INHALATION EXPOSURE DUR	ING MIXING AND LOADING						
Inhalation exposure/kg a.s.	0,02	mg/kg a.s.					
Inhalation exposure/day	0,0036	mg/day					
RPE	none						
Transmission through RPE	100	%					
Inhalation exposure to a.s.	0,0036	mg/day					
*		0 ,					
DERMAL EXPOSURE DURING	SPRAY APPLICATION						
Application technique	Hand-held sprayer: hydraulic no	zzles. Outdoor. h	igh level target				
. ipplication teelinique	Head	Hands		Rest of body			
Dermal contamination/kg a s	4.8	10.6		25			
Dermal contamination/day	-,0	1 908		15			
Protective clothing	0,804	1,908		4,5			
Transmission to shin	100	100	;	100	0/		
Transmission to skin	100	100		100	%0		
Total dermal exposure to a.s.	7,272	mg/day					
INHALATION EXPOSURE DUR	ING SPRAYING						
Inhalation exposure/kg a.s.	0,3	mg/kg a.s.					
Inhalation exposure/day	0,054	mg/day					
RPE	none						
Transmission through RPE	100	%					
Inhalation exposure to a.s.	0,054	mg/day					
-							
ABSORBED DOSE							
	Mix/load		Application				
Dermal exposure to a s	3 78	mg/day	pp.:.eution	7 272	ma/day		
Percent absorbed	5,70	0/2		1,272	0%		
Absorbed dose (dormal route)	0 2268	70 mg/dov		0 42622	/0 mg/day		
Absolution and a sum a sum to a s	0,2208	ilig/day		0,43032	mg/uay		
Tatal automica and a suma	0,0036	mg/uay		0,054	mg/day		
i otal systemic exposure	0,2304	mg/day		0,49032	mg/day		
PREDICTED EXPOSURE	A						
I otal systemic exposure	0,72072	mg/day					
Operator body weight	60	kg					
Operator exposure	0,012012	mg/kg bw/day					
<b>Operator exposure % of AOEL</b>	182	%					

# I. German model: hand-held, orchard with PPE using Dimilin WG-80

Application method	Hand-held sprayer: hydraulic nozzles. Outd	oor, high level target		-			
Product	Dimilin WG-80		Active substance	e		diflubenzuron	
Formulation type	WG 🔻		a.s. concentratio	n		800 g/kg	
Dermal absorption from product	6	%	Dermal absorpti	on from spray		<mark>6</mark> %	
RPE during mix/loading	None 💌		RPE during app	lication		None	-
PPE during mix/loading	Gloves 💌						_
PPE during application: Head	None 💌	Hands	Gloves	-	Body	None	-
Dose	0,225	kg product/ha	Work rate/day			1 ha	_
AOEL	0,0066	mg/kg bw/day					
DERMAL EXPOSURE DURING	MIXING AND LOADING						
Hand contamination/kg a.s.	21	mg/kg a.s.					
Hand contamination/day	3,78	mg/day					
Protective clothing	gloves						
Transmission to skin	1	%					
Dermal exposure to a.s.	0,0378	mg/day					
INHALATION EXPOSURE DUR	ING MIXING AND LOADING						
Inhalation exposure/kg a.s.	0,02	mg/kg a.s.					
Inhalation exposure/day	0,0036	mg/day					
RPE	none	8 9					
Transmission through RPE	100	%					
Inhalation exposure to a.s.	0.0036	mg/dav					
r in the r	· · · · ·	0					
DERMAL EXPOSURE DURING	SPRAY APPLICATION						
Application technique	Hand-held sprayer: hydraulic no	zzles. Outdoor, h	igh level target				
	Head	Hands		Rest of body			
Dermal contamination/kg a.s.	4.8	10.6	5	25			
Dermal contamination/day	0.864	1.908		4.5			
Protective clothing	none	gloves		none			
Transmission to skin	100	1		100	%		
Total dermal exposure to a s	5 38308	mg/dav		100	, 0		
	5,56566	iiig aag					
INHALATION EXPOSURE DUR	ING SPRAYING						
Inhalation exposure/kg a.s.	0.3	mg/kg a.s.					
Inhalation exposure/day	0.054	mg/dav					
RPE	none	8					
Transmission through RPE	100	%					
Inhalation exposure to a.s.	0,054	mg/day					
r in the r	- )	0					
ABSORBED DOSE							
	Mix/load		Application				
Dermal exposure to a.s.	0,0378	mg/day		5,38308	mg/day	,	
Percent absorbed	6	%		6	%		
Absorbed dose (dermal route)	0.002268	mg/day		0 3229848	mø/dav	r	
Inhalation exposure to a s	0.0036	mg/day		0.054	mg/dav	,	
Total systemic exposure	0.005868	mg/day		0.3769848	mg/day	,	
roar systemic exposure	0,005000			0,5707070	m <sub>b</sub> / ady		
PREDICTED EXPOSURE							
Total systemic exposure	0.3828528	mg/dav					
Operator body weight	60	kg					
Operator exposure	0,00638088	mg/kg bw/dav					
<b>Operator exposure % of AOEL</b>	97	%					
· ·							

# J. German model: hand-held, orchard with PPE using Dimilin WG-80

Application method	Hand-held sprayer: hydraulic nozzles. Outd	oor, high level target	-			
Product	Dimilin WG-80		Active substance		diflubenzuron	
Formulation type	WG 🔻		a.s. concentration		800 g/kg	
Dermal absorption from product	6	%	Dermal absorption from spray		<b>6</b> %	
RPE during mix/loading	None 💌		RPE during application		None	
PPE during mix/loading	Gloves		Soff and			
PPE during application: Head	None	Hands	Gloves	Body	Coverall and sturdy footwear	
Dose	0.225	kg product/ha	Work rate/day	] = = = )	1 ha	- 7
AOEL	0.0066	mg/kg bw/day	i on face, aug			
DERMAL EXPOSURE DURING	MIXING AND LOADING					
Hand contamination/kg a s	21	ma/ka a s				
Hand contamination/kg a.s.	21	mg/kg a.s.				
Protoctions alothing	5,78	ilig/day				
Protective clothing	gioves	0/				
I ransmission to skin	1	%				
Dermal exposure to a.s.	0,0378	mg/day				
INHALATION EXPOSURE DUR	ING MIXING AND LOADING					
Inhalation exposure/kg a.s.	0,02	mg/kg a.s.				
Inhalation exposure/day	0,0036	mg/day				
RPE	none	:				
Transmission through RPE	100	%				
Inhalation exposure to a.s.	0,0036	mg/day				
I II I I I I I I I I I I I I I I I I I		8				
DERMAL EXPOSURE DURING	SPRAY APPLICATION					
Application technique	Hand-held sprayer: hydraulic no	zzles Outdoor hi	igh level target			
Application teeninque	Hand-heid sprayer. Hydraune he	Hande	Rest of body			
Dormal contamination/kg a s	1 9	10.6	25			
Definal contamination/kg a.s.	4,0	1 0.0	23			
Dermai contamination/day	0,804	1,908	4,3			
Protective clothing	none	gioves	coverall and sturdy footwear			
Transmission to skin	100	1	5	%		
Total dermal exposure to a.s.	1,10808	mg/day				
INHALATION EXPOSURE DUR	ING SPRAYING					
Inhalation exposure/kg a.s.	0,3	mg/kg a.s.				
Inhalation exposure/day	0,054	mg/day				
RPE	none	;				
Transmission through RPE	100	%				
Inhalation exposure to a.s.	0,054	mg/day				
-						
ABSORBED DOSE						
	Mix/load		Application			
Dermal exposure to a s	0.0378	mg/day	1 10808	mg/day	,	
Percent absorbed	0,0576	0/2	1,10000	0%		
Absorbed dose (dermal route)	0.002268	/0 mg/day	0.0664848	ma/day	7	
Absoluted dose (definal foute)	0,002208	mg/day	0,0004848	mg/day		
T the second sec	0,0030	nig/day	0,034	mg/uay		
i otal systemic exposure	0,005868	mg/day	0,1204848	mg/day	1	
PREDICTED EXPOSURE						
Total systemic exposure	0,1263528	mg/day				
Operator body weight	60	kg				
Operator exposure	0,00210588	mg/kg bw/day				
Operator exposure % of AOEL	32	%				

# K. German model: Estimated dermal and inhalation exposure during mixing/loading with aerial application in forestry using Dimilin WG-80 without PPE

Application method	Hand-held sprayer: hydraulic nozzles. Outo	loor, high level target	-	
Product	Dimilin WG-80		Active substance	diflubenzuron
Formulation type	WG 🔻		a.s. concentration	800 g/kg
Dermal absorption from product	6	<b>6</b> %	Dermal absorption from spray	y <b>6</b> %
RPE during mix/loading	None 💌		RPE during application	None
PPE during mix/loading	None 💌			
PPE during application: Head	None 💌	Hands	None	Body None 🗸 🗸
Dose	0,06	kg product/ha	Work rate/day	1000 ha
AOEL	0,0066	mg/kg bw/day		
DEDMAL EVDOSUDE DUDING	MIVING AND LOADING			
Used contention for a s	MIAING AND LOADING			
Hand containination/kg a.s.	1008	mg/kg a.s.		
Protoction alathing	1008	mg/day		
Protective clothing	none	e 0/		
I ransmission to skin	100	%		
Dermal exposure to a.s.	1008	mg/day		
INHALATION EXPOSURE DUR	ING MIXING AND LOADING			
Inhalation exposure/kg a s	0.02	mg/kg a s		
Inhalation exposure/day	0,02	mg/day		
DDE	0,90	iiig/day		
KFE Transmission through DDE	100	0/		
	100	70 		
Inhalation exposure to a.s.	0,96	mg/day		
DERMAL EXPOSURE DURING	SPRAY APPLICATION			
Application technique	Hand-held spraver: hydraulic no	ozzles. Outdoor, h	nigh level target	
	Head	Hands	s Rest of body	V
Dermal contamination/kg a s	4.8	10.6	6 24	5
Dermal contamination/day	230.4	508.8	8 120	)
Protective clothing	none		e none	2
Transmission to skin	100	2 100	100	0/2
Total dermal exposure to a s	1939.2	mg/day	100	/0
Total definal exposure to a.s.	1959,2	iiig/uay		
INHALATION EXPOSURE DUR	ING SPRAYING			
Inhalation exposure/kg a.s.	0,3	mg/kg a.s.		
Inhalation exposure/day	14,4	mg/day		
RPE	none	•		
Transmission through RPE	100	%		
Inhalation exposure to a.s.	14,4	mg/day		
ABSORBED DOSE	Min/land		A	
Demost energy to the		۱	Application	
Dermal exposure to a.s.	1008	mg/day	1939,2	mg/day
Percent absorbed	6	%	6	%
Absorbed dose (dermal route)	\ 60,48	mg/day	116,352	mg/day
Inhalation exposure to a.s.	0,96	mg/day	χ 14,4	mg/day
Total systemic exposure	61,44	mg/day	130,752	mg/day
PREDICTED EXPOSURE			$\mathbf{A}$	
Total systemic exposure	102 102	mg/day		
Operator body weight	172,192	hg/uay	Operator expo	sure =1.024 mg/kg
Operator exposure	3 2032	ng/kg hw/day	bw/dav	
Operator exposure % of AOFL	48533	1 %	L	
SPHILLON CAPOSATE /0 OF HOEL	10555			

# L. German model: Estimated dermal and inhalation exposure during mixing/loading with aerial

# application in forestry using Dimilin WG-80 with $\ensuremath{\mathsf{PPE}}$

Application method	Hand-held sprayer: hydraulic nozzles. Outdo	oor, high level target	-			
Product	Dimilin WG-80		Active substance		diflubenzuron	
Formulation type	WG 🔻		a.s. concentration		800 g/kg	
Dermal absorption from product	6	%	Dermal absorption from spray	,	<b>6</b> %	
RPE during mix/loading	A1P2		RPE during application		None	-
PPE during mix/loading	Gloves		5 HI			_
PPE during application: Head	None	Hands	None	Body	None	-
Dose	0.06	kg product/ha	Work rate/day	] = )	1000 ha	_
AOEL	0,0066	mg/kg bw/day				
DERMAL EXPOSURE DURING	MIXING AND LOADING					
Hand contamination/kg a.s.	21	mg/kg a.s.				
Hand contamination/day	1008	mg/day				
Protective clothing	gloves					
Transmission to skin	1	%				
Dermal exposure to a.s.	10,08	mg/day				
INITAL ATION EXPOSIBLE DUD	INC MIVING AND LOADING					
INFIALATION EAPOSURE DUR		ma/lea o a				
Innalation exposure/kg a.s.	0,02	mg/kg a.s.				
Inhalation exposure/day	0,96	mg/day				
RPE	A1P2					
Transmission through RPE	2	%				
Inhalation exposure to a.s.	0,0192	mg/day				
DERMAL EXPOSURE DURING	SPRAY APPLICATION					
Application technique	Hand-held sprayer: hydraulic no	zzles Outdoor h	igh level target			
Application technique	Hand-field sprayer. Hydraulie no	ZZICS. Outdoor, II	Bast of body			
Dermal contamination/leg.o.g	Head 4.9	10.4				
Dermal containination/kg a.s.	4,0	10,0	23			
Dermai contamination/day	230,4	508,8	1200			
Protective clothing	none	none	e none	0/		
I ransmission to skin	100	100	100	%		
Total dermal exposure to a.s.	1939,2	mg/day				
INHALATION EXPOSURE DUR	ING SPRAYING					
Inhalation exposure/kg a s	0.3	mg/kg a.s.				
Inhalation exposure/day	14.4	mg/day				
RPF	none	ing, any				
Transmission through RPE	100	0/2				
Inhalation exposure to a s	100	/0 mg/day				
initiation exposure to a.s.	17,7	iiig/day				
ABSORBED DOSE						
	Mix/load		Application			
Dermal exposure to a.s.	10,08	mg/day	1939,2	mg/day		
Percent absorbed	6	%	6	%		
Absorbed dose (dermal route)	0.6048	mg/dav	116.352	mg/day	,	
Inhalation exposure to a.s.	0.0192	mg/dav	14.4	mg/day		
Total systemic exposure	0,624	mg/day	130,752	mg/day	т.	
- *						
PREDICTED EXPOSURE						
Total systemic exposure	131,376	mg/day	Operator exposure	=0.010	4 mg/kg hw/dav	
Operator body weight	60	kg	$0/ \text{ of } \Lambda \text{OEI} = 1570$	6.010 <sup>.</sup>	. mg/ng bm/uay	
Operator exposure	2,1896	mg/kg bw/day	70 UI AUEL - 15/ %	0		
<b>Operator exposure % of AOEL</b>	33176	%				

# M. German model: tractor-mounted, forestry, without PPE using Dimilin WG-80 THE GERMAN MODEL (GEOMETRIC MEAN VALUES)

Application method	Tractor-mounted/trailed broadcast air-assis	ted sprayer			
Product	Dimilin WG-80		Active substance		diflubenzuror
Formulation type	WG 🔫		a.s. concentration		800 g/kg
Dermal absorption from product	6	%	Dermal absorption from spray	r	<mark>6</mark> %
RPE during mix/loading	None 🔫		RPE during application		None
PPE during mix/loading	None				
PPE during application: Head	None	Hands	None	Body	None
Dose	0,06	kg product/ha	Work rate/day		8 <mark>ha</mark>
AOEL	0,0066	mg/kg bw/day			
DERMAL EXPOSURE DURING	MIXING AND LOADING				
Hand contamination/kg a s	2	ma/ka a s			
Hand contamination/day	0.768	mg/day			
Protective clothing	0,700	ing day			
Transmission to skin	100	0/2			
Dermel experimente e e	0 768	/0 mg/day			
Definal exposure to a.s.	0,708	iiig/day			
INHALATION EXPOSURE DUF	RING MIXING AND LOADING				
Inhalation exposure/kg a.s.	0,008	mg/kg a.s.			
Inhalation exposure/day	0,003072	mg/day			
RPE	none				
Transmission through RPE	100	%			
Inhalation exposure to a.s.	0,003072	mg/day			
DERMAL EXPOSURE DURING	SPRAY APPLICATION				
Application technique	Tractor-mounted/trailed broadca	ast air-assisted spi	rayer		
~	Head	Hands	Rest of body	r	
Dermal contamination/kg a.s.	1,2	0,1	9,6	•	
Dermal contamination/day	0,4608	0,2688	3,6864		
Protective clothing	none	none	e none	;	
Transmission to skin	100	100	100	%	
Total dermal exposure to a.s.	4,416	mg/day			
INHALATION EXPOSURE DUE	RING SPRAYING				
Inhalation exposure/kg a s	0.018	mo/ko a s			
Inhalation exposure/day	0.006912	mg/day			
RPF	0,000912	iiig/duy			
Transmission through RPF	100	0/0			
Inhalation exposure to a s	0.006012	ma/day			
initiation exposure to a.s.	0,000912	iiig/day			
ABSORBED DOSE					
	Mix/load	l	Application		
Dermal exposure to a.s.	0,768	mg/day	4,416	mg/day	
Percent absorbed	6	%	6	%	
Absorbed dose (dermal route)	0,04608	mg/day	0,26496	mg/day	
Inhalation exposure to a.s.	0,003072	mg/day	0,006912	mg/day	
Total systemic exposure	0,049152	mg/day	0,271872	mg/day	
PKEDICIED EXPOSURE	0.201024	m a/dar			
Operator body weight	0,321024	ing/day			
Operator body weight	60	Kg ma/lea boold			
Operator exposure	0,0053504	mg/kg.pw/day			
Operator exposure % of AOEL	81	70			

# N. German model: hand-held, orchard without PPE using Dimilin WG-80

Application method	Hand-held spraver; hydraulic nozzles, Outdo	oor, high level target	•			
Product	Dimilin WG-80	, j	Active substance		diflubenzuron	
Formulation type	WG 🔫	•	a.s. concentration		800 g/kg	
Dermal absorption from product	6	%	Dermal absorption from spra	/	<mark>6</mark> %	
RPE during mix/loading	None 🔫		RPE during application		None	•
PPE during mix/loading	None 💌			_		
PPE during application: Head	None	Hands	None	Body	None	-
Dose	0,06	kg product/ha	Work rate/day		1 <mark>ha</mark>	
AOEL	0,0066	mg/kg bw/day				
DERMAL EXPOSURE DURING	MIXING AND LOADING					
Hand contamination/kg a.s.	21	mg/kg a.s.				
Hand contamination/day	1,008	mg/day				
Protective clothing	none					
Transmission to skin	100	%				
Dermal exposure to a.s.	1,008	mg/day				
INHALATION EXPOSURE DUR	ANG MIXING AND LOADING	_				
Inhalation exposure/kg a.s.	0,02	mg/kg a.s.				
Inhalation exposure/day	0,00096	mg/day				
RPE	none					
Transmission through RPE	100	%				
Inhalation exposure to a.s.	0,00096	mg/day				
DERMAL EXPOSURE DURING	SPRAY APPLICATION					
Application technique	Hand-held sprayer: hydraulic no	zzles. Outdoor, hi	igh level target			
	Head	Hands	Rest of bod	/		
Dermal contamination/kg a.s.	4,8	10,6	2	5		
Dermal contamination/day	0,2304	0,5088	1,	2		
Protective clothing	none	none	non	e		
Transmission to skin	100	100	100	%		
Total dermal exposure to a.s.	1,9392	mg/day				
INHALATION EXPOSURE DUR	LING SPRAYING					
Inhalation exposure/kg a.s.	0,3	mg/kg a.s.				
Inhalation exposure/day	0,0144	mg/day				
RPE	none					
Transmission through RPE	100	%				
Inhalation exposure to a.s.	0,0144	mg/day				
ABSORBED DOSE						
	Mix/load		Application			
Dermal exposure to a.s.	1,008	mg/day	1,9392	mg/day		
Percent absorbed	6	%	6	%		
Absorbed dose (dermal route)	0,06048	mg/day	0,116352	mg/day		
Inhalation exposure to a.s.	0,00096	mg/day	0,0144	mg/day		
Total systemic exposure	0,06144	mg/day	0,130752	mg/day		
PREDICTED EXPOSURE						
Total systemic exposure	0,192192	mg/day				
Operator body weight	60	kg				
Operator exposure	0,0032032	mg/kg bw/day				
Operator exposure % of AOEL	49	%				

# O. German model: Estimated dermal and inhalation exposure during mixing/loading for mushroom

grower in greenhouse using automatic spraying of Dimilin WG-80 without PPE

Application method	Hand-held sprayer: hydraulic nozzles. Outdo	oor, high level target	▼			
Product	Dimilin WG-80	-	Active substance		diflubenzuron	
Formulation type	WG 🗶		a.s. concentration		800 g/kg	
Dermal absorption from product	6	%	Dermal absorption from spray		<mark>6</mark> %	
RPE during mix/loading	None 💌		RPE during application		None	-
PPE during mix/loading	None 💌					
PPE during application: Head	None 💌	Hands	None	Body	None	•
Dose	12,5	kg product/ha	Work rate/day		0,15 ha	
AOEL	0,0066	mg/kg bw/day				
DERMAL EXPOSURE DURING	MIVING AND LOADING					
Hand contamination/kg a s	MIAING AND LOADING	ma/ka a s				
Hand contamination/day	21	mg/day				
Protective clothing	51,5	ilig/uay				
Transmission to skin	100	0/				
Dermal exposure to a s	100	70 mg/day				
Dermai exposure to a.s.	31,5	mg/uay				
INHALATION EXPOSURE DUR	ING MIXING AND LOADING					
Inhalation exposure/kg a.s.	0.02	mg/kg a s				
Inhalation exposure/day	0.03	mg/day				
RPE	0,05					
Transmission through RPF	100	%				
Inhalation exposure to a s	0.03	mg/day				
minution exposure to a.s.	0,05	ing/uuy				
DERMAL EXPOSURE DURING	SPRAY APPLICATION					
Application technique	Hand-held spraver: hvdraulic no	zzles. Outdoor hi	igh level target			
rr	Head	Hands	Rest of body			
Dermal contamination/kg a s	4.8	10.6	25			
Dermal contamination/day	7 2	15.9	37 5			
Protective clothing	none	none	none			
Transmission to skin	100	100	100	%		
Total dermal exposure to a.s.	60.6	mg/day	100			
	00,0					
INHALATION EXPOSURE DUR	ING SPRAYING					
Inhalation exposure/kg a.s.	0,3	mg/kg a.s.				
Inhalation exposure/day	0,45	mg/day				
RPE	none					
Transmission through RPE	100	%				
Inhalation exposure to a.s.	0,45	mg/day				
	_					
ABSORBED DOSE						
	Mix/load		Application			
Dermal exposure to a.s.	31,5	mg/day	60,6	mg/day		
Percent absorbed	6	%	6	%		
Absorbed dose (dermal route)	1,89	mg/day	۸ <sup>3,636</sup>	mg/day		
Inhalation exposure to a.s.	0,03	mg/day	0,45	mg/day		
Total systemic exposure	1,92	mg/day	4,086	mg/day		
BREDICTED EVBOULDE			•			
PKEDICTED EXPOSURE	<i></i>					
1 otal systemic exposure	6,006	mg/day	Operator exposure =	=0.032	mg/kg bw/day	1
Operator body weight	60 0 1001	Kg	% of AOEL = 484 %	6		
Operator exposure % of AOFI	U,1UUI 1517	mg/kg Dw/uay				
Operator exposure 70 of AOEL	1317	/0				

# P. German model: Estimated dermal and inhalation exposure during mixing/loading for mushroom

# grower in greenhouse using automatic spraying of Dimilin WG-80 with PPE

Application method	Hand-held sprayer: hydraulic nozzles. Outd	oor, high level target	<b>~</b>			
Product	Dimilin WG-80		Active substance		diflubenzuron	
Formulation type	WG 💌		a.s. concentration		<b>800</b> g/kg	
Dermal absorption from product	6	%	Dermal absorption from spray	,	<mark>6</mark> %	
RPE during mix/loading	None 🔻		RPE during application		None	-
PPE during mix/loading	Gloves 💌					
PPE during application: Head	Hood and visor 🔹 💌	Hands	Gloves	Body	Coverall and sturdy footwear	-
Dose	12,5	kg product/ha	Work rate/day		0,15 ha	
AOEL	0,0066	mg/kg bw/day	-			
DERMAL EXPOSURE DURING	MIXING AND LOADING					
Hand contamination/kg a.s.	21	mg/kg a.s.				
Hand contamination/day	31,5	mg/day				
Protective clothing	gloves					
Transmission to skin	1	%				
Dermal exposure to a s	0.315	mg/dav				
	*,===					
INHALATION EXPOSURE DUR	ING MIXING AND LOADING					
Inhalation exposure/kg a s	0.02	mg/kg a s				
Inhalation exposure/day	0,02	mg/day				
DDE	0,05	ing/day				
Transmission through DDE	100	0/_				
	100	70 				
innalation exposure to a.s.	0,03	mg/day				
DEDMAL EXPOSURE DUDING	CDD A V A DDI ICATION					
DERMAL EXPOSURE DURING	SPRAY APPLICATION	1	1.1.1			
Application technique	Hand-neid sprayer: nydraulic no	zzies. Outdoor, hi	ign level target			
5 1	Head	Hands	Rest of body	/		
Dermal contamination/kg a.s.	4,8	10,6	2:	) 		
Dermal contamination/day	7,2	15,9	37,5	,		
Protective clothing	hood and visor	gloves	coverall and sturdy footwea	ſ		
Transmission to skin	5	1	5	%		
Total dermal exposure to a.s.	2,394	mg/day				
INHALATION EXPOSURE DUR	ING SPRAYING					
Inhalation exposure/kg a.s.	0,3	mg/kg a.s.				
Inhalation exposure/day	0,45	mg/day				
RPE	none					
Transmission through RPE	100	%				
Inhalation exposure to a.s.	0,45	mg/day				
ABSORBED DOSE						
	Mix/load		Application			
Dermal exposure to a.s.	0,315	mg/day	2,394	mg/day		
Percent absorbed	6	%	6	%		
Absorbed dose (dermal route)	0,0189	mg/day	0,14364	mg/day		
Inhalation exposure to a.s.	0.03	mg/day	0.45	mg/dav		
Total systemic exposure	0.0489	mg/day	0.59364	mg/dav		
,		0		6		
PREDICTED EXPOSURE						
Total systemic exposure	0.64254	mg/day	Orneretes		000015	/d.a
Operator body weight	60	kg	Operator expo	sure =0	.000815 mg/kg bw/	uay
Operator exposure	0,010709	mg/kg bw/dav	% of AOEL =	12 %		
Operator exposure % of AOEL	162	%				

# Q. German model: Estimated dermal and inhalation exposure during mixing/loading for mushroom

# grower in greenhouse using Dimilin WG-80 and hand-held sprayer without PPE

Application method	Hand-held sprayer: hydraulic nozzles. Outd	oor, high level target		-			
Product	Dimilin WG-80		Active substanc	e		diflubenzuron	
Formulation type	WG 🔻	•	a.s. concentration	on		800 g/kg	
Dermal absorption from product	6	%	Dermal absorpt	ion from spray		6 %	
RPE during mix/loading	None 🗸 🗸	•	RPE during app	lication		None	-
PPE during mix/loading	None 💌		0 11				_
PPE during application: Head	None	Hands	None	-	Body	None	-
Dose	12.5	kg product/ha	Work rate/day		1 5	0.15 ha	
AOEL	0.0066	mg/kg bw/day	i on inco, any			0,10 III	
DERMAL EXPOSURE DURING	MIXING AND LOADING						
Hand contamination/kg a s		ma/ka a s					
Hand contamination/kg a.s.	21	mg/day					
Protoctions alothing	51,5	iiig/day					
Protective clothing	none	0 /					
I ransmission to skin	100	%					
Dermal exposure to a.s.	31,5	mg/day					
INHALATION EXPOSURE DUR	ING MIXING AND LOADING						
Inhalation exposure/kg a.s.	0,02	mg/kg a.s.					
Inhalation exposure/day	0,03	mg/day					
RPE	none						
Transmission through RPE	100	%					
Inhalation exposure to a s	0.03	mg/day					
initiation exposure to u.s.	0,00						
DERMAL EXPOSURE DURING	SPRAV APPLICATION						
Application technique	Hand hald sprayar: hydraulia no	zzlas Outdoor h	igh lavel target				
Application technique	Trand-neid sprayer. Itydraulie no	JZZIES. Outdoor, I		Deat of he day			
Den 1 de la districta d	Head	Hand	5	Rest of body			
Dermal contamination/kg a.s.	4,8	10,0	)	25			
Dermal contamination/day	7,2	15,9	)	37,5			
Protective clothing	none	none	9	none			
Transmission to skin	100	100		100	%		
Total dermal exposure to a.s.	60,6	mg/day					
INHALATION EXPOSURE DUR	ING SPRAYING						
Inhalation exposure/kg a.s.	0,3	mg/kg a.s.					
Inhalation exposure/day	0,45	mg/day					
RPE	none						
Transmission through RPE	100	%					
Inhalation exposure to a s	0.45	mg/day					
	•,••						
ABSORBED DOSE							
ABSORBED DOSE	Mix/load		Application				
Demuel competence of	21.5		Application	(0.(			
Dermai exposure to a.s.	31,5	mg/day		00,0	mg/day		
Percent absorbed	6	%0		6	%		
Absorbed dose (dermal route)	1,89	mg/day		3,636	mg/day	7	
Inhalation exposure to a.s.	0,03	mg/day		0,45	mg/day	T.	
Total systemic exposure	1,92	mg/day		4,086	mg/day	T	
PREDICTED EXPOSURE							
Total systemic exposure	6,006	mg/day					
Operator body weight	60	kg					
Operator exposure	0,1001	mg/kg bw/day					
<b>Operator exposure % of AOEL</b>	1517	%					

**R.** German model: Estimated dermal and inhalation exposure during mixing/loading for mushroom grower in greenhouse using Dimilin WG-80 and hand-held sprayer with PPE

Application method	Hand-held sprayer: hydraulic nozzles. Outo	oor, high level target	-			
Product	Dimilin WG-80		Active substance		diflubenzuron	
Formulation type	WG 🔻		a.s. concentration		800 g/kg	
Dermal absorption from product	6	%	Dermal absorption from sp	ay	<mark>6</mark> %	
RPE during mix/loading	A1P2 🗸 🗸	• •	RPE during application	Ĩ	None	-
PPE during mix/loading	Gloves 🗸 🗸		0 11			_
PPE during application: Head	Hood and visor	Hands	Gloves	▼ Body	Coverall and sturdy footwear	-
Dose	12.5	kg product/ha	Work rate/day		0.15 ha	_
AOEL	0,0066	mg/kg bw/day				
		0 0 0				
DERMAL EXPOSURE DURING	MIXING AND LOADING					
Hand contamination/kg a s	21	mø/kø a s				
Hand contamination/day	31.5	mg/day				
Protoctive electhing	aloves	iiig/day				
Transmission to also	gioves	0/				
	1	<sup>%0</sup>				
Dermal exposure to a.s.	0,315	mg/day				
INHALATION EXPOSURE DUR	ING MIXING AND LOADING					
Inhalation exposure/kg a.s.	0,02	mg/kg a.s.				
Inhalation exposure/day	0,03	mg/day				
RPE	A1P2					
Transmission through RPE	2	%				
Inhalation exposure to a.s.	0,0006	mg/day				
DERMAL EXPOSURE DURING	SPRAY APPLICATION					
Application technique	Hand-held sprayer: hydraulic no	zzles. Outdoor, h	igh level target			
	Head	Hands	Rest of bo	dv		
Dermal contamination/kg a.s.	4.8	10.6		25		
Dermal contamination/day	7 2	15.9	) 3	75		
Protective clothing	hood and viso	· gloves	s coverall and sturdy footw	-,- Par		
Transmission to skin	5	1	coverant and startey rootw	5 %		
Total darmal exposure to a s	2 204	ma/day		5 /0		
Total definal exposure to a.s.	2,394	iiig/uay				
INITAL ATION EXPOSTIBE DUD	INC SDD A VINC					
Inflation exposure/kg a g		malia				
Initialitation exposure/kg a.s.	0,5	mg/kg a.s.				
Innalation exposure/day	0,45	mg/day				
RPE	none	;				
Transmission through RPE	100	%				
Inhalation exposure to a.s.	0,45	mg/day				
ABSORBED DOSE						
	Mix/load		Application			
Dermal exposure to a.s.	0,315	mg/day	2,39	04 mg/day	7	
Percent absorbed	6	%		6 %		
Absorbed dose (dermal route)	0,0189	mg/day	0,143	64 mg/day	7	
Inhalation exposure to a.s.	0,0006	mg/day	0,4	5 mg/day	t	
Total systemic exposure	0,0195	mg/day	0,593	64 mg/day	t	
- *	,		,	6 7		
PREDICTED EXPOSURE						
Total systemic exposure	0.61314	mg/day				
Operator body weight	60	kg				
Operator exposure	0,010219	mg/kg bw/dav				
Operator exposure % of AOEL	155	%				

Addendum to Draft Assessment Report



# DIFLUBENZURON

Volume 3 Annex B.7 Residue data

Rapporteur Member State: Sweden

December 2008



# Volume 1

Level 1: Statement of subject matter and purpose for which the monograph was prepared

Level 2: Reasoned statement of the overall conclusions drawn by the Rapporteur Member State Appendix 1: Standard terms and abbreviations Appendix 2: Specific terms and abbreviations

Appendix 3: List of endpoints

- Level 3: Proposed decision with respect to the application for inclusion of the active substance in Annex I
- Level 4: Further information to permit a decision to be made, or to support a review of the conditions and restrictions associated with the proposed inclusion in Annex 1

#### Volume 2

Annex A: List of the tests and studies submitted and of information available

#### Volume 3

#### Annex B: RMS summary, evaluation and assessment of the data and information

Annex B.1: Identity Annex B.2: Phys/chem. Annex B.3: Data application and further information. Annex B.4: Proposal for classification and labelling Annex B.5: Analytical method Annex B.6: Toxicology and metabolism **Annex B.7: Residues in crop** Annex B.8: Fate and behaviour

# Annex B.9: Ecotoxicology

#### Volume 4

Annex C: Confidential information and summary and assessment of information relating to the collective submission of dossiers

# Table of contents

## B.7 Residue data 109

B.7.6 Residues resulting from supervised residue trials (Annex IIA 6.3; Annex IIIA 8.2) 109
### B.7 Residue data

### B.7.6 Residues resulting from supervised residue trials (Annex IIA 6.3; Annex IIIA 8.2)

### *Reporting table point 3 (15)*

RMS to report the US trials on mushrooms in an addendum for considering in expert meeting

Reference:	<b>Report 04:</b> Gaydosh K.A (1998) Dimilin 25W and Dimilin 4L in Mushrooms: Magnitude of the Residue Study. Report
	Uniroval chemical Inc. USA NO RP-97004
	DI - 11455
Test Material:	Mushroom
Guideline:	US EPA Pesticide Assessment Guidelines:
GLP:	Yes
Material and methods:	
Test concentration:	The application rates for the casing treatment in this study were similar
	to the rate proposed within the E.U. ( <i>i.e.</i> 4 g Dimilin WP-25/m <sup>2</sup> or 2 g
	Dimilin 4L/m <sup>2</sup> , equivalent to 1 and 0.8 g a.s./m <sup>2</sup> , respectively).
Test system:	Dimilin WP-25 and Dimilin 4L can be used to control larvae of sciarid flies in
	mushroom growing medium, preventing damage to the developing mushrooms. Either
	formulation may be applied to the compost, between filling and spawning, and/or to
	the casing in the U.S.A In this study, the magnitude of the residues of diflubenzuron
	and its possible metabolites, 4-chlorophenylurea and 4-chloroaniline, were determined
	in mushrooms after application of either Dimilin WP-25 (containing 25 $\%$ w/w
	difluben zuron) or Dimilin 4L (containing 40.4 $\%$ w/w difluben zuron) according to the
	U.S. maximum label rates for mushrooms. The plots were located at 2 commercial
	mushroom production facilities and the crops were grown and maintained under
	conditions typical of the cultural practice in a commercial facility.
Sampling time points:	The mushrooms were harvested according to commercial practice at 4 flushes (breaks)
	and the samples were shipped to the analytical testing facility for analysis.
Method of analysis:	Separate methods were used to analyse the mushrooms for each of the
	three analytes, diflubenzuron (DFB), 4-chlorophenylurea (CPU), and 4-
	chloroaniline (PCA). The methods for diflubenzuron and CPU used
	external standards, while the method for PCA used an internal standard.

The accuracy, reliability, and reproducibility of each method was demonstrated through acceptable recoveries of the fortified analytes during a method of verification conducted prior to sample analysis, and through procedural recoveries conducted concurrently with sample analysis. The limit of quantification (LOQ) were established at 0.01 ppm for Diflubenzuron and CPU, and 0.0050 ppm for PCA. The time from harvest to latest analysis was for Pennsylvania for DFB 37-39 days, CPU 29-39 days, and PCA 43-78 days. The time from harvest to latest analysis was for California for DFB 64-76 days, CPU 64-71 days, and PCA 57-146 days. 1997-1998

Date of experiment:

Trial	Analyte	Residue mg/kg*					
Formulation	1 mary te	Dimilin	WP-25	<b>Dimilin 4L</b>			
	DFB	< 0.01 0.04 0.02 0.09	< 0.01 0.06 0.02 0.09	0.01 0.05 <0.01 0.05	0.02 0.04 <0.01 0.05		
Califormia	CPU	< 0.01 < 0.01 0.01 0.01	< 0.01 < 0.01 < 0.01 < 0.01	< 0.01 < 0.01 < 0.01 < 0.01	< 0.01 < 0.01 < 0.01 < 0.01		
	РСА	<0.0050 <0.0050 0.0051 0.0235	<0.0050 <0.0050 <0.0050 0.0148	<0.0050 <0.0050 0.0100 0.0154	<0.0050 <0.0050 0.0100 0.0154		
Pennsylvania	DFB	0.07 0.06 0.04 <0.01	0.06 0.07 0.04 <0.01	0.14 0.05 0.03 0.02	0.14 0.05 0.03 0.02		
	CPU	0.02 0.02 0.02 <0.01	0.02 0.03 0.02 <0.01	0.04 0.03 0.03 0.02	0.04 0.03 0.03 0.02		

 Table 6.3-6: Residues in mushrooms after casing treatment with Dimilin WP-25 or

 Dimilin 4L

	РСА	<0.0050 <0.0050 0.0051 <0.0050	<0.0050 <0.0050 <0.0050 0.0059	<0.0050 <0.0050 <0.0050 0.0065	<0.0050 <0.0050 <0.0050 0.0100			
*Figures represent duplicate values from 4 flushes (breaks)								

### Comment:

Residues for diflubenzuron (DFB) ranged from < 0.01 to 0.14 mg/kg, for 4-chlorophenylurea (CPU) from < 0.01 to 0.04 mg/kg and for 4-chloroaniline (PCA) from <0.0050 to 0.0235mg/kg. The levels of residues from DFB, CPU and PCA were higher than residues reported from European residue trials (DAR B.7.6).

The time from harvest to storage is adequate for DFB, and CPU as data show that these substances are stable for 18-19 months (DAR, Tables 6.2.2 and 6.2.3). However PCA is not stable during time from harvest to analysis in the experiment (DAR, table 6.2-3) after 30 days of storage 14% of PCA was recovered, and after 18 months 27% of PCA was recovered. Mushrooms analysed for PCA should best be analysed directly after harvest as the metabolite is degraded or binds to plant tissue under storage conditions. However, the result for PCA shows the concentration of available PCA residues in mushrooms with the available analytical method.

# Corrigendum to the Draft Assessment Report of May 2005



# DIFLUBENZURON

Volume 3 Annex B.7 Residue data

December 2008



### Volume 1

Level 1: Statement of subject matter and purpose for which the monograph was prepared

Level 2: Reasoned statement of the overall conclusions drawn by the Rapporteur Member State Appendix 1: Standard terms and abbreviations Appendix 2: Specific terms and abbreviations

Appendix 3: List of endpoints

- Level 3: Proposed decision with respect to the application for inclusion of the active substance in Annex I
- Level 4: Further information to permit a decision to be made, or to support a review of the conditions and restrictions associated with the proposed inclusion in Annex 1

### Volume 2

Annex A: List of the tests and studies submitted and of information available

### Volume 3

### Annex B: RMS summary, evaluation and assessment of the data and information

- Annex B.1: Identity Annex B.2: Phys/chem. Annex B.3: Data application and further information. Annex B.4: Proposal for classification and labelling Annex B.5: Analytical method Annex B.6: Toxicology and metabolism **Annex B.7: Residues in crop** Annex B.8: Fate and behaviour Annex B.9: Ecotoxicology
  - Appendix 1: Standard terms and abbreviations
  - Appendix 2: Specific terms and abbreviations

### Volume 4

Annex C: Confidential information and summary and assessment of information relating to the collective submission of dossiers

### Table of contents

Intr	oduction 115	
B.7	2 Metabolism, distribution and expression of residues in livestock 115	
B.7.2.	Metabolism studies on laying hen	115
B.7	7 Effects of industrial processing and/or household preparation (Annex IIA 6.5; Annex IIIA 8.4)	125
B.7.7.	Effects of processing on the nature of residue in mushrooms	125
B.7	8 Livestock feeding studies (Annex IIA 6.4; Annex IIIA 8.3) 128	

### Introduction

This corrigendum was prepared in response to the requirements of the Reporting table rev. 1-0 (20.12.2007);

### B.7.2 Metabolism, distribution and expression of residues in livestock

### Reporting table point 3 (2).

For the laying hen study, information should be given on the evolution of the residue levels in eggs, reflecting the accumulation capacity of diflubenzuron. RMS to consider a corrigendum.

### B.7.2.1 Metabolism studies on laying hen

Reference: Report 01a	Gifford, L.J. Dunsire, J.P. (1994). The disposition of [ <sup>14</sup> C]-Diflubenzuron in the laying							
	hen. Report Inveresk Research International, Scotland No. 56354/19/1993. D1-8935							
Report 01b	Cnubben N., H., P., Bie, A., T., M., J. De, Ommen B.van (1996)							
	Extraction, quantification, storage stability, metabolite profiling and							
	metabolite identification of <sup>14</sup> C-Diflubenzuron and its metabolites in							
	edible tissues of the laying hen. Report TNO Nutrition and Food							
	Research institute, the Netherlands. V94.426. DI - 8935							
Test Material:	[ <sup>14</sup> C]-Diflubenzuron uniformly labelled in both phenyl rings, batch number							
	AO189K30A, purity 99,8%, AIS9247AA purity 99%, A0188K034A purity 97,5%.							
	[ <sup>14</sup> C]-4-chloroaniline PCA (batch number CFQ5464, specific radioactivity 22.4							
	mCi/g), [ <sup>14</sup> C]-4-chlorophenylurea CPU (batch number AIS9112AAspecific							
	radioactivity 11.0 mCi/g) and [ <sup>14</sup> C]-4-chloroacetanilide PCAA (batch number							
	AIS9223AB), specific radioactivity 15.3 mCi/g) for the determination of recoveries.							
Guideline:	US EPA-FIFRA guideline 171-4.							
GLP:	Yes							
Material and methods:								
Test concentration:	1 mg/kg bw/day (11 15 mg/kg feed/day) and 10 mg/kg bw/day (101 26 mg/kg							

feed/day).Test system:Oral administration twice daily for 10 days. Doses were administrated as a suspension<br/>in 1% gum tragacanth. Group 1 (control group 1% gum tragacanth only) Group 2

	(1mg/kg/day), Group 3 (10 mg/kg/day).
Duration:	20 days
Sampling time points:	Eggs were collected when laid. Excreta were collected prior to each dose and at
	sacrifice. Skin, liver, kidney, muscle, bone marrow and fat were sampled at sacrifice.
Method of analysis:	Samples of each commodity were extracted and fractionated to determine the quantity
	and qualitative nature of residue. Radioactive residues were quantified with
	combustion analysis and liquid scintillation analysis. The qualitative analysis were
	performed with HPLC, LC-MS-MS and GC-MS.
Number of animals:	Group 1 three hens, group 2 six hens and group 3 three hens
Date of experiment:	October 1992 - March 1993

**Group 2: low dose level: 1 mg/kg/day:** Analysis of eggs indicated low levels of radioactivity associated with egg whites (table 6). Mean levels of radioactivity in egg whites plateau at 24 ng equiv.g<sup>-1</sup> after the fifth dose (2.5 days) and thereafter only increased slightly until mean of 28 ng equiv.g<sup>-1</sup> at post dose 19. Higher levels of radioactivity were detected in egg yolk (table 7). An increase from a mean of 1 ng equiv.g<sup>-1</sup> post dose 1 to 769 ng equiv.g<sup>-1</sup> post dose 15 (7.5 days) and thereafter a small increase until a mean of 819 ng equiv.g<sup>-1</sup> post dose 19.

				TABLE 6				
			Grou	up 2 (Low Dos	e)			
	Level o Ora	f Total Radio L Administrat Targ	activity ions of get Dose	y in Egg White [ <sup>14</sup> C]-diflub Level 1 mg.k	e Followi enzuron t gʻl.dayʻ	ng 20 Twice ( o Laying Hens	Daily S	
Γ	Time	139		149		159		
	Point (h)	ng equiv.g <sup>.1</sup>	% Dose	ng equiv.g <sup>.1</sup>	% Dose	ng equiv.g '	% Dose	Mean ng
Р	redose 1	2	0.00	1	0.00	1	0.00	equiv.g
0	-8	1	0.00	0**	0.00**	0*	0.00*	
8	-24	NS	NS	NS	NS	NS	NS	
2	4-32	17	0.00	19	0.00	16	0.00	
3	2-48	NS	NS	NS	NS	NS	NS	17.2
4	8-56	23	0.00	25	0.01	24	0.00	1/.3
5	6-72	NS	NS	NS	NS	NS	NS	24
7	2-80	26	0.00	33	0.01	24	0.00	24
8	0-96	NS	NS	NS	NS	NS	NS	27
9	6-104	26	0.00	34	0.01	24	0.00	21
1	04-120	NS	NS	NS	NS	NS	NS	
1	20-128	28	0.00	32	0.01	24	0.00	28
1	28-144	NS	NS	NS	NS	NS	NS	20
1	44-152	29	0.01	32	0.01	24	0.00	28
1	52-168	NS	NS	NS	NS	NS	NS	
1	68-176	30	0.01	31	0.01	24	0.00	
1	76-192	NS	NS	NS	NS	NS	NS	28
1	92-200	32	0.01	27	0.00	36	0.01	
2	00-216	NS	NS	NS	NS	พร	NS	28
2	16-224	27	0.00	32	0.01	24	0.00	
2	24-226	NS	NS	NS	NS	NS	NS	

\* = Results based on data <30 d.p.m. above background \*\* = Results based on data <10 d.p.m. above background NS = No sample

### TABLE 7

### Group 2 (Low Dose)

# Levels of Total Radioactivity in Egg Yolk Following 20 Twice Daily Oral Administrations of [14C]-diflubenzuron to Laying Hens Target Dose Level 1 mg.kg<sup>-1</sup>.day<sup>-1</sup>

Time Point	139		149		159		
(h)	ng equiv.g <sup>.1</sup>	% Dose	ng equiv.g $^{\cdot 1}$	% Dose	ng equiv.g <sup>-1</sup>	% Dose	
Predose 1	0**	0.00**	1*	0.00*	0**	0.00**	
0-8	1*	0.00*	2	0.00	0**	0.00**	
8-24	NS	NS	NS	NS	NS	NS	
24-32	33	0.00	41	0.00	41	0.00	
32-48	NS	NS	NS	NS	NS	NS	
48-56	124	0.01	145	0.01	169	0.01	
56-72	NS	NS	NS	NS	NS	NS	
72-80	228	0.02	262	0.02	254	0.02	
80-96	NS	NS	NS	NS	NS	NS	
96-104	331	0.03	440	0.03	357	0.03	
104-120	NS	NS	NS	NS	NS	NS	
120-128	444	0.04	608	0.05	481	0.04	
128-144	NS	NS	NS	NS	NS	NS	
144-152	542	0.05	666	0.06	571	0.05	
152-168	NS	NS	NS	NS	NS	NS	
168-176	683	0.06	854	0.07	670	0.06	
176-192	NS	NS	NS	NS	NS	NS	
192-200	940	0.08	746	0.06	662	0.06	
200-216	NS	NS	NS	NS	NS	NS	
216-224	773	0.07	967	0.08	697	0.06	
224-226	NS	NS	NS	NS	NS	NS	

\* = Results based on data <30 d.p.m. above background \*\* = Results based on data <10 d.p.m. above background NS = No sample

TABLE	7	(continued)

Time Point	Time Point 169		179		189		Mean	
(h)	ng equiv.g <sup>∙1</sup>	% Dose	ng equiv.g <sup>∙1</sup>	% Dose	ng equiv.g <sup>.1</sup>	% Dose	ng eqµiv.g	% Dose
Predose 1	1*	0.00*	0**	0.00**	0**	0.00**	0	0.00
0-8	0**	0.00**	1*	0.00**	1*	0.00*	1	0.00
8-24	NS	NS	NS	NS	NS	NS	NS	NS
24-32	40	0.00	41	0.00	41	0.00	40	0.00
32-48	NS	NS	NS	NS	NS	NS	NS	NS
48-56	141	0.01	156	0.01	135	0.01	145	0.01
56-72	NS	NS	NS	NS	NS	NS	NS	NS
72-80	254	0.02	299	0.02	261	0.02	260	0.02
80-96	NS	NS	NS	NS	NS	NS	NS	NS
96-104	387	0.03	462	0.04	390	0.03	394	0.03
104-120	NS	NS	NS	NS	NS	NS	NS	NS
120-128	545	0.04	596	0.05	505	0.04	530	0.04
128-144	NS	NS	NS	NS	NS	NS	NS	NS
144-152	697	0.06	770	0.06	635	0.05	647	0.06
152-168	NS	NS	NS	NS	NS	NS	NS	NS
168-176	819	0.07	861	0.07	724	0.06	769	0.07
176-192	NS	NS	NS	NS	NS	NS	NS	NS
192-200	864	0.07	832	0.07	747	0.07	799	0.07
200-216	NS	NS	NS	NS	NS	NS	NS	NS
216-224	845	0.07	849	0.07	782	0.07	819	0.07
224-226	NS	NS	NS	NS	NS	NS	NS	NS

\* = Results based on data <30 d.p.m. above background

\*\* = Results based on data <10 d.p.m. above background

NS = No sample

**Group 3: high dose level: 10 mg/kg.day:** Analysis of eggs indicated low levels of radioactivity associated with egg whites (table 13). Mean levels of radioactivity reached a plateau of 0.2  $\mu$ g equiv. g<sup>-1</sup> following administration of the fifth dose (2.5 days). Higher levels of radioactivity were detected in egg yolks (table 14). An increase from a mean of 0.3  $\mu$ g equiv. g<sup>-1</sup> post dose 3 to 7.3  $\mu$ g equiv. g<sup>-1</sup> post dose 15 (7.5 days) was observed, thereafter the levels remained constant. Thus, a plateau was reached at dose 15 (7, 5 days) which also was observed in the low dose administration (table 7). 8

### TABLE 13

### Group 3 (High Dose)

# Levels of Total Radioactivity in Egg White Following 20 Twice Daily Oral Administrations of [14C]-diflubenzuron to Laying Hens Target Dose Level 10 mg.kg<sup>-1</sup>.day<sup>-1</sup>

Time (h)	109		119		129		Mear	) 
T THE CITY	$\mu$ g equiv.g $^{\cdot 1}$	Total % Dose	$\mu$ g equiv.g $^{-1}$	Total % Dose	$\mu$ g equiv.g $^{\cdot 1}$	Total % Dose	$\mu$ g equiv.g <sup>.1</sup>	Total % Dose
Predose 1	0.0**	0.00**	0.0**	0.00**	0.0**	0.00**	0.0	0.00
0-8	0.0**	0.00**	0.0*	0.00*	0.0**	0.00**	0.0	0.00
8-24	0.1	0.00	NS	NS	NS	NS	0.1	0.00
24-32	NS	NS	0.1	0.00	0.1	0.00	0.1	0.00
32-48	NS	NS	NS	NS	NS	NS	NS	NS
48-56	0.2	0.00	0.3	0.00	NS	NS	0.2	0.00
56-72	NS	NS	NS	NS	NS¢	NSØ	NS	NS
72-80	0.2	0.00	0.3	0.00	NS	NS	0.2	0.00
80-96	NS	NS	NS	NS	NS	NS	NS	NS
96-104	0.2	0.00	0.2	0.00	0.3	0.01	0.2	0.00
104-120	NS	NS	NS	NS	NS	NS	NS	NS
120-128	0.2	0.00	0.2	0.00	0.3	0.01	0.2	0.00
128-144	NS	NS	NS	NS	NS	NS	NS	NS
144-152	0.1	0.00	0.2	0.00	0.3	0.01	0.2	0.00
152-168	NS	NS	NS	NS	NS	NS	NS	NS
168-176	0.2	0.00	0.2	0.00	0.2	0.01	0.2	0.00
176-192	NS	NS	NS	NS	NS	NS	NS	NS
192-200	0.2	0.00	0.2	0.00	0.2	0.01	0.2	0.00
200-216	NS	NS	NS	NS	NS	NS	NS	NS
216-224	0.2	0.00	0.2	0.00	0.2	0.01	0.2	0.00
224-226	NS	NS	NS	NS	NS	NS	NS	NS

\* = Results based on data <30 d.p.m. above background \*\* = Results based on data <10 d.p.m. above background  $\phi$  = Egg laid at this time was broken, therefore analysed with excreta

NS = No sample

### TABLE 14

### Group 3 (High Dose)

Levels of Total	Radioectivity	r in Egg	Yolk Follow	fng 20	Twice Daily
Oral Adminis	strations of	( <sup>14</sup> C] -dit	lubenzyron	to Layi	ng Hens
	Target Dose L	Level 10	ng.kg <sup>-1</sup> .dey	-1	

}			Animal Nu	inber			Hann		
Time (h)	109		119		129		Rea	1	
	µg equiv.g¹	Total X Dose	µg equiv.g⁻ <sup>.</sup>	Total % Dose	μg equiv.g <sup>-1</sup>	Total % Dose	µg equiv.gʻ	Total X Dose	
Predose 1	0.0**	0.00**	0.0*	0.00*	6.0**	0.00**	0.0	0.00	
0-8	0.0*	0.00*	0.0*	0.00*	0.0*	0.00*	Q.0	0.00	
8-24	0.2	0.00	NS	NS	KS	NES	0.2	0.00	
24-32	WS	RS	0.3	0.00	0.3	0.00	0.3	0.00	
32-48	NS	KS	NS	NS	NS	KS	NS	NS	
48-56	0.7	0.01	1.5	0.01	NS	KS	1.1	0.01	
56-72	NS	NS	NS	NS	N3¢	NS∳	NS	NS	
72-80	1.7	0.01	3.1	0.03	NS	NS	2.4	0.02	
80-96	2K	NS	NS	NS	NS	NS	NS	NS	
96-104	2.7	0.03	4.8	0.04	4.8	0.04	4.1	0.04	
104-120	NS	NS	NS	NS	NS	NS	NS	NS	
120-128	3.9	0.04	6.2	0.05	6.9	0.05	5.7	0.05	
128-144	XS	WS	as .	NS	NS	NS	N5	NŞ	
144-152	4.9	0.05	7.3	0.06	7.2	0.06	6.5	0.06	
152-168	NS	NS	NS	NS	MS	NS	NS	NS -	
168-176	5.6	0.05	7.9	0.06	8.5	0.07	7.3	0.06	
176-192	NS	NS	litS	NS	NS	ЯS	NS	NS	
192-200	5.9	0.05	8.2	0.06	8.3	D.07	7.5	0.06	
200-216	WS	NS	NS	NS	MS.	NS	NS	NS	
216-224	5.9	0.05	7.8	0.06	8.2	0.06	7.3	0.06	
224-226	NS	NS	MS	NS	IIS	NS	IIS	NS	

\* = Results based on data <30 d.p.m. above background \*\* = Results based on data <10 d.p.m. above background  $\phi$  = Egg laid at this time was broken, therefore analysed with excrete

NS = No sample

Comment: The study shows an accumulation of radioactive residues in egg yolks. Levels reached a plateau after the fifteenth dose following 20 twice daily oral administrations of [14C]-Diflubenzuron at 1 mg/kg bw/day (table 7) and 10 mg/kg bw/day (table 14). 769 ng equiv. $g^{-1}_{and}$  7.3 µg equiv.  $g^{-1}$  respectively.

### Reporting table point 3 (5) and 3(6).

It is not stated whether results in table reflect the 1mg/kg bw/d or 10 mg/kg bw/d dose. RMS to consider a corrigendum.

The target doses for the study were 1 and 10 mg/kg bw/day. As there was insufficient radioactive material, the high doses were reduced from about 10 mg/kg bw (doses 1-5) to about 9 mg/kg bw (doses 6-11) to about 8 mg/kg bw (doses 12-20). Since the levels in the tissues will be mainly determined by the doses at the end of the treatment period, the high dose is taken to be 8 mg/kg bw/day.

 Table B.7.2.1-5. Amounts of parent compound and metabolites in tissue sample from Laying hen taken 2 hours after the last oral dose of diflbenzuron HPLC system 2\*

Sample	Dose level	<sup>14</sup> C, diflube	nzuron equv	ivalents mg/l	kg and (% of	Sum of residues as	Total residues
	bw/day	CPU	PCAA	PCA	diflubenzuron	% of total <sup>14</sup> C in	mg/kg diflubenzuron
Liver	<mark>1</mark> 8	0.12 (20)	0.015 (2.6)	0.018(3.1) 0.048(1.3)	0.20 (34)	59 72	0.67 4 0
Kidney	1 8	0.089(23) 0.5(28)	nd nd	0.014 (3.6)	0.048(12) 0.40(22)	38	0.44
Muscle	1 8	0.020(14) 0.14(15)	nd nd	nd nd	0.10 (71) 0.72 (76)	85 91	0.15
Fat	1 8	0.008 (0.8)	$\begin{array}{c} 0.005 \ (0.5) \\ 0.026 \ (0.3) \end{array}$	nd nd	0.99 (98)	99 100	1.0
Skin	1 8	0.016 (3.8) 0.082 (2.6)	nd nd	nd nd	0.38 (90) 3.0 (94)	94 96	0.42
Egg-yolk (post-dose)	1 8	nd 0.56 (11)	nd nd	nd nd	0.26 (75) 4.2 (80)	75 91	0.81 5.6
Egg white (post-dose)	<mark>1</mark> 8	nd nd	0.007 (37) nd	nd nd	0.001 (5.3) nd	42 nd	0.024 0.29

nd = not detected.

\*= The figures have been calculated with the aid of JMPRs evaluation of diflubenzuron from 2002

### *Reporting table point 3 (7).*

Storage stability data in the tables should not only be given in mg/kg but also in percentage of the starting value. RMS to consider a corrigendum.

Table: B.7.2.1-7:	Storage stability	of egg volk.	spiked control	homogenate from	Laving hen
1 40101 01/12/11 / 1	Storage stability	or egg young	spinea control	nomogenate nom	Laying nen

Identity	Spike	Amount in fraction (in mg/kg) after storage							
	$\mu g/g^*$	10 months -195°C		12 months - 80°C		10 months - 20°C			
CPU	0.040	0.034	<mark>85%</mark>	0.032	<mark>80%</mark>	0.032	<mark>80%</mark>		
PCAA	0.040	0.036	<mark>90%</mark>	0.034	<mark>85%</mark>	0.034	<mark>85%</mark>		
PCA	0.020	0.017	<mark>85%</mark>	0.018	<mark>106%</mark>	0.018	<mark>106%</mark>		
diflubenzuron	0.040	0.036	<mark>90%</mark>	0.033	<mark>92%</mark>	0.033	<mark>92%</mark>		

\* The amounts are expressed as  $\mu g/g$  of tissue instead of  $\mu g/g$  of homogenate

Identity	Spike	Amount in fraction (in mg/kg) after storage						
	$\mu g/g^*$	10 months -195°C		12 months - 80°C		15 months - 20°C		
CPU	0.040	0.037	<mark>93%</mark>	0.033	<mark>83%</mark>	0.053	<mark>133%</mark>	
PCAA	0.040	0.057	<mark>143%</mark>	0.032	<mark>80%</mark>	0.023	<mark>58%</mark>	
PCA	0.020	0.007	<mark>35%</mark>	0.016	<mark>80%</mark>	0.005	<mark>25%</mark>	
diflubenzuron	0.040	0.039	<mark>98%</mark>	0.032	<mark>80%</mark>	0.032	<mark>80%</mark>	

Table: B.7.2.1-8: Storage stability of liver, spiked control homogenate from Laying hen

\* The amounts are expressed as  $\mu g/g$  of tissue instead of  $\mu g/g$  of homogenate.

Table:	B.7.2.1-9	Storage	stability	of muscle.	spiked	homogenate
			Secondy			nomogeneee

Identity	Spike	Amount in	Amount in fraction (in mg/kg) after storage							
	$\mu g/g^*$	10 months -195°C		12 months - 80°C		15 months - 20°C				
CPU	0.040	0.036	<mark>90%</mark>	0.036	<mark>90%</mark>	0.031	<mark>86%</mark>			
PCAA	0.040	0.068	<mark>170%</mark>	0.067	<mark>168%</mark>	0.048	<mark>120%</mark>			
PCA	0.020	<llo**< td=""><td><mark>0%</mark></td><td><llo**< td=""><td><mark>0%</mark></td><td>0.005</td><td><mark>25%</mark></td></llo**<></td></llo**<>	<mark>0%</mark>	<llo**< td=""><td><mark>0%</mark></td><td>0.005</td><td><mark>25%</mark></td></llo**<>	<mark>0%</mark>	0.005	<mark>25%</mark>			
diflubenzuron	0.040	0.035	<mark>88%</mark>	0.037	<mark>93%</mark>	0.036	<mark>90%</mark>			

\* The amounts are expressed as  $\mu g/g$  of tissue instead of  $\mu g/g$  of homogenate.

\*\* <LLOQ means below lower limit of quantification.

**Comment:** The storage stability of the three tissues (muscle, liver and egg yolk) was studied at different storage conditions varying in temperature as well as time. For the spiked egg yolk, the metabolite profile remains similar at the different storage conditions, with high recovery for all metabolites including 4-chloroaniline (PCA). In the spiked liver and muscle the recover of 4-chlorophenylurea (CPU) and 4-chloroacetanilide (PCAA) were sometime above theoretical maximum while 4-chloroaniline. PCA however, was only recovered from 0-25% at all storage conditions.

### **B.7.3** Residue definitions in plants and animals

### Reporting table point 3 (11).

**Open point**: RMS should provide an evaluation of the existing data from available reports and publication on metabolites of diflubenzuron (CPU, DFBA and PCA) and suggest which end-points could be used to characterise their toxicological properties (same end points as diflubenzuron or other end points). On the basis of that evaluation, the residue definition for risk assessment should be re-examined in particular for mushrooms MS to discuss residue definition for plants commodities in an expert meeting.

Residue definition for plants commodities will be discussed in an expert meeting, see Evaluation table

### Reporting table point 3 (12).

**Open point**: For ruminants it is difficult to conclude on a residue definition as residues were identified only in milk and liver. Meat and fat were not investigated although the metabolism in hens demonstrated a lipophilic behaviour of diflubenzuron. A new metabolism study should be requested unless clear evidence can be supported that the exposure of ruminants leads to a no-residue situation in ruminant tissues or unless based on expert judgment it could be considered that the residue definition proposed by the RMS, including parent and CPU is safe for the consumer. MS to discuss residue definition for animals commodities in an expert meeting.

Residue definition for plants commodities will be discussed in an expert meeting, see Evaluation table

### Reporting table point 3 (17).

Data requirement

Notifier to submit further residue data in mushrooms taking into account the storage stability of compounds to be determined.

RMS has asked Notifier to submit further residue trials 080122.

No new studies have been submitted, see Evaluation table data gap:

### Reporting table point 3 (21 and 22).

Table B.7.5.1 Identification of critical GAPs. The rate per treatment for the application in mushrooms must be 1 g as  $/m^2$  (the value 0.25 is incorrect). The spray volume in forestry for ULV should be 3-5 "water + oil" in stead of "oil" (the oil is added to the water to prevent evaporation). RMS to consider a corrigendum.

### Table B.7.5-1. Critical EU-GAP information for diflubenzuron in Europe

Crop	Country	Formula	Applicatio	n					PHI	
		tion							(day	
		type	Method	Kg as/ha/	Rate	Spray conc.,	Number	BBCH		
		(code)		treatment	kg as/ha	kg as/hl	maxi	stages		
		&								
		content								
		of a.i.								
		(g/kg)								

Apples and Pears	Northern and Southern Europe	Dimilin WG-80 F	Spray, Directed air- assisted spray equipme nt	0.18	0.15-0.18	0.01 - 0.12	2 14-28 days intervals between	Spring or autumn application dependant on the pest to be controlled	14
Mushrooms	Northern and Southern Europe	Dimilin WG-80 I	Spray boom/ lance		1 g as/m <sup>2</sup>	N.A	1	Course spray, immediate after casing	na
Forestry	Northern and Southern Europe	Dimilin WG-80 F	Spray, ariel and ground applicati on includin g ULV	0.048	0.8	3-5 water + oil	1	Dependant on the pest to be controlled	na

na= Not applicable

### B.7.7 Effects of industrial processing and/or household preparation (Annex IIA 6.5; Annex IIIA 8.4)

### Reporting table point 3 (27).

For mushrooms, apparently one processing study for canned mushrooms is available (study AF/6263/UR/1). In the list of end points it is mentioned that 5 studies are available, this should be corrected. RMS to consider a corrigendum.

Four residue trials were conducted on mushrooms during 2002, two in UK (AF/6263/UR1 and 2) and two in the Netherlands (AF/6263/UR 3 and 4). All these trials are reported as residue trials in DAR table B. 7.6-3. At trial AF/ 6263/UR/1 specimens were also taken for processing into canned mushrooms. This study is reported below.

### B.7.7.2 Effects of processing on the nature of residue in mushrooms

Reference:	Gilles, N. (2004)
	To determine the magnitude of diflubenzuron residues at harvest in the raw
	agricultural commodity mushrooms and processed fractions resulting from a single
	application of Dimilin SC-48 or Dimilin WG-80 in the UK and The Netherlands
	Interim Report Agrisearch Uk Ltd, England No.AF/6263/UR
	DI – 11748 (Final report was submitted after the dossier was delivered).
Test Material:	Mushrooms from residue trials. The trials have been reported in DAR B 7.6
Guideline:	7029/VI/95 rev.5 and the guideline; Processing Phase Plane for Processing mushroom
	into canned mushrooms, established by CCRA Technology Limited.
GLP:	Yes

### Material and methods:

Test concentration:	At trial AF/6263/UR/1 a single application of DIMILIN SC-48 (480g/L
	diflubenzuron) - treatment 2 or DIMILIN WG-80 (80%w/w
	diflubenzuron) - treatment 3 was applied at 0.96grams a.s./m <sup>2</sup> , diluted
	with water immediately prior to application to a spray volume similar to
	commercial practice.
Test system:	At trial AF/6263/UR/1 specimens were also taken for processing into canned
-	mushrooms. Preparation of canned mushrooms: Sorting to remove foreign material or
	damaged mushroom; Washing to remove gross debris; Cutting to reduce size of largest
	mushrooms; Blanching to remove air from mushrooms; Draining and rapid cooling to
	maintain product texture; Filling into cans; Brine preparation for addition to the cans;
	Brining- the brine solution was poured into the mushroom filled cans; Seaming to
	produce a hermetic seal on the cans; Heat processing to produce a commercially sterile
	product; Cooling to reduce the product temperature and minimize the risk of post
	process contamination; Drying before handling to reduce the risk of post process
	contamination. The canned mushrooms were in-container heat processed using a steam
	retort. The retort was set to a temperature of 121.1 °C and the cans were processed at
	this temperature for 31 minutes. The cans were partially cooled in the processing
	vessel and then transferred to a chlorinated bath to further reduce the intaernal can
	temperature. The cans were allowed to dry before being transferred to a frozen storage
	area operating at below $-16$ °C on the next working day after processing.
Sampling time points:	Specimens for processing were taken only at the first flush after
	application. Sampling date was Feb 02 and extraction date was Dec 03.
Method of analysis:	Crop specimens were analysed for residues of diflubenzuron using Agrisearch Method
	'Diflubenzuron/Rice/KLS/03/1'. The method involves extraction in dichloromethane
	followed by purification on a Florisil chromatography column. Any diflubenzuron
	present is hydrolysed to form 4-chloroaniline, which is subsequently derivatised with
	heptafluorobutyric anhydride and the derivative quantified by gas chromatography
	with mass selective detection (MSD). Limit of determination for Diflubenzuron, 4-
	chlorophenylurea in mushrooms were 0.01 mg/kg. Limit of determination for 4-
	chloroaniline was 0.005 mg/kg.
Date of experiment:	2002

**Findings:** Procedural recoveries run concurrently with test specimens at levels of 0.01 mg/kg, and 0.1 mg/kg gave an overall mean recovery of 95 % for whole mushrooms and 78 % for canned mushrooms.

The residue levels of diflubenzuron found in whole mushrooms are summarised below in table B.7.7.2-1.

Trial no.	No. and rate of application (g a.s./m <sup>2</sup> )	Timing	Interval after final application	Crop portion	DFB (mg/kg)	PCA (mg/kg)	CPU (mg/kg)
	1x 0.96 <sup>1,2</sup>	S1 19 W		Whole mushroom	0.01	< 0.01	0.01
	1x 0.96 <sup>2</sup>	<b>S</b> 1	19	Whole mushroom	0.02	< 0.01	< 0.01
AE/6263/UP/1	1x 0.96 <sup>3</sup>	S2	31	Whole mushroom	0.01	< 0.01	< 0.01
AF/0205/UK/1	1x 0.96 <sup>3</sup>	S2	31	Whole mushroom	0.01	< 0.01	< 0.01
	1x 0.96 <sup>3</sup>	S3	41	Whole mushroom	< 0.01	< 0.01	< 0.01
	1x 0.96 <sup>3</sup>	S3	41	Whole mushroom	0.02	< 0.01	0.01
1. Whole mushroom used for canning							

Table B.7.7.2-1 Magnitude of diflubenzuron residues in whole mushrooms

Dimilin SC-48 2

3. Dimilin WG-80

The residue levels of diflubenzuron found in canned mushrooms are summarised in table B.7.7.2-2.

Table I		Manufada	. f. d. fl., h		
I able I	5././.2-2	Magnitude	of diffugenzuron	residues in	canned musnrooms
		0			

Trial no.	No. and rate ofapplication (g a.s./m <sup>2</sup>	Timing	Interval after final application	Crop portion	DFB (mg/kg)	PCA (mg/kg)	CPU (mg/kg)
AF/6263/U R/1	1x 0.96	S3	19	Canned mushroom	< 0.01	< 0.01	< 0.01

Comment: Results from one study of residues in canned mushroom shows no detectable parent diflubenzuron or its metabolites were found after canning.

### Reporting table point 3 (28).

Table B.7.7.1.1 (processing of apple). It is recommended to include an extra column in the table for the processing factor of each processing measurement. RMS to consider in a corrigendum.

Table B.7.	7.1-1 N	Magnitude o	f diflubenzuron	residues in	processed a	nnle samples
I abic Diff		magnitude o	1 unitubenzui on	i coluco m	processeu a	ppic samples

Trial number	Matrix	g a.s./ha	Timing	Interval (days)	Residues mg/kg	<mark>Transfer</mark> factors
AF/6843/UR/1	Whole apple	4 x 150	S1	14	0.22	
	Washed apple	4 x 150	S1	14	0.22	1
	Washing water	4 x 150	S1	14	0.08	<mark>0.36</mark>
	Wet pomace	4 x 150	S1	14	0.82	3.7
	Raw juice	4 x 150	S1	14	< 0.05	0.23
	Apple juice	4 x 150	S1	14	< 0.05	0.23
	Blanching water	4 x 150	S1	14	< 0.05	0.23
	Seeds + peels	4 x 150	S1	14	0.65	<mark>2.95</mark>
	Puree	4 x 150	S1	14	< 0.05	0.23
AF/6843/UR/2	Whole apple	4 x 150	S1	14	0.41	
	Washed apple	4 x 150	S1	14	0.20	<mark>0.48</mark>
	Washing water	4 x 150	S1	14	0.07	<mark>0.17</mark>
	Wet pomace	4 x 150	S1	14	0.79	1.9

Trial number	Matrix	g a.s./ha	Timing	Interval (days)	Residues mg/kg	Transfer factors
	Raw juice	4 x 150	S1	14	< 0.05	<mark>0.12</mark>
	Apple juice	4 x 150	S1	14	< 0.05	0.12
	Blanching water	4 x 150	S1	14	< 0.05	<mark>0.12</mark>
	Seeds +peels	4 x 150	S1	14	0.62	1.5
	Puree	4 x 150	S1	14	0.05	<mark>0.12</mark>
AF/6843/UR/3	Whole apple	4 x 150	S1	14	0.26	
	Washed apple	4 x 150	S1	14	0.14	<mark>0.54</mark>
	Washing water	4 x 150	S1	14	0.05	<mark>0.19</mark>
	Wet pomace	4 x 150	S1	14	0.99	<mark>3.8</mark>
	Raw juice	4 x 150	S1	14	< 0.05	<mark>0.19</mark>
	Apple juice	4 x 150	S1	14	< 0.05	<mark>0.19</mark>
	Blanching water	4 x 150	S1	14	< 0.05	<mark>0.19</mark>
	Seeds + peels	4 x 150	S1	14	0.89	<mark>3.4</mark>
	Puree	4 x 150	S1	14	< 0.05	<mark>0.19</mark>

**Comment**: There is a concentration of residues in wet apple pomace. The concentration factors recorded in the different trials are between 1.9-3.8. In JMPRs evaluation of diflubenzuron from 2002 the concentration factor of residues in apple pomace was 5 in wet apple pomace and 13 in dry apple pomace.

### B.7.8 Livestock feeding studies (Annex IIA 6.4; Annex IIIA 8.3)

### Reporting table point 3 (29).

The argumentation provided by the RMS for not requiring feeding studies should be reconsidered. The calculation of the expected exposure of livestock (expressed as mg/kg diet) is not found in the DAR. A calculation was provided under point 7.2 (animal metabolism) but contains inadequacies (the transfer factor from fresh fruits to pomace was not considered and the STMR should have been used instead of the MRL as highest residue likely to occur. MS to discuss the need for a feeding study in lactating cows in an expert meeting

Residue definition for plants commodities will be discussed in an expert meeting, see Evaluation table

### **B.7.12 MRL calculations**

### Reporting table point 3 (33)

For the data set of Northern Europe, XX calculated different values of  $R \max = 0.77 \operatorname{mg/kg}$  and a Rber (2x0.75) = 0.98 mg/kg. However, it is rounded to the same MRL value of 1.0 mg/kg

According to guideline 7039/VI/95 EN 22/7/1997 the maximum residue levels of classes are; 0.01, 0.02, 0.05, 0.1, 0.2, 0.3, 0.5 1.0, 2.0, 3.0 etc. Thus, there is no class in between 0.5 and 1.0. Both Rmax and Rber is closer to 1.0 than to 0.5 and therefore 1.0 mg/kg was chosen as MRL value.

### **B.7.15 Intake calculations**

### Reporting table point 3 (31)

As far as the intake calculations for British sub-populations are concerned, the practice is to consider that only 2 commodities (those resulting in the highest intakes) can be together consumed at the 97.5<sup>th</sup> percentile of the consumption. For the other commodities, the mean consumption value should be taken

The TMDIs were calculated according to the PSD Guidance on the estimation of dietary intakes of pesticides residues, Part Three/A3/Appendix 1c (1999). Results of the calculations are shown in Tables B. 7.15-3 – 7.15-12.

Table B.7.15-3 Theoretical Maximum Daily Intake (TMDI) according to UK consumer exposure model –adults – 76.0 kg bw

Commodity	European intake (kg/person/day)	STMR (mg/kg)	Exposure (mg/nerson/day)
Apples high exp.	0.1064	0.5	0.0532
Pears high exp.	0.2038	0.5	0.1019
Strawberry mean exp.	0.0454	0.1	0.00454
Raspberry mean exp.	0.0544	0.1	0.00544
Blackberry mean exp.	L/C	0.1	-
Mushrooms mean exp.	0.0289	0.3*	0.00867

\*Codex MRL

Total exposure (mg/person/day)	0.17375
Total exposure (mg/kg bw/day) (TMDI)	0.00228
Proposed ADI (mg/kg bw/day)	0.02
Total dietary exposure (% of ADI)	11.4

LC = Low % consumers (Less than 60 consumers in survey).

Commodity	European intake (high exposure) (kg/child/day)	STMR (mg/kg)	Exposure (mg/child/day)
Apples high exp.	0,0733	0.5	0.03665
Pears high exp.	0,0222	0.5	0.0111
Strawberry mean exp.	0,0019	0.1	0.00019
Raspberry mean exp.	L/C	0.1	-
Blackberry mean exp.	L/C	0.1	-
Mushrooms mean exp.	0,0001	0.3*	0.003

Table B.7.15-4	Theoretical M	faximum Daily	Intake (TMDI)	according to UI	K consumer exj	posure model -	– infant 8.7 kg
bw kg bw							

\*Codex MRL

Total exposure (mg/child/day)	0.05094
Total exposure (mg/kg bw/day) (TMDI)	0.005855
Proposed ADI (mg/kg bw/day)	0.02
Total dietary exposure (% of ADI)	29.3

Commodity	European intake (high exposure) (kg/toddler/day)	STMR (mg/kg)	Exposure (mg/toddler/day)
Apples high exp.	0,2156	0.5	0.1078
Pears high exp.	0,0947	0.5	0.04735
Strawberry mean exp.	0,0029	0.1	0.00029
Raspberry mean exp.	0,0015	0.1	0.00015
Blackberry mean exp.	0,0001	0.1	0.0001
Mushrooms <i>mean exp</i> .	0,0009	0.3*	0.00027

### Table B.7.15-5 Theoretical Maximum Daily Intake (TMDI) according to UK consumer exposure model –1.5-4.5 year toddlers; 14.5 kg bw

\*Codex MRL

Total exposure (mg/toddler/day)	0.15596
Total exposure (mg/kg bw/day) (TMDI)	0.01076
Proposed ADI (mg/kg bw/day)	0.02
Total dietary exposure (% of ADI)	53.7

LC = Low % consumers (Less than 60 consumers in survey).

### Table B.7.15-6 Theoretical Maximum Daily Intake (TMDI) according to UK consumer exposure model – 4-6 years old 20.5 kg bw

Commodity	European intake (high exposure) (kg/infant/day)	STMR (mg/kg)	Exposure (mg/child/day)
Apples high exp.	0,1934	0.5	0.0967
Pears high exp.	0,0745	0.5	0.037
Strawberry <i>mean exp</i> .	0,0029	0.1	0.00029
Raspberry mean exp.	0,0001	0.1	0.00001
Blackberry mean exp.	L/C	0.1	-
Mushrooms <i>mean exp</i> .	0,0010	0:3*	0.0003

\*Codex MRL

Total exposure (mg/infant/day)	0.1343
Total exposure (mg/kg bw/day) (TMDI)	0.0066
Proposed ADI (mg/kg bw/day)	0.02
Total dietary exposure (% of ADI)	32,7

## Table B.7.15-7 Theoretical Maximum Daily Intake (TMDI) according to UK consumer exposure model – 7-10 years old; 30.9 kg bw

Commodity	European intake (high exposure) (kg/infant/day)	STMR (mg/kg)	Exposure (mg/child/day)
Apples <i>high exp</i> .	0,2324	0.5	0.1162
Pears high exp.	0,0682	0.5	0.0341

Strawberry mean exp.	0,0038	0.1	0.00038
Raspberry mean exp.	0,0002	0.1	0.00002
Blackberry <i>mean exp</i> .	0,0001	0.1	0.00001
Mushrooms <i>mean exp</i> .	0,0013	0:3*	0.0039

\*Codex MRL

Total exposure (mg/infant/day)	0.15461
Total exposure (mg/kg bw/day) (TMDI)	0.0050
Proposed ADI (mg/kg bw/day)	0.02
Total dietary exposure (% of ADI)	25,0

# Table B.7.15-8 Theoretical Maximum Daily Intake (TMDI) according to UK consumer exposure model – 11-14 years old; 48.0 kg bw

Commodity	European intake (high exposure) (kg/infant/day)	STMR (mg/kg)	Exposure (mg/child/day)
Apples <i>high exp</i> .	0,1969	0.5	0.09845
Pears high exp.	0,0886	0.5	0.0443
Strawberry <i>mean exp</i> .	0,0028	0.1	0.00028
Raspberry mean exp.	0,0001	0.1	0.00001
Blackberry <i>mean exp</i> .	0,0001	0.1	0.00001
Mushrooms <i>mean exp</i> .	0,0020	0:3*	0.0006

\*Codex MRL

Total exposure (mg/infant/day)	0.14365
Total exposure (mg/kg bw/day) (TMDI)	0.00299
Proposed ADI (mg/kg bw/day)	0.02
Total dietary exposure (% of ADI)	14,9

# Table B.7.15-9 Theoretical Maximum Daily Intake (TMDI) according to UK consumer exposure model – 15-18 years old; 63,8 kg bw.

Commodity	European intake (high exposure) (kg/infant/day)	STMR (mg/kg)	Exposure (mg/child/day)
Apples <i>high exp</i> .	0,2279	0.5	0.11395
Pears high exp.	0,0926	0.5	0.0463

Strawberry <i>mean exp</i> .	0,0023	0.1	0.00023
Raspberry mean exp.	0,0001	0.1	0.00001
Blackberry <i>mean exp</i> .	0,0001	0.1	0.00001
Mushrooms <i>mean exp</i> .	0,0036	0:3*	0.00108

\*Codex MRL

Total exposure (mg/infant/day)	0.16158
Total exposure (mg/kg bw/day) (TMDI)	0.00253
Proposed ADI (mg/kg bw/day)	0.02
Total dietary exposure (% of ADI)	12,7

# Table B.7.15-10 Theoretical Maximum Daily Intake (TMDI) according to UK consumer exposure model – Vegeterian; 66.7 kg bw

Commodity	European intake (high exposure) (kg/infant/day)	STMR (mg/kg)	Exposure (mg/vegeterian/day)
Apples <i>high exp</i> .	0,2227	0.5	0.11135
Pears high exp.	0,1254	0.5	0.0627.
Strawberry mean exp.	0,0050	0.1	0.0005
Raspberry mean exp.	0,0006	0.1	0.00006
Blackberry mean exp.	0,0003	0.1	0.00003
Mushrooms <i>mean exp</i> .	0,0084	0:3*	0.00252

\*Codex MRL

Total exposure (mg/infant/day)	0.17716
Total exposure (mg/kg bw/day) (TMDI)	0.002656
Proposed ADI (mg/kg bw/day)	0.02
Total dietary exposure (% of ADI)	13.3

# Table B.7.15-11 Theoretical Maximum Daily Intake (TMDI) according to UK consumer exposure model – Elderly own; 70,8 kg bw

Commodity	European intake (high exposure) (kg/infant/day)	STMR (mg/kg)	Exposure (mg/Elderly own/day)
Apples high exp.	0,0659	0.5	0.03295
Pears high exp.	0,0736	0.5	0.0368
Strawberry mean exp.	0,0044	0.1	0.00044

Raspberry mean exp.	0,0001	0.1	0.00001
Blackberry mean exp.	0,0002	0.1	0.00002
Mushrooms <i>mean exp</i> .	0,0025	0:3*	0.00075

\*Codex MRL

Total exposure (mg/infant/day)	0.07097
Total exposure (mg/kg bw/day) (TMDI)	0.00100
Proposed ADI (mg/kg bw/day)	0.02
Total dietary exposure (% of ADI)	5,0

# Table B.7.15-12 Theoretical Maximum Daily Intake (TMDI) according to UK consumer exposure model – Elderly residential; 61.6 kg bw

Commodity	European intake (high exposure) (kg/infant/day)	STMR (mg/kg)	Exposure (mg/Elderly residential/day)
Apples <i>high exp</i> .	0,0659	0.5	0.03295
Pears high exp.	0,0736	0.5	0.0368
Strawberry mean exp.	0,0044	0.1	0.00044
Raspberry mean exp.	0,0001	0.1	0.00001
Blackberry mean exp.	L/C	0.1	-
Mushrooms <i>mean exp</i> .	0,0009	0:3*	0.00027

\*Codex MRL

Total exposure (mg/infant/day)	0.07047
Total exposure (mg/kg bw/day) (TMDI)	0.00114
Proposed ADI (mg/kg bw/day)	0.02
Total dietary exposure (% of ADI)	5,7

### Table B.7.15-7 Estimation of the potential through the diet

Model	Consumer Group	Total TMDI	ADI	Total TMDI in %
		(mg/kg bw)	(mg/kg bw/day)	of ADI
WHO (1997)	Adult (60 kg bw)	0.00086	0.02	4.4
German BBA (1993)	Girl (13.5 kg bw)	0.00362	0.02	18.4
<mark>UK PDS (1999)</mark>	Adult (76 kg bw)	0.00228	0.02	<mark>11.4</mark>
	11-12 (48.0 kg bw)	<mark>0.0031</mark>	0.02	<mark>15.5</mark>
	Toddler (14.5 kg bw)	<mark>0.01076</mark>	0.02	<mark>53.7</mark>
	Infant (8.7 kg bw)	0.005855	0.02	<mark>29.3</mark>
	4-6 year (20.5 kg bw)	<mark>0.0066</mark>	0.02	32.7
	7-10 year (30.9 kg bw)	<mark>0.0050</mark>	0.02	<mark>25.0</mark>
	15-18 year (63.8 kg bw)	0.00253	0.02	<mark>12.7</mark>
	Vegetarian ( 66.7 kg bw)	<mark>0.002656</mark>	0.02	<mark>13.3</mark>
	Elderly own (70.8 kg bw)	0.002656	0.02	5

Eldlery residential (61.6 kg bw)	<mark>0.00100</mark>	<mark>0.02</mark>	<mark>5.7</mark>

**Comment:** Considering the present intended use for Diflubenzuro, TMDI is not expected to exceed ADI for any consumer group.

### *Reporting table point 3 (32)*

The calculations provided under table B.7.15-8 are irrelevant as apple pomace is not a commodity for human consumption. This should be deleted from the DAR. The calculations provided under table B.7.15-8 are irrelevant as apple pomace is not a commodity for human consumption.

Table B.7.15-8 should be deleted from the DAR.

### Reporting table point 3 (34)

The header of the table suggests that calculation is made on intake of PCA (chloroaniline). However, this is misleading since the calculation reflects the risk assessment based on diflubenzuron data only.

The calculations provided under table B.7.15-8 are irrelevant as apple pomace is not a commodity for human consumption. Table B.7.15-8 should be deleted from the DAR.

Addendum to Draft Assessment Report



# DIFLUBENZURON Volume 3 Annex B.8 and B.9 Environmental Fate and Behaviour Ecotoxicology

Rapporteur Member State: Sweden

December 2008



### Volume 1

Level 1: Statement of subject matter and purpose for which the monograph was prepared

- Level 2: Reasoned statement of the overall conclusions drawn by the Rapporteur Member State Appendix 1: Standard terms and abbreviations Appendix 2: Specific terms and abbreviations Appendix 3: List of endpoints
- Level 3: Proposed decision with respect to the application for inclusion of the active substance in Annex I

Level 4: Further information to permit a decision to be made, or to support a review of the conditions and restrictions associated with the proposed inclusion in Annex 1

### Volume 2

Annex A: List of the tests and studies submitted and of information available

### Volume 3

### Annex B: RMS summary, evaluation and assessment of the data and information

Annex B.1: Identity Annex B.2: Phys/chem. Annex B.3: Data application and further information. Annex B.4: Proposal for classification and labelling Annex B.5: Analytical method Annex B.6: Toxicology and metabolism Annex B.7: Residues in crop Annex B.8: Fate and behaviour Annex B.9: Ecotoxicology Appendix 1: Standard terms and abbreviations

Appendix 2: Specific terms and abbreviations

### Volume 4

Annex C: Confidential information and summary and assessment of information relating to the collective submission of dossiers

### Table of contents

B.8	Environmental fate and behaviour	.139
B.8.2	Adsorption, desorption and mobility in soil	.139
B.8.2.1	Adsorption/desorption studies	139
B.8.4.3	Ready biodegradibility	.140
B.8.6	Predicted environmental concentrations in surface water and in groundwater (PEC <sub>sw</sub> , PEC <sub>gw</sub> )	
	(Annex IIIA 9.2.1, 9.2.3)	141
B.8.6.1	Predicted environmental concentrations in ground water (PEC <sub>GW</sub> )	141
B.8.6.2	Predicted environmental concentrations in surface water (PEC <sub>sw</sub> )	143
B.8.6.2.1	Predicted environmental concentrations in surface water (PEC <sub>sw</sub> ) and sediment (PECsed) follow	ing
	aerial application to forests	143
B.8.6.1.2	Predicted environmental concentrations in surface water (PEC <sub>sw</sub> ) following forestry hand held	
	application	149
B.8.6.2	PECsw following application in orchards	.151
B. 8.6.2.1	FOCUS step 4 for tractor mounted application in orchards (buffer zones >30 m)	151
B. 8.6.2.2	PECsw following hand held application in orchards (FOCUS simulation)	151
B.9	Ecotoxicology	.152
B.9.1	Effects on birds	152
B.9.1.5	Risk assessment birds	.155
B.9.2	Effects on aquatic organisms	.156
B.9.2.3.	Aquatic Risk assessment for metabolites CPU and DFBA	.156
B.9.2.5	Risk assessment for aquatic organisms	.157
B.9.3	Risk assessment mammals	. 162
B.9.4.	Effects on bees	165
B.9.4.2	Cage and field tests	165
APPENDIX	Ι	

169

### **B.8** Environmental fate and behaviour

### B.8.2 Adsorption, desorption and mobility in soil

### B.8.2.1 Adsorption/desorption studies

### **Open point 4.2:**

The notifier submitted a detailed account on how the  $K_{OC}$  for the metabolite DFBA was estimated using PCKOCWIN<sup>TM</sup> v 1.66, which is summarised below.

Reference:	Uwe Wanner (Dec 21, 2006). Description of the QSAR model used for the	
	estimation of the adsorption coefficient of DFBA	
Methods	The adsorption coefficient of DFBA was calculated with PCKOCWIN™ v. 1.66	
	within Estimation Program Interface Suite <sup><math>TM</math></sup> (see Appendix A of the complete EPI	
	Suite <sup>TM</sup> results printout). A detailed description of EPI Suite <sup>TM</sup> can be found on	
	EPA's webpage http://www.epa.gov/oppt/exposure/pubs/episuite.htm	
	The EPI (Estimation Programs Interface) SuiteTM is a Windows® based suite of	
	physical/chemical property and environmental fate estimation models developed	
	by the EPA's Office of Pollution Prevention Toxics and Syracuse Research	
	Corporation (SRC). EPI SuiteTM runs of one single input, a representation of the	
	chemical structure in SMILES notation. SMILES is "Simplified Molecular Input	
	Line Entry System"; a description of this system is available with the EPI	
	SuiteTM.	
	The Soil Adsorption Coefficient Program (PCKOCWIN™) estimates the soil	
	adsorption coefficcient (Koc) of organic compounds. Traditional estimation	
	methods rely upon the octanol/water partition coefficient or related parameters, but	
	recently the first-order molecular connectivity index (1-MCI) has been used	
	successfully to predict Koc values for hydrophobic organic compounds.	
	PCKOCWIN uses 1-MCI and a series of group contribution factors to predict Koc.	
	The group contribution method outperforms traditional estimation methods based	
	on octanol/water partition coefficients and water solubility. Meylan et al. (1992)	
	summarizes the methodology to predict the sorption coefficient as follows:	
	"The first-order molecular connectivity index (MCI) has been successfully used to	
	predict soil sorption coefficients (Koc) for nonpolar organics, but extension of the	
	model to polar compounds has been problematic. To address this, we developed a	
	new estimation method based on MCI and series of statistically derived fragment	
	contribution factors for polar compounds. After developing an extensive database	
	of measured Koc values, we divided the dataset into a training set of 189 chemicals	
	and an independent validation set of 205 chemicals. Two linear regressions were	
	then performed. First, measured log Koc values for nonpolar compounds in the	

training set were correlated with MCI. The second regression was developed by using the deviations between measured log Koc and the log Koc estimated with the nonpolar equation and the number of certain structural fragments in the polar compounds. The final equation for predicting log Koc accounts for 96% and 86% of the variation in the measured values for the training and validation sets, respectively. Results also show that the model outperforms and covers a wider range of chemical structures than do models based on octanol-water partition coefficients (Kow) or water solubility."

In summary Meylan et al (1992) the general equation used to estimate log Koc of any compound is:

 $\log \text{Koc} = 0.53 \text{ MCI} + 0.62 + \text{Summation (Pf)}$ 

where MCI is the first order molecular connectivity index and Summation (Pf) is the summation product of all applicable correction factors. A list of the correction factors is presented in Appendix B. See Appendix C, Appendix D and Appendix F for lists of the chemicals used in the regressions and a supplemental validation list. References:

Meylan, W., P.H. Howard and R.S. Boethling (1992) "Molecular Topology/Fragment Contribution Method for Predicting Soil Sorption Coefficients", Environ. Sci. Technol. 26: 1560-7. http://www.epa.gov/oppt/exposure/pubs/episuite.htm

### **Results**:

Soil Adsorption Coefficient (PCKOCWIN v1.66): Koc : 39.61; Log Koc: 1.598

### **Comments**:

This account is a more detailed description of the method used and the result is not different from the result presented in the DAR.

### B.8.4.3 Ready biodegradibility

### **Open point 4.3:**

Comments were received that diflubenzuron does not pass the criteria regarding the theoretical CO<sub>2</sub> production as stipulated in the OECD 301B since such studies should be a measure of ultimate biodegradation (i.e. mineralisation) and as 50% of the initial applied diflubenzuron appeared to remain as metabolite CPU after 28 d. The RMS agree with the comments from other MS and considers diflubenzuron as being non biodegradable. This will result in an alteration of the proposed classification. Since DFB is not readily biodegradable and the  $DT_{50}$  of diflubenzuron and its classifiable metabolite CPU (96h-LC50 for fish 70 mg CPU/L;whole system water/sediment DT50= 37.6 d) is > 16 days the RMS considers that diflubenzuron should be classified as R53 in addition to R50 (see also addendum to section B.4). The notifier has submitted a document (DIFLUBENZURON - Arguments against R53 classification. Uwe Wanner. December, 2006) arguing against the R 50/53 of diflubenzuron. This document was however available also for the Meeting on Environmental Effects of Existing Chemicals, Pesticides & New Chemicals in JRC Ispra - January 25, 2007 (Technical Committee on the Classification and Labelling of Dangerous Substances). The TC C&L agreed to classify the substance as N; R50-53 with an M-factor of 100. Hence, the RMS does not consider that this issue needs to be discussed further in this report.

## **B.8.6** Predicted environmental concentrations in surface water and in groundwater (PEC<sub>sw</sub>, PEC<sub>gw</sub>) (Annex IIIA 9.2.1, 9.2.3)

### **B.8.6.1** Predicted environmental concentrations in ground water (PEC<sub>GW</sub>)

### **Point of clarification 4.1:**

EFSA and one member state noted that the ground water simulation for the metabolite was performed using the QSAR estimated  $K_{OW}$  for DFBA. Normally  $K_{OC}$ =0 has been used when no  $K_{OC}$  experimentally could be derived. The notifier agreed to submit an assessment for DFBA with  $K_{OC}$ =0, and this is summarised below.

Reference:	Uwe Wanner. 2007. Predicted Environmental Concentrations of 2,6-			
	Difluorobenzoic Acid (DFBA), Soil Degradation Product Diflubenzuron in			
	Groundwater following the Application of DIMILIN WG-80® to Orchards in			
	the EU using FOCUS PELMO 3.3.2 and FOCUS PEARL 3.3.3			
Methods	The predicted environmental concentration in groundwater ( $PEC_{GW}$ ) of the			
	metabolites, DFBA following typical use of Dimilin WG-80 in the EU was			
	investigated using the standardised modelling recommendations of the FOCUS			
	groundwater working group. Simulations were conducted using the PELMO model			
	(FOCUS version 3.3.2, July 2002) and FOCUS PEARL 3.3.3.			
	The annual application rate used for the groundwater calculations is based on the			
	proposed Good Agricultural Practice for the use of Dimilin WG-80® on pome			
	fruit. The application rate of diflubenzuron for this use pattern is 180 g (a.s.) per			
	hectare, applied twice with an interval of 14 days. In order to obtain realistic			
	worse-case groundwater assessment, the calculations are based on an early			
	application Dimilin WG-80®, i.e., 14 days after the default settings for leaf			
	emergence. The peak concentration of DFBA of 13.3% of applied dose was			
	reached after 3 days after the application in the water/sediment studies. Therefore,			
	the initial application of DFBA occurred 17 days after the default day for leaf			
	emergence, followed by a second application 14 days later. The FOCUS			
	interception value of 50% for early applications (i.e., no leaf canopy present) was			
	used for this assessment. In the absence of data on uptake and translocation in			
	plants, a plant uptake factor of 0 was assumed for the degradation products DBFA.			
	Adsorption data for the metabolite DFBA was set to 0. The aerobic soil			
	degradation rate of DFBA was measured in one soil type at 20°C and a further two			
	soil types at 24°C. The observed degradation rate in each soil was then normalised			

according to the calculation shown in Table 8.6.1.c.. The overall geometric mean  $DT_{50} = 5.9$  days was used in the simulation.

### Table 8.6.1.a. Calculation of equivalent DFBA application rates

Metabolite	Molecular weight	Parent application rate	Metabolite application rate <sup>1</sup>	Maximum observed soil concentration	Sampling Interval	Crop interception	Equivalent metabolite application rate
DFBA	158.1	180 g a.s./ha	91.6 g a.s./ha	13.3%	3 days	50 %	16.1 g a.s./ha

<sup>1</sup>100 % transformation of parent to metabolite

### Table 8.6.1.b Summary of the relevant physical chemical properties of DFBA.

Property	Data
Molecular weights	DFBA 158.1 g/mol
Water solubility at 25°C pH 4 pH 7 pH 10 unbuffered	3063 (calculated based on chemical structure using EPI Suite version 3.10)
Vapour pressure at 25°C	0.235 (calculated based on chemical structure using EPI Suite version 3.10)
Octanol/water partition coefficient, K <sub>OW</sub>	DFBA -0.02
Adsorption K <sub>OC</sub>	DFBA 0 ml/g
Degradation rate (corrected to standard temperature and moisture)	DFBA 5.9 d (geometric mean from 3 soils)

### Table 8.6.1.c. Conversion of DFBA DT<sub>50</sub> values to a common moisture content.

Soil	DT50 [days] reported	Correction factor	DT50 [days] moisture corrected	Geometric mean at 20°C & pF2
Soil I	9.0	1.06541 (i.e. 1)	9.0	
Soil II	7.9	0.90294	7.1	5.9
Soil III	3.6	0.90816	3.3	

### **Result:**

Results of the FOCUS PELMO 3.3.2 and FOCUS PEARL 3.3.3 PEC groundwater calculations for DFBA after annual application of Dimilin WG-80 $^{\text{®}}$  in orchards are listed in the table below.

Table 8.6.1.e. Predicted 80 <sup>th</sup> percentile annual average of	oncentrations for DFBA in groundwate	r (µg/L) at 1 m depth
following use in orchards at a an application rate of 180	g/ha.	

Location	FOCUS PELMO	FOCUS PEARL
Chateaudun	0.011	0.017
Hamburg	0.003	0.034
Jokioinen	0.020	0.071
Kremsmunster	0.006	0.015
Okehampton	0.005	0.020
Piacenza	0.007	0.016
Porto	0.000	0.000
Sevilla	0.000	0.006
Thiva	0.000	0.000

**Comments:** The predicted environmental concentrations (PECs) DFBA after the application of the Dimilin in

orchards were calculated using FOCUS PELMO 3.3.2 and FOCUS PEARL 3.3.3. These calculations were based

on the assumption that DFBA does not show any adsorption to soil ( $K_{OC}=0$  mL/g). The PEC<sub>GW</sub> of all relevant locations were calculated to be less than 0.1  $\mu$ g/L.

The following difference from the original modelling in the DAR was noted; A crop interception value of 50 % was used when calculating the metabolite application rate, this is considered as acceptable by the RMS. Further, the vapour pressure was estimated to 0.235 Pa and used to model dissipation through volatilisation; in the DAR this dissipation route was excluded in the absence of data. The estimated DFBA vapour pressure implies that DFBA is moderately volatile, and hence volatilisation may have had an impact on the final PECgw estimated in the modelling. The acceptability of the estimated vapour pressure may need to be discussed at an expert meeting. Pending the outcome of the discussion the LoEP needs to be revised.

### **B.8.6.2** Predicted environmental concentrations in surface water (PEC<sub>sw</sub>)

Field of use	Method of application	RMS assessment
Orchards Han upw	Tractor-mounted sprayer; spray directed upwards and sideways	PECsw for step 4 with 30 m buffer zones available, however further refinements needed for TER above trigger.
	Hand-held sprayer; spray directed upwards and sideways	Not available. No further information submitted, the notifier considers that this use is covered by the highest load application in orchards.
Forestry and woody ornamentals	Aerial application -ultra low volume (ULV) -low volume (LV)	PECsw calculations submitted by the notifier, however these were not considered as acceptable for risk assessment, see below.
	Ground application -tractor mounted spray	Not available. No further information submitted, the notifier considers that this use is covered by the highest load application in orchards.
	-hand-held sprayer <sup>3</sup>	Available. Acceptable TER with 20 m bufferzone
	Automatic sprayer	No PECsw provided, not required by RMS
Mushrooms	Hand-held sprayer; high volume spray directed downwards	No PECsw provided, not required by RMS

Table 0.0.2.a. Summary of I DC.	Table	8.6.2.a.	Summary	of PECs
---------------------------------	-------	----------	---------	---------

## **B.8.6.2.1** Predicted environmental concentrations in surface water (PEC<sub>sw</sub>) and sediment (PECsed) following aerial application to forests

### **Open Point 4.8:**

Forest application is not a standard scenario with in the EU evaluation of pesticides under 91/414/EEC. In the DAR the PEC<sub>sw</sub> following the use of diflubenzuron in forestry was calculated by RMS assuming spray drift deposition into a 30 cm deep water body, using a drift value of 33.2 % for aerial application as given in the guidance "FOCUS surface water scenarios in the EU evaluation process under 91/414/EEC

(SANCO/4802/2001-rev1)". In the Draft Assessment Report submitted in May 2005 no acceptable risk for the aquatic environment could be demonstrated for the proposed use in forests by aerial application. Therefore the notifier submitted a new assessment for the Predicted Environmental Concentrations in surface water following

aerial application in their updated summary dossier (Doc M III, Annex III A, Tier II). The notifier also submitted the back ground report to the new PECsw assessment 'Predicted Environmental Concentrations of Diflubenzuron in surface waters following the use of Dimilin in forests in the EU' by Wanner (2005). For these new PEC calculations the notifier used AGDISP, distributed by the US Department of Agriculture, Forest Service, Forest Health Technology Enterprise Team. Version 8.15, to calculate the spray drift following application in forestry. This model has not been evaluated for the use in the risk assessment of pesticides under 91/414/EEC. The RMS has evaluated the new assessment and report see below.

Reference:	Wanner, U, (2005). Predicted environmental concentrations of diflubenzuron
	in surface waters following use of 'Dimilin' WG-80 in forests in the EU
Material and methods:	PECs were obtained by combining the spray drift results, calculated with the
	computer model AGDISP, and the standard FOCUS surface water tools for
	orchards, as a surrogate for forestry.
	AGDISP is a dedicated aerial spray simulation model to calculate spray drift of
	pesticides in forestry uses, distributed by the US Department of Agriculture, Forest
	Service, Forest Health Technology Enterprise Team. Version 8.15 of this model
	was used to calculate deposition of diflubenzuron on nearby water bodies, resulting
	from aerial application in forestry at the recommended GAP in the EU (48 g
	a.s./ha) under realistic worst-case conditions, in which all major parameters that
	influence the off-target movement of diflubenzuron were taken into consideration.
	Three different drop sizes (i.e. 80, 100 and 120 $\mu$ m Volume Median Diameter),
	derived from typical application equipment and operating conditions, were
	simulated at two release heights (10- and 15 m) and two canopy heights (i.e. 10-
	and 24 m).
	The application is performed either with fixed-wing aircrafts or with helicopters.
	The application volumes range between 3-5 liters per hectare for 'ultra-low
	volume' (ULV) applications and 30-50 liters per hectare in case of 'low volume'
	(LV) applications. The LV applications use only water as carrier whereas in the
	case of ULV applications up to 0.5 liter of oil per hectare is added to the water
	carrier in the tank mix. Dimilin <sup>®</sup> WG 80 is usually applied in late spring/early
	summer. Therefore, the chosen application window ranged from beginning of May
	until end of May. The aquatic habitats for this study were aligned parallel to the
	flight line and perpendicular to the wind direction. Three different surface water
	geometries (ditch, stream and pond) were created based on the documentation
	provided with the spray drift calculator of the FOCUS surface water tools.
	The highest surface water concentration found in AGDISP, was used to obtain the
	maximum mass load of diflubenzuron per surface area. This parameter was then
	included into FOCUS surface water calculations in order to estimate the spray drift
	in forestry applications. Potential surface run-off and drainage of diflubenzuron
	were evaluated within the FOCUS surface water tools based on orchards as
surrogate for forests.

The surface water PECs were calculated with the help of SWASH (Surface Water Scenarios Help) model (=shell) version 1(=2.1, 9 April 2003), database version 1(=2.2, 9 April 2003). There is no "forest" scenario in the current version of SWASH, as "forests" are not considered as standard crops. In order to evaluate the potential mass load of diflubenzuron via run-off or drainage after the application of Dimilin<sup>®</sup> WG-80, the crop scenario "orchards" (pome/stone fruits, early applications) was selected as surrogate scenario for forests. As recommended for the use of Dimilin<sup>®</sup> WG-80 on forests, the simulations were conducted with an application window between May 1st and May 31st (Julian days 121 and 151). The main characteristics of each scenario are presented in the table below.

Scenario	Run-off / drainage	Selected weather data set	Description	Waterbody
D3	Drainage	Vredepeel/ NL	Soil type, topography & climatic conditions typical for Northern EU	FOCUS ditch
D4	Drainage	Skousbo/ DK	Similar to D3, soil not suitable for root vegetables	FOCUS pond & FOCUS stream
D5	Drainage	La Jailliere/ F	Soil type/climate combination not suitable for root crops	FOCUS pond & FOCUS stream
R1	Run-off	Weiherbach/GER	Extensive run-off scenario for wide range of crop	FOCUS pond & FOCUS stream
R2	Run-off	Porto/P	Southern EU, terraced crop production,with high rainfall	FOCUS stream
R3	Run-off	Bologna/I	Southern EU, gently to moderately sloping	FOCUS stream
R4	Run-off	Roujan/F	Southern EU, hot dry summers, irrigation at times of water deficit	FOCUS stream

The SWASH runs were calculated twice. During the initial evaluations, the potential mass load of diflubenzuron via run-off was calculated using PRZM within the SWASH tools. Potential contributions of diflubenzuron to surface waters via drain-flow were simulated with MACRO within SWASH. After these calculations the initial PECs were calculated with TOXSWA within SWASH using the standard drift values given for 'air-blast' in orchards. In a re-run of these TOXSWA evaluations the incorrect application pattern (air-blast in orchards) was corrected by implementing the results obtained from the spray-drift evaluations for forestry uses obtained by AGDISP. This was established by adjusting the spray-drift loads within the TOXSWA files with a value derived from the AGDISP scenarios, which resulted in the highest surface water contamination (in this case

the potential contamination of a ditch after a helicopter application). In the case of stream scenarios this value was multiplied by a factor of 1.2 in order to account for the up gradient drift that is assumed to occur in the stream watershed.

#### **Results:**

The results of the AGDISP spray drift evaluation are presented for twelve different "cases" in which the drop size distribution (i.e., volume median diameters VMD), the release height, the air speed, the application volume and the aircraft was varied. Each of these twelve "cases" was run for a canopy height of 10 m (equivalent to a young forestation) and 24 m (old forest). The results of these AGDISP evaluations are presented in the table below:

	Low Volume application									
Case No.	Aircraft type	Droplet size VMD	Release height (m)	Speed (km)	Ditch (µg/L) Canopy height		Stream (µg/L) Canopyheight		Pond (µg/L) Canopy height	
		(μm)	()		10 m	24 m	10 m	24 m	10 m	24 m
1	Helicopter	100	10	100	0.028	0.006	0.027	0.006	0.005	0.001
2	Helicopter	80	10	100	0.005	< 0.001	0.005	< 0.001	< 0.001	< 0.001
3	Helicopter	120	10	100	0.074	0.023	0.073	0.023	0.013	0.005
4	Helicopter	100	15	100	0.015	0.004	0.015	0.004	0.005	0.001
5	Helicopter	100	10	80	0.025	0.006	0.025	0.006	0.005	0.001
6	Airplane	100	10	200	0.020	0.005	0.020	0.005	0.005	0.001
7	Airplane	80	10	200	0.003	< 0.001	0.003	< 0.001	< 0.001	< 0.001
8	Airplane	120	10	200	0.059	0.023	0.059	0.023	0.014	0.005
9	Airplane	100	15	200	0.013	0.003	0.013	0.003	0.004	0.001
10	Airplane	100	10	180	0.021	0.005	0.021	0.005	0.005	0.001
			Ultı	a Low V	olume appli	cation oil c	arrier			
		Dronlet								
Case	Aircraft	size	Release height	Speed	Ditch (µg/	L)	Stream (µ	g/L)	Pond (µg/	L)
no.	type	VMD (um)	(m)	(km)	Canopy he	ight	Canopyhe	eight	Canopy h	eight
		(µ)			10 m	24 m	10 m	24 m	10 m	24 m
11	Helicopter	100	10	100	0.095	0.041	0.094	0.041	0.020	0.011
12	Airplane	100	10	200	0.091	0.042	0.091	0.042	0.023	0.012

Table 8.6.1.1.a. AGDISP predicted deposition of diflubenzuron in nearby water bodies (µg/L)

Based on these 24 individual evaluations, the highest concentrations in a surface water directly next to a treated forest, i.e. the highest potential spray-drift, occurred in "case" no. 11 (10m forest), which represents ultra-low volume applications of an oil-containing formulation on a forest with an adjacent FOCUS ditch and which is based on an application with a helicopter flying at a speed of 100 km/h at a height of 10 meters above the canopy of a young forestation with a drop size distribution, which can be qualified as "very fine" to "fine" (volume median diameter VMD =  $100\mu$ m). AGDISP calculated an aquatic concentration of 0.095 µg/L for this FOCUS ditch scenario with a length of 100m, a width of 1 m and a depth of 0.3 m.

Hence, the total mass of diflubenzuron in this FOCUS ditch is therefore:  $0.095 \ \mu g/L \times 100 \ m \times 1 \ m \times 0.3 \ m \times 1000 \ L/m^3 = 2850 \ \mu g.$ The mass load per surface area is equal to:  $2850 \ \mu g/100 \ m^2 = 28.5 \ \mu g/m^2 = 0.029 \ m g/m^2.$ 

<u>Results of the FOCUS TOXWA calculations</u> - The calculated mass load of diflubenzuron per surface area of  $0.029 \text{ mg/m}^2$  based on the results obtained from the FOCUS ditch scenario in AGDISP was used to evaluate all SWASH scenarios. For the FOCUS stream scenarios the mass load was multiplied by a factor of 1.2 (= 0.034 mg/m<sup>2</sup>) to account for the up gradient drift that is assumed to occur in the stream watershed.

The global maximum concentrations in surface water and sediment of the different FOCUS ditch, pond and stream scenarios are listed in the table below.

FOCUS scenario	PECsw (µg/L)	PECsed (µg/kg dry sediment)
	Actual	Actual
FOCUS ditch, drainage scenario D3	0.095	0.045
FOCUS pond, drainage scenario D4	0.029	0.032
FOCUS stream, drainage scenario D4	0.104	0.008
FOCUS pond, drainage scenario D5	0.029	0.031
FOCUS stream, drainage scenario D5	0.106	0.004
FOCUS pond, run-off scenario R1	0.029	0.034
FOCUS stream, run-off scenario R1	0.081	0.007
FOCUS stream, run-off scenario R2	0.111	0.008
FOCUS stream, run-off scenario R3	0.116	0.021
FOCUS stream, run-off scenario R4	0.105	0.052

Table 8.6.1.1.b. Global maximum PECs for surface water and sediment (FOCUS - all scenarios)

#### **Comments:**

In the worst case simulation a surface water concentration of 0.095  $\mu$ g/L was predicted by the AGDISP in a surface water body with a length of 100 m, a width of 1 m and a depth of 0.3 m, with a distance of 1 m between the down-wind edge of the spray swath to the up-wind edge of the aquatic environment. A surface water concentration of 0.095  $\mu$ g/L in surface water body with a length of 100 m, a width of 1 m and a depth of 0.3 m is equivalent to a surface deposition of 28.5  $\mu$ g/m<sup>2</sup> which corresponds to a drift of 0.6%. (i.e. (0.0285/4.8)×100). This is very much lower than the drift suggested for the EU process in the FOCUSsw document. As can be seen from the tables 8.6.1.1.c & d (originally from the report by Esterly, D. (2005) " The potential for off target movement of diflubenzuron (Dimilin® WG 80) during aerial applications" which was submitted by the notifier upon request by the RMS and is the basis for the notifier's assessment in the report by U. Wanner "Predicted Environmental Concentrations of Diflubenzuron in Surface Waters following use of 'Dimilin® WG-80' in Forests in the EU" which is summarized above) the canopy removal factor is substantial, e.g. for the ULV application the canopy removes > 95 % of the drift.

	Low Volume Application Water Carrier						
Case Name	Case No.	Ditch (µg/l)	Stream (µg/l)	Pond (µg/l)	Canopy Removal (%)		
Base Case Helicopter = BaseH	1	0.028	0.027	0.005	66		
Base H 80 VMD	2	0.005	0.005	< 0.001	51		
Base H 120 VMD	3	0.074	0.073	0.013	77		
Base H 15 RH	4	0.015	0.015	0.005	27		
Base H 80 KM	5	0.025	0.025	0.005	76		
Base Case Fixed Wing = BaseF	6	0.020	0.020	0.005	34		
Base F 80 VMD)	7	0.003	0.003	< 0.001	17		
Base F 120 VMD	8	0.059	0.059	0.014	49		
Base F 15 RH	9	0.013	0.013	0.004	17		
Base F 180 KM	10	0.021	0.021	0.005	35		
		Ultra Low	Volume Appl	ication Oil Car	rier		
Case Name	Case No.	Ditch (µg/l)	Stream (µg/l)	Pond (µg/l)	Canopy Removal (%)		
Base H Oil	11	0.095	0.094	0.020	>95		
Base F Oil	12	0.091	0.091	0.023	>95		

#### Table 8.6.1.1.c. Model Results for a 10 meter Evergreen Canopy Aquatic Concentration

Table 8.6.1.1.d. Model Results for a 24 meter Evergreen Canopy Aquatic Concentration

	Low Volume Application Water Carrier							
Case Name	Case No.	Ditch (µg/l)	Stream (µg/l)	Pond (µg/l)	Canopy Removal (%)			
Base Case Helicopter = BaseH	1	0.006	0.006	0.001	79			
Base H 80 VMD	2	< 0.001	< 0.001	< 0.001	71			
Base H 120 VMD	3	0.023	0.023	0.005	85			
Base H 15 RH	4	0.004	0.004	0.001	29			
Base H 80 KM	5	0.006	0.006	0.001	86			
Base Case Fixed Wing = BaseF	6	0.005	0.005	0.001	60			
Base F 80 VMD	7	< 0.001	< 0.001	< 0.001	49			
Base F 120 VMD	8	0.023	0.023	0.005	85			
Base F 15 RH	9	0.003	0.003	0.001	16			
Base F 180 KM	10	0.005	0.005	0.001	68			
		Ultra Low	Volume Appli	cation Oil Car	rier			
Case Name	Case No.	Ditch (µg/l)	Stream (µg/l)	Pond (µg/l)	Canopy Removal (%)			
Base H Oil	11	0.041	0.041	0.011	>95			
Base F Oil	12	0.042	0.042	0.012	>95			

The RMS asked the US-EPA for advice when evaluating the AGDISP simulation (AGDISP Technical response No. 07-035). The US-EPA pointed out that in this model the most important factor for reducing the off-target drift deposition appears to be the canopy. When the model includes a canopy, the canopy is assumed to be everywhere including over the water body. This may be a valid assumption for a small water body within the treatment area but outside the forested area a higher deposition can be expected. Furthermore in the simulations where the pesticide is applied in a water solution it is evaporating down to very small droplets that are being blown far downwind, distributing the application over a very large area.

The contact person at US-EPA made a rerun of one of the scenarios (Base F, one of the aircraft cases), but removed the canopy and included an oil carrier in the model. This simulation resulted in that close to 10% of the application rate depositing 200m downwind of the application. This indicates that a considerable higher deposition than 0.6 %, as suggested by the notifier as worst case, is possible. Furthermore, the simulation shows that the highest amount of the deposition may occur at a considerable distance from the forest edge (Fig. 8.6.1.1.a).



Figure 8.6.1.1.a. Diflubenzuron deposition at various distances from sprayed area.

In conclusion, the RMS considers that the notifier's assessment of the PECsw resulting from application of diflubenzuron in forest using AGDISP and FOCUS SW cannot be considered to represent a realistic worst case and can hence not be acceptable for the risk assessment.

# **B.8.6.1.2** Predicted environmental concentrations in surface water (PEC<sub>sw</sub>) following forestry hand held application

The notifier submitted a new calculation of the PECsw for the proposed hand application in forests in the updated summary dossier. The same methodology for calculation as in the DAR was applied, i.e. using spray drift values by Rautmann et al. 2001 and a 30 cm deep water body as a model system. However the notifier proposed a new  $DT_{50}$  for the calculations, see table below.

Table 8.0.1.2.a. Aqueous phase degradation rates of dinubenzuron, Cr O and Dr DA proposed by the notifier						
Compound	Average DT <sub>50</sub> at 20°C in the aqueous phase (days)					
Diflubenzuron	2.25					
2,6-difluorobenzoic acid (DFBA)	2.85					
4-chlorophenylurea (CPU)	24.95					

Table 8.6.1.2.a. Aqueous phase degradation rates of diflubenzuron, CPU and DFBA proposed by the notifier

However, the average  $DT_{50}$  for diflubenzuron, as suggested by the notifier, includes results from a study not considered as reliable by the RMS, i.e. the study by Thus et al. 1994. Furthermore, since FOCUS SW simulation is not used for the calculation the worst case water dissipation  $DT_{50}$  should be used (in the DAR it is in the text

149

stated that the average degradation  $DT_{50}$  was used, however the RMS used the average dissipation  $DT_{50}=3$  when performing the calculations). In the table 8.6.1.2.b. the worst case dissipation  $DT_{50}$  are listed which the RMS consider appropriate for PEC calculations. In Table 8.6.1.2.b. the resulting PECsw are shown, which are slightly different from those presented in the DAR. However, since only the PECinitial was used for the risk assessment the slight change in PEC-values does not alter the aquatic risk assessment and the RMS considers that no further action is required and the assessment in the DAR is still valid.

Table 8.6.1.2.b. Aqueous phase dissipation rates of diflubenzuron, CPU and DFBA considered as appropriate for PEC calculations by the RMS.

Compound	Worst case DT <sub>50</sub> at 20°C in the aqueous phase (days)
Diflubenzuron	3.2
2,6-difluorobenzoic acid (DFBA)	4.2
4-chlorophenylurea (CPU)	31.8

Table 8.6.1.2.c. PECsw and time-weighted PECsw values ( $\mu$ g/L) for diflubenzuron and its metabolites CPU and DFBA following forest application using drift values for late vines obtained from Rautmann (1999) into a 30 cm deep water body. For the calculation of TWA PEC the worst case Dis-DT<sub>50</sub> was used.

Scenario	Time after	PEC <sub>sw</sub>		PEC <sub>sw</sub>		PEC <sub>sw</sub>	
	maximum	Diflubenzuro	on	CPU		DFBA	
		Actual	TWA	Actual	TWA	Actual	TWA
		(µg/L)	(µg/L)	(µg/L)	(µg/L)	$(\mu g/L)$	$(\mu g/L)$
Forestry 48 g a.s./ha,	Initial	1.280		0.311		0.110	
hand application,	24 hours	1.031	1.151	0.304	0.308	0.094	0.102
crop height >50 cm	2 days	0.830	1.039	0.298	0.305	0.079	0.094
	4 days	0.538	0.856	0.285	0.298	0.057	0.081
	7 days	0.281	0.659	0.267	0.289	0.035	0.065
	14 days	0.062	0.402	0.229	0.268	0.011	0.043
	21 days	0.014	0.278	0.197	0.250	0.003	0.031
	28 days	0.003	0.211	0.169	0.233	0.001	0.024
	42 days	0.000	0.141	0.125	0.204	0.000	0.016

#### 8.6.1.3 PECsw following tractor mounted application in forestry

#### Point of clarification No. 4.2:

No calculation has been provided. The notifier states that several safe uses for the highest load applications, i.e. orchard uses based on the NOEC (or EAC) of 0.7  $\mu$ g/L has been provided which thus cover the risk resulting from the forest scenario. However the EAC will be discussed by the ecotoxicology expert meeting. RMS considers that the EAC should be 0.07  $\mu$ g/L and using this EAC no safe use is demonstrated for the orchard scenario and the notifiers reasoning fail.

If the ecotox meeting agrees with the notifier that the EAC should be 0.7  $\mu$ g/L then safe use has been demonstrated for some FOCUS scenarios if a bufferzone of 20 m is implemented for the orchard use. Nevertheless it will still be unclear which buffer zones that will be needed for the tractor mounted application in forest since the application rates differ from the orchard use (48 g/ha compared to 180 g/ha). The corrected values are included in the revised LoEP.

#### **B.8.6.2** PECsw following application in orchards

#### B. 8.6.2.1 FOCUS step 4 for tractor mounted application in orchards (buffer zones >30 m)

Risk for surface waters was identified for the tractor mounted application also when buffer zones of 30 m was implemented in the FOCUS Step 4 calculations. Hence the RMS and other commenting MS (reporting table no. 4(27)) suggested that modelling using wider buffer zones should be performed.

However, the notifer has not submitted any further calculation instead they submitted a position paper (see APPENDIX I) in which it was stated that drift reducing technologies would be sufficient to reduce drift to an acceptable level for aquatic ecosystems. For this position the notifier referred to the FOCUS report "Landscape and mitigation factors in Aquatic Ecological risk assessment (version 1 draft June 2004)". In this report it is stated spray-drift can be mitigated by up to 99% by drift reducing technologies and bufferzones, and that this should be considered at MS level. The PPR Panel does not agree with the maximum spray drift reduction of 99%, which is considered to be not realistic in praxis. Instead the PPR panel (Opinion of the Scientific Panel on Plant protection products and their residues on a request from EFSA on the Final Report of the FOCUS Working Group on Landscape and Mitigation Factors in Ecological Risk Assessment, December 2006) suggest that the maximum cap for spray drift reduction should be set to 85%.

However, FOCUS Landscape is still under discussion and at present only spray drift reduction trough buffer zones may be assessed at EU level, other potential mitigation measures will be only considered on case to case basis for EU risk assessment taking into account that these risk mitigations options are not general available for all MS, however the information provided may be useful for MS.

#### B. 8.6.2.2 PECsw following hand held application in orchards (FOCUS simulation)

#### Point of clarification No. 4.2:

No calculation has been submitted, see above 8.6.1.3.

#### **B.9** Ecotoxicology

#### **B.9.1** Effects on birds

#### **Open point 5 (2):**

Further details on the reproductive parameters for the Subchronic toxicity and reproduction was requested.

# Reference:Beavers, J.B., Corbitt, A., Hawrot, R. et al (1990 a). A one-generation<br/>reproduction study with the mallard (*Anas platyrhynchos*).

TABLE 5								
	BODY WEIGHT DATA (g) - HATCHLINGS							
		MALL	ARD					
	DIFLUBENZUR	ON - PROJ	IECT NUMBER 2	25-103				
				DIFLUBENZURON				
	0	PPM	250 PPM	500 PPM	1000 PPM			
No. of Ducklings W	leighed	281	212	253	338			
Mean Body Weight (	g) 33 <u>+</u>	2	34 <u>+</u> 3	34 <u>+</u> 3	34 <u>+</u> 2			

The above differences from the control are not statistically significant.

			TABLE 5A						
	BODY WEIGHT	DATA	(g) - 14	-DAY S	URVIVORS				
			MALLARD						
	DIFLUBENZU	RON -	PROJECT	NUMBER	225-103				
					DIFLUB	NZURO	N		
	0	PPM	250	PPM	500	PPM	1000	PPM	
No. of Ducklings	Weighed	273		202		243	:	325	
Mean Body Weight	(g) 229 <u>+</u>	37	240 <u>+</u>	19	246 <u>+</u>	23	240 <u>+</u>	16	

The above differences from the control are not statistically significant.

~

.....

TABLE 3							
REPRODUCTIVE DATA - MALLARD							
DIFLUBENZURON - PROJECT NUMBER 225-103							
		D	IFLUBENZURO	N			
	O PPM	250 PPM	500 PPM	1000 PPM			
Eggs Laid Eggs Cracked Eggs Set@ Viable Embryos Live 3-Week Embryos Hatchlings 14-Day Old Survivors Eggs Laid/Hen Eggs Laid/Hen/Day @@ 14-Day Old Survivors/Hen  @ - Eggs laid minus eggs crack	622 10 556 450 443 282 273 39 0.59 17 ed, eggs	618 4 560 518 502 212 202 41 0.62 13 taken for shel	680 15 600 475 471 253 243 43 0.64 15	634 9 562 528 510 338 325 40 0.60 20 , abnormal			
eggs and eggs inadvertentl @@ - Based on 66 days.	y damaged						
	TAB	LE 3A					
REPRODUCTI	VE DATA -	(MEAN %^) - M	ALLARD				
DIFLUBENZ	URON - PR	DJECT NUMBER 2	25-103				
		D	IFLUBENZURO	N 			
	O PPM	250 PPM	500 PPM	1000 PPM			
Eggs Laid Eggs Laid/Max. Laid (%) Eggs Cracked/Eggs Laid (%) Viable Embryos/Set (%) Live 3-Week Embryos/Viable (%) Hatchlings/3-Week (%) 14-Day Old Survivors/Hatch (%) Hatchlings/Set (%) 14-Day Old Survivors/Set (%) Hatchlings/Max. Set (%)	622 66 1 82 98 61 98 51 49 33 33 %) 32	618 70 1 92 97 42 94 38 36 26 25	680 72 2 77 98 45 96 38 37 29 28	634 67 94 96 64 95 58 58 58 58 58 39 38			

**Reference:** 

Beavers, J.B., Corbitt, A., Hawrot, R. Et Al (1990 b). A one-generation reproduction study with the bobwhite (*Colinus virginianus*).

#### TABLE 3

#### **REPRODUCTIVE DATA - BOBWHITE** DIFLUBENZURON - PROJECT NUMBER 225-102

#### -----. . . . . . . . . . . DIFLUBENZURON PM 500 PPM 1000 PPM 250 PPM O PPM Eggs Laid Eggs Cracked Eggs Set@ Viable Embryos Live 3-Week Embryos Hatchlings 14-Day Old Survivors Eggs Laid/Hen Eggs Laid/Hen/Day @@ 14-Day Old Survivors/Hen 459 35 363 325 312 270 35 0.49 21 674 31 571 539 536 505 468 42 0.59 29 595 489 595 23 507 433 427 391 342 31 398 340 338 314 271 33 0.45 18 40 0.55 23

eggs laid minus eggs cracked, eggs taken for shell thickness, abnormal eggs and eggs inadvertently damaged.
 eggs and r 72 days.

#### TABLE 3A

#### REPRODUCTIVE DATA - (MEAN %^) - BOBWHITE

#### DIFLUBENZURON - PROJECT NUMBER 225-102 DIFLUBENZURON 0 PPM 250 PPM 500 PPM 1000 PPM Eggs Laid Eggs Laid/Max. Laid (%) Eggs Cracked/Eggs Laid (%) Viable Embryos/Set (%) Live 3-Week Embryos/Viable (%) Hatchlings/3-Week (%) 14-Day Old Survivors/Hatch (%) Hatchlings/Set (%) Hatchlings/Max. Set (%) Hatchlings/Max. Set (%) 674 69 5 95 595 65 4 86 459 58 88 99 89 86 77 66 37 489 53 59 98 92 80 92 80 69 37 32 99 94 93 98 92 88 79 68 47 89 83 56 52 41

 $^{\prime}$  = Mean % values from Appendix VII. The above differences from the control are not statistically significant.

#### TABLE 4

EGG SHELL THICKNESS DATA - (mm)

BOBWHITE

#### DIFLUBENZURON - PROJECT NUMBER 225-102

		DIFLUBENZURON				
	O PPM	250 PPM	500 PPM	1000 PPM		
No. of Eggs Measured	59	51	67	54		
Mean Egg Shell Thickness (mm)	0.207	0.212	0.210	0.213		
<u>+</u> standard deviation	± 0.011	± 0.011	<u>+</u> 0.008	<u>+</u> 0.013		

-----

The above differences from the control are not statistically significant.

154

TABLE	5

BODY WEIGHT DATA (g) - HATCHLINGS

BOBWHITE

DIFLUBENZURON - PROJECT NUMBER 225-102

			DIFLUBENZURON		
	0 PPM	250 PPM	500 PPM	1000 PPM	
No. of Chicks Weighed	391	308	505	314	
Mean Body Weight (g)	5.7 <u>+</u> 0.5	5.9 <u>+</u> 0.5	5.9 <u>+</u> 0.4	5.9 <u>+</u> 0.6	
	from the contr	ol and not ci	tatictically ci	anificant	
the above utilierences	Trom the contr	or are not si	calistically si	quirilcanc.	

			TABLE 5A				
BODY W	EIGHT	DATA	(g) - 14	-DAY SU	JRVIVORS		
		В	OBWHITE				
DIFLUE	ENZUR	ON - P	ROJECT N	UMBER 2	225-102		
					DIFLUBE	NZURON	
	0	PPM	250	PPM	500	PPM	1000 PPM
No. of Chicks Weighed		342		270		468	271
Mean Body Weight (g)	23 <u>+</u>	2	23 <u>+</u>	2	22 <u>+</u>	2	22 <u>+</u> 2
The at							

#### B.9.1.5 Risk assessment birds

#### **Point of clarification 5.1:**

EFSA requested an assessment for the risk for birds resulting from consumption of contaminated drinking water and this is given below. The risk assessment for exposure via drinking water was carried out in accordance with the SANCO/4145/2000 guidance.

Exposure via drinking water; Orchards:

The concentration in drinking water that birds may be exposed to was considered to be equal to the PEC<sub>SW</sub>. Hence the PEC <sub>DRINKING WATER</sub> was assumed to be 15.7  $\mu$ g a.s./L (Step 2, FOCUS calculation) and the total water ingestion rate for a small bird was calculated as 0.059\*bw<sup>0.67</sup> (=0.0027 L/day). The daily dose of diflubenzuron was calculated as PEC <sub>DRINKING WATER</sub>\*total water ingestion rate/bw (= 4.23  $\mu$ g/kg d) which was compared to the acute LD<sub>50</sub> > 5000 mg/kg bw and the long term NOEC of 42.7 mg as/kg bw day, resulting in a TER<sub>ACUTE</sub> of 1182033 and a TER <sub>LONG TERM</sub> of 10000, which both are above the Annex VI triggers. Assuming that birds would drink from puddles formed following hand- or tractor mounted spraying in the field during summer months the PEC <sub>Drinking Water</sub> was calculated to be 0.024 g a.s./L, assuming a dilution factor of 5. The daily dose of diflubenzuron was calculated as PEC <sub>DRINKING WATER</sub>\*total water ingestion rate/bw (0.024\*0.0027/0.01=) which was compared to the acute LD<sub>50</sub> of > 5000 mg as/kg bw, resulting in a TER of 772 which is considered acceptable given that the annex VI trigger is 10

Exposure via drinking water Forest:

For the aerial application the RMS used the  $PEC_{SW}$  as calculated by the RMS in the DAR, i.e. 5.31 µg/L as an estimate of the PEC <sub>DRINKING WATER</sub>. The PEC<sub>SW</sub> of 1.28 µg/l was used for the hand held application. For the tractor mounted application no estimate was available, but it is considered that the drift rate used for calculating aerial application, i.e. 33.2 % is protective for this application.

The total water ingestion rate for a small bird was calculated as  $0.059*bw^{0.67} = 0.0027$  L/day. The daily dose of diflubenzuron was calculated as PEC <sub>DRINKING WATER</sub>\*total water ingestion rate/bw (1.28\*0.0027/0.01 and 5.31\*0.0027/0.01 µg/kg bw d, for the hand held and aerial application, respectively). This was compared to the acute LD<sub>50</sub> > 5000 mg/kg bw and the long term NOEC of 42.7 mg as/kg bw day, resulting in a TER<sub>ACUTE</sub> of 166666667 and a TER <sub>LONG TERM</sub> of 142333 for the hand held application, and for TER<sub>ACUTE</sub> 3571428 of and a TER <sub>LONG TERM</sub> of 30500 for the aerial application. Hence the risk for birds resulting from drinking surface water is low as all TER are above the Annex VI triggers.

Assuming that birds would drink from puddles formed following hand- or tractor mounted the PEC<sub>DRINKING</sub>  $_{WATER}$  was calculated to be 0.016 g a.s./L, assuming a dilution factor of 5. The daily dose of diflubenzuron was calculated as PEC  $_{DRINKING WATER}$ \*total water ingestion rate/bw (0.016\*0.0027/0.01) which was compared to the acute LD<sub>50</sub> of >5000 mg as/kg bw, resulting in a TER of 312 which is considered acceptable given that the annex VI trigger is 10. Exposure via drinking contaminated water from leaf axils or puddles has not been considered for aerial applications for forests. The mix volumes of spray applied per hectare for the ultra-low volume or high volume aerial applications are 3 and 40 L, respectively. Given that these application volumes result in rates of 0.3 or 4 mL/m<sup>2</sup> it is unlikely that sufficient spray liquid will be available to form puddles either on the ground or in leaf axils.

#### **B.9.2** Effects on aquatic organisms

#### B.9.2.3. Aquatic Risk assessment for metabolites CPU and DFBA.

#### **Open point 5.8:**

#### Risk of bio-concentration of metabolites CPU and DFBA

The log Pow of CPU is 1.14 and of DFBA -0.02 (this information will be included in an addendum to B.2.), hence the risk of bio-concentration of these metabolites is low.

#### B.9.2.5 Risk assessment for aquatic organisms

#### Open point 5.7 and 5.15:

In the DAR it was suggested that the EAC for aquatic risk assessment should be  $0.07 \mu g/L$ . This was based on a microcosm study (Moffett et al. 1995. Effects, persistence and distribution of diflubenzuron in littoral enclosures, see the DAR), in which a NOAEC for zooplankton could be determined to  $0.7 \mu g/L$ , and it is further supported by information in a literature review in a weight of evidence approach. The RMS applied a safety factor of 10 on this NOAEC to obtain an EAC since sufficient information on the sensitivity of other aquatic invertebrates than zooplankton not could be derived from the studies. The abundance of amphipods was affected at the lowest concentration ( $0.7 \mu g/L$ ) and aquatic insect were not abundant enough for a conclusion to be made on their sensitivity in the littoral enclosure study. The notifier did not agree to this conclusion and submitted a literature review (Risk assessment of diflubenzuron on aquatic organisms with particular emphasis on aquatic invertebrates. Pijst and Wyness, January 2005) in which it was suggested that the EAC should be 13.6  $\mu g/L$ . The RMS did not consider that the information in the literature review was sufficient for such a conclusion and maintained the EAC of 0.07  $\mu g/L$ , for argumentation see the DAR.

In the updated summary dossier the notifier argues for an EAC of  $0.7\mu g/L$  and to support this conclusion they have submitted another literature review, i.e. 'Crompton Europe B.V. proposal for an ecologically acceptable concentration (EAC) in the Draft Assessment Report for diflubenzuron.' by Wyness and Pijst (June 2005). In this literature review the same studies, except for one study, as in the previous literature review (Risk assessment of diflubenzuron on aquatic organisms with particular emphasis on aquatic invertebrates. Pijst and Wyness, January 2005) is cited and the evaluation of these studies is not repeated in the addendum but can be obtained from the DAR. However, in order to provide a transparent assessment the notifiers arguments for an EAC of 0.7  $\mu g/L$  as well as the notifiers summary of the newly submitted paper is reproduced below.

Furthermore during the commenting round (rep. tab 5(25)) the RMS was asked to clarify the weight of evidence approach used to conclude an EAC of 0.07  $\mu$ g/L this is done in the RMS discussion section below.

Reference:	L. Wyness and H.L.A. Pijst (2005). Crompton Europe B.V. proposal for an ecologically acceptable concentration (EAC) in the Draft Assessment Report for diflubenzuron. Performing Laboratories: Crompton Europe B.V. and TSGE				
	The fate and behaviour of diflubenzuron in the aquatic environment indicates				
	that recovery of impacted invertebrate populations will recover				
	The rapid dissipation of diflubenzuron from the water column (1.1 to 3.2 days) and the rapid microbial decay of residues in the sediment (half-life in entire water/sediment systems of 3.4 to 25 days) must lead to a conclusion that following entry to surface waters, diflubenzuron will fall to below toxic threshold levels within a period of about one month. Thus, any resting stages of aquatic invertebrates present in the contaminated waterbody area when hatched will not be affected. Adults or juveniles, which migrate from outside of the waterbody or from refugia within the waterbody, will not be exposed to toxic threshold levels of diflubenzuron and so population recovery can occur. The field data support this hypothesis (in particular see Ali et al., 1988).				
	Thus, from a theoretical standpoint, aquatic invertebrates, which are capable of movement within and out exposed waterbodies, or capable of movement from uncontaminated waterbodies or have adult or resting stages lasting longer than a				

few days, will be able to re-populate in a previously exposed waterbody.

Reassurance can be achieved for recovery of impacted populations between seasons given that diflubenzuron does not accumulate in the water column or sediment.

#### The biology (life cycle) and mode of action of diflubenzuron would suggest that amphipods and other aquatic invertebrates are less likely to be as sensitive as the Cladocera

Comprehensive field data on the sensitivity and recovery of amphipods are absent. This indicates that amphipods were not present as dominant fauna in the waterbodies under investigation in the various field studies. In accordance with the guidance in support of 91/414/EEC, the CLASSIC workshop recommendation was that 'Structural and functional endpoints are generally equal in importance.' Key ecological process such as the decomposition of organic matter, which is a process that some key amphipod species undertake, are often maintained even when effects occur on structure (e.g. rotifers are relatively insensitive to diflubenzuron and so will continue to contribute to decomposition processes). In all of the eight field studies used in support of Annex I listing of diflubenzuron, amphipods were never dominant (nor were any significant effects observed in one study in which they were present).

Despite a lack of comprehensive field data an informed judgement can be made on the likelihood of impact and recovery of amphipods following exposure of waterbodies to diflubenzuron.

The mode of action of diflubenzuron is such that any exposed invertebrate with a cuticle and with moulting stage is very likely to be affected. In the study by Colwell and Schaefer (1980), the reduction in copepod densities in treated ponds were of lesser magnitude and of shorter duration than cladoceran reductions. Cladocerans moult (synthesising chitin) in all life stages, whereas copepods do not moult after reaching the adult instar. Some adult (non-moulting) copepods can live for more than three weeks and so these individuals will provide a reservoir group until the levels of diflubenzuron decline to below toxic threshold concentrations. This argument can be extended to amphipods. Different amphipod species have different life-cycle processes. Some freshwater amphipods may lay eggs only once per season. Others may lay eggs during each of the last five or six instars (e.g. gammarids). Moulting may begin shortly after hatching and continue through to maturity, although as amphipods increase in size, moulting usually slows to once every 20 to 30 days. The average instar lasts 15 days (U.S. Fish and Wildlife Service, January 1989). The high potential reproductive capacity of gammarids, with rapid production of numerous successive broods when sexual maturity is finally achieved, indicates adaptation to high mortality during relatively long periods of growth to sexual maturity. This provides scope for an opportunistic strategy of emigration from centres of population abundance to colonise new territory when conditions are favourable. So, not only would adult, non-moulting adults be unaffected there would also be sufficient numbers of unaffected individuals or unhatched eggs in and outwith contaminated areas to ensure recovery of affected populations following the rapid dissipation of diflubenzuron from the water column. The Cladocera with more continuous moulting but rapid reproduction would be expected to be affected, but would also be expected to recover, and this is substantiated from numerous field studies.

In summary, there is no scientific basis for assuming that amphipods will be more sensitive to cladocerans and there is no basis for assuming that recovery would not occur. In two studies, the littoral enclosure study and that of Kingsbury et al. (1987) amphipods were present but were caged, thus preventing any opportunity for recovery. Therefore, coming to an overall conclusion on amphipod recovery has shortcomings if based solely on these two studies.

#### Alternative EAC proposal

An EAC of 0.07  $\mu$ g/L would have to be reconciled with recovery of sampled invertebrate taxa from three outdoor studies following exposure at concentrations of diflubenzuron approximately x 180 higher and in other studies at concentrations at least x10 higher.

A ten-fold safety factor in the context of higher-tier data and assessments is very large and would indicate fundamental or substantial unresolved concerns. For diflubenzuron, the DAR points to concerns of amphipods and their recovery. The contribution of amphipods in aquatic community is arguable, based on the sampled invertebrates from field studies and indirect evidence points to recovery potential. Direct field evidence exists and is not ideal, but is supportive of the indirect evidence.

The EAC, at the very least, may be set at 0.7  $\mu$ g/L, accepting that recovery has been demonstrated in different aquatic environments at concentrations x18 this initial maximum concentration.

A final judgement on an EAC value which protects aquatic environments can be decided by expert groups (e.g. EPCO) in the context of the EU evaluation procedure for leading to the Annex I inclusion of diflubenzuron.

#### Colwell and Schaefer (1980) - not previously submitted to RMS

Of nine experimental ponds of 0.01 ha and depth 1.2m, five were treated once with diflubenzuron, resulting in a mean measured initial concentration of 13.2  $\mu$ g/L (1 hour post-treatment). Fish were present in the ponds (study objective was to assess changes in fish diets).

The cladoceran (5 genera) densities were reduced in the treated ponds by > 99% compared to pre-treatment levels. Recovery of cladocerans was observed after 4 weeks and returned to pre-treatment levels after 5 weeks. Copepod reductions in treated ponds were observed but were less so than cladocerans and recovery was more rapid. Rotifers were unaffected by treatment. The odonate and chironomid benthic invertebrates declined in treated ponds by about 35% to 47% then increased by day 14 to 16. However, these changes were also observed in the controls and the changes may not have been due to treatment. Gastropod densities decreased by 86% in the first 8 days but natural variation precluded statistical interpretation of impact. Oligochaetes were unaffected. The authors also comment on the failure of an organism to reappear in a specific pond, after impact by diflubenzuron. They quote an example for *Daphnia sp.*, where recovery was not observed in one pond but was observed in another similarly treated pond. This was speculated to be due to a lack of chance re-introduction, lack of pre-treatment ephippia, variable predator abundance or other non-treatment related factors.

With respect to the question of sensitivity and recovery:

- Under experimental conditions of enclosed ponds the most sensitive invertebrates, the Cladocera recovered within a 5 week period after exposure to levels of diflubenzuron which reduced their population densities by more than 90%;
- The Cladocera were the most sensitive invertebrates sampled.

Collwell, A.E., Schaefer, C.H., 1980. Diets of *Ictalurus nebulosus* and *Pomoix nigromaculatus* altered by diflubenzuron Can.J.Fish.Aquat.Sci., 37, 632-639

#### **RMS comments:**

The RMS agrees that the fate property of diflubenzuron indicates that the concentration following contamination likely will fall below toxic threshold levels within a period of about one month. The notifier therefore claims that aquatic invertebrates which are capable of movement within andout of exposed water bodies or have resting stages lasting longer than a few days will be able to re-populate a previously exposed water body. The RMS agrees that this is possible (but this is true for all pesticides which are not persistent), however the important question is if recovery occur within an acceptable period of time. Since many species of aquatic insects are univolatine and often have synchronised life cycles the RMS considers that there is a risk of long lasting effects on such species if exposure occurs during a sensitive stage. The RMS considers that not enough information was provided by the notifier to resolve this concern. The RMS agrees that insects that are not in a moulting stage will likely be less severely affected by exposure to diflubenzuron as argued by the notifier for e.g. gammarids. However, since aquatic insects species may have synchronised lifecycles it is possible that a large proportion of a population in an aquatic ecosystem will be in a sensitive stage and thus affected by exposure.

The notifier claims that the function of amphipods and aquatic insects in aquatic ecosystems can be maintained by other organisms not sensitive to diflubenzuron, e.g. rotifers. However, rotifers do not occupy the same ecological niche as amphipods or as aquatic insects, which shred much larger particles than rotifers.

The notifier also claims that there is no basis to assume that amphipods will be more sensitive than cladocerans to diflubenzuron exposure. However, the RMS does not consider that the information provided in the literature reviews clearly shows that they are not. Furthermore, the concern is not only for amphipods but also for aquatic insects. The RMS agrees that the study by Colwell and Schaefer (1980) indicates that recovery of zooplankton is possible 6-8 weeks after exposure to a relatively high concentration of diflubenzuron (average in water column after 24 h 5.5-8.7  $\mu$ g/L). This study also indicated that the chironomids and odonate larvae in the treated ponds were less sensitive compared to the cladocerans. However, effects on aquatic arthropod invertebrates may have been obscured due to the presence of fish in the ponds.

#### **RMS discussion of EAC**

In the reporting table the RMS was asked by other memberstates to clarify the weight of evidence approach used to conclude an EAC of 0.07  $\mu$ g/L. A rational for the EAC of 0.07  $\mu$ g/l is given below, references and further details can be found in the DAR:

The study by Berends and Laan (1994) indicates that the toxicity of diflubenzuron to zooplankton (i.e. *D. magna*) likely will disappear after a period of days-weeks in the water column of natural systems. Hence, under field conditions there is a potential for recovery of zooplankton from unexposed refugia after a period of days-weeks.

The results presented in the tables from the study by Ali and colleagues (1988) shows that no large decrease in the abundance of zooplankton occurred due to treatment (measured 0.197  $\mu$ g diflubenzuron /L) in a pond. However, the study has several drawbacks, e.g. there were large

differences in the shape of the control and treatment pond and the treatment was not replicated. Nevertheless, the RMS considers that the study can be part of a weight of evidence approach.

Even though no full recovery of zooplankton occurred in the study by Mulla and colleagues (1975) it indicates that there is a potential for recovery following exposure since the numbers of cladocerans and copepods increased the two last sampling occasions (11 and 15 days after exposure) at both exposure concentrations (i.e 6.8 and 13.6  $\mu$ g/L). Also the newly cited study by Colwell and Schaefer (1980), see above, shows that recovery of zooplankton is possible within a month following exposure.

The RMS considers that these studies taken together with the results from the littoral enclosure study can be used in a weight of evidence approach to indicate that there is a potential for recovery of zooplankton following exposure to  $0.7 \mu g/l$  (and possibly also following higher exposure concentrations) depending on availability of unaffected populations/life-stages as source of recolonistation and that this line of evidence can be used to support a NOAEC for the zooplankton community of  $0.7 \mu g/L$ . However, uncertainty regarding the risk for the aquatic arthropod community remains and hence a safety factor is needed on the zooplankton NOAEC in order to obtain an EAC which also covers the insect community. The magnitude of this factor should be discussed at an expert meeting. However, the RMS considers that a similar factor as would be applied on a single species Daphnia test is warranted in order to account for the variation in species sensitivity since the notifier has not provided information which resolve the uncertainty regarding the sensitivity of the aquatic arthropod community. Hence, the RMS considers that a factor of 10 is appropriate even if higher tier data from microcosms and field studies are available.

Furthermore, the RMS performed a none comprehensive literature search of the open literature and found articles on the effects of diflubenzuron on aquatic organisms which were not cited in the literature review by the notifier. For example in one study (Harray et al. 1994) on the toxicity of diflubenzuron to mayflies (mainly *Cynygmula subaequalis*) it was found that the mortality following exposure to 0.6  $\mu$ g/l was 45%. The mortality was measured after 96 hours of exposure and 32 days in clean water conditions which is necessary for a species with a long lifecycle given the mode of action of diflubenzuron. The acute toxicity (48-h EC<sub>50</sub>) to *Daphnia* was 2.6  $\mu$ g/L (Groeneveld et al 1995, see the DAR), indicating that mayflies may be more sensitive to diflubenzuron compared to cladocerans.

Following exposure of indoor complex laboratory streams to nominal 1 µg diflubenzuron/L (continuous exposure, two replicates per treatment level) Hansen and Garton (1982) found that the insect fauna suffered from

161

direct toxic effects. Several species of Ephemeroptera and Plecoptera were eliminated following exposure to 1  $\mu$ g/L at the first sampling occasion which occurred 1 month after treatment. The treatment in this study can be considered as worst case since the exposure was continuous. However, since effects were observed already the first sampling occasion the onset of effects may have been rapid. Following treatment of the streams with 0.1  $\mu$ g diflubenzuron/L no or only slight effects could be observed. Recovery could not be observed in this study since it was conducted under indoor conditions. In a study by Griffith et al. (1996) the emergence of the stonefly Peltoperla arcuata decreased during the first 4 months after treatment of the catchments of two streams with 35.1 g diflubenzuron/ha compared to two reference streams. No effects on other aquatic insects were observed in this study the authors however state that this likely was due to that the other shredder species present in their sampling not are obligate leaf feeder but fed on other material during the study period which was conducted before leaf abscission, while P. arcuata is an obligate leaf feeder and likely ingested the few leaves that fell into the streams during the study period and therefore was affected. In a study by Satake and Yasuno (1987) effects on the invertebrate community was found following treatment of a stream for one hour with 1.25 mg/L (a relatively high but short exposure) compared to a control, in the study most invertebrates were eliminated within 2 weeks, but effect on *Hydropsyche* were more gradual. The RMS considers that the results from these studies support an EAC of 0.07 µg diflubenzuron/L.

In conclusion, the RMS does not consider that the argumentation provided by the notifier in the updated summary dossier or in the literature review can resolve the uncertainty regarding possible effect on aquatic insects and maintain that a safety factor should be applied to the NOAEC for zooplankton (0.7  $\mu$ g diflubenzuron/L). The RMS propose that a factor of 10 should be but this need to be discussed at the expert meeting.

#### References

Harray et al. 1994. The effects of diflubenzuron (Dimilin) on selected mayflies (Heptageniidae) and stoneflies (Peltoperlidae and Pteronarcyidae). Env. Toxicol. Chem. 13:517-522

Hansen and Garton 1982. The effects of diflubenzuron on a complex laboratory stream community. Arch. Environ. Contam. Toxicol. 11:1-10.

Griffith et al. 1996. Effects of aerial application of diflubenzuron on emergence and flight of adult insects. J. Econ. Entomol. 89:442-446

Satake and Yasuno 1987. The effects of diflubenzuron on invertebrates and fishes in a river. Jpn. J. Sanit. Zool. 38: 303-316

#### **B.9.3** Risk assessment mammals

#### **Point of clarification 5.2:**

EFSA requested an assessment for the risk for mammals resulting from consumption of contaminated drinking water, as well as for secondary poisoning, and this is given below. The risk assessment for exposure via drinking water was carried out in accordance with the SANCO/4145/2000 guidance.

Exposure via drinking water Orchards The concentration in drinking water that mammals may be exposed to was considered to be equal to the PEC<sub>SW</sub>, i.e. 15.7  $\mu$ g a.s./L (i.e. PEC<sub>SW</sub> from Step 2, FOCUS calculation) and the total water ingestion rate for a small mammal (10 g) was calculated as 0.099\*bw<sup>0.90</sup> (=0.0016 L/day). The daily dose of diflubenzuron was calculated as PEC drinking water\*total water ingestion rate/bw (2.46  $\mu$ g as/kg bw d) which was compared to the acute LD50 of > 4640 mg/kg bw and to the long term NOEL of 3678 mg as/kg bw day, resulting in a TER<sub>A</sub> of 1886178 TER<sub>LT</sub> 1495000 which are above the Annex VI triggers.

Assuming that mammals would drink from puddles formed field the  $PEC_{drinking water}$  was calculated to be 0.024 g a.s./L, assuming a dilution factor of 5. The daily dose of diflubenzuron was calculated as PECdrinking water\*total water ingestion rate/bw (0.024\*0.0016/0.01) which was compared to the acute LD50 of > 4640 mg/kg bw, resulting in a TER of 1208 which is above the annex VI trigger.

#### Forest

For the aerial application the RMS used the  $PEC_{SW}$  as calculated by the RMS in the DAR, i.e. 5.31 µg/L. The  $PEC_{SW}$  of 1.28 µg/l was used for the hand held application For the tractor mounted application no estimate was available, but it is considered that the drift rate used for calculating aerial application, i.e. 33.2 % is protective for this application.

The total water ingestion rate for a small mammal was calculated as  $0.099*bw^{0.90} = 0.0016$  L/day. The daily dose of diflubenzuron was calculated as PEC <sub>DRINKING WATER</sub>\*total water ingestion rate/bw (5.31\*0.0016/0.01) which was compared to the acute LD50 of > 4640 mg/kg bw and to the long term NOEL of 3678 mg as/kg bw day, resulting in a TER<sub>A</sub> of 5461393 and a TER<sub>LT</sub> 4329096 for the aerial application, TER<sub>A</sub> of 22656250 and a TER<sub>LT</sub> 17958984 for the hand held application, which all are above the Annex VI triggers.

Assuming that mammals would drink from puddles formed following hand- or tractor mounted spraying in the field during summer months the PEC <sub>DRINKING WATER</sub> was calculated to be 0.016 g a.s./L, assuming a dilution factor of 5. The daily dose of diflubenzuron was calculated as PEC <sub>DRINKING WATER</sub>\*total water ingestion rate/bw (0.016\*0.0016/0.01) which was compared to the acute LD<sub>50</sub> of > 4640 mg/kg bw, resulting in a TER of 1812 which is above the annex VI trigger. Exposure via drinking contaminated water from leaf axils or puddles has not been considered for aerial applications for forests. The mix volumes of spray applied per hectare for the ultra-low volume or high volume aerial applications are 3 and 40 L, respectively. Given that these application volumes result in rates of 0.3 or 4 mL/m<sup>2</sup> it is unlikely that sufficient spray liquid will be available to form puddles either on the ground or in leaf axils.

#### Secondary poisoning risk assessment

The Log octanol:water partition coefficient of the active substance diflubenzuron is 3.89. Therefore, the potential risks from bioaccumulation in the food chain (i.e. secondary poisoning effects) require an assessment as pointed out by EFSA in their comments to the DAR. The secondary poisoning risk to birds following the use of diflubenzuron is based on an assessment of exposure from the ingestion of earthworms, fish, birds and mammals.

The risk assessment for secondary poisoning was carried out in accordance with the SANCO/4145/2000 guidance. The BCF (earthworm fresh weight to soil dry weight) was calculated to according to the following formula:

 $BCF=(0.84 + 0.01 K_{OW})/f_{OC} \times K_{OC},$ 

where  $K_{OW} = 7762.5$  (see B.2.1.8),  $K_{OC} = 4609$  (see B.8.2.1) and a default value of 0.02 for the organic carbon content of soil ( $f_{oc}$ ) was used. This calculation resulted in a BCF of 0.85.

The estimation of residues in earthworms are based on the following equation:

 $PEC_{WORM} = PEC_{SOIL} \times BCF$ ,

where the  $PEC_{SOIL}$  (21-day time-weighted average) is 0.057 mg/kg (see section B.8.3) for use in orchards. The resulting  $PEC_{WORM}$  is 0.048 mg/kg following the proposed representative use in orchards. The earthworm residue estimates are converted to a daily dose (mg/kg/bw/day) by multiplication with a factor 1.4, assuming a 10-g mammal eating 14 g per day. This is compared with the long-term NOEL, based on a daily dose. In the case of use in orchards, the TER for earthworm-eating mammals is 54732 (3678/(1.4×0.048)). This assessment is protective for uses in forests where the exposure to mammals via earthworms will be less than in orchards since the application rate is lower. Given that the TER value is significantly greater than 5, the risk for secondary poisoning of mammals from the ingestion of earthworms after the representative use of diflubenzuron in orchards and forests is considered to be low.

#### Fish-eating mammals

The risk to mammals resulting from consumption of fish was assessed in accordance with the SANCO/4145/2000 guidance document. The 21-day time-weighted average PEC in water and the experimentally-determined (whole-fish) bioconcentration factor (BCF) for fish were used to estimate fish residues following the application of diflubenzuron as follows:

 $PEC_{fish} = PEC_{sw} \times BCF$ ,

where the 21-day time-weighted average PECsw values are  $1.77 \mu g/L$  (see section B.8.6.2) following the application of diflubenzuron to orchards (FOCUS step2), and the whole-body BCF is 320 (see section B.9.2.3.). This calculation resulted in PEC<sub>fish</sub> values of 0.57 mg/kg. The fish residue estimates are converted to a daily dose (mg/kg/bw/day) by multiplication with a factor of 0.13, assuming a 3000-g mammal eating 390 g fish/day. This value is compared with the long-term NOEL, based on a daily dose. In the case of use in orchards, the TER for fish-eating birds is 49635 (3678/0.13×0.57).

Since no FOCUS simulations was available for any of the PEC for forestry the initial PECsw for aerial application (5.31  $\mu$ g/L, see section B.8.6.2) was used in the calculations as a worst case. These calculations resulted in a TER= 16650 (3678/(0.00531×320×0.13)). Given that the TER values are greater than 5, the secondary poisoning risk to mammals from the ingestion of fish after the use of diflubenzuron in forests is considered to be low.

#### **B.9.4.** Effects on bees

#### **B.9.4.2** Cage and field tests

#### Open point 5.20:

Reference:	Beuschel, S. (2006). Dimilin WG 80: Assessment of side effects to the honey bee ( <i>Apis Mellifera L.</i> ) In the field following application during bee-flight in germany 2005. Report Gab Biotechnologie GMBH, Germany no. 20051124/g1-bfeu.	
Guideline: GLP:	OEPP/EPPO Guideline No. 170 (3); 2001 Yes	Bulletin of Insectology 56 (1); 2003

#### Material and methods:

Test substance:	Dimilin WG-80
Species:	Honey bee (Apis Mellifera L.)
Treatments:	Dimilin WG-80 at an application rate of 180 g a.i./ha in 200 L water/ha was applied
	twice with an interval of 9 days (3 and 9 July) during daily flight activity of the bees
	and during flowering. An untreated field served as control.
Number of animals:	Four bee colonies for treatment and four for control with 25000-30000 bees per
	colony.
Duration:	3 July- 19 September
Test conditions:	The size of each test field with flowering of Phacelia tanacetifolia was at least 3400
	m <sup>2</sup> . The colonies were placed at the border of each field before the first application
	of the test item.
Observations:	Mortality in front of the bee hives and in the field. Flight intensity (number of
	forager bees/m <sup>2</sup> ). Conditions of the colonies (strength) and brood development
	Behaviour of the bees at the entrance of the hives and in the field.
	The termination rate was calculated as each cell with successful development was
	titled with a 1 and everyone with an termination with 0. Subsequently, the sum of
	development was formed and the termination rate was determined as follows:
	Termination rate $[\%] = 100 - 100 \text{ x} \underline{\text{sum of development}}$ sum of observed cells
Data analysis	None

#### **Results:**

Neither after the first application of the test item nor after the second application an increase of mortality was observed compared to the values observed before application as well as compared to the control up to the end of observation period, see table below. Comparing the values before application to the after application in the test item no decrease of flight intensity was observed neither after the first nor after the second application.

	Treatment	Control
Average Mortality Rate[dead bees / hive /	day]	

Average values for day -3 to 0	3.9	8.1		
Day after first application	0.8	1.0		
Day after second application	1.5	2.3		
Mean value for days $0 - 36$ after application	3.1	5.4		
Average Flight Intensity [foraging bees/ m²/day]				
Average values for day -3 to 0         3.4         4.4				
Day after first application	8.4	10.0		
Day after second application	8.3	10.2		
Mean value for days $0 - 36$ after application	6.1	7.6		

By comparing the individual brood assessments of single cells, the indices (the values of the different brood stages of all cells in each hive, assessed at the same date, summed up and divided by the number of observed cells) showed the course to be expected in natural bee development cycle in all four hives of the test item treatment and in three hives of the control treatment at the first observed development period (BFD before first application) and in three hives of the test item and control treatment each at the second observed development period (BFD before second application) and most of the eggs which were marked at the start of the test developed until hatch.

Treatment		A	Assessment d	ate	
	BFD	BFD+5	BFD+9	BFD+15	BFD+21
	01.07.05	06.07.05	10.07.05	16.07.05	22.07.05
1T1	1.00	1.86	3.63	3.51	4.36
1T2	1.00	1.98	3.90	3.97	4.90
1T3	1.00	1.97	3.87	4.00	4.87
1T4	1.00	1.90	3.73	3.75	4.65
Mean	1.00	1.93	3.78	3.81	4.70
STD	0.00	0.06	0.13	0.23	0.25
Treatment		ŀ	Assessment d	ate	
	BFD	BFD+5	BFD+9	BFD+15	BFD+21
1C1	1.00	2.41	3.77	3.80	4.77
1C2	1.00	1.59	3.39	3.55	4.18
1C3	1.00	1.98	3.77	3.93	4.63
1C4	1.00	2.02	3.87	3.90	4.76
Mean	1.00	2.00	3.70	3.80	4.58
STD	0.00	0.34	0.21	0.17	0.28

#### Table 9.4.2.b. Brood indices of the first development period

Table 9.4.2.c. Brood indices of the second development period

Treatment	Assessment date				
	BFD	BFD+6	BFD+12	BFD+16	BFD+22
	10.07.05	16.07.05	22.07.05	26.07.05	01.08.05
2T1	1.00	3.23	3.82	3.82	4.82
2T2	1.00	2.98	3.94	3.94	4.92
2T3	1.00	2.03	2.97	2.97	3.97
2T4	1.00	3.18	3.73	3.73	4.71
Mean	1.00	2.86	3.61	3.61	4.61
STD	0.00	0.56	0.44	0.44	0.43
2C1	1.00	3.46	3.87	3.88	4.87
2C2	1.00	2.67	2.98	3.01	4.03
2C3	1.00	3.30	3.54	3.56	4.52
2C4	1.00	3.08	3.73	3.79	4.82
Mean	1.00	3.13	3.53	3.56	4.56
STD	0.00	0.34	0.39	0.39	0.39

The termination rate was in the same range except hive 3 of test item treatment in the second development period (26.52 %) and hive 2 of the control at both development periods. Most of the cells remained empty up to the end of the development period, which resulted in lower brood indices on each assessment date compared to the values of the other hives of the same treatment and development period. The mean termination rate of the test item treatment was in both observed development periods below the level of the control, see below.

Table 9.4.2.d. Termination rate of the first development period

Treatment	1T1	1T2	1T3	1T4
Termination %	13.45	2.40	3.25	8.87
Mean %		6	.99	
Treatment	1C1	1C2	1C3	1C4
Termination %	5.65	33.06	7.32	7.32
Mean		13	3.34	·

Table 9.4.2.e. Termination rate of the second development per
---

Treatment	2T1	2T2	2T3	2T4
Termination %	4.62	1.53	26.52	0.0
Mean	8.16			
Treature	201	202	203	204
i reatment	201	202	203	204
Termination %	4.55	27.69	12.24	7.41

No behavioural differences of the bees in the test item (Dimilin WG 80) treatment group were observed during the entire post-application period neither after the first nor after the second application compared to the bees in the control group.

**Comments:** The study was well performed and is considered as valid for risk assessment. In this study no adverse effects on honey bees were observed following treatment with diflubenzuron.

However, the RMS notes that diflubenzuron is mentioned as a reference substance in the OECD Draft guidance document on honey bee (*Apis mellifera L.*) brood test under semi-field conditions (February 2006) and consider

that this fact need to be discussed at an expert meeting before the restriction that diflubenzuron should not be applied to flowering crop is removed.

Furthermore, the RMS searched the open literature and found an article by H. Thompson et al. (The Effects of Four Insect Growth-Regulating (IGR) Insecticides on Honeybee (Apis mellifera L.) Colony Development, Queen Rearing and Drone Sperm Production, Ecotoxicology ) in which significant effects on honey bees in field were observed following exposure to diflubenzuron. In this study significant effects on brood replacement was observed week 5 and 6 after treatment. There was no significant effect on the development of the brood the following spring but there did appear to be a slower increase in levels of brood compared to controls.

#### **APPENDIX I**

#### Diflubenzuron Step 4 surface water assessment and latest opinion of the Scientific Panel in the EU Uwe Wanner, MDBY January 18, 2007

#### **History:**

After completing Step 1-3 surface water assessment using FOCUS surface water models the obtained highest PECs after the use of Dimilin WG 80 in orchards ranged between 0.915-13.622 µg/L, i.e., all above our own NOEC trigger value of 0.7 µg/L stated in Chemtura's Annex I Dossier. KEMI, the RMS for diflubenzuron, disagreed with the NOEC and added a safety factor of 10 leading to a NOEC of 0.07 µg/L. Further, KEMI was concerned about the potential effect of surface water runoff which might have a potential effect on the PECs in surface waters (pond, ditch & stream) in the EU. Therefore, higher-tiered modeling was required. KEMI suggested using the 2004 draft version of the FOCUS report "Lansdscape and Mitigation Factors in Aquatic and Ecological Risk Assessment" (version 1, draft, June 18, 2004). This report includes possible strategies to mitigate factors such as spray-drift and run-off. I conducted these higher-tiered, initial Step 4 PECs implementing buffer zones of 10m, 20m & 30m and wrote & submitted a supplemental report to the initial PEC surface water report (2004-011) on April 01, 2005. The inclusion of a 10m-buffer led to the reduction of PECs in pond scenarios below our internal trigger of 0.7  $\mu$ g/L (0.583-0.631  $\mu$ g/L). Larger buffer even further decreased the PECs. At this time point the decision was made to submit the additional report, as we felt strongly that we have proven safe scenarios for the inclusion of diflubenzuron into Annex I. Further, the assessment revealed that runoff, which occurs 14 days after the application, only increased the actual concentration in a pond in 1 run-off scenario; however, the amount was even below KEMI's trigger value (0.058 µg/L). Therefore, no mitigation for run-off was necessary. KEMI insisted in the DAR, that a safety factor of 10 is still necessary. Therefore, KEMI concluded that Chemtura hasn't provided evidence of safe uses as our lowest predicted concentration was still above KEMI's NOEC of 0.07 µg/L.

#### **Further Step 4 assessments**

At the same time when I wrote the supplemental report I conducted additional higher-tiered assessments following the draft version of the FOCUS mitigation document. This document was finalized in May 2005. There are certain differences between the draft version I used and the final document; yet, the sections 3.2 "General principles for implementing risk mitigation measures under 91/414" and 3.4 "Risk mitigation for spray drift", I referred to, did not change significantly: "…[Recommendation 2] There is already sufficient evidence to implement certain measures into ecological risk assessment and it is recommended that this is done immediately. Authorisations of products that present unacceptable ecological risk under standard use conditions can be made subject to the application of suitable restrictions ensuring mitigation of the risk. These mitigation measures should be grouped by the extent to which they reduce exposure in the following categories: 50, 75, 90, 95 and 99%…"

RMS: SE

"...Three types of mitigation measure are recommended for immediate implementation into the risk assessment. These are the use of no-spray buffer zones, the application of drift-reducing technology and the reduction of exposure using windbreaks... No-spray buffer zones are widely implemented at present and have been successfully incorporated into the risk assessment over several years. Implementation into the risk assessment should continue as at present with the FOCUS drift calculator used to demonstrate the mitigating effect for assessments supporting Annex I listing... Technical solutions to reduce spray drift have advanced significantly over the last 10 years. Drift-reducing nozzles are widely adopted by farmers in some Member States and have been incorporated into the risk assessment. It is recommended that the use of this technology is incorporated into risk assessment at the European as well as Member State level. Specific technologies that are recommended for use include drift-reducing nozzles, air assistance,

tunnel sprayer, shielded spraying, and band spraying. The application of a particular technique can be considered to cause a relative reduction in deposition of pesticide that is selected as a conservative value from the possible distribution of effects. It should be noted that drift-reducing techniques only need to be implemented for applications made in the area of crop bordering the edge-of-field/water body, since drift interception beyond this point reduces drift to insignificant levels. At the European level, it will only be necessary to stipulate the reduction in exposure via spray drift necessary to reduce risk to acceptable levels. The relevant technology can then be applied at Member State level based on classification systems for drift-reducing techniques which already exist in several Member States... [Recommendation 6] It is recommended that the maximum values identified in Table 5 act as an absolute cap for the incorporation of mitigation into risk assessments for Annex 1 listing (more differentiated maxima can be derived on a case-by-case basis according to the use conditions and options for mitigation)..."

Based on these recommendations I calculated the PECs starting with the Step 3 results. The buffer between the orchard trees and the surface water is standardized in Step 3 and basically directly adjacent. Different inflows of the pesticide into the surface water are calculated using the Spray Drift Calculator, PRZM (for potential run-off) and MACRO (for potential drainage). All of these inputs are fed into TOXSWA which calculates the PECs in different surface water scenarios including effects of degradation, water flow etc.

In order to see the effect of buffer zones, the "mass load by spray drift" (mlsd) value in each Step 3 TOXSWA file for each of the 10 orchard scenarios is manually changed. The "mlsd" value is calculated with the Spray Drift Calculator at different buffer zones (10m, 20m, & 30m).

Similarly, the effect of spray drift mitigating equipment (50%, 75%, 90%, 95% and 99% reduction) can be calculated by changing the "mlsd" value accordingly. It turned out, not surprisingly, that, e.g. a reduction of the "mlsd" value by 50% results in a reduction of highest PECs between 50.0-50.1% or a reduction of the "mlsd" value by 99% results in a reduction of highest PECs between 97.6-99.1%. This evaluation of spray-drift reducing equipment involved 5 days of non-stop computing. The end results seemed to be pretty obvious: If the spray drift is reduced by X% the resulting highest PECs are reduced by a similar percentage.

This effect allowed me to quickly evaluate the impact of combinations of buffer zones and spray drift mitigating equipment on the PECs. For example: I combined the reduction of the "mlsd" value based on buffer zones with the range of PEC reductions achieved with equipment mitigation (e.g., effective PEC reduction of 97.6-99.1% in case of a 99% equipment reduction). The results of these assessments are in the Excel file "Landscape & equipment mitigation for buffer zones for different NOEC.xls" and were communicated within Chemtura.

170

#### Effect of the opinion by the Scientific Panel on plant protection products

The Panel does not fully agree with the exposure reduction groups of 50%, 75% 90%, 95% and 99%. They suggest that the grouping needs to be done according to real field situations. They consider the 5 given groups as exaggerated and not relevant because it can be different for different kinds of mitigation measure. However, they agree with "Recommendation 3" which basically states that the actual measure to mitigate the risk does not need to be specified on Annex I level. Individual Member States need to decide on national authorizations the exact measure to assure X% of mitigation. So, basically my approach is okay; yet, they don't agree with the %-age groups.

The Panel agrees with the FOCUS statement that spray drift mitigation is generally well established. Further, they agree that mitigating effects such as re-population of surface waters due to interconnected water systems should not be used on a field scale. These effects are true, yet, they are on a more "landscape scale" which is above & beyond the "field scale" used as the basis of risk assessments for Annex I.

The Panel does not agree with the maximum spray drift reduction of 99%, which is considered to be not realistic in the praxis. Instead they suggest that the maximum cap for spray drift reduction should be set to 85%. Further, the opinion paper states their disagreement on the proposed probabilistic risk assessments, on new scenario development and the catchment scale modeling. All of these are irrelevant in our diflubenzuron Step 4 assessment. I found it interesting that monitoring data can be used as supportive evidence; yet, only when uncertainties are taken into consideration. The Panel is of the opinion that the current state-of-the-art monitoring programs are not supportive as none of them would be able to detect short-term effects caused by short-term peak concentrations of pesticides.

The remaining discussion on GIS based mitigation etc. is once again not relevant for this Step 4 assessment.

#### **Conclusion:**

The Panel considers the FOCUS report as a "promising vision for higher tier approaches"; yet, in order to have it implemented as a real guidance document it needs to be revised.

So, de facto, there is currently no guideline on higher-tiered risk assessments for surface water. I still think, that the approach I used is sound and robust; yet, I am pretty sure that KEMI is aware of this position paper and is, therefore, likely to be extremely critical on any higher-tiered assessment derived from the FOCUS document (although they suggested to use it...).

Addendum 2 to Draft Assessment Report



# DIFLUBENZURON

Volume 3 Annex B.6 Toxicology

Rapporteur Member State: Sweden

February 2009



#### Volume 1

Level 1: Statement of subject matter and purpose for which the monograph was prepared

Level 2: Reasoned statement of the overall conclusions drawn by the Rapporteur Member State

Appendix 1: Standard terms and abbreviations Appendix 2: Specific terms and abbreviations Appendix 3: List of endpoints

Level 3: Proposed decision with respect to the application for inclusion of the active substance in Annex I

Level 4: Further information to permit a decision to be made, or to support a review of the conditions and restrictions associated with the proposed inclusion in Annex 1

#### Volume 2

Annex A: List of the tests and studies submitted and of information available

### Volume 3

#### Annex B: RMS summary, evaluation and assessment of the data and information

Annex B.1: Identity Annex B.2: Phys/chem. Annex B.3: Data application and further information. Annex B.4: Proposal for classification and labelling Annex B.5: Analytical method **Annex B.6: Toxicology and metabolism** Annex B.7: Residues in crop Annex B.8: Fate and behaviour Annex B.9: Ecotoxicology Appendix 1: Standard terms and abbreviations

Appendix 2: Specific terms and abbreviations

#### Volume 4

Annex C: Confidential information and summary and assessment of information relating to the collective submission of dossiers

#### Table of contents

New open point 2.7 identified at PRAPeR 64 meeting: Information submitted by the applicant on PCA to be evaluatedby the RMS.175B.6.14Exposure data (Annex IIIA 7.2)Appendix 1195

# New open point 2.7 identified at PRAPeR 64 meeting: Information submitted by the applicant on PCA to be evaluated by the RMS.

RMS has received the following document about 4-chloroaneline (PCA) from the notifier.

# Toxicological Evaluation of 4-Chloroaniline1 (PCA): A Minor Impurity in Technical Diflubenzuron

#### September 5, 2006

#### Summary

Diflubenzuron contains 4-chloroaniline (PCA) as a minor impurity. The maximum certified level of PCA in technical diflubenzuron from Chemtura is 30 ppm. PCA does not constitute a toxicological or more specifically a carcinogenic risk as an impurity in Chemtura's technical diflubenzuron.

#### 4-Chloroaniline (PCA) toxicity review

Results of toxicity testing with PCA are publicly available (CICAD, NTP, HSDB). Repeated exposure to PCA leads to cyanosis and methemoglobinemia, followed by effects in blood, liver, spleen, and kidneys, manifested as changes in hematological parameters, splenomegaly, and moderate to heavy hemosiderosis in spleen, liver, and kidney, partially accompanied by extramedullary hematopoiesis. These effects occur secondary to excessive compound-induced hemolysis and are consistent with a regenerative anemia (HSDB, 2006). A variety of *in vitro* genotoxicity tests (Salmonella mutagenicity test, mouse lymphoma assay, chromosomal aberration test, induction of sister chromatid exchange) indicate that PCA is possibly genotoxic, although results are sometimes conflicting. Due to lack of data, it is impossible to make any conclusion about PCA's *in vivo* genotoxicity. No studies are available on reproductive toxicity.

PCA has been tested for its carcinogenic potential in rats and mice. The proposed carcinogenic mechanism of action is that the methemoglobin bound with PCA and similar aniline compounds or their reactive metabolites is broken down in the red pulp of the spleen and the reactive metabolites are released, binding to splenic mesenchymal tissues and resulting in fibrosis, which progresses to the formation of splenic tumors. Another proposed mechanism suggests that the splenic tumors are a result of erythrocyte toxicity. The damaged erythrocytes are scavenged by the spleen, where they cause vascular congestion, hyperplasia, fibrosis, and tumors. Whether the mechanism of carcinogenesis is mediated through genotoxic or non-genotoxic events is not resolved. PCA is genotoxic *in vitro* but appears to be dependent on metabolism for its full expression. There is one positive study *in vivo* (micronucleus test), but this was positive only at a dose level in the range of the LD<sub>50</sub> (HSDB, 2006). PCA is a threshold carcinogen with clear

carcinogenic results in only one animal species, at a dose level exhibiting overt systemic toxicity.

Synonym: parachloroaniline

## <u>Critical Review of the U.S. National Toxicology Program (NTP) Carcinogenicity Studies</u> with PCA

Critical assessment of the PCA studies reveal that PCA is weakly carcinogenic upon dietary exposure and these carcinogenic effects in both the dietary and oral gavage studies occur in the presence of excessive toxicity.

NTP concluded that PCA may have carcinogenic potential based on gavage studies in rodents (clear evidence in male rats, equivocal in female rats, some in male mice and no evidence in female mice; NTP, 1989). The levels used in these gavage studies were 0, 2, 6, 18 mg/kg/day in rats and 0, 3, 10, 30 mg/kg/day in mice. There was clear evidence of overt toxicity including methemoglobinemia, including overt cyanosis and extensive non-neoplastic pathology in the spleen at the 6 and 18 mg/kg/day doses in which a clear carcinogenic response was observed in the rat study. Other non-neoplastic findings in the rat chronic study include bone marrow hyperplasia, hepatic hemosiderosis and splenic fibrosis which correlate with the toxic effect of PCA on the hematopoietic system. In B6C3F1 mice administered PCA by gavage, there was an increased incidence of hepatocellular tumors in male mice, and an increased incidence of hemangiosarcomas in the liver and spleen of high dose male mice only. NTP considered that there was "some" or limited evidence for PCA carcinogenicity is not very strong, with only one sex in one species showing a response considered by the NTP to be "clear" evidence of a neoplastic effect in gavage studies with high and toxic dose levels.

Dietary chronic studies of PCA concluded that sufficient evidence was not found to establish the carcinogenicity of 4-chloroaniline in rats and mice (equivocal in male rats, negative in female rats, equivocal in male mice and equivocal in female mice). These studies support the conclusion that PCA is a relatively weak carcinogen, with equivocal neoplastic effects only in a single target tissue in the presence of extensive non-neoplastic pathology resulting from the primary action of PCA inducing methemoglobinemia. The levels used in the dietary studies were 250 and 500 ppm for rats and 2500 and 5000 ppm for mice (NTP 1979). Dietary studies in rats with PCA at 250 or 500 ppm showed marked non-neoplastic proliferative and chronic inflammatory lesions in the spleens of treated rats, with only a slight non-statistically significant increase in fibromas or fibrosarcomas of the spleen of male rats. Similar equivocal findings were made in mice at dietary dose levels of 2500 and 5000 ppm with non-statistically significant increases in hemangiomatous tumors in the spleen, kidney and other sites. In treated mice there were also significant non-neoplastic proliferative and inflammatory pathologic findings in the spleen. The conclusion from the dietary studies was that there was insufficient evidence to establish the carcinogenicity of PCA.

There are important toxicological and biotranformational (absorption, distribution, metabolism and excretion) differences between gavage and dietary administration of test substances. Although both study designs involve "oral" administration and digestive absorption, the implications of bolus gavage dosing must be considered in evaluating toxicological studies. The introduction of a bolus dose involves immediate delivery of the full administered dose directly to the stomach. Doses are usually given in the morning, and as rodents are nocturnal and eat in accordance, their stomachs are usually empty. This allows for increased absorption and decreased food interaction (slowing of digestion). In contrast, a dietary study allows the animal a more true to life and applicable administration through the diet with interaction with food and at levels which are not excessive or bolus. Furthermore, bolus administration may overwhelm normal metabolic capacities that are involved in the detoxification reactions. In conclusion, the dietary exposure studies are a more true evaluation of the toxic potential of a test material and are definitely more predictable for the evaluation of PCA in diflubenzuron.

## Adequate Testing of PCA Levels in Diflubenzuron

A full toxicological testing package is available for diflubenzuron. Technical diflubenzuron used in our toxicological testing was a typical representative sample, containing 18-19 ppm of the impurity PCA.

Diflubenzuron is not metabolized *in vivo* to PCA, as experimentally demonstrated in the diflubenzuron rat metabolism study (Cameron, 1990). The major urinary metabolite identified in the Cameron study was 4-chloroaniline-2-sulfate. This metabolite is most likely responsible for the formation of methemoglobinemia formation in the diflubenzuron study, since components of this type (ring halogenated/hydroxylated anilines) are known methemoglobin producers (Kiese, 1974).

The testing results of technical diflubenzuron further demonstrated that the test substance is not overtly toxic, is not mutagenic, is not a reproductive or developmental toxicant and is not carcinogenic when tested up to 10,000 ppm in dietary studies with rats and mice. Diflubenzuron is considered a category E substance by the US EPA for carcinogenic classification. The European Agency for the Evaluation of Medicinal Products - Veterinary Medicines (EMEA, 1999) and the Joint FAO/WHO Meeting on Pesticide Residues (JMPR) reached similar conclusions in their most recent re-evaluation of diflubenzuron's toxicological data package (WHO, 2002).

As mentioned above, this toxicological data set for diflubenzuron was generated with test material containing PCA at 18-19 ppm. Therefore, PCA was tested experimentally through the whole

diflubenzuron toxicology package. The risk of exposure to trace levels of PCA in DIMILIN<sup>®</sup> has therefore been adequately assessed through testing and is experimentally demonstrated not to be toxic, mutagenic or carcinogenic!

In addition, the previous review of PCA demonstrates that PCA is only a toxicological concern at overtly toxic levels, which is clearly not the case at the levels present in diflubenzuron. The results of our testing have demonstrated the low toxicity of diflubenzuron.

# **Conclusion**

PCA has not been shown to be a strong carcinogen, and the carcinogenicity of PCA is clearly established to occur only in the presence of extensive non-neoplastic damage to the hematopoietic system. There is a critical threshold of PCA exposure below which toxic responses do not occur. It is clear that at low doses of PCA, for example at the level present as an impurity in technical diflubenzuron (max. 30 ppm), there is no evidence of adverse toxicological effects, as demonstrated by the favorable diflubenzuron toxicity profile.

Therefore, at the levels present in diflubenzuron, PCA is not considered to be a carcinogenic or toxicological concern.

## **References**

- Cameron, B.D., Henderson, A., McGuire, G.M. (1990). The metabolism of [14C]diflubenzuron in the rat: profiling of radioactivity in urine, feces and bile. Unpublished Report No.56629/64/1990. Inveresk Research International, Scotland. March 26, 1990.
- 2. CICAD (2003). Concise International Chemical Assessment Document 48 http://www.inchem.org/documents/cicads/cicad48.htm
- 3. HSDB (2006). Hazardous Substance Data Bank. http://toxnet.nlm.nih.gov/cgibin/sis/search/f?./temp/~syQOUx:1
- 4. NTP (1989). Toxicology and Carcinogenesis Studies of *para*-chloroaniline in F344/N Rats and B6C3F1 Mice. NTP report number TR-351. http://ntp.niehs.nih.gov/ntpweb/index.cfm?objectid=0708739B-CA09-276E-7B0CD2249A83E12A
- 5. NTP (1979). Bioassay of p-Chloroaniline for Possible Carcinogenicity (CAS No. 106-47-8). NTP report number TR-189.
- 6. Kiese, M. 1974 Methemoglobinemia: A Comprehensive Treatise pp. 80-83.
- 7. WHO (2002). Pesticide residues in food 2001 evaluations. Part II Toxicological. World Health Organization, WHO/PCS/02.1, 2002, nos 980-992 on INCHEM

8. EMEA (1999). Committee for Veterinary Medicinal Products – Diflubenzuron Summary Report (2). EMEA/MRL/621/99-Final, June 1999 http://www.emea.europa.eu/pdfs/vet/mrls/062199en.pdf
#### Evaluation of the document by RMS and some additional information of diflubenzuron metabolites:

The metabolic fate of diflubenzuron has been studied in various species. The major route of metabolism in mammals is via hydroxylation. The major metabolites in sheep, swine, and chickens are 2,6-difluorobenzoic acid and 4-chlorophenylurea (CPU); minor metabolites are 2,6-difluorobenzamide and 4-chloroaniline (PCA). In rats and cattle, 80% of the metabolites are 2,6-difluoro-3-hydroxydiflubenzuron, 4-chloro-2-hydroxy-diflubenzuron and 4-chloro-3-hydroxydiflubenzuron. The metabolic studies indicate that little or no 4-chloroaniline is formed in rats or cattle.

No human studies on the kinetics and metabolism of diflubenzuron, including the extent of biotransformation to 4-chloroaniline, are available. However, 4-chloroaniline has been reported to cause methaemoglobinaemia in exposed workers and in neonates inadvertently exposed. Some individuals who are deficient in NADH-methaemoglobin reductase may be particularly sensitive to 4-chloroaniline and, hence, to diflubenzuron exposure (ref 1). The tolerable intake of PCA has been set to  $2\mu g/kg$  bw and day (ref 2)

In the toxicological studies in the diflubenzuron dossier similar effects are seen as in studies with PCA (e.g. methemoglobinemia, effects of blood parameters, increased spleen and liver weight, haemosiderosis in spleen, liver and kidney and extramedullary hematopoiesis.

With the existing information it is impossible to know if the effects seen in the diflubenzuron studies are due to the PCA contamination in the used diflubenzuron (maximum 30ppm but in the five batch analysis 18-19 ppm) or due to metabolism of diflubenzuron to PCA, although under the detection limit (0.4ppb) in the Wang et al rat study, or due to the major urinary metabolite 4-chloroaniline-2-sulfate (suggested by the notifier). It is possible that PCA is formed but quickly metabolised to metabolites that react with the erythrocytes. N-hydroxylation seems to be the critical enzymatic step that forms the metabolite that causes methemoglobinemia (which is the case for PCA and the similar compound aniline). If also 4-chloroaniline-2-sulfate can be metabolised by N-hydroxylation is unknown.

In the PCA studies discussed in the notifier's statement paper the carcinogenic potential seems to be slightly higher in the gavage than the feeding studies. The notifier has compared the carcinogenic potential between gavage and feeding studies and concludes that "the dietary studies are a more true evaluation of the toxic potential a test material and are definitely more predictable for the evaluation of PCA". RMS does not agree with this statement as PCA has been found to be unstable in feed (ref 3) and the animals in the feeding study thereby might have received a lower concentration then expected.

Anyhow, PCA has to be regarded as a carcinogen as it has been classified according to Directive 67/548/EEC as Carcinogen Cat 2; R 45 (May cause cancer) T; R 23/24/25 (Toxic by inhalation, in contact with skin and if swallowed) R43 (May cause sensitization by skin contact).

In the five batch analysis the content of PCA in the batches of diflubenzuron used was 18-19 ppm. The Notifier therefore concludes that PCA was tested experimentally through the whole diflubenzuron toxicology package. This would have been true if we had known that the content of PCA was 18-19 ppm in all the batches used but

this information is not available. The concentration of PCA could have been lower in some of the batches for example.

#### **Conclusion**

PCA has to be regarded as a carcinogen and it can not be excluded that PCA is formed in humans exposed to diflubenzuron. Diflubenzuron is metabolised differently in different mammalian species; rats and cows being similar (less toxic route) and swine, hen and sheep being similar (more toxic rote). PCA has to be considered as a metabolite of toxicological concern.

#### 4-chlorophenylurea, CPU

EPA has previously concluded that "CPU by association with PCA has carcinogenic potential and the same carcinogenic potency as PCA. In the NTP report of the PCA bioassay, it is proposed that PCA undergoes N-hydroxylation to form the corresponding N-hydroxylamine metabolites. This metabolite is then conjugated to form the ultimate carcinogen capable of ionizing and reacting with DNA to form adducts which results in splenic tumor formation. An alternate mechanism involving toxicity resulting in erythrocyte damage, splenic scavenging, hemorrhage, hyperplasia and fibrosis and ultimately splenic tumor formation is also proposed, but both mechanisms are based on the formation of N-hydroxy PCA." However, in more recent rat studies (both dietary and gavage), it has been demonstrated that CPU does not induce methemoglobin formation and is neither metabolised to PCA nor forms an N-hydroxylamine derivate. Since N-hydroxylation is the required first step in mechanism of action of PCA's (ref 4). Moreover, Significant levels of CPU was observed in the urine from rats (DAR B.6.1.2). Therefore the toxicity CPU is covered by the diflubenzuron toxicity packet.

#### DFBAM, 2,6-difluorobenzamide and DFBA, 2,6-difluorobenzoic acid

Significant levels of 2,6-difluorobenzoic acid and 2,6-difluorobenzamide and were observed in the urine from rats (DAR B.6.1.2). Therefore the toxicity of these two metabolites is covered by the diflubenzuron toxicity packet.

#### References

- 1) IPCS, Health and Safety Guide No. 99, World Health Organization, Geneva 1995
- 2) IPCS, CICADS 48, 2003, 4-Chloroaniline
- 3) IPCS, CICADS 48, 4-Chloroaniline, 2003
- 4) EPA, Federal register, Dec 14, vol. 66, Number 241, 2001: Notice of filing pesticide petitions to establish a tolerance for a certain pesticide chemical I or on food.

# **B.6.14** Exposure data (Annex IIIA 7.2)

Dimilin WG-80 is a water-dispersible granular (WG) formulation containing 800 g diflubenzuron/kg recommended for use in pome fruit, mushrooms and forestry. Dimilin WG-80 is applied to pome fruit by tractor-mounted or hand-held spray equipment, to mushrooms by hand-held spray equipment or automatic sprayer, and to forestry by aerial application. A summary of the application methods and the recommended "worst case" application rates are provided in the following table:

Field of use	Method of application	Max. application rate	Spray volume	Max. application concentration
Pome fruit	Tractor-mounted sprayer; spray directed upwards and sideways	180 g a s /ha	1 500 L/ha	0 12 g a s /I
	Hand-held sprayer; spray directed upwards and sideways	100 g u.s./nu	1 500 L/ma	0.12 g u.s./ E
Forestry	Aerial application - ultra low volume (ULV)	48 g a s /ha	3 - 5 L/ha in oil	16 g a.s./L
	Aerial application - low volume (LV)	10 g u.s./ iu	30 - 50 L/ha in water	1.6 g a.s./L
Mushrooms	Automatic sprayer	$1 \text{ g a.s./m}^2$	2	
	Hand-held sprayer; high volume spray directed downwards	(=10 000 g a.s./ha)	1 - 1.5 L/m <sup>2</sup>	1 g a.s./L

Table B.6.14-1: Summary of application methods and rates of Dimilin WG-80 relevant for the operator exposure assessment

#### **B.6.14.1** Operator exposure

#### **B.6.14.1.1** Estimation of operator exposure in orchards

#### Estimation of operator exposure in orchards using UK POEM and the German model

The estimates of total diflubenzuron exposure predicted by UK POEM<sup>7</sup>(Predictive operator exposure model) and the German model<sup>8</sup> were calculated as a proportion of the proposed AOEL for the active ingredient. Two different application techniques are used: Tractor-mounted sprayer (spray directed upwards and sideways) and hand-held sprayer (spray directed upwards and sideways).

Additional assumptions/data utilised in the models are as follows:

Area Treated in One Day:	15 ha/day (UK model) or 8 ha/day (German model) for
	tractor-mounted sprayer
	1 ha for hand-held treatment
Application Rate:	180 g as./ha

<sup>&</sup>lt;sup>7</sup> Scientific Subcommittee on Pesticides and British Agrochemicals Joint Medical Panel., Estimation of Exposure and Absorption of Pesticides by Spray Operators (UK MAFF) 1986 and the Predictive Operator Exposure Model (POEM – UK MAFF) 1992

<sup>&</sup>lt;sup>8</sup> Uniform Principles for Safeguarding the Health of Applicators of Plant Protection Products (Uniform Principles for Operator Protection); Mitteilungen aus der Biologischen Bundesanstalt für Land- und Forstwirtschaft, Berlin-Dahlem, no. 277, 1992

Inhalation Exposure for Mixer/Loader:	0.01 ml/hr
Application Volume – Groundboom Application:	1 500 l/ha
Inhalation absorption	100%
Dermal absorption	6 %

#### Tractor-mounted and hand-held sprayer in orchards

The estimated operator exposure values for tractor-mounted sprayer and hand-held sprayer in orchards, determined on the basis of the model scenarios without or with minimum acceptable protective clothing, were set out in Table B.6.14.1.1-1. Systemic exposure was taken into consideration in relation to the AOELsystemic. Total systemic exposure was calculated from the addition of dermal and inhalation exposure (see also calculation in Appendix 1, A-H).

 Table B.6.14.1.1-1: Estimations of operator exposure to Dimilin WG-80 and comparison in relation to the systemic AOEL in orchards

 DIMU IN WG-80

DIMITIV M.Q.00					
Tractor-mounted spray	/er				
РРЕ	<b>Operator total exposure (</b> mg kg <sup>-1</sup> bw day <sup>-1</sup> <b>)</b>	% of AOEL <sup>1)</sup>	_		
	ИК РОЕМ				
Without	0.0415	125 %			
With gloves during	0.0219	66 %			
mixing and loading and					
during spraying					
	German model				
Without	0.0172	52 %			
With gloves during	0.0139	42 %			
mixing and loading and					
during spraying					
Hand-held sprayer	1 1	1)			
	<b>Operator total exposure</b> (mg kg <sup>-1</sup> bw day <sup>-1</sup> )	% of AOEL <sup>1</sup>			
PPE	UK POEM				
Without	0.0401	121 %			
With gloves during	0.0063	19 %			
mixing and loading and					
during spraying					
	German model				
Without	0.0103	31 %			
With gloves during	0.0055	17 %			
mixing and loading and		1, , ,			
during spraving					

AOELsys=0.033 mg kg<sup>-1</sup> bw day<sup>-1</sup>; Dermal exposure 6%

#### **Conclusion:**

The modelling data based on UK POEM and the German model for tractor-mounted spraying in orchards showed that the exposure to diflubenzuron is acceptable if gloves are used during mixing and loading and during spraying, 66 % (UK-model) and 42 % (German model) of the AOEL. The exposure during hand-held spraying is also acceptable if gloves are used during mixing and loading and during spraying, 19 % (UK-model) and 17 % (German model) of the AOEL.

#### **B.6.14.1.2** Estimation of operator exposure in forestry

The scenario for application Dimilin WG-80 in forestry is either by aerial application using fixed-wing aircraft or helicopters with enclosed cockpits or by ground application by tractor-mounted or hand –held spray. All the applications are done by specialist companies who are licensed by local government bodies. The intended use of Dimilin WG-80 in forestry is dependent on the biological cycle of the pest but no more than one application per crop and year. The applications are made in spring or autumn. Treatments are not sprayed routinely but if an infestation of the pest is present. For aerial application separate operators do the mixing/loading and the applications.

#### Aerial application by aircraft or helicopter

Mixing and loading is done in the same way as for applications by tractor-mounted equipment. The appropriate weight of product is mixed with the required volume of water for low volume (LV) applications or with water plus mineral oil or crop oil for ultra-low volume (ULV) applications. Sufficient product is mixed to apply up to 200 ha per flight.

Applications by air are generally made in early morning (four to five hours spraying time) and/or late afternoon (two to three hours spraying time) to reduce drift and evaporation of the droplets during windy or hot weather conditions. For ULV applications, the nozzles are designed to apply droplets of between 80 and 120  $\mu$ m to give good crop coverage and to reduce drift. Each flight takes approximately one hour for application to 200 ha. Based on a working day of 8 hours, assuming 0.5 hours for mixing/loading and 4 times taking off and landing the airplane (5 x 0.5 hour = 2.5 hours), the maximum flying time would be 5 hours per day. Therefore, the maximum area that could be treated in a day is 1 000 ha. This can be considered to represent the worst-case use for the assessment of operator exposure.

'Ground markers' or 'flaggers', i.e. persons on the ground who direct the pilots to the correct location for spraying, are not used in forestry. The crop canopy is high and such persons would not be visible from the air. Modern forest plantations are set out in separate blocks allowing the pilot to locate the correct target area. The potential exposure of operators during aerial application is therefore limited to persons involved in mixing/loading and to the pilots of the aircraft or helicopters.

#### Ground application by tractor-mounted or hand-held spray

The application of Dimilin WG-80 could be done by tractor-mounted spray or hand –held spry equipment, "high" crop application.

*Estimation of mixing/loading and application based on the German model during aerial and ground application* Exposure during mixing prior to application by air can be estimated using the German model as the product is prepared in the same way as for application by tractor-mounted equipment. The exposure was 0.878 mg kg<sup>-1</sup> bw day<sup>-1</sup> without PPE and 0.00891 mg kg<sup>-1</sup> bw day<sup>-1</sup> using gloves, corresponding to 2660 % respective 68 % of the AOEL. (For calculations se Appendix 1 I-J) Total systemic exposure was calculated for Dimilin WG-80: application to forest with tractor-mounted or hand – held spray equipment, from the addition of dermal and inhalation exposure (see also calculation in Appendix 1). Without the use of PPE the exposure was 0.00459 and 0.00275 mg kg<sup>-1</sup> bw day<sup>-1</sup> respectively which corresponds to 14and 8 % of the AOEL. (For calculations se Appendix 1 K-L)

Additional assumptions/data utilised in the models are as follows:

	Application from air	Ground application Tractor-mounted spray	Ground application Hand-held spray
Area Treated in One Day:	1 000 ha	8 ha	1 ha
Application Rate:	48 g as./ha	48 g as./ha	48 g as./ha
Inhalation absorption	100%	100%	100%
Dermal absorption	6 %	6 %	6 %

Table B.6.14.1.2-1: Estimations of operator exposure during mixing/loading and application to Dimilin WG-80 with and without PPE and comparison in relation to the systemic AOEL in aerial and ground application

DIMILIN WG-80			
<b>Application-Fores</b>	t		
PPE		% of AOEL <sup>1)</sup>	
	Aerial application		
	Calculation only for exposure during mixing and load	ding (mg kg <sup>-1</sup> bw day <sup>-1</sup> )	
	German model mixing and loading		
Without	0.878	2660 %	
With gloves	0.00891	68 %	
	Ground application		
	<b>Operator total exposure</b> (mg kg <sup>-1</sup> bw day <sup>-1</sup> )		
	Tractor-mounted sprayer (German model)		
Without	0 00459	14 %	
() Informe		11,0	
	Hand-held sprayer(German model)		
Without	0.00275	8 %	

<sup>1</sup>AOELsys=0.033 mg kg<sup>-1</sup> bw day<sup>-1</sup>; Dermal exposure 6%

#### Conclusion

The exposure of the operators to diflubenzuron during mixing/loading in the scenario of aircraft application has been calculated from the German model; the exposure during mixing and loading, using gloves was 68% of the AOEL. However, there are no EU-models for estimating the exposure for aerial application and therefore the decision of use have to be left to the national product authorisation step. Ground application using either tractor-mounted or hand-held sprayer resulted in exposure 14 % and 8 % of the AOEL respectively, without the use of PPE. The application using either tractor-mounted or hand-held spray is acceptable.

#### B.6.14.1.3 Estimation of operator exposure in greenhouse using mushrooms grower

Mushrooms are grown in insulated houses and planted in compost in wooden trays or aluminium shelves stacked in tiers on either side of a central aisle. The compost consists of peat and is pasteurised prior to use. Mushroom spawn (mycelium culture) is incorporated into the compost and this is subsequently covered with casing medi, which is typically a mixture of peat and sugar beet lime. Mushroom farms vary in size and an average area of production would be approximately 300 to 400 m<sup>2</sup> with the largest farms growing a total of up to 1 500 m<sup>2</sup>, i.e. 0.15 ha, in three to four mushroom houses. Applications are made routinely to the casing media as a high volume low pressure sprays drench. There is one application of Dimilin WG-80 per cropping cycle (which takes 6 to 8 weeks) and up to five cycles per year. Cycles start at different times within a mushroom house to provide continuous cropping and so an application of Dimilin WG-80 could be made once a week with each application taking approximately one hour. The same operators do the mixing/loading and the applications. Product is prepared and used by each mushroom grower and applications are not made at several mushroom farms by spray contractors.

Applications are made automatically through the irrigation system in many modern houses. Alternatively, applications are made using hand-held equipment. The product is mixed and loaded prior to application by both methods but application by hand-held equipment involves the higher potential for exposure of operators. Sprays are applied at high volume (up to  $1.5 \text{ L/m}^2$ , equivalent to  $15\ 000\ \text{L/ha}$ ) and the spray is directed downwards to the casing media. The water volume incorporates the active substance into the casing media.

Additional assumptions/data utilised in the models are as follows:

Area Treated in One Day:	1 ha
Application Rate:	10 kg a.s./ha
Application volume:	15 000 L/ha
Inhalation absorption	100 %
Dermal absorption	6 %

#### Estimation of operator exposure in greenhouse for growing mushrooms during mixing and loading

The operator exposure during mixing and loading is estimated using the German model. It is assumed that a maximum of 0.15 ha/day can be treated as the farmers are not bigger (see above). Based on a maximum use rate of 1 g a.s./m<sup>2</sup> (10 kg a.s./ha), this will result in the following estimated exposure of spray operators to diflubenzuron without or with personal protective equipments (see also Appendix 1, M-O):

DIMILIN WG-80		
Aerial application-mush	iroom	
PPE	<b>Operator total exposure</b> (mg kg <sup>-1</sup> bw day <sup>-1</sup> )	% of AOEL <sup>1)</sup>
****	German model automatic spraying (only mixing and loading)	
Without	0.0274	83 %
	German model hand-held spraying	
Without	0.0858	260 %
With gloves during	0.0150	46 %
mixing and loading and		
gloves, coverall and		
sturdy footwear during		
spraying		

 Table B.6.14.1.3-1: Estimations of operator exposure during mixing/loading to Dimilin WG-80 with and without PPE and comparison in relation to the systemic AOEL in greenhouse using mushrooms grower

<sup>1</sup>AOELsys=0.033 mg kg<sup>-1</sup> bw day<sup>-1</sup>; Dermal exposure 6%

No calculations have been presented by the notifier on the operator exposure during spraying in greenhouse. The arguments are that the application in greenhouse is comparable to "high" crops in orchards. RMS doesn't agree with this argument since the greenhouses are closed rooms and the operator exposure could be higher than

outside. However, the operator exposure during spraying automatically is consider as acceptable, the exposure during mixing/loading is 83 % of AOEL and since the operator doesn't need to be in the greenhouse during spraying the exposure during spraying should be negligible. The operator exposure with hand-held sprayer is acceptable if gloves are used during mixing and loading and gloves together with coverall and sturdy footwear during spraying (46 % of AOEL). In conclusion, the operator exposure to diflubenzuron in greenhouse using mushrooms grower is considered as acceptable using automatic sprayer and it is also acceptable using hand-held spraying if PPE is used.

#### **B.6.14.1.4 Summary of operator exposure**

The proposed AOEL for diflubenzuron is  $0.033 \text{ mg kg}^{-1} \text{ day}^{-1}$  using 100 as safety factor and correlated with an oral absorption of 33%. Skin absorption value of 6% for the concentrated product and the spray solution is used.

The operator exposure of diflubenzuron for pome fruit using tractor-mounted sprayer and hand-held sprayer was calculated using the German model and the UK POEM. The outcome exposure was below the systemic AOEL when gloves were used. In forestry and greenhouse, the operator exposure during mixing/loading was also calculated using the German model. If gloves was used during the mixing and loading for areal application the exposure level was lower then the AOEL. However, no appropriate calculations were presented by the notifier for the exposure during spraying from the air in forestry. Spraying in the forestry using tractor-mounted or hand-held sprayer is accepted. In greenhouse, the operator exposure during automatic spraying was considered as negligible and accepted as the exposure was less than AOEL during the mixing and loading step. During hand-held sprayer the operator exposure was considered acceptable, not even when all possible PPE was worn.

The overall exposure modelling assessments is presented in Table below:

Field of use	Method of application	Dose (kg a.s./ha) Work rate (ha/day)	Exposure mg kg <sup>-1</sup> day <sup>-1</sup>	% AOEL <sup>1</sup>	PPE
Pome fruit	Tractor-mounted sprayer; spray directed upwards and sideways	0.18 $8^{2}$ $15^{3}$	$\begin{array}{c} 0.0415^2 \\ 0.0219^2 \\ 0.0172^3 \end{array}$	>100 % 66 % 52 %	no yes <sup>4</sup> no
Pome truit	Hand-held sprayer; spray directed upwards and sideways	0.18 1	$\begin{array}{c} 0.0401^2 \\ 0.0063^2 \\ 0.0103^3 \end{array}$	>100 % 19 % 31%	no yes <sup>4</sup> no
	Aerial application - ultra low volume (ULV) Aerial application - low volume (LV)	0.048 1000	Mix/loading only: 0.878 <sup>3</sup> 0.00891 <sup>3</sup>	>100 % 68 %	no yes <sup>4</sup>
Forestry	Ground application Tractor-mounted sprayer Hand-held sprayer	$8^{3}$ $1^{3}$	$0.00459^3$ $0.00275^3$	14 % 8 %	no no
Mushrooms	Automatic sprayer	10	Mix/loading only: 0.0274 <sup>3</sup>	83 %	no

Table B.6.14.1.4-1: Summary of the predicted operator exposure using Dimilin WG-80 in pome fruit, forestry and mushrooms

Hand-held sprayer; high volume	1	0.0858 <sup>3</sup>	>100 %	no
spray directed downwards		0.0150	46 %	yes <sup>5</sup>
<sup>1</sup> AOEL= 0.033 mg kg <sup>-1</sup> dav <sup>-1</sup> ; <sup>2</sup> UK POEM; <sup>3</sup> German model; <sup>4</sup> gloves; <sup>5</sup> gloves and overall during spraving				

In conclusion, the operator exposure of diflubenzuron in pome fruit with tractor mounted and hand-held application is acceptable when PPE are used. The exposure of the operators to diflubenzuron during mixing/loading in the scenario of aircraft application has been calculated and found to be acceptable using gloves. However, there are no EU-models for estimating the exposure for aerial application and therefore the decision of use have to be left to the national product authorisation step. The application using either tractor-mounted or hand-held spray is acceptable. The operator exposure to diflubenzuron in greenhouse using mushrooms grower is considered as acceptable using automatic sprayer and it is also acceptable using hand-held spraying if PPE is used.

#### **B.6.14.2** Bystander exposure

### Orchard

Bystanders could be exposed to spray drift if they were walking next to an orchard being treated with Dimilin WG-80. However, the bystander can always be expected to be several metres away from the spray boom. At 10 m from the sprayer, estimates that for pome fruit the maximum drift estimate (90th percentile data, single application; late application for pome fruit) is  $3.60\%^9$ .

Based on the maximum application rate for diflubenzuron to pome fruit of 0.18 kg/ha and assuming a bystander is located 10 m from the sprayer, they could receive 3.6% drift, i.e. 0.65 mg diflubenzuron/m<sup>2</sup>. Assuming that 50% of a body surface, assumed to be 2 m<sup>2</sup> in total (US EPA<sup>10</sup>), is covered with clothing and that dermal exposure is reduced to 50 % with long shirt and trousers, direct deposition on the skin could be 0.975 mg diflubenzuron. Using 6 % skin absorption, the absorbed dose of diflubenzuron would be 0.0585 mg.

As a worst case scenario the inhalation value can be assumed to be the same as for the operator and can be taken from the German model, tractor-mounted sprayer which is 0.01152 mg/day.

Taken together the dermal and inhalation exposure is 0.07 mg and assuming a 60 kg body weight (as appropriate for adult men and women), the systemic exposure would be 0.001167 mg kg<sup>-1</sup> day<sup>-1</sup>.

<sup>&</sup>lt;sup>9</sup>Rautmann, D., Streloke, M., Winkler, R. (2001) New basic drift values in the authorisation procedure for plant protection products. In: Workshop on risk assessment and risk mitigation measures in the context of the authorisation of plant protection products (WORMM; Forster, R., Streloke, M. Eds.), 27-29 September, 1999, Heft 383, Biologischen Bundesanstalt für Land - und Fortwirtschaft, Berlin and Braunschweig, Germany.

<sup>&</sup>lt;sup>10</sup> Central estimate for adults. The EPA Exposure Factors Handbook (1997)

Compared with the AOEL for diflubenzuron of 0.033 mg kg<sup>-1</sup> day<sup>-1</sup>, the potential exposure of bystanders is 3.5 % of systemic AOEL. Therefore, the bystander exposure during the use of Dimilin WG-80 is considered as acceptable.

#### Forestry

Bystanders could be exposed to spray drift if they were walking next to a forestry being treated with Dimilin WG-80. However, as the maximum application rate for diflubenzuron to pome fruit is 180 g/ha and only 48 g/ha in the forest the calculation for bystander exposure made for the orchard can be used as a worst case for the bystanders in forestry. Thus, the bystanders in the forestry would be exposed to less than 3.5 % of AOEL which is an acceptable exposure.

#### Mushroom houses

Bystanders are not expected to be present in mushroom houses during application.

#### B.6.14.3 Worker exposure

#### B.6.14.3.1 Estimation of worker exposure in orchards

Worker exposure to diflubenzuron during re-entering the application area in orchards has been estimated using the coefficients from EUROPOEM<sup>11</sup>. Table below shows the calculation of the potential dermal exposure:

#### Table B.6.14.3.1-1: Worker exposure of Dimilin 80WG in orchards

Dimilin 80WG in orchards

Worker exposure=	DFR*T(	C*T * DA/b	DA/bw		
Dislogeable foliar residue (DFR) Transfer Coefficient (TC) Time in contact with the crop (T)	3 4500 8	µg/cm2 cm2/h h			
Dermal abs (DA): Body weight (bw)	6 60	% kg			
Worker exposure of Dimilin 80 W	G Pome fi	ruit =	0.108	mg kg-1 day-1	
%AOEL (0.033 mg kg <sup>-1</sup> day <sup>-1</sup> )		327 %			

The systemic exposure for workers harvesting pome fruit or carrying out maintenance operations such as pruning without PPE is  $0.108 \text{ mg kg}^{-1} \text{ day}^{-1}$ , equivalent to 327 % of the AOEL of  $0.033 \text{ mg kg}^{-1} \text{ day}^{-1}$ . If the workers wear gloves, the dermal absorption could be reduced to 0.6 % and give an exposure of 0.0108 mg kg<sup>-1</sup> day<sup>-1</sup>

<sup>&</sup>lt;sup>11</sup> EUROPOEM-the developmenta, maintenance and dissemination of generic european databases and predictive exposure models to plant protection products. Final report December 2002

<sup>1</sup>, equivalent to 33 % of the AOEL. In conclusion, the worker exposure of Dimilin WG-80 is acceptable in orchards for pome fruit under the conditions that PPE is used.

### B.6.14.3.2 Estimation of re-entry exposure in forestry

RMS has made a re-entry calculation for 2 h scouting activities in a Dimilin WG-80 in treated forest. Table B.6.14.3.2-1: Re-entry exposure of Dimilin 80WG in forest

Dimilin 80WG in forest

Re-entry exposure=	DFR*T	C*T * DA/b	/bw			
Dislogeable foliar residue (DFR) Transfer Coefficient (TC) Time in contact with the crop (T)	3 4500 2	μg/cm2 cm2/h h				
Dermal abs (DA): Body weight (bw)	6 60	% kg				
Worker exposure of <i>Dimilin 80 W</i>	G Pome f	fruit =	0.027	mg kg-1 day-1		
%AOEL (0.033 mg kg <sup>-1</sup> day <sup>-1</sup> )		81 %				

The systemic exposure for re-entering the forest is 0.027 mg kg<sup>-1</sup> day<sup>-1</sup>, equivalent to 81 % of the AOEL of 0.033 mg kg<sup>-1</sup> day<sup>-1</sup>. This is a conservative value as a person walking in the forest would probably not be in contact with trees and leafs all the time.

### B.6.14.3.3 Estimation of worker exposure in greenhouse using mushrooms grower

A study to measure the exposure of workers handling treated compost, which is relevant to harvesting mushrooms treated with Dimilin WG-80 is summarised below.

<b>R</b> eference 01:	BELCHER,T. (1997). GREENHOUSE WORKER REENTRY EXPOSURE TO ETRIDIAZOLE
Formulation/a.s.	Terrazole 35%WP/ Etridiazole or Truban 5g Granular fungicide/4.58% etridiazole
Guideline/GLP:	OPPTS Harmonised Test Guideline Series 875 (875.2200, 875.1200 and 875.1400)/yes
Acceptability:	Yes
Test system:	The exposure of workers to etridiazole residues when handling soil media treated with 'Terrazole 35% Wettable Powder' (a WP formulation containing 33.39% etridiazole) or 'Truban 5G Granular Fungicide' (a G formulation containing 4.58% etridiazole) was measured under greenhouse conditions in California, USA. The results with 'Terrazole 35% Wettable Powder' are considered to be applicable to Dimilin WG-80 as a WP formulation type is similar to a WG, whereas a G formulation is designed to release active substance more slowly over time. The results with 'Truban 5G Granular Fungicide' are therefore not considered further. Soil media consisting of bark, peat moss and sand was treated evenly with 'Terrazole 35% Wettable Powder' at a nominal rate of 37.2 g a.s./m3. At 4 hours, 12 hours and 24 hours after application (re-entry times), four workers each filled 12 plastic pots (10 cm diameter) by scooping them into the treated soil media with their bare hands. They then brushed off excess soil media so that the media was level with the top of the pot, and placed the full pot in a pot holder. All workers were observed and actions such as brushing their faces with their hands noted. Dermal

exposure was measured using whole body dosimeters (worn over workers underwear and under cotton trousers and shirt), facial and neck swabs of cotton gauze and hand washings. Inhalation exposure was measured using personal air sampling tubes clipped to the shirt collar and fitted to a personal sampling pump on the workers belt. Monitoring took place over approximately a 4-hour period at each interval. Samples of treated and untreated soil media were also collected and 'dislodged' 0, 4, 8, 12, 24, 48 and 72 hours after treatment for measurement of residue decline. Samples were analysed for etridiazole after extraction from the matrices using gas chromatography with electron capture detection. Field fortifications were made for all matrices.

## **Findings:**

Etridiazole residues in the soil media declined from 14.4  $\mu$ g/g immediately after application to 11.3 4  $\mu$ g/g after 72 hours (Table B.6.14.3.3-1). The data were used to construct a decline curve using linear regression. The dislodgeable soil residues at 4, 12 and 24 hours were calculated from the regression line.

Sampling interval (hours)	Dislodgeable etridiazole residues in soil media (µg/g)
0	14.3
4	14.6
8	9.83
12	9.57
24	9.05
48	10.8
72	11.3

 Table B.6.14.3.3-1: Dislodgeable residues of etridiazole in soil following application of 'Terrazole 35% WP'

Etridiazole residues were found in sections of the cotton whole body dosimeters and all inhalation tubes at all reentry times. Residues in facial swabs were absent with the exception of one worker at the 12-hour re-entry time. Residues in hand washings were found in the 4-hour re-entry time but not in other samplings. The residues found were used to calculate total dermal and inhalation exposure. From these values, total exposure for an 8hour working day and the total exposure rate were calculated. Transfer factors were calculated by dividing the exposure rate by the dislodgeable soil residues at each re-entry time. Transfer factors for the 4, 12 and 24-hour time intervals were 9.15, 5.45 and 8.62 g/hour, respectively (Table B.6.14.3.3-2). The worst case value for the transfer factor was 9.15 g/hour and was found after 4 hours. The mean transfer factor was 7.74 g/hour.

Table B.6.14.3.3-2:	Measured	exposure o	f etridiazole	residues	and calcu	lated transfe	r factors	from soil	l dislodgeab
residues									

Parameter	4 hours	12 hours	24 hours
Dermal exposure over 8 hours (µg)	249.6	143.3	177.9
Inhalation exposure over 8 hours (µg)	595.5	352.8	591.2
Dermal plus inhalation exposure over 8 hours (µg)	845.1	496.1	769.1
Total exposure rate (μg/hour)	105.6	62.0	96.1
Dislodgeable soil residues (µg/g)*	11.54	11.38	11.15

Transfer factor (g/hour)	9.15	5.45	8.62
Worst case/Mean transfer factor (g/hour)	9.15/7.74		
* Calculated from regression line from decline curve.			

For workers handling soil media treated with etridiazole, a mean soil transfer factor of 7.74 g/hour from dislodgeable soil residues to human exposure was calculated.

Dimilin WG-80 is recommended for application to the casing media at 1 g diflubenzuron/m<sup>2</sup>. The active substance is incorporated into the casing media by the high volume of water applied. Assuming the active substance is incorporated evenly to a depth of 15 cm, the concentration of diflubenzuron in the casing media would be 6.67 g a.s./m<sup>3</sup>.

In the study with 'Terrazole 35% Wettable Powder', etridiazole was applied to soil media at 37.2 g a.s./m<sup>3</sup>. Assuming that the density of the soil media in the study and the casing media used in mushroom growing in the EU are the same, the concentration of etridiazole was approximately 5.6 times the expected concentration of diflubenzuron. Dislodgeable residues of etridiazole in soil media 0 and 4 hours after application were 14.3 and 14.6  $\mu$ g/g (mean 14.5  $\mu$ g/g). The mean of the values at 0 and 4 hours can be used as surrogates for diflubenzuron. Residues of etridiazole at later samplings are not applicable as levels declined and this decline is likely to be specific to etridiazole. Thus, the application of 'Terrazole 35% Wettable Powder' at a rate of active substance 5.6 times higher than Dimilin WG-80 led to dislodgeable residues in soil media of 14.5  $\mu$ g/g. Therefore, at the recommended rate of Dimilin WG-80, dislodgeable residues of diflubenzuron can be expected to be 2.6  $\mu$ g/g a.s.

In the worker exposure study, workers scooped treated soil media into plastic pots and brushed off the excess with their hands. These tasks are considered to be a suitable surrogate for workers harvesting mushrooms by hand. Harvesting involves leaning over the mushroom beds to pick the ripe crop and this would involve contact with diflubenzuron treated casing media. In the study with etridiazole, a worst case soil transfer factor of 9.15 g/hour was calculated.

Therefore, the daily exposure to diflubenzuron for an 8-hour working day and a worker of body weight 60 kg is calculated as follows:

Exposure without PPE =  $0.0026 \text{ mg/g x } 9.15 \text{ g/hour x } 8 \text{ hours/day} \div 60 \text{ kg} = 0.0032 \text{ mg kg}^{-1} \text{ day}^{-1}$ 

The systemic exposure for workers harvesting mushrooms without PPE and without taking the dermal absorption into consideration was 10 % of the AOEL. The exposure of workers carrying out other tasks in mushroom houses is likely to be lower than during harvesting as contact with the casing media would be lower. Therefore, the risk to workers is considered to be acceptable and it is not necessary to set a re-entry period before workers can re-enter mushroom houses to harvest the crop or handle the treated casing media after applications of Dimilin WG-80, and it is not necessary for workers to wear personal protective equipment.

## B.6.14.3.4 Summary of worker exposure

The worker exposure of Dimilin WG-80 in pome fruits, forestry and mushrooms are considered as acceptable under the conditions studied. PPE are needed for the workers using Dimilin WG-80 in the orchards.

# Appendix 1

# A. UK POEM: tractor-mounted, orchard without PPE using Dimilin WG-80

## THE UK PREDICTIVE OPERATOR EXPOSURE MODEL (POEM) WITH GERMAN MODEL MIX/LOAD DATA (75th PERCENTILE)

Application method	Tractor-mounted/trailed broadcast air-assis	ted sprayer: 500 l/ha	•	
Product	Dimilin WG80		Active substance	diflubenzuron
Formulation type	WG or SG		a.s. concentration	<mark>800</mark> mg/g
Dermal absorption from product	6	%	Dermal absorption from spray	<b>6</b> %
PPE during mix/loading	None		PPE during application	None
Dose	0,225	kg product/ha	Work rate/day	15 ha
Application volume	1500	l/ha	Duration of spraying	6 h
AUEL	0,033	mg/kg bw/day		
DERMAL EXPOSURE DURING	MIXING AND LOADING			
Hand contamination/kg a s	572	mo/ko a s		
Hand contamination/day	15 444	mg/day		
Protective clothing	None	ing duy		
Transmission to skin	100	0/_		
Dermal exposure to a s	15 444	/0 mg/day		
Definal exposure to a.s.	15,111	mgaay		
INHALATION EXPOSURE DUR	RING MIXING AND LOADING			
Inhalation exposure/kg a.s.	0,242	mg/kg a.s.		
Inhalation exposure/day	0,6534	mg/day		
RPE	None	6 5		
Transmission through RPE	100	%		
Inhalation exposure to a.s.	0,6534	mg/day		
_				
DERMAL EXPOSURE DURING	SPRAY APPLICATION			
Application technique	Tractor-mounted/trailed broadca	ast air-assisted spi	ayer: 500 l/ha	
Application volume	1500	spray/ha		
Volume of surface contamination	400	ml/h		
Distribution	Hands	Trunk	Legs	
~	10%	65%	25%	
Clothing	None	Permeable	Permeable	
Penetration	100%	2%	5%	
Dermal exposure	10	5,2	5	ml/h
Duration of exposure	6	h		
I otal dermal exposure to spray	121,2	ml/day		
Concentration of a.s. in spray solut	ti 0,12	mg/mi		
Dermal exposure to a.s.	14,544	mg/day		
INHALATION EXPOSURE DUR	RING SPRAYING			
Inhalation exposure to spray	0,05	ml/h		
Duration of exposure	6	h		
Concentration of a.s. in spray	0,12	mg/ml		
Inhalation exposure to a.s.	0,036	mg/day		
Percent absorbed	100	%		
Absorbed dose	0,036	mg/day		
ADCORDED DOCE				
ABSORBED DOSE	Mindaad		Amplication	
Dermal exposure to a a	IVIIX/IOAd	mg/day	Application 14 544	ma/day
Definal exposure to a.s.	13,444	111g/uay	14,344	11g/day
Absorbed dose (dermal route)	0 0764	∕0 ma/day	0 87764	/0 ma/day
Inhalation exposure to a s	0,52004	mg/day	0.036	mg/day
Absorbed dose	1.58004	mg/day	0.90864	mg/day
	1,50004		0,0004	
PREDICTED EXPOSURE				
Total absorbed dose	2,48868	mg/day		
Operator body weight	60	kg		
Operator exposure	0,041478	mg/kg bw/day		
<b>Operator exposure % of AOEL</b>	125,6909091	%		

## B. UK POEM: tractor-mounted, orchard with PPE using Dimilin WG-80

## THE UK PREDICTIVE OPERATOR EXPOSURE MODEL (POEM) WITH GERMAN MODEL MIX/LOAD DATA (75th PERCENTILE)

Application method	Tractor-mounted/trailed broadcast air	assisted sprave	r: 500 l/ba	•			
Product	Dimilin WG80	assisted spraye	1. 500 1/114	Active substance		diflubenzuron	
Formulation type	WG or SG			a.s. concentration		<b>800</b> mg/g	
Dermal absorption from product		<mark>6</mark> %		Dermal absorption from sp	ray	<mark>6</mark> %	
PPE during mix/loading	Gloves	<b>▼</b>		PPE during application		Gloves	•
Dose	0	<b>225</b> kg pro	duct/ha	Work rate/day		15 ha	
AOEL	0.0	$\frac{300}{B3}$ mg/kg	bw/day	Duration of spraying		0 n	
		<b>~~</b>	<u></u>				
DERMAL EXPOSURE DURING	MIXING AND LOADING						
Hand contamination/kg a.s.	5	,72 mg/kg	a.s.				
Hand contamination/day	15,4	144 mg/day	/				
Protective clothing	Gle	oves					
Transmission to skin	0.15	1 %					
Dermal exposure to a.s.	0,154	144 mg/day	/				
INHALATION EXPOSURE DUE	NIG MIXING AND LOADI	NG					
Inhalation exposure/kg a s		140 147 mo/ko	a s				
Inhalation exposure/day	0.6	534  mg/day	1.5.				
RPE	0,0. N	one					
Transmission through RPE		100 %					
Inhalation exposure to a.s.	0,6:	534 mg/day	/				
DERMAL EXPOSURE DURING	SPRAY APPLICATION						
Application technique	Tractor-mounted/trailed bro	adcast air-a	ssisted spra	iyer: 500 l/ha			
Application volume	1:	500 spray/	ha				
Volume of surface contamination	4	100 ml/h		-			
Distribution	Ha	ands	Trunk	L	egs		
Clothing	Cl	10% Weg	03% Dermeeble	2 Dermee	0% ble		
Penetration	UI	10%	2%	1 chilica	5%		
Dermal exposure		4	5.2		5 ml/h		
Duration of exposure		6 h	0,2		5 111/11		
Total dermal exposure to spray	8	5,2  ml/day	/				
Concentration of a.s. in spray solu	ti 0	,12 mg/ml					
Dermal exposure to a.s.	10,2	224 mg/day	/				
INHALATION EXPOSURE DUP	RING SPRAYING	0.5 1.4					
Inhalation exposure to spray	0	,05 ml/h					
Concentration of a s in spray	0	0  II 12 mg/m	1				
Inhalation exposure to a s	0.0	,12 mg/m 36 mg/da	v				
Percent absorbed	0,	100 %	y				
Absorbed dose	0,0	)36 mg/da	v				
	,	U					
ABSORBED DOSE							
	Mix/	oad		Application			
Dermal exposure to a.s.	0,154	144 mg/day	/	10,2	24 mg/d	ay	
Percent absorbed		6 %			6 %		
Absorbed dose (dermal route)	0,00920	664 mg/da	У	0,613	44 mg/d	ay	
Inhalation exposure to a.s.	0,63	54 mg/da	у	0,0	36 mg/d	ay	
Ausoided dose	0,06260	104 mg/da	у	0,649	+4 mg/d	лу	
PREDICTED EXPOSURE							
Total absorbed dose	1.31210	)64 mg/da	v				
Operator body weight	1,0121	60 kg					
Operator exposure	0,02186	844 mg/kg	g bw/day				
<b>Operator exposure % of AOEL</b>	66,2	268 %					

# C. German model: tractor-mounted, orchard without PPE using Dimilin WG-80

Application method	Tractor-mounted/trailed broadcast air-assis	ted spraver		•		_		
Product	Dimilin WG-80		Active substanc	e		diflu	benzuron	
Formulation type	WG 🔻		a.s. concentratio	n		8(	00 g/kg	
Dermal absorption from product	6	%	Dermal absorpti	on from spray			<mark>6</mark> %	
RPE during mix/loading	None 💌		RPE during app	lication		None		-
PPE during mix/loading	None 🔫		0 11					
PPE during application: Head	None 🔫	Hands	None	-	Body	None		-
Dose	0,225	kg product/ha	Work rate/day		-		8 <mark>ha</mark>	
AOEL	0,033	mg/kg bw/day						
DERMAL EXPOSURE DURING	MIXING AND LOADING							
Hand contamination/kg a s	2	mø/kø a s						
Hand contamination/day	2.88	mg/day						
Protective clothing	2,00	ing auy						
Transmission to skin	100	%						
Dermal exposure to a s	288	mg/day						
Dennai exposure to a.s.	2,00	ing day						
INHALATION EXPOSURE DUR	RING MIXING AND LOADING							
Inhalation exposure/kg a.s.	0,008	mg/kg a.s.						
Inhalation exposure/day	0,01152	mg/day						
RPE	none							
Transmission through RPE	100	%						
Inhalation exposure to a.s.	0,01152	mg/day						
DERMAL EXPOSURE DURING	SPRAY APPLICATION							
Application technique	Tractor-mounted/trailed broadca	est air-assisted sn	aver					
rippiroution teeninque	Head	Hande	uyer	Rest of body				
Dermal contamination/kg a s	1.2	0.7		9.6				
Dermal contamination/day	1 728	1 008		13 824				
Protective clothing	none	none		none				
Transmission to skin	100	100	, ,	100	%			
Total dermal exposure to a s	16.56	mg/day		100	/0			
Total definal exposure to a.s.	10,50	ing/day						
INHALATION EXPOSURE DUR	RING SPRAYING							
Inhalation exposure/kg a.s.	0,018	mg/kg a.s.						
Inhalation exposure/day	0,02592	mg/day						
RPE	none							
Transmission through RPE	100	%						
Inhalation exposure to a.s.	0,02592	mg/day						
ABSORBED DOSE								
	Mix/load		Application					
Dermal exposure to a s	2.88	mg/dav	pp	16.56	mg/dav			
Percent absorbed	2,00	%		10,00	%			
Absorbed dose (dermal route)	0.1728	mg/day		0.9936	mo/dav			
Inhalation exposure to a s	0.01152	mg/day		0.02592	mg/day			
Total systemic exposure	0,18432	mg/day		1,01952	mg/day			
	,			*	6 7			
PREDICTED EXPOSURE								
Total systemic exposure	1,20384	mg/day						
Operator body weight	70	kg						
Operator exposure	0,01/19//14	mg/kg bw/day						
Operator exposure % of AOEL	52	70						

# D. German model: tractor-mounted, orchard with PPE using Dimilin WG-80

Product Dimite WG.80 Active absance diffuberarous   Dermal absorption from ropate % 0 Dermal absorption from spany 8   PFE during mix/solating Nore 0 0 0   PFE during mix/solating 0 0 0 0   Hand contamination/day 2.88 mg/g/g a.s. 0   Protective clothing gloves 0 0 0   Inhalation exposure da a. 0.008 mg/g a.s. 0   Inhalation exposure da a. 0.0018 mg/g a.s. 0   Inhalation exposure da a. 0.01152 mg/d av   Protective clothing Tactor-mounter/furtiled broadcast air-assisted sprayer   Transmission to skin 100 1 100   Portective clothing none gloves none   Transmission to skin 100 1 100   Protective clothing none gloves	Application method	Tractor-mounted/trailed broadcast air-assis	ted spraver		-				
Instrumition type         vac         of         a. concentation         800 g/sg           PEF during mix-loading PEF during application:         New         New <td< td=""><td>Product</td><td>Dimilin WG-80</td><td>iou spiujoi</td><td>Active substance</td><td></td><td></td><td>diflul</td><td>benzuron</td><td></td></td<>	Product	Dimilin WG-80	iou spiujoi	Active substance			diflul	benzuron	
Dermal absorption from product     6%     Dermal absorption from spay     6%       PEF daring mix/loading     None     RPE daring application     None     Image: Comparison from spay     None     None     Image: Comparison from spay     None     None <t< td=""><td>Formulation type</td><td>WG</td><td></td><td>a s concentration</td><td>, 1</td><td></td><td>80</td><td>0 g/kg</td><td></td></t<>	Formulation type	WG		a s concentration	, 1		80	0 g/kg	
PEP dring mix-loading PEP dring application:       two:       two:       weil:       weil: <thweil:< th="">       weil:       <thweil:<< td=""><td>Dermal absorption from product</td><td>6</td><td>%</td><td>Dermal absorptio</td><td>n from sprav</td><td></td><td>00</td><td>6%</td><td></td></thweil:<<></thweil:<>	Dermal absorption from product	6	%	Dermal absorptio	n from sprav		00	6%	
PFF dring mix/bading       come       Item       Come       Item       Come       Item       Come       Come <t< td=""><td>RPE during mix/loading</td><td>None</td><td>/0</td><td>R PE during appl</td><td>ication</td><td></td><td>None</td><td></td><td>-</td></t<>	RPE during mix/loading	None	/0	R PE during appl	ication		None		-
PF: during application       Head       None       Image of the state of the	PPE during mix/loading	Gloves		iti D daring appr	leadon		None		
Desc ACEL     0.225 kg podactha     Work nate/day     8 ha       ACEL     0.037 mg/kg bwday     8 ha       DERMAL EXPOSURE DURING MIXING AND LOADING       Hard contamination/kg a.s.     2 mg/kg a.s.       Hard contamination/day     2.88 mg/day       Potective clothing     gloves       Transmission to skin     1 %       Demal exposure to a.s.     0.008 mg/kg a.s.       Inhalation exposure/day     0.01152 mg/day       RPE     none       Transmission through RPE     100 %       Inhalation exposure/day     0.01152 mg/day       DERMAL EXPOSURE DURING SPRAY APPLICATION     Application technique       Transmission through RPE     100 %       Inhalation exposure to a.s.     1,728 1.008 13.824       Potective clothing     none       Transmission to skin     100 1       Total demal exposure to a.s.     15.5028 mg/day       Notective clothing     none       Transmission to skin     100 1       Inhalation exposure to a.s.     0.02592 mg/day       Notective clothing     none       Transmission to skin     100 1       Inhalation exposure/day     0.02592 mg/day       NHALATION EXPOSURE DURING SPRAYING       Inhalation exposure (a.s.     0.02592 mg/day       NTALATION EXPOSURE DURING SPRAYING <tr< td=""><td>PPE during application: Head</td><td>None</td><td>Hands</td><td>Gloves</td><td>T</td><td>Body</td><td>Nono</td><td></td><td>-</td></tr<>	PPE during application: Head	None	Hands	Gloves	T	Body	Nono		-
NOEL     Note is by the by day     Note is by day       DERMAL EXPOSURE DURING MIXING AND LOADING       Hard contamination/day     2,88 mg/day       Protective clothing     gloves       Transmission to skin     1 %       Dermal exposure to a.s.     0,008 mg/day       NHALATION EXPOSURE DURING MIXING AND LOADING       Inhalation exposure/ga s.     0,0152 mg/day       RPE     none       Transmission through RPE     100 %       Inhalation exposure/ga s.     0,01152 mg/day       RPE     100 %       Inhalation exposure/ga s.     0,01152 mg/day       DERMAL EXPOSURE DURING SPRAY APPLICATION       Application technique     Tractor-mounted/trailed broadcast air-assisted sprayer       Memal contamination/dg a.s.     1,2 0,7 96       Dermal contamination/dg a.s.     1,2 0,7 96       Dermal contamination/dg a.s.     1,2 0,7 96       Dermal contamination/dg a.s.     1,728 1,008 13,824       Protective cloting     none     gloves       Total dermal exposure to a.s.     0,018 mg/kg a.s.       Inhalation exposure/day     0,02592 mg/day       NHALATION EXPOSURE DURING SPRAYING     Inhalation exposure/day       Inhalation exposure/day     0,02592 mg/day       ABSORBED DOSE     Mix/load     Application       Perecent absorbed     6 %	Dose	0.225	kg product/ha	Work rate/day	-	Douy	None	8 ha	
DERMAL EXPOSURE DURING MIXING AND LOADING         Had centamination/day       2.8 k mg/day         Protective clothing       glows         Transmission to skin       1 %         Dermal exposure to a.s.       0.0028 mg/day         Rhalation exposure/dag       0.008 mg/kg ga.s.         Inhalation exposure/dag       0.015 mg/day         RPE       none         Transmission through RPE       100 %         Inhalation exposure/dag       0.0152 mg/day         POE       none         Protective clothing       Tactor-mounted/trailed broadcast air-assisted sprayer         Application technique       Tactor-mounted/trailed broadcast air-assisted sprayer         Poemal contamination/dag a.s.       1,2       0,7       9,6         Dermal contamination/dag a.s.       1,72       1,008       13,824         Protective clothing       none       glows       none         Transmission to skin       100       1       100 %         Total dermal exposure to a.s.       0,2592       mg/day         Protective clothing       none       1       100 %         Total dermal exposure to a.s.       0,02592       mg/day       1       5,6028       m/day         Proteclow clothing       none	AOEL	0,033	mg/kg bw/day	Work futo day				0 III	
Hand contamination/kg a.s. 2 mg/kg a.s. Hand contamination/kg a.s. 2,88 mg/day Protective clothing gl/oves Transmission to skin 1 % Dermal exposure to a.s. 0,028 kmg/day INHALATION EXPOSURE DURING MINING AND LOADING Inhalation exposure/kg a.s. 0,008 mg/kg a.s. Inhalation exposure (day 0,01152 mg/day RPE none Transmission through RPE 010 % Inhalation exposure to a.s. 0,01152 mg/day DERMAL EXPOSURE DURING SPRAY APPLICATION Application technique Tractor-mounted/trailed broadcast air-assisted sprayer Transmission to skin 1,2 0,7 9,6 Dermal contamination/kg a.s. 1,56208 mg/day Tractor-mounted/trailed broadcast air-assisted sprayer Transmission to skin 100 1 100 % Total dermal exposure to a.s. 0,018 mg/kg a.s. Inhalation exposure to a.s. 0,02892 mg/day RPE none Transmission to skin 00 1 100 % Total dermal exposure to a.s. 0,02892 mg/day RPE none Transmission to cas. 0,02892 mg/day ABSORBED DOSE MixIoad Application Dermal exposure to a.s. 0,0288 mg/day 0,02592 mg/day ABSORBED DOSE MixIoad Application Dermal exposure to a.s. 0,0288 mg/day 0,05292 mg/day RPE none Transmission through RPE 000 % Inhalation exposure to a.s. 0,0288 mg/day 0,05292 mg/day ABSORBED DOSE MixIoad Application Dermal exposure to a.s. 0,0288 mg/day 0,05292 mg/day Total systemic exposure 0,013248 mg/day 0,05292 mg/day Total systemic exposure 0,013248 mg/day 0,05292 mg/day PREDCTED EXPOSURE Total systemic exposure 0,013248 mg/day Operator body weight 0,7 70 MgE bw/day Operator body weight 0,7 70 Operator body weight 0,7 70 Operator body weight 0,7 70 Operator exposure % OAOEL 42 %	DERMAL EXPOSURE DURING	MIXING AND LOADING							
Hand contamination/day 2,88 mg/day Protective clothing gloves Transmission to skin 1 % Dermal exposure to a.s. 0,0288 mg/day NHALATION EXPOSURE DURING MIXING AND LOADING Inhalation exposure/kg a.s. 0,001 mg/day RPE none Transmission through RPE 100 % Inhalation exposure to a.s. 0,01152 mg/day DERMAL EXPOSURE DURING SPRAY APPLICATION Application technique Tractor-mounted/mailed broadcast air-assisted sprayer Dermal contamination/kg a.s. 1,2 0,7 9,6 Dermal contamination/kg a.s. 1,2 0,07 1,100 % Total dermal exposure to a.s. 15,56208 mg/day NHALATION EXPOSURE DURING SPRAYING Inhalation exposure kg a.s. 0,0118 mg/kg a.s. Inhalation exposure kg a.s. 0,02392 mg/day ABSORBED DOSE Mix/load Application Dermal exposure to a.s. 0,02392 mg/day ABSORBED DOSE Mix/load Application Dermal exposure to a.s. 0,01328 mg/day 0,032528 mg/day Total systemic exposure to a.s. 0,013248 mg/day 0,02592 mg/day Total systemic exposure 0,013248 mg/day 0,02592 mg/day Total systemic exposure 0,013248 mg/day 0,02592 mg/day PREDICTED EXPOSURE Total systemic exposure 0,013248 mg/day Operator body weight 70 kg Operator body weight 70 kg	Hand contamination/kg a s	2	mø/kø a s						
Initial containing in gloves         Transmission to skin       1 %         Demal exposure to a.s.       0.0288 mg/day         NNIALATION EXPOSURE DURING MIXING AND LOADING       Inhalation exposure/kg a.s.       0.00152 mg/day         Inhalation exposure/kg a.s.       0.00152 mg/day       Inhalation exposure/kg a.s.       0.01152 mg/day         PRE       none       Inhalation exposure/kg a.s.       0.01152 mg/day         DERMAL EXPOSURE DURING SPRAY APPLICATION       Application technique       Traterinsion funculy hPE       100 %         Demal contamination/kg a.s.       1,2       0,7       9,6         Demal contamination/kg a.s.       1,2       0,7       9,6         Demal contamination/kg with the set of body       100 %       100 %         Total demal exposure to a.s.       15,56208 mg/day       100 %         Total demal exposure to a.s.       15,56208 mg/day       100 %         Inhalation exposure/kg a.s.       0,018 mg/kg a.s.       Inhalation exposure/kg a.s.       0,02892 mg/day         ABSORBED DOSE       Mix/load       Application       6       %         Demal exposure to a.s.       0,0288 mg/day       15,56208 mg/day       Mix/loag         ABSORBED DOSE       6       %       6       %         Demal exposure to a.s. <td>Hand contamination/day</td> <td>2.88</td> <td>mg/day</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	Hand contamination/day	2.88	mg/day						
Intervention of skin       1         Dermal exposure to a.s.       0,0288         Inhalation exposure/kg a.s.       0,0038         Inhalation exposure/kg a.s.       0,00152         Inhalation exposure day       0,01152         Inhalation exposure to a.s.       0,00152         DERMAL EXPOSURE DURING SPRAY APPLICATION         Application technique       Tractor-mounted/tnilled broadcast air-assisted sprayer         Head       Hands         Portective colling       none         Portective colling       none         Trastrinsion to skin       1,2         Otal dermal exposure to a.s.       1,5,608         Inhalation exposure day       0,018         Inhalation exposure day       0,0282         Inhalation exposure day       0,02892         Inhalation exposure to a.s.       0,02892         Inhalation exposure to a.s.       0,02892         Inhalation exposure to a.s.       0,0288	Protective clothing	z,00	ing auy						
International in the set of body indication exposure to a.s.       0.0288 mg/day         Invaluation exposure of a s.       0.008 mg/day         Inhabition exposure/day       0.01152 mg/day         RPE       none         Transmission through RPE       100 %         Inhabition exposure to a.s.       0.01152 mg/day         DERMAL EXPOSURE DURING SPRAY APPLICATION       Application technique         Tractor-mounted/trailed broadcast air-assisted sprayer       Head         Head       Hands       Rest of body         Dermal contamination/day       1,728       1,000 %         Portective clothing       none       gloves         Transmission to skin       100 1       100 %         Total dermal exposure to a.s.       15,56208 mg/day       NO8         NHALATION EXPOSURE DURING SPRAYING       Inhabition exposure/ga a.s.       1,00 %         Inhabition exposure to a.s.       0,02592 mg/day       RE         RPE       none       Transmission through RPE       100 %         Inhabition exposure to a.s.       0,02592 mg/day       100 %         Inhabition exposure to a.s.       0,02592 mg/day       100 %         Inhabition exposure to a.s.       0,02592 mg/day       100 %         Inhabition exposure to a.s.       0,0152 mg/day	Transmission to skin	gioves	0/_						
Internal explosure to a.s.     0.0285 mg day       INHALATION EXPOSURE DURING MIXING AND LOADING Inhalation exposure/day     0,01152 mg/day       Inhalation exposure/day     0,01152 mg/day       RPE     none       Transmission through RPE     100 %       Inhalation exposure to a.s.     0,01152 mg/day       DERMAL EXPOSURE DURING SPRAY APPLICATION     Application technique       Transmission through RPE     100 %       Dermal contamination/dag a.s.     1,2       0,7     9,6       Dermal contamination/dag a.s.     1,2       0,018     gloves       none     gloves       Transmission to skin     100       10     1       100     1       101     100 %       1021     15,56208 mg/day       Inhalation exposure/day     0,02592 mg/day       RPE     none       Transmission through RPE     100       101     100 %       1021     mode       Transmission through RPE     100       101     100 %       1028     mg/day       RPE     000 %       Inhalation exposure/day     0,02592 mg/day       RPE     000 %       Inhalation exposure/day     0,02592       Operation exposure to a.s.     0,0288 <td></td> <td>0.0288</td> <td>0 maa/daa</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>		0.0288	0 maa/daa						
NHALATION EXPOSURE DURING MIXING AND LOADING Inhalation exposure/day0,008 mg/dayInhalation exposure/day0,01152 mg/dayPPEnomeTransmission through RPE1000Inhalation exposure to a.s.0,01152 mg/dayDERMAL EXPOSURE DURING SPRAY APPLICATION Application techniqueTractor-mounted/trailed broadcast air-assisted sprayerHeadHandsRest of bodyDermal contamination/day1,7281,0081,120,79,6Dermal contamination/day1,7281,0081,230,018mg/dayProtective clothingnoneglovesInhalation exposure to a.s.15,56208mg/dayNTALATION EXPOSURE DURING SPRAYING Inhalation exposure to a.s.0,018mg/kg a.s.Inhalation exposure/day0,02592mg/dayRPEnome1000Transmission through RPE100Mablation exposure to a.s.0,018MBSORBED DOSEMix/loadApplicationPercent absorbed6%6Absorded dose (darmal route)0,01728mg/day0,013248mg/day0,9337248mg/day1halation exposure to a.s.0,01324mg/day0,013248mg/day0,9596448mg/dayPrecent absorbed6%6PREDICTED EXPOSUREmg/day0,9596448mg/dayPREDICTED EXPOSURETodi ystemic exposure0,013248mg/dayOperator exposure % of AOEL0,013288 <td< td=""><td>Demai exposure to a.s.</td><td>0,0288</td><td>mg/day</td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	Demai exposure to a.s.	0,0288	mg/day						
Inhalation exposure/day0,008mg/kg a.s. mg/dayInhalation exposure/day0,01152mg/dayRPEnoneTransmission through RPE100%Inhalation exposure to a.s.0,01152mg/dayDERMAL EXPOSURE DURING SPRAY APPLICATIONApplication techniqueTractor-mounted/trailed broadcast air-assisted sprayerHeadHandsRest of bodyDermal contamination/kg a.s.1,20,79,6Dermal contamination/kg a.s.1,281,00813,824Protective clothingnoneglovesnoneTransmission to skin1001100%Total dermal exposure to a.s.15,56208mg/dayNHALATION EXPOSURE DURING SPRAYING Inhalation exposure/day0,02592mg/dayInhalation exposure to a.s.0,018mg/kg a.s.none000%ABSORBED DOSEMix/loadApplicationPercent absorbed6%6Absorbed dose (kermal route)0,01728mg/day0,013248mg/day0,9337248mg/day10ation exposure to a.s.0,013248mg/day0,9596448PREDICTED EXPOSURETotal specine0,9728928mg/dayOperator exposure0,013248mg/day0,9596448PREDICTED EXPOSURE70kgOperator exposure0,013248mg/dayOperator exposure0,013248mg/dayOperator exposure0,013248mg/dayOperator exposure0,0	INHALATION EXPOSURE DUP	RING MIXING AND LOADING							
Inhalation exposure/day     0,01152     mg/day       PRE     none       Transmission through RPE     100     %       Inhalation exposure to a.s.     0,01152     mg/day       DERMAL EXPOSURE DURING SPRAY APPLICATION     Application technique     Tractor-mounted/trailed broadcast air-assisted sprayer       Dermal contamination/kg a.s.     1,2     0,7     9,6       Dermal contamination/day     1,728     1,008     13,824       Protective clothing     none     gloves     none       Transmission to skin     100     1     100     %       Total dermal exposure to a.s.     15,56208     mg/day       PRE     none     gloves     none       Transmission through RPE     100     %     1       Inhalation exposure/day     0,02592     mg/day     PRE       RPE     none     Transmission through RPE     100     %       ABSORBED DOSE     Mix/load     Application       Demal exposure to a.s.     0,01328     mg/day     0,9337248     mg/day       Absorbed dose (dermal route)     0,01325     mg/day     0,9337248     mg/day       PREDICTED EXPOSURE     0,01328     mg/day     0,9596448     mg/day       PREDICTED EXPOSURE     0,013288     mg/day     0,959644	Inhalation exposure/kg a.s.	0,008	mg/kg a.s.						
RPE       none         Transmission through RPE       1000%         Inhalation exposure to a.s.       0,01152 mg/day         DERMAL EXPOSURE DURING SPRAY APPLICATION       Application technique         Application technique       Tractor-mounted/trailed broadcast air-assisted sprayer         Demal contamination/kg a.s.       1,2       0,7       9,6         Demal contamination/day       1,728       1,008       13,824         Protective clothing       none       gloves       none         Transmission to skin       100       1       100 %         Total demal exposure to a.s.       15,56208       mg/day         NHALATION EXPOSURE DURING SPRAYING       Inhalation exposure/kg a.s.       0,018       mg/kg a.s.         Inhalation exposure/day       0,02592       mg/day       100 %         Inhalation exposure to a.s.       0,02592       mg/day       15,56208       mg/day         Preseries       none       100 %       15,56208       mg/day       15,56208       mg/day         Protective clothing       0,015292       mg/day       0,2592       mg/day       15,56208       mg/day         Protective assisted to a.s.       0,02592       mg/day       0,9337248       mg/day       15,56208       mg/day<	Inhalation exposure/day	0,01152	mg/day						
Transmission through RPE       100       %         Inhalation exposure to a.s.       0,01152       mg/day         DERMAL EXPOSURE DURING SPRAY APPLICATION	RPE	none							
Inhalation exposure to a.s.       0,01152       mg/day         DERMAL EXPOSURE DURING SPRAY APPLICATION       Hands       Rest of body         Application technique       Tractor-mounted/trailed broadcast air-assisted sprayer       9.6         Dermal contamination/kg a.s.       1,2       0,7       9.6         Dermal contamination/kg a.s.       1,728       1,008       13,824         Protective clothing       none       gloves       none         Transmission to skin       100       1       100       %         Total dermal exposure to a.s.       15,56208       mg/day       %         NHALATION EXPOSURE DURING SPRAYING       more       none       gloves       none         RPE       none       none       none       gloves       none         ABSORBED DOSE       Mix/load       Application       %       mg/day         Percent absorbed       6       %       6       %         Absorbed dose (dermal route)       0,01728       mg/day       0,02592       mg/day         Inhalation exposure to a.s.       0,01728       mg/day       0,032748       mg/day         Inhalation exposure to a.s.       0,01728       mg/day       0,93596448       mg/day         Inhalation e	Transmission through RPE	100	%						
DERMAL EXPOSURE DURING SPRAY APPLICATION Tractor-mounted/trailed broadcast air-assisted sprayerHeadHandsRest of bodyDermal contamination/kg a.s.1,20,79,6Dermal contamination/kg a.s.1,20,079,6Dermal contamination/kg a.s.1,7281,00813,824Protective clothingnoneglovesnoneTransmission to skin1001100 %Total dermal exposure to a.s.15,5628mg/dayNHALATION EXPOSURE DURING SPRAYING Inhalation exposure/kg a.s.0,018mg/kg a.s.Inhalation exposure/kg a.s.0,02592mg/dayPPEnone7Transmission through RPE100%Inhalation exposure to a.s.0,02592mg/dayPREnone6Mix/loadApplicationDermal exposure to a.s.0,02782mg/dayAbsorbed Dose6%Pretent absorbed6%Absorbed dose (dermal route)0,01728mg/dayOperator exposure0,013248mg/day0,9596448Total systemic exposure0,013248mg/dayOperator exposure0,013298mg/dayTotal systemic exposure0,013248mg/dayOperator exposure0,013298mg/dayTotal dermal coversure0,013248mg/dayDermal exposure to a.s.0,013248mg/dayTotal systemic exposure0,013248mg/dayTotal systemic exposure0,013298mg/day<	Inhalation exposure to a.s.	0,01152	mg/day						
Dermine Drewning	DERMAL EXPOSURE DURING	SPRAV APPI ICATION							
Head       Hands       Rest of body         Dermal contamination/kg a.s.       1,2       0,7       9,6         Dermal contamination/kg a.s.       1,728       1,008       13,824         Protective clothing       none       gloves       none         Transmission to skin       100       1       100 %         Total dermal exposure to a.s.       15,56208       mg/day         Inhalation exposure/kg a.s.       0,018       mg/ga a.s.         Inhalation exposure/day       0,02592       mg/day         RPE       none       Transmission through RPE       100 %         Inhalation exposure/day       0,02592       mg/day         RPE       none       Transmission through RPE       100 %         Inhalation exposure to a.s.       0,02592       mg/day         ABSORBED DOSE	Application technique	Tractor-mounted/trailed broadca	est air-assisted sn	aver					
Dermal contamination/kg a.s.1.20.79.6Dermal contamination/day1,7281,00813,824Protective clothingnoneglovesnoneTransmission to skin1001100 %Total dermal exposure to a.s.15,56208mg/dayINHALATION EXPOSURE DURING SPRAYINGInhalation exposure/kg a.s.0,018mg/kg a.s.Inhalation exposure/kg a.s.0,018mg/kg a.s.Inhalation exposure/day0,02592mg/dayRPEnoneTransmission through RPE100%Inhalation exposure to a.s.0,02592mg/dayABSORBED DOSEMix/loadApplicationDermal exposure to a.s.0,0258mg/day0,01258mg/day0,9337248mg/dayPercent absorbed6%6Absorbed dose (dermal route)0,001728mg/day0,01328mg/day0,9337248mg/dayTotal systemic exposure0,913848mg/day0,9596448PREDICTED EXPOSURE70kgTotal systemic exposure0,013848mg/dayOperator exposure0,0138469mg/kg bw/dayOperator exposure % of AOEL42 %	Application teeninque	Hand	Uando	ayer	Post of body				
Demia contamination kg a.s. 1,2 0,7 5,6 Demia contamination kg a.s. 1,72 1,008 13,824 Protective clothing none gloves none Transmission to skin 100 1 100 % Total demal exposure to a.s. 15,56208 mg/day INHALATION EXPOSURE DURING SPRAYING Inhalation exposure/kg a.s. 0,018 mg/kg a.s. Inhalation exposure/kg a.s. 0,018 mg/kg a.s. Inhalation exposure/kg a.s. 0,02592 mg/day RPE none Transmission through RPE 100 % Inhalation exposure to a.s. 0,02592 mg/day ABSORBED DOSE Mix/load Application Dermal exposure to a.s. 0,0288 mg/day 15,56208 mg/day Percent absorbed 6 % 6 % Absorbed dose (dermal route) 0,001728 mg/day 0,9337248 mg/day Inhalation exposure to a.s. 0,01152 mg/day 0,9337248 mg/day Inhalation exposure to a.s. 0,01152 mg/day 0,9596448 mg/day Inhalation exposure to a.s. 0,013288 mg/day 0,9596448 mg/day PREDICTED EXPOSURE Total systemic exposure 0,013288 mg/day 0,9596448 mg/day Operator exposure 0,013288 mg/day Operator exposure 0,013888 mg/day Operator exposure 0,013888 mg/day Operator exposure 0,013888 mg/day Operator exposure 0,01388 mg/day Operator exposure 0,013888 mg/day Operator exposure 0,013888 mg/day Operator exposure 0,013888 mg/day Operator exposure 0,013888 mg/day	Domest contonvinction (1.2.2.2	neau 1.2							
Dermal exposure to a.s. 0,02592 mg/day ABSORBED DOSE Dermal exposure to a.s. 0,0152 mg/day ABSORBED DOSE Dermal exposure to a.s. 0,0152 mg/day Preterive to a.s. 0,02592 mg/day ABSORBED DOSE Dermal exposure to a.s. 0,02592 mg/day PECTORE to a.s. 0,01152 mg/day 0,0337248 mg/day Inhalation exposure to a.s. 0,01152 mg/day 0,02592 mg/day PREDICTED EXPOSURE PECTORE to a.s. 0,013288 mg/day PREDICTED EXPOSURE Total systemic exposure 0,013288 mg/day Operator exposure 0 dots mg/day Operator exposure % of AOEL 42 %	Dermal contamination/kg a.s.	1,2	1.000		9,0				
Protective clothing none gloves none Transmission to skin 100 1 100 % Total dermal exposure to a.s. 15,56208 mg/day INHALATION EXPOSURE DURING SPRAYING Inhalation exposure/day 0,02592 mg/day RPE none Transmission through RPE 100 % Inhalation exposure to a.s. 0,02592 mg/day ABSORBED DOSE Mix/load Application Dermal exposure to a.s. 0,0288 mg/day 15,56208 mg/day Percent absorbed 6 % 6 % Absorbed dose (dermal route) 0,001728 mg/day 0,9337248 mg/day Inhalation exposure to a.s. 0,01152 mg/day 0,02592 mg/day PREDICTED EXPOSURE Total systemic exposure 0,013248 mg/day 0,02592 mg/day PREDICTED EXPOSURE Total systemic exposure 0,09728928 mg/day Operator exposure (0,013898469 mg/kg bw/day Operator exposure % of AOEL 42 %	Dermai contamination/day	1,728	1,008	•	13,824				
Transmission to skin     100     1     100     %       Total demial exposure to a.s.     15,56208     mg/day     100     %       Inhalation exposure/kg a.s.     0,018     mg/kg a.s.     1     100     %       Inhalation exposure/kg a.s.     0,018     mg/kg a.s.     1     100     %       Inhalation exposure/day     0,02592     mg/day     1     100     %       Inhalation exposure/day     0,02592     mg/day     1     100     %       Inhalation exposure/day     0,02592     mg/day     1     100     %       Inhalation exposure to a.s.     0,02592     mg/day     1     100     %       Dermal exposure to a.s.     0,02592     mg/day     1     15,56208     mg/day       Percent absorbed     6     %     6     %       Absorbed dose (dermal route)     0,001728     mg/day     0,9337248     mg/day       Inhalation exposure to a.s.     0,01152     mg/day     0,92592     mg/day       Total systemic exposure     0,013248     mg/day     0,9596448     mg/day       PREDICTED EXPOSURE     70     kg     Kg     Kg/day     Kg/day       Operator exposure     0,013898469     mg/kg bw/day     0,9596448     mg/day </td <td>Protective clothing</td> <td>none</td> <td>gloves</td> <td>5</td> <td>none</td> <td></td> <td></td> <td></td> <td></td>	Protective clothing	none	gloves	5	none				
Total dermal exposure to a.s.       15,56208       mg/day         INHALATION EXPOSURE DURING SPRAYING       mailed and the sposure/day       0,018       mg/kg a.s.         Inhalation exposure/day       0,02592       mg/day         RPE       none       mone         Transmission through RPE       100       %         Inhalation exposure to a.s.       0,02592       mg/day         ABSORBED DOSE       Mix/load       Application         Dermal exposure to a.s.       0,0288       mg/day         Absorbed dose (dermal route)       0,001728       mg/day         Inhalation exposure to a.s.       0,01152       mg/day         Percent absorbed       6       %       6         Absorbed dose (dermal route)       0,001728       mg/day       0,02592       mg/day         Inhalation exposure to a.s.       0,01152       mg/day       0,02592       mg/day         Total systemic exposure       0,013248       mg/day       0,9596448       mg/day         PREDICTED EXPOSURE       Total systemic exposure       0,9728928       mg/day       0,9596448       mg/day         Operator exposure       0,013898469       mg/kg bw/day       0,9596448       mg/day       Mg/day         Operator exposure	Transmission to skin	100	1		100	%			
NHALATION EXPOSURE DURING SPRAYINGInhalation exposure/day0,02592mg/dayInhalation exposure/day0,02592mg/dayRPEnoneTransmission through RPE100%Inhalation exposure to a.s.0,02592mg/dayABSORBED DOSEDermal exposure to a.s.0,0288mg/dayPercent absorbed6%6Absorbed dose (dermal route)0,001728mg/day0,013248mg/day0,9337248mg/dayInhalation exposure to a.s.0,013248mg/day0,9596448Percent absorbed6%6Mix Joan0,013248mg/day0,9596448Precent exposure to a.s.0,9728928mg/day0,9596448Precent absorbed0,9728928mg/day0,9596448Precent exposure to a.s.0,9728928mg/day0,9596448Precent exposure0,913248mg/day0,9596448Precent exposure to a.s.0,9728928mg/day0,9596448Precent exposure0,913898469mg/day0,9596448Precent body weight70kgPoperator exposure0,013898469mg/dayPrecent body weight70kgPoperator exposure % of AOEL42%	Total dermal exposure to a.s.	15,56208	mg/day						
Inhalation exposure/kg a.s.0,018mg/kg a.s.Inhalation exposure/day0,02592mg/dayRPEnoneTransmission through RPE100%Inhalation exposure to a.s.0,02592mg/dayABSORBED DOSEMix/loadApplicationDermal exposure to a.s.0,0288mg/day15,56208mg/dayPercent absorbed6%Absorbed dose (dermal route)0,001728mg/day0,013248mg/day0,0337248mg/dayInhalation exposure to a.s.0,01152mg/day0,02592Percent absorbed6%6Absorbed dose (dermal route)0,001728mg/day0,02592Inhalation exposure to a.s.0,01152mg/day0,02592PREDICTED EXPOSUREmg/day0,9596448mg/dayOperator body weight70kgygOperator body weight70kgOperator exposure0,013898469mg/kg bw/dayOperator exposure % of AOEL42%	INHALATION EXPOSURE DUF	RING SPRAYING							
Inhalation exposure/day 0,02592 mg/day RPE none Transmission through RPE 100 % Inhalation exposure to a.s. 0,02592 mg/day ABSORBED DOSE Mix/load Application Dermal exposure to a.s. 0,0288 mg/day 15,56208 mg/day Percent absorbed 6 % 6 % Absorbed dose (dermal route) 0,001728 mg/day 0,9337248 mg/day Inhalation exposure to a.s. 0,01152 mg/day 0,02592 mg/day Total systemic exposure 0,013248 mg/day 0,9596448 mg/day PREDICTED EXPOSURE Total systemic exposure 0,9728928 mg/day Operator body weight 70 kg Operator exposure 0,013898469 mg/kg bw/day Operator exposure % of AOEL 42 %	Inhalation exposure/kg a.s.	0,018	mg/kg a.s.						
RPE       none         Transmission through RPE       100 %         Inhalation exposure to a.s.       0,02592 mg/day         ABSORBED DOSE       Mix/load       Application         Dermal exposure to a.s.       0,0288 mg/day       15,56208 mg/day         Percent absorbed       6 %       6 %         Absorbed dose (dermal route)       0,001728 mg/day       0,9337248 mg/day         Inhalation exposure to a.s.       0,01152 mg/day       0,02592 mg/day         Total systemic exposure       0,013248 mg/day       0,9596448 mg/day         PREDICTED EXPOSURE       70 kg       Voperator body weight       70 kg         Operator body weight       70 kg       mg/kg bw/day       Voperator exposure % of AOEL       42 %	Inhalation exposure/day	0,02592	mg/day						
Transmission through RPE100%Inhalation exposure to a.s.0,02592mg/dayABSORBED DOSE	RPE	none	0 9						
Inhalation exposure to a.s.       0,02592 mg/day         ABSORBED DOSE       Mix/load       Application         Dermal exposure to a.s.       0,0288 mg/day       15,56208 mg/day         Percent absorbed       6 %       6 %         Absorbed dose (dermal route)       0,001728 mg/day       0,9337248 mg/day         Inhalation exposure to a.s.       0,01152 mg/day       0,02592 mg/day         Inhalation exposure to a.s.       0,01152 mg/day       0,02592 mg/day         Total systemic exposure       0,013248 mg/day       0,9596448 mg/day         PREDICTED EXPOSURE       Total systemic exposure       0,9728928 mg/day         Operator body weight       70 kg       Kg         Operator exposure       0,013898469 mg/kg bw/day       Herke bw/day         Operator exposure % of AOEL       42 %	Transmission through RPE	100	%						
ABSORBED DOSEMix/loadApplicationDermal exposure to a.s.0,0288mg/day15,56208mg/dayPercent absorbed6%6%Absorbed dose (dermal route)0,001728mg/day0,9337248mg/dayInhalation exposure to a.s.0,01152mg/day0,02592mg/dayTotal systemic exposure0,013248mg/day0,9596448mg/dayPREDICTED EXPOSURETotal systemic exposure0,9728928mg/dayOperator body weight70kgyg/dayOperator exposure % of AOEL42%	Inhalation exposure to a.s.	0,02592	mg/day						
Mix/load ApplicationDermal exposure to a.s.0,0288mg/day15,56208mg/dayPercent absorbed6%6%Absorbed dose (dermal route)0,001728mg/day0,9337248mg/dayInhalation exposure to a.s.0,01152mg/day0,02592mg/dayTotal systemic exposure0,013248mg/day0,9596448mg/dayPREDICTED EXPOSURETotal systemic exposure0,9728928mg/dayOperator body weight70kgValueOperator exposure0,013898469mg/kg bw/dayValueOperator exposure % of AOEL42 %%	A DSODDED DOSE								
Dermal exposure to a.s.0,0288mg/day15,56208mg/dayPercent absorbed6%6%Absorbed dose (dermal route)0,001728mg/day0,9337248mg/dayInhalation exposure to a.s.0,01152mg/day0,02592mg/dayTotal systemic exposure0,013248mg/day0,9596448mg/dayPREDICTED EXPOSURETotal systemic exposure0,9728928mg/day0,9596448mg/dayOperator body weight70kg70kg0Operator exposure0,013898469mg/kg bw/dayUUOperator exposure % of AOEL42 %%UU	ADSUKDED DUSE	Mir/lood		Application					
Definite exposure to a.s.0,0286mg/day15,56208mg/dayPercent absorbed6%6%Absorbed dose (dermal route)0,001728mg/day0,9337248mg/dayInhalation exposure to a.s.0,01152mg/day0,02592mg/dayTotal systemic exposure0,013248mg/day0,9596448mg/dayPREDICTED EXPOSURETotal systemic exposure0,9728928mg/dayOperator body weight70kgVOperator exposure0,013898469mg/kg bw/dayOperator exposure % of AOEL42 %	Dormal ownees to a a	0.0200	ma/day	лирисанон	15 56000	ma/da-			
Percent absorbed       6       %       6       %         Absorbed dose (dermal route)       0,001728       mg/day       0,9337248       mg/day         Inhalation exposure to a.s.       0,01152       mg/day       0,02592       mg/day         Total systemic exposure       0,013248       mg/day       0,9596448       mg/day         PREDICTED EXPOSURE       Total systemic exposure       0,9728928       mg/day         Operator body weight       70       kg       Voperator exposure       0,013898469       mg/kg bw/day         Operator exposure % of AOEL       42 %       %       Volume       Volume       Volume	Definal exposure to a.s.	0,0288	mg/day		15,56208	mg/day			
Absorbed dose (dermal route)       0,001728       mg/day       0,9337248       mg/day         Inhalation exposure to a.s.       0,01152       mg/day       0,02592       mg/day         Total systemic exposure       0,013248       mg/day       0,9596448       mg/day         PREDICTED EXPOSURE       Total systemic exposure       0,9728928       mg/day         Operator body weight       70       kg         Operator exposure % of AOEL       42 %	Percent absorbed	6	%		6	%			
Inhalation exposure to a.s.     0,01152     mg/day     0,02592     mg/day       Total systemic exposure     0,013248     mg/day     0,9596448     mg/day       PREDICTED EXPOSURE     Total systemic exposure     0,9728928     mg/day       Operator body weight     70     kg       Operator exposure % of AOEL     42 %	Absorbed dose (dermal route)	0,001728	mg/day		0,9337248	mg/day			
Total systemic exposure     0,013248     mg/day     0,9596448     mg/day       PREDICTED EXPOSURE     0,9728928     mg/day       Total systemic exposure     0,9728928     mg/day       Operator body weight     70     kg       Operator exposure     0,013898469     mg/kg bw/day       Operator exposure % of AOEL     42 %	Inhalation exposure to a.s.	0,01152	mg/day		0,02592	mg/day			
PREDICTED EXPOSURE       mg/day         Total systemic exposure       0,9728928       mg/day         Operator body weight       70       kg         Operator exposure       0,013898469       mg/kg bw/day         Operator exposure % of AOEL       42       %	Total systemic exposure	0,013248	mg/day		0,9596448	mg/day			
Total systemic exposure0,9728928mg/dayOperator body weight70kgOperator exposure0,013898469mg/kg bw/dayOperator exposure % of AOEL42 %	PREDICTED EXPOSURE								
Operator body weight70kgOperator exposure0,013898469mg/kg bw/dayOperator exposure % of AOEL42 %	Total systemic exposure	0,9728928	mg/day						
Operator exposure0,013898469 mg/kg bw/dayOperator exposure % of AOEL42 %	Operator body weight	70	kg						
Operator exposure % of AOEL 42 %	Operator exposure	0,013898469	mg/kg bw/day						
	<b>Operator exposure % of AOEL</b>	42	%						

## E. UK POEM: hand-held, orchard without PPE using Dimilin WG-80

Amplication method				
Application method	Hand-held rotary atomiser equipment (2.5	I tank). Outdoor, high lev	vel target	110.1
Product	Dimilin WG80		Active substance	diflubenzuron
Formulation type	WG or SG		a.s. concentration	800 mg/g
Dermal absorption from product	(	<mark>)</mark> %	Dermal absorption from spray	<mark>6 %</mark>
PPE during mix/loading	None 💌		PPE during application	None 🔻
Dose	0,225	kg product/ha	Work rate/day	1 ha
Application volume	1500	l/ha	Duration of spraving	6 h
AOEL	0,033	mg/kg bw/day	. , , ,	
	,			
DERMAL EXPOSURE DURING	MIXING AND LOADING			
Hand contamination/kg a s	171.4	ma/ka a s		
Hand contamination/kg a.s.	20.952	ing kg a.s.		
Hand contamination/day	30,852	mg/day		
Protective clothing	None			
Transmission to skin	100	%		
Dermal exposure to a.s.	30,852	mg/day		
INHALATION EXPOSURE DUR	ING MIXING AND LOADING			
Inhalation exposure/kg a.s.	0.0628	mg/kg a.s.		
Inhalation exposure/day	0.011304	mg/day		
DDE	0,011504 None	inguay		
	Noile	; 0/		
Transmission through RPE	100	%		
Inhalation exposure to a.s.	0,011304	mg/day		
DERMAL EXPOSURE DURING	SPRAY APPLICATION			
Application technique	Hand-held rotary atomiser equip	oment (2.5 l tank).	Outdoor, high level target	
Application volume	1500	spray/ha		
Volume of surface contamination	50	ml/h		
Distribution	Hands	. Trunk	Less	
Distribution	10%	65%	25%	
Clothing	None	Permeable	Permeshle	
Devetertier	1000/	150/		
Penetration	100%	15%	20%	
Dermal exposure	5	4,875	2,5	ml/h
Duration of exposure	6	h		
Total dermal exposure to spray	74,25	ml/day		
Concentration of a.s. in spray solut	ti 0,12	mg/ml		
Dermal exposure to a.s.	8,91	mg/day		
*				
INHALATION EXPOSURE DUR	ING SPRAYING			
Inhalation exposure to spray	0.01	ml/h		
Duration of exposure	0,01	h		
Concentration of a s in spray	0.12	ma/ml		
Inholotion our course to a c	0,12	mg/m		
Innalation exposure to a.s.	0,0072	mg/day		
Percent absorbed	100	%		
Absorbed dose	0,0072	mg/day		
ABSORBED DOSE				
	Mix/load	1	Application	
Dermal exposure to a.s.	30,852	mg/dav	8.91	mg/day
Percent absorbed	6	0/0	6	°/2
Absorbed dose (dermal route)	1 85112	mg/day	0 5246	mg/day
Inhalation exposure to a s	0.011204	mg/day	0,0072	mg/day
A basehod dogo	1.962424	mg/uay	0,00/2	mg/day
Absorbed dose	1,862424	mg/day	0,5418	mg/day
PREDICTED EXPOSURE				
Total absorbed dose	2,404224	mg/day		
Operator body weight	60	kg		
Operator exposure	0,0400704	mg/kg bw/day		
<b>Operator exposure % of AOEL</b>	121,4254545	%		

## THE UK PREDICTIVE OPERATOR EXPOSURE MODEL (POEM) WITH GERMAN MODEL MIX/LOAD DATA (75th PERCENTILE)

## F. UK POEM: hand-held, orchard with PPE using Dimilin WG-80

Amplication mathed				
Application method	Hand-held rotary atomiser equipment (2.5	I tank). Outdoor, high le	evel target	1.0.1
Product	Dimilin WG80		Active substance	diflubenzuron
Formulation type	WG or SG		a.s. concentration	800 mg/g
Dermal absorption from product	6	%	Dermal absorption from spray	<b>6</b> %
PPE during mix/loading	Gloves		PPE during application	Gloves
Dose	0,225	kg product/ha	Work rate/day	1 ha
Application volume	1500	l/ha	Duration of spraying	6 h
AOEL	0,033	mg/kg bw/day		
DERMAL EXPOSURE DURING	MIXING AND LOADING			
Hand contamination/kg a.s.	171,4	mg/kg a.s.		
Hand contamination/day	30,852	mg/day		
Protective clothing	Gloves	0,		
Transmission to skin	1	%		
Dermal exposure to a s	0 30852	mg/day		
Definal exposure to a.s.	0,50852	inguay		
NILLAL A TLON EVDOCUDE DUD				
INHALATION EXPOSURE DUR	ING MIAING AND LOADING			
Innalation exposure/kg a.s.	0,0628	mg/kg a.s.		
Inhalation exposure/day	0,011304	mg/day		
RPE	None			
Transmission through RPE	100	%		
Inhalation exposure to a.s.	0,011304	mg/day		
DERMAL EXPOSURE DURING	SPRAY APPLICATION			
Application technique	Hand-held rotary atomiser equir	ment (2.5 l tank)	). Outdoor, high level target	
Application volume	1500	sprav/ha	,	
Volume of surface contamination	50	ml/h		
Distribution	Hande	Trun	k Leas	
Distribution	109/	650	۲ الدوم ۱۰۰۶ ۲۰۰۶ ۲۰۰۶ ۲۰۰۶ ۲۰۰۶ ۲۰۰۶ ۲۰۰۶ ۲۰۰۶	
Clothing	Clavas	Dormochl	a Darmaahla	
Clouing	010065	renneadi		
Penetration	10%	15%	~ <u>20</u> %	
Dermal exposure	0,5	4,875	2,5	ml/h
Duration of exposure	6	h		
Total dermal exposure to spray	47,25	ml/day		
Concentration of a.s. in spray solut	0,12	mg/ml		
Dermal exposure to a.s.	5,67	mg/day		
INHALATION EXPOSURE DUR	ING SPRAYING			
Inhalation exposure to spray	0,01	ml/h		
Duration of exposure	6	h		
Concentration of a s. in spray	0.12	mg/ml		
Inhalation exposure to a s	0.0072	mg/day		
Percent absorbed	100	%		
Absorbed dose	0.0072	/0 mg/day		
Absorbed dose	0,0072	ilig/uay		
A DEODDED DOGE				
ABSORBED DOSE			A 11 - 21	
	Mix/load		Application	
Dermal exposure to a.s.	0,30852	mg/day	5,67	mg/day
Percent absorbed	6	%	6	%
Absorbed dose (dermal route)	0,0185112	mg/day	0,3402	mg/day
Inhalation exposure to a.s.	0,011304	mg/day	0,0072	mg/day
Absorbed dose	0,0298152	mg/day	0,3474	mg/day
PREDICTED EXPOSURE				
Total absorbed dose	0.3772152	mg/dav		
Operator body weight	60	kg		
Operator exposure	0 00628692	o mø/kø hw/dav		
Operator exposure % of AOFL	19 05127273	%		
Sperator exposure /0 01/10EL	17,0012/2/0	, .		

## THE UK PREDICTIVE OPERATOR EXPOSURE MODEL (POEM) WITH GERMAN MODEL MIX/LOAD DATA (75th PERCENTILE)

# G. German model: hand-held, orchard without PPE using Dimilin WG-80

Application method	Hand-held sprayer: hydraulic pozzles. Outdo	or high level target		•	
Product	Dimilin WG-80	ior, nightiotor target	Active substance		diflubenzuron
Formulation type	WG		a.s. concentration		800 g/kg
Dermal absorption from product	6	%	Dermal absorption from	m sprav	<b>6</b> %
RPE during mix/loading	None	/ 0	RPE during application	n	None
PPE during mix/loading	None		8 8	-	
PPE during application: Head	None	Hands	None	<b>T</b> Body	None
Dose	0,225	kg product/ha	Work rate/day		1 ha
AOEL	0,033	mg/kg bw/day	,		
DERMAL EXPOSURE DURING	MIXING AND LOADING				
Hand contamination/kg a s		malkaas			
Hand contamination/day	2 7 8	mg/day			
Protective clothing	5,78	inguay			
Transmission to skin	100	0/_			
	2.78	/0			
Dermal exposure to a.s.	3,/8	mg/day			
INHALATION EXPOSURE DUR	ING MIXING AND LOADING				
Inhalation exposure/kg a.s.	0,02	mg/kg a.s.			
Inhalation exposure/day	0,0036	mg/day			
RPE	none				
Transmission through RPE	100	%			
Inhalation exposure to a.s.	0,0036	mg/day			
DEDMAL EXDOSLIDE DUDING	CDD A V A DDI IC A TION				
Amplication technique	SPRAT APPLICATION	laa Outdaan h	ink laval taunat		
Application technique	Hand-heid sprayer. hydraulic ho	zzies. Outdoor, n	ign ievel target	61 1	
	Head	Hands	Rest	of body	
Dermal contamination/kg a.s.	4,8	10,6	)	25	
Dermal contamination/day	0,864	1,908	5	4,5	
Protective clothing	none	none		none	
Transmission to skin	100	100		100 %	
Total dermal exposure to a.s.	7,272	mg/day			
INHALATION EXPOSURE DUR	ING SPRAYING				
Inhalation exposure/kg a.s.	0.3	mg/kg a.s.			
Inhalation exposure/day	0.054	mg/dav			
RPE	none				
Transmission through RPE	100	%			
Inhalation exposure to a.s.	0,054	mg/day			
*	,				
ABSORBED DOSE			A 11 /		
	Mix/load		Application	<b>7 070</b>	
Dermal exposure to a.s.	3,78	mg/day		7,272 mg/day	
Percent absorbed	6	%		6 %	
Absorbed dose (dermal route)	0,2268	mg/day	0	,43632 mg/day	
Inhalation exposure to a.s.	0,0036	mg/day		0,054 mg/day	
Total systemic exposure	0,2304	mg/day	0	,49032 mg/day	
PREDICTED EXPOSURE					
Total systemic exposure	0 72072	mg/dav			
Operator body weight	5,72072	kg			
Operator exposure	0,010296	mg/kg bw/dav			
Operator exposure % of AOEL	31	%			
-r-ingrade /ooritolii					

# H. German model: hand-held, orchard with PPE using Dimilin WG-80

Application method	Hand hold sprayer, bydraulic pezzles. Outd	or high lovel target		-				
Product	Dimilin WG-80	oor, nign iever target	Active substance	e		diflub	enzuron	
Formulation type	WG		a.s. concentratio	'n		80	0 g/kg	
Dermal absorption from product	6	%	Dermal absorpti	on from spray			<mark>6</mark> %	
RPE during mix/loading	None		RPE during app	lication		None		-
PPE during mix/loading	Gloves 🔫		0 11		-			
PPE during application: Head	None 🗨	Hands	Gloves	-	Body	None		•
Dose	0,225	kg product/ha	Work rate/day				1 <mark>ha</mark>	
AOEL	0,033	mg/kg bw/day						
DEDMAL EXPOSURE DUD NG	MINING AND LOADDIG							
DERMAL EXPOSURE DURING	MILAING AND LUADING							
Hand contamination/kg a.s.	21	mg/kg a.s.						
Protective clothing	5,/6 gloves	ing/uay						
Transmission to skin	gioves	0/_						
	0.0278	70 						
Definal exposure to a.s.	0,0378	mg/day						
INHALATION EXPOSURE DUF	RING MIXING AND LOADING							
Inhalation exposure/kg a.s.	0.02	mg/kg a.s.						
Inhalation exposure/day	0.0036	mg/day						
RPE	none	8						
Transmission through RPE	100	%						
Inhalation exposure to a s	0.0036	mg/day						
	0,0000	ing any						
DERMAL EXPOSURE DURING	SPRAY APPLICATION							
Application technique	Hand-held sprayer: hydraulic no	zzles. Outdoor, h	igh level target					
	Head	Hand	5	Rest of body				
Dermal contamination/kg a.s.	4,8	10,6	5	25				
Dermal contamination/day	0,864	1,908	3	4,5				
Protective clothing	none	glove	5	none				
Transmission to skin	100	1		100	%			
Total dermal exposure to a.s.	5,38308	mg/day						
INHALATION EXPOSURE DUP	ANG SPRAYING							
Inhalation exposure/kg a.s.	0,3	mg/kg a.s.						
Innalation exposure/day	0,054	mg/day						
KPE Transmission through DDE	100	0/						
Infansmission unrough KPE	100	70 						
Innalation exposure to a.s.	0,054	mg/day						
ABSORBED DOSE								
ABSORDED DOSE	Mix/load		Application					
Dermal exposure to a s	0.0378	mg/day	rippiloution	5 38308	mø/dav			
Percent absorbed	6,0576	%		5,50500	%			
Absorbed dose (dermal route)	0.002268	mg/day		0 3229848	mg/dav			
Inhalation exposure to a s	0.0036	mg/day		0.054	mg/day			
Total systemic exposure	0.005868	mg/day		0.3769848	mg/dav			
	0,00000			0,0,0000				
PREDICTED EXPOSURE								
Total systemic exposure	0,3828528	mg/day						
Operator body weight	70	kg						
Operator exposure	0,005469326	mg/kg bw/day						
<b>Operator exposure % of AOEL</b>	17	%						

## I. German model: Estimated dermal and inhalation exposure during mixing/loading with aerial

## application in forestry using Dimilin WG-80 without PPE

Application method	Hand-held sprayer: hydraulic nozzles. Outdo	or, high level target		▼			
Product	Dimilin WG-80	in fight level target	Active sub	stance		diflubenzuro	n
Formulation type	WG		a s concen	tration		800 g/kg	-
Dermal absorption from product	6	0/0	Dermal abs	sorption from spray		6 %	
RPE during mix/loading	None	/0	RPE during	application		Nono	
PPE during mix/loading	Nano		ICI L' during	Supplication		NOTE	
PPE during application: Head	Napo	Hande	None	-	Body	Nono	-
Pre-during application. Tread		lig product/ho	Work roto/	darr	Bouy	1000 ha	•
AOFL	0,00	ng/kg hw/day	work rate/	uay		1000 11a	
NOLL	0,000	ing/kg 0w/day					
DERMAL EXPOSURE DURING	MIXING AND LOADING						
Hand contamination/kg a s	21	mo/ko a s					
Hand contamination/day	1008	mg/day					
Protective electhing	1000	iiig/day					
Transmission to alsin	100	0/					
Transmission to skin	100	<sup>%0</sup>					
Dermal exposure to a.s.	1008	mg/day					
BULLI ATION EXPOSURE DUR							
INHALATION EXPOSURE DUR	LING MILAING AND LUADING						
Inhalation exposure/kg a.s.	0,02	mg/kg a.s.					
Inhalation exposure/day	0,96	mg/day					
RPE	none						
Transmission through RPE	100	%					
Inhalation exposure to a.s.	0,96	mg/day					
DERMAL EXPOSURE DURING	SPRAY APPLICATION						
Application technique	Hand-held sprayer: hydraulic no	zzles. Outdoor, h	igh level targ	get			
	Head	Hands		Rest of body			
Dermal contamination/kg a.s.	4,8	10,6		25			
Dermal contamination/day	230.4	508.8		1200			
Protective clothing	none	none		none			
Transmission to skin	100	100	·	100	0/0		
Total dermal exposure to a s	1939.2	mg/day		100	/0		
	, <u>-</u>	ing aug					
INHALATION EXPOSURE DUR	ING SPRAYING						
Inhalation exposure/kg a.s.	0,3	mg/kg a.s.					
Inhalation exposure/day	14.4	mg/day					
R PE	none	ing au					
Transmission through PDE	100	0/					
Inhalation avecaure to a s	100	/0 mg/day					
initialation exposure to a.s.	14,4	ilig/day					
ABSORBED DOSE							
ABSORDED DOSE	Mix/load		Application	n			
Dermal expegure to a g	1008		Application	1020.2	ma/day		
Definal exposure to a.s.	1008			1939,2	nig/uay		
Percent absorbed	0	<sup>%</sup> 0	)	0	70		
Absorbed dose (dermal route)	60,48	mg/day	/	116,352	mg/day		
Inhalation exposure to a.s.	0,96	mg/day		14,4	mg/day		
Total systemic exposure	61,44	mg/day		130,752	mg/day		
			$\overline{}$				
PREDICTED EXPOSURE	100.000	(1					
I otal systemic exposure	192,192	mg/day		*			
Operator body weight	70	kg		Operator oxposure	- 0.879~	a/ka	
Operator exposure	2,7456	mg/kg bw/day		2660 % of AOEL	- 0.0701	·9' ·9	
Operator exposure % of AOEL	8320	%					

## J. German model: Estimated dermal and inhalation exposure during mixing/loading with aerial

## application in forestry using Dimilin WG-80 with PPE

Application method	Hand-held sprayer: bydraulic pozzles. Outdo	or high level target					
Product	Dimilin WG-80	or, night over target	Active subst	ance		diflubenzuron	
Formulation type	WG		a s concentra	ation		800 g/kg	
Dermal absorption from product	6	0/2	Dermal abso	rption from spray		6 %	
BPE during mix/loading	Nano	70	RPE during	application		Nono	
PPE during mix/loading	Claves		Ki L during a	application		NUTIE	· ·
DDE during application: Head	Name -	Handa	Nees	-	Dody		_
Deep	None		Warls ant a / da	· ·	Бойу	None	<b>`</b>
	0,00	kg product/ha	work rate/da	iy		1000 na	
AUEL	0,033	nig/kg 0w/day					
DERMAL EXPOSURE DURING	MIXING AND LOADING						
Hand contamination/kg a s		ma/ka a s					
Hand containination/kg a.s.	1008	nig/kg a.s.					
Hand contamination/day	1008	mg/day					
Protective clothing	gloves						
Transmission to skin	1	%					
Dermal exposure to a.s.	10,08	mg/day					
INHALATION EXPOSURE DUR	ING MIXING AND LOADING						
Inhalation exposure/kg a.s.	0,02	mg/kg a.s.					
Inhalation exposure/day	0,96	mg/day					
RPE	none						
Transmission through RPE	100	%					
Inhalation exposure to a.s.	0,96	mg/day					
DERMAL EXPOSURE DURING	SPRAY APPLICATION						
Application technique	Hand-held sprayer: hydraulic no	zzles. Outdoor, h	igh level targe	et			
	Head	Hands		Rest of body			
Dermal contamination/kg a.s.	4.8	10.6	ĥ	25			
Dermal contamination/day	230.4	508.8		1200			
Protective clothing	none	none	,	none			
Transmission to skin	100	100	, ,	100	0/		
Total dermal exposure to a s	100	100 mg/day		100	70		
Total definal exposure to a.s.	1959,2	iiig/uay					
INHALATION EXPOSURE DUR	ING SPRAYING						
Inhalation exposure/kg a s	03	mø/kø a s					
Inhalation exposure/day	14.4	mg/day					
B DE	14,4	ilig/uay					
	100	0/					
I ransmission through RPE	100	%					
Inhalation exposure to a.s.	14,4	mg/day					
ADCORDED DOCE							
ABSORBED DOSE	Aire (Inc. of		A				
Demas 1 error error (	Mix/load		Application	1020.2			
Dermai exposure to a.s.	10,08	mg/day		1939,2	mg/day		
Percent absorbed	6	%		6	%		
Absorbed dose (dermal route)	0,6048	mg/day		116,352	mg/day		
Inhalation exposure to a.s.	0,96	mg/day		14,4	mg/day		
Total systemic exposure	1,5648	mg/day		130,752	mg/day		
PREDICTED EXPOSURE							_
Total systemic exposure	132,3168	mg/day	ſ	Operator exposur	e = 0.008	91ma/ ka bw/ daa	
Operator body weight	70	kg		68 % of AOEL	0.000		
Operator exposure	1,89024	mg/kg bw/day	L	-			-
<b>Operator exposure % of AOEL</b>	5728	%					

## K. German model: tractor-mounted, forestry, without PPE using Dimilin WG-80

Application method	Tractor mounted/trailed broadcast -isi-t	od apravor			
Product	Dimilin WC 80	eu sprayer	Active substance		diflubenzuror
Formulation type			Active substance		
Dermal absorption from product	wg 🖌	0/0	Dermal absorption from spr	6 %	
RPE during mix/loading	Nana	/0	RPE during application	, y	Nana
PPE during mix/loading	None		Ki E during application		None
PPE during application: Head	None	Hands	Nono	Body	Nona
Dose	0.06	kg product/ha	Work rate/day	Douy	8 ha
AOFI	0.033	mg/kg bw/day	work fate day		0 na
NOLL	0,055	ing/kg 0w/day			
DEPMAL EXPOSURE DURING	MIXING AND LOADING				
Hand contamination/kg a s	MIAING AND LOADING	ma/ka a s			
Hand contamination/kg d.s.	0.768	mg/kg a.s.			
Protective elething	0,708	iiig/uay			
Transmission to alsin	100	0/			
	0.768	70 mg/day			
Dermai exposure to a.s.	0,768	mg/day			
NULLIATION EXPOSIBE DUD					
INHALATION EXPOSURE DUR	ING MIXING AND LOADING				
Inhalation exposure/kg a.s.	0,008	mg/kg a.s.			
Inhalation exposure/day	0,003072	mg/day			
RPE	none				
Transmission through RPE	100	%			
Inhalation exposure to a.s.	0,003072	mg/day			
DERMAL EXPOSURE DURING	SPRAY APPLICATION				
Application technique	Tractor-mounted/trailed broadca	st air-assisted spr	ayer		
	Head	Hands	Rest of boo	y	
Dermal contamination/kg a.s.	1,2	0,7	9	6	
Dermal contamination/day	0,4608	0,2688	3,686	4	
Protective clothing	none	none	nor	ie	
Transmission to skin	100	100	10	) %	
Total dermal exposure to a.s.	4,416	mg/day			
INHALATION EXPOSURE DUR	ING SPRAYING				
Inhalation exposure/kg a.s.	0,018	mg/kg a.s.			
Inhalation exposure/day	0,006912	mg/day			
RPE	none				
Transmission through RPE	100	%			
Inhalation exposure to a.s.	0,006912	mg/day			
1	,	6 5			
ABSORBED DOSE					
	Mix/load		Application		
Dermal exposure to a.s.	0.768	mg/dav	4.41	5 mg/day	7
Percent absorbed	6	%	,	5 %	
Absorbed dose (dermal route)	0.04608	mg/dav	0.2649	5 mg/day	7
Inhalation exposure to a s	0.003072	mg/day	0.00691	2 mg/day	r
Total systemic exposure	0.049152	mg/day	0 27187	2 mg/day	r
of otomic exposure	0,019132		0,27107.		
PREDICTED EXPOSURE					
Total systemic exposure	0 321024	mg/day			
Operator body weight	70	kg			
Operator exposure	0.004586057	mg/kg hw/dav			
Operator exposure % of AOEL	14	%			
r					

# L. German model: hand-held, forestry, without PPE using Dimilin WG-80

Application method	Hand-beld sprayer: bydraulic pozzles. Outdo	or high level target			
Product	Dimilin WC-80		Active substance		diflubenzuron
Formulation type			Active substance		
Portulation type	WG	07	Dermal abaamtian	c	<b>600</b> g/kg
Dermai absorption from product		70	Dermai absorption	from spray	0 %
RPE during mix/loading	None		RPE during applica	tion	None
PPE during mix/loading	None			1-1-	
PPE during application: Head	None	Hands	None	Bo	dy None
Dose	0,06	kg product/ha	Work rate/day		1 ha
AOEL	0,033	mg/kg bw/day			
DERMAL EXPOSURE DURING	MIXING AND LOADING				
Hand contamination/kg a.s.	21	mg/kg a.s.			
Hand contamination/day	1,008	mg/day			
Protective clothing	none				
Transmission to skin	100	%			
Dermal exposure to a s	1 008	mg/day			
Definal exposure to a.s.	1,000	iiig/day			
INITAL ATION EXPOSURE DUR	ING MIVING AND LOADING				
INHALATION EAFOSORE DOR					
Innalation exposure/kg a.s.	0,02	mg/kg a.s.			
Inhalation exposure/day	0,00096	mg/day			
RPE	none				
Transmission through RPE	100	%			
Inhalation exposure to a.s.	0,00096	mg/day			
DERMAL EXPOSURE DURING	SPRAY APPLICATION				
Application technique	Hand-held sprayer: hydraulic no	zzles. Outdoor, h	igh level target		
	Head	Hands	s Re	est of body	
Dermal contamination/kg a s	4.8	10.6		25	
Dermal contamination/day	0.2304	0 5088	2	1.2	
Protective elething	0,2504	0,5000	,	1,2	
Transmission to also	100	100	5	100 0/	
Transmission to skin	100	100		100 %	
I otal dermal exposure to a.s.	1,9392	mg/day			
INHALATION EXPOSURE DUR	ING SPRAYING				
Inhalation exposure/kg a.s.	0,3	mg/kg a.s.			
Inhalation exposure/day	0,0144	mg/day			
RPE	none				
Transmission through RPE	100	%			
Inhalation exposure to a.s.	0,0144	mg/day			
*		0 ,			
ABSORBED DOSE					
	Mix/load		Application		
Dermal exposure to a s	1 008	mg/day	1 ppiloution	1.9392 mg	/day
Definite exposure to a.s.	1,008	0/		1,7572 mg	uay
Alexal absorbed	0 0 0 0 1 0	70		0 11(252	(1)
Absorbed dose (dermai route)	0,06048	mg/day		0,116352 mg	day
Inhalation exposure to a.s.	0,00096	mg/day		0,0144 mg	day
Total systemic exposure	0,06144	mg/day		0,130752 mg	/day
PREDICTED EXPOSURE					
Total systemic exposure	0,192192	mg/day			
Operator body weight	70	kg			
Operator exposure	0,0027456	mg/kg bw/day			
<b>Operator exposure % of AOEL</b>	8	%			

### M. German model: Estimated dermal and inhalation exposure during mixing/loading for mushroom

grower in greenhouse using automatic spraying of Dimilin WG-80 without PPE

Application method	Hand-held sprayer: hydraulic pozzles. Outdo	or high level target			
Product	Dimilin WG-80	sor, mginiever target	Active substan	ce	diflubenzuron
Formulation type	WG T		a s_concentrat	ion	800 g/kg
Dermal absorption from product	6	%	Dermal absorn	tion from spray	6 %
RPE during mix/loading	None		RPE during an	nlication	None
PPE during mix/loading	None		iti 2 uuiing up	p	
PPE during application: Head	None	Hands	None	▼ Body	None
Dose	12.5	kg product/ha	Work rate/day	20uj	0.15 ha
AOEL	0,033	mg/kg bw/day			• <u>,</u>
DERMAL EXPOSURE DURING	MIXING AND LOADING				
Hand contamination/kg a.s.	21	mg/kg a.s.			
Hand contamination/day	31,5	mg/day			
Protective clothing	none	0/			
Transmission to skin	100	%			
Dermal exposure to a.s.	31,5	mg/day			
INHALATION EXPOSURE DUR	ING MIXING AND LOADING				
Inhalation exposure/kg a s	0.02	mg/kg a s			
Inhalation exposure/day	0.03	mg/day			
RPF	0,05	ing duy			
Transmission through RPE	100	0/0			
Inhalation exposure to a s	0.02	70 mg/day			
mination exposure to a.s.	0,05	iiig/uay			
DERMAL EXPOSURE DURING	SPRAY APPLICATION				
Application technique	Hand-held sprayer: hydraulic no	zzles. Outdoor, hi	igh level target		
	Head	Hands		Rest of body	
Dermal contamination/kg a.s.	4,8	10,6		25	
Dermal contamination/day	7,2	15,9		37,5	
Protective clothing	none	none		none	
Transmission to skin	100	100		100 %	
Total dermal exposure to a.s.	60,6	mg/day			
INHALATION EXPOSURE DUR	ING SPRAYING				
Inhalation exposure/kg a.s.	0,3	mg/kg a.s.			
Inhalation exposure/day	0,45	mg/day			
RPE	none				
Transmission through RPE	100	%			
Inhalation exposure to a.s.	0,45	mg/day			
ABSORBED DOSE					
	Mix/load		Application		
Dermal exposure to a.s.	31.5	mg/day		60,6 mg/dav	
Percent absorbed	6	%		6 %	
Absorbed dose (dermal route)	1.89	mg/day	)	3,636 mg/dav	
Inhalation exposure to a.s.	0.03	mg/day	/	0.45 mg/dav	
Total systemic exposure	1,92	mg/day		4,086 mg/day	
		`			
PREDICTED EXPOSURE		11	$\sim$		
I otal systemic exposure	6,006	mg/day		Operator exposure = 0.0	)274mg/ kg bw/ day
Operator body weight	70	кg		83 % of AOEL	
Operator exposure	0,0858	mg/kg bw/day			
Operator exposure % of AOEL	260	70			

## N. German model: Estimated dermal and inhalation exposure during mixing/loading for mushroom

## grower in greenhouse using Dimilin WG-80 and hand-held sprayer without PPE

Application method	Hand-held sprayer: hydraulic pozzles. Out	loor, high level target		▼			
Product	Dimilin WG-80	assi, niginiever target	Active substance			diflubenzuron	
Formulation type	WG $\checkmark$		a.s. concentration	1		800 g/kg	
Dermal absorption from product		<b>i</b> %	Dermal absorptic	n from spray		6 %	
RPE during mix/loading	None		RPE during application		None	-	
PPE during mix/loading	None		iti D during upph	loution		None	
PPE during application: Head	None	Hands	None	-	Body	None	-
Dose	12	kg product/ha	Work rate/day		Douy	0 15 ha	
AOEL	0,033	mg/kg bw/day	in one rate, any			0,10 Ilu	
DEDMAL EVROPTIDE DUDING	MINING AND LOADING						
DERMAL EXPOSURE DURING	MIXING AND LOADING						
Hand contamination/kg a.s.	21	mg/kg a.s.					
Pand contamination/day	31,5	mg/day					
Protective clothing	non	e 0/					
I ransmission to skin	100	%					
Dermal exposure to a.s.	31,5	mg/day					
INHALATION EXPOSURE DUR	ING MIXING AND LOADING						
Inhalation exposure/kg a.s.	0,02	mg/kg a.s.					
Inhalation exposure/day	0,03	mg/day					
RPE	non	2					
Transmission through RPE	100	%					
Inhalation exposure to a.s.	0.03	mg/dav					
	,	5 9					
DERMAL EXPOSURE DURING	SPRAY APPLICATION						
Application technique	Hand-held sprayer: hydraulic n	ozzles. Outdoor, h	igh level target				
	Hea	l Hands	5	Rest of body			
Dermal contamination/kg a.s.	4,	3 10,6	<u>,</u>	25			
Dermal contamination/day	7,1	2 15,9	)	37,5			
Protective clothing	non	e none	e	none			
Transmission to skin	100	100		100 %	6		
Total dermal exposure to a.s.	60,6	mg/day					
	ING SDD A VING						
Inhalation exposure don	LING SERATING						
Innalation exposure/kg a.s.	0,.	mg/kg a.s.					
Innalation exposure/day	0,45	mg/day					
KPE	non	e 0/					
I ransmission through RPE	100	%					
Inhalation exposure to a.s.	0,45	mg/day					
ABSORBED DOSE							
	Mix/loa	1	Application				
Dermal exposure to a.s.	31.5	mg/day		60,6	mg/dav		
Percent absorbed	6	%		6	%		
Absorbed dose (dermal route)	1.89	mg/day		3,636	mg/dav		
Inhalation exposure to a.s.	0.03	mg/day		0.45	mg/dav		
Total systemic exposure	1,92	mg/day		4,086	mg/day		
-							
PREDICTED EXPOSURE		(1					
I otal systemic exposure	6,006	mg/day					
Operator body weight	70	kg					
Operator exposure	0,0858	mg/kg bw/day					
Operator exposure % of AOEL	26	J %0					

## O. German model: Estimated dermal and inhalation exposure during mixing/loading for mushroom

## grower in greenhouse using Dimilin WG-80 and hand-held sprayer with PPE

Application method	Hand-held sprayer; hydraulic nozzles. Outdo	oor, high level target	▼			
Product	Dimilin WG-80		Active substance		diflubenzuron	
Formulation type	WG 🗸		a.s. concentration		800 g/kg	
Dermal absorption from product	6	%	Dermal absorption from spray		6 %	
RPE during mix/loading	None 🗸 🗸		RPE during application		None	-
PPE during mix/loading	Gloves 💌		<i>c m</i>			
PPE during application: Head	None 💌	Hands	Gloves 🔻	Body	Coverall and sturdy footwear	-
Dose	12,5	kg product/ha	Work rate/day		0,15 <mark>ha</mark>	
AOEL	0,033	mg/kg bw/day				
DERMAL EXPOSURE DURING	MIXING AND LOADING					
Hand contamination/kg a s	21	mø/kø a s				
Hand contamination/day	31.5	mg/day				
Protective clothing	gloves	ing duy				
Transmission to skin	1	%				
Dermal exposure to a s	0.315	mg/day				
Definal exposure to a.s.	0,515	iiig/uay				
INHALATION EXPOSURE DUR	ING MIXING AND LOADING					
Inhalation exposure/kg a.s.	0,02	mg/kg a.s.				
Inhalation exposure/day	0,03	mg/day				
RPE	none					
Transmission through RPE	100	%				
Inhalation exposure to a.s.	0,03	mg/day				
DEDMAL EVDOSLIDE DUDING	SDD AV ADDI ICATION					
Application technique	Jond hald approval hydroulia no	arlas Outdoor bi	ich loval target			
Application technique	Hand-neid sprayer: hydraulic no Head	zzies. Outdoor, fil Hands	ign ievel target Rest of body			
Dermal contamination/kg a s	18	10.6	25			
Dermal contamination/day	7,0	10,0	25			
Protective clothing	7,2 none	rloves	coverall and sturdy footwear			
Transmission to skin	100	gioves	coverall and sturdy lootwear	0/		
Total dermal exposure to a s	0 224	1 ma/day	5	70		
Total definal exposure to a.s.	9,234	ilig/day				
INHALATION EXPOSURE DUR	ING SPRAYING					
Inhalation exposure/kg a.s.	0,3	mg/kg a.s.				
Inhalation exposure/day	0,45	mg/day				
RPE	none					
Transmission through RPE	100	%				
Inhalation exposure to a.s.	0,45	mg/day				
ADCORDED DOCE						
ADOURDED DOOSE	Mir/lood		Application			
Dormal averaging to a -	WIIX/IOad	mg/day	Application	ma/1-		
Dennal exposure to a.s.	0,315	mg/day	9,234	mg/day		
Absorbed does (James I must	0.0190	/0 mg/day	0	70 ma/-1-		
Ausorbed dose (dermai route)	0,0189	mg/day	0,55404	ing/day		
Innalation exposure to a.s.	0,03	mg/day	0,45	mg/day		
i otal systemic exposure	0,0489	mg/day	1,00404	mg/day		
PREDICTED EXPOSURE						
Total systemic exposure	1,05294	mg/day				
Operator body weight	70	kg				
Operator exposure	0,015042	mg/kg bw/day				
<b>Operator exposure % of AOEL</b>	46	%				



### Volume 1

Level 1: Statement of subject matter and purpose for which the monograph was prepared

- Level 2: Reasoned statement of the overall conclusions drawn by the Rapporteur Member State Appendix 1: Standard terms and abbreviations Appendix 2: Specific terms and abbreviations Appendix 3: List of endpoints
- Level 3: Proposed decision with respect to the application for inclusion of the active substance in Annex I
- Level 4: Further information to permit a decision to be made, or to support a review of the conditions and restrictions associated with the proposed inclusion in Annex 1

#### Volume 2

Annex A: List of the tests and studies submitted and of information available

#### Volume 3

#### Annex B: RMS summary, evaluation and assessment of the data and information

Annex B.1: Identity Annex B.2: Phys/chem. Annex B.3: Data application and further information. Annex B.4: Proposal for classification and labelling Annex B.5: Analytical method Annex B.6: Toxicology and metabolism Annex B.7: Residues in crop Annex B.8: Fate and behaviour Annex B.9: Ecotoxicology Appendix 1: Standard terms and abbreviations

Appendix 2: Specific terms and abbreviations

#### Volume 4

Annex C: Confidential information and summary and assessment of information relating to the collective submission of dossiers

## Table of contents

B.9.2.5.	Risk assessment for aquatic organism	.214
B.9.5	Effects on other arthropod species (Annex IIA 8.3.2; Annex IIIA 10.5)	.216

#### **B.9.2.5.** Risk assessment for aquatic organism

At PRAPeR 63 it was concluded that the risk to zooplankton could be addressed by this endpoint (0.7  $\mu$ g/L) together with an AF of 5. However, for the insect community no NOAEC could be determined in the littoral enclosure study. The experts were of the opinion that the risk to insects (and amphipods) needs to be addressed by further data, to demonstrate that they are less sensitive or that a recovery can take place in an acceptable time after the exposure event. The TER values for the zooplankton community are given below.

Application rate (kg as/ha)	Сгор	Organism	Time scale	Toxicity endpoint (µg/L)	PEC <sub>initial,sw</sub> * μg a.s./L	Distance (m)	TER	Annex VI Trigger
0.048	Forest, aerial application	D. magna	21 d	0.04	5.31	3 m	0.008	10
0.048	Forest, hand application	D. magna	21 d	0.04	1.28	3 m	0.03	10
0.048	Forest, aerial application	EAC NOEAEC zooplankton	-	<del>0.07</del> 0.14	5.31	3 m	0.013 0.026	1
0.048	Forest, hand application	EAC NOEAEC zooplankton	-	<del>0.07</del> 0.14	1.28	3 m	<del>0.054</del> <del>5</del> 0.109	1
0.048	Forest, hand application	EAC NOEAEC zooplankton	-	<del>0.07</del> 0.14	0.2	10	0.035 0.7	1
0.048	Forest, hand application	EAC NOEAEC zooplankton	-	<del>0.07</del> 0.14	0.07	20	+2	1

Crop and application rate: Forest 0.048 kg a.s./ha. Test substance a.s.

\* PEC based on spray drift over a static 30-cm deep waterbody. Distance x m from treated area, drift rates according to "Focus surface water scenarios in the EU evaluation process under 91/414/EEC (SANCO/4802/2001-rev-1)".

\*\* the risk to insects (and amphipods) needs to be addressed by further data

## Refined aquatic risk assessment using higher tier FOCUS modelling. FOCUS Step 3

Crop and application rate: Pome fruit 2 applications á 180 g /ha, 14 days interval. Test substance: a.s.

Scenario <sup>1</sup>	Water	Test organism <sup>3</sup>	Time	Toxicity	PEC <sub>initial,sw</sub>	TER	Annex VI
	body		scale	endpoint	μg a.s./L		trigger
	type <sup>2</sup>			(µg/L)			
D3	ditch	D. magna	21 d	0.04	11.989	0.003	10
D4	pond	D. magna	21 d	0.04	0.976	0.041	10
D4	stream	D. magna	21 d	0.04	11.400	0.004	10
D5	pond	D. magna	21 d	0.04	0.989	0.040	10
D5	stream	D. magna	21 d	0.04	12.494	0.003	10
R1	pond	D. magna	21 d	0.04	0.915	0.044	10
R1	stream	D. magna	21 d	0.04	9.629	0.004	10
R2	stream	D. magna	21 d	0.04	12.756	0.003	10
R3	stream	D. magna	21 d	0.04	13.622	0.003	10

DIFLUBENZURON
Addendum to Annex B.8 and B.9.

D 4	4	D	01.1	0.04	0.606	0.004	10
R4	stream	D. magna	21 d	0.04	9.686	0.004	10
D3	ditch	EAC-NOEAEC	-	<del>0.07</del> 0.14		0.006	1
		zooplankton			11.989	0.012	
D4	pond	EAC-NOEAEC	-	<del>0.07</del> 0.14		<del>0.072</del>	1
		zooplankton			0.976	0.144	
D4	stream	EAC-NOEAEC	-	<del>0.07</del> 0.14		<del>0.006</del>	1
		zooplankton			11.400	0.012	
D5	pond	EAC-NOEAEC	-	<del>0.07</del> 0.14		0.0355	1
		zooplankton			0.989	0.071	
D5	stream	EAC-NOEAEC	-	<del>0.07</del> 0.14		0.006	1
		zooplankton			12.494	0.012	
R1	pond	EAC-NOEAEC	-	<del>0.07</del> 0.14		0.077	1
		zooplankton			0.915	0.154	
R1	stream	EAC-NOEAEC	-	<del>0.07</del> 0.14		0.007	1
		zooplankton			9.629	0.014	
R2	stream	EAC-NOEAEC	-	<del>0.07</del> 0.14		<del>0.005</del>	1
		zooplankton			12.756	0.01	
R3	stream	EAC-NOEAEC	-	<del>0.07</del> 0.14		0.005	1
		zooplankton			13.622	0.01	
R4	stream	EAC-NOEAEC	-	<del>0.07</del> 0.14		0.007	1
		zooplankton **			9.686	0.014	

\*\* the risk to insects (and amphipods) needs to be addressed by further data

# FOCUS Step 4

Scenario <sup>‡</sup>	Water body type <sup>2</sup>	Test organism <sup>3</sup>	Time scale	Toxicity endpoint (mg/L)	Buffer zone distance	PEC <sub>initial,sw</sub> μg a.s./L	TER	Annex VI trigger
D3	ditch	EAC-NOEAEC zooplankton**	-	<del>0.07</del> 0.14	20 m	1.42	0.049 0.098	1
D4	pond	EAC-NOEAEC zooplankton **	-	<del>0.07</del> 0.14	20 m	0.19	0.372 0.736	1
D4	stream	EAC-NOEAEC zooplankton**	-	<del>0.07</del> 0.14	20 m	1.48	0.047 0.094	1
D5	pond	EAC-NOEAEC zooplankton**	-	<del>0.07</del> 0.14	20 m	0.19	0.37 0.74	1
D5	stream	EAC-NOEAEC zooplankton**	-	<del>0.07</del> 0.14	20 m	1.62	0.043 0.86	1
R1	pond	EAC-NOEAEC zooplankton **	-	<del>0.07</del> 0.14	20 m	0.18	0.40 0.8	1
R1	stream	EAC-NOEAEC zooplankton**	-	<del>0.07</del> 0.14	20 m	1.25	0.056 0.115	1
R2	stream	EAC-NOEAEC zooplankton**	-	<del>0.07</del> 0.14	20 m	1.66	0.042 0.084	1
R3	stream	EAC-NOEAEC zooplankton**	-	<del>0.07</del> 0.14	20 m	1.77	0.040 0.080	1
R4	stream	EAC-NOEAEC	-	<del>0.07</del> 0.14	20 m	1.26	0.056	1

		zooplankton **					0.112	
D3	ditch	EAC-NOEAEC		<del>0.07</del> 0.14	20	0.40	<del>0.14</del>	1
		zooplankton <sup>**</sup>	-		30 m	0.49	0.07	
D.4		EAC-NOEAEC		<del>0.07</del> 0.14	20	0.00	0.84	
D4	pond	zooplankton **	-		30 m	0.08	1.68	I
<b>D</b> .(		EAC-NOEAEC		0.07 0.14 30 m	20	0.51	0.14	1
D4	stream	zooplankton <sup>**</sup>	-		30 m		0.28	
5.5	pond	EAC-NOEAEC		<del>0.07</del> 0.14	30 m	0.00	0.83	1
D5		zooplankton <sup>**</sup>	-			0.08	1.66	
	stream	EAC-NOEAEC zooplankton**0.07	• •	0.50	0.13	1		
D5			-		30 m	0.56	0.26	1
DI	1	EAC-NOEAEC	-	<del>0.07</del> 0.14	30 m	0.08	0.90	1
KI	pond	zooplankton **					1.80	
D 1	stream	EAC-NOEAEC zooplankton**	-	<del>0.07</del> 0.14	30 m	0.43	0.16	1
KI							0.32	
R2	stream	EAC-NOEAEC zooplankton**		<del>0.07</del> 0.14	30 m	0.57	0.12	1
			-				0.24	1
R3	stream	EAC-NOEAEC		<del>0.07</del> 0.14	30 m	0.61	0.12	1
		zooplankton <sup>**</sup>	-				0.24	1
R4	stream	ream EAC-NOEAEC zooplankton **		<del>0.07</del> 0.14	30 m	0.43	0.16	1
			-				0.32	

\*\* the risk to insects (and amphipods) needs to be addressed by further data

#### B.9.5 Effects on other arthropod species (Annex IIA 8.3.2; Annex IIIA 10.5)

At the PRAPeR it was concluded that a correction factor of 5 should be used for the calculation of the drift rate according to the recommendations for higher tier risk assessment in ESCORT 2. Resulting in the following alterations of the off-crop risk assessment.

**OFF-crop risk assessment for non-target arthropods** 

Application rate	Сгор	Organism	Distance from edge	Drift rate early application * (g a.s./ha)	Drift rate late application * (g a.s./ha)	LR50
180 g/ha	Pome fruit	C. carnea	3	<del>78</del> 390	<del>37</del> 185	1.3
	Pome fruit	C. carnea	5	<del>52</del> 260	<del>21</del> 105	1.3
	Pome fruit	C. carnea	10	<del>29</del> 145	<del>10</del> 50	1.3
	Pome fruit	C. carnea	15	<del>17</del> 85	<del>5</del> 25	1.3
	Pome fruit	C. carnea	20	<del>8</del> 40	<del>3</del> 15	1.3
	Pome fruit	C. carnea	30	<del>3</del> 24	<del>1</del> 5	1.3
	Pome fruit	C. carnea	40	<del>1</del> 5	<del>0.7</del> 3.5	1.3
	Pome fruit	C. carnea	50	3.5	2.5	1.3
	Pome fruit	C. carnea	75	1	1	1.3
	Pome fruit	C. carnea	100	0.5	0.5	1.3
Application rate	Сгор	Organism	Distance from edge	Drift rate * (g a.s./ha)	LR50	
------------------	----------------------------	-----------	-----------------------	-----------------------------	------	
48 g a.s./ha	Forest, hand application	C. carnea	3	<del>3.84</del> 19.2	1.3	
	Forest, hand application	C. carnea	5	<del>1.7</del> 8.5	1.3	
	Forest, hand application	C. carnea	10	<del>0.59</del> 2.95	1.3	
	Forest, hand application	C. carnea	15	<del>0.31</del> 1.55	1.3	
	Forest, aerial application	C. carnea	3	<del>15.8</del> 79	1.3	

\* For the calculation of the drift rate a correction factor of 5 has been used according to the recommendations for higher tier risk assessment in ESCORT 2.

## Field or semi-field tests:

Additional data was submitted in the form of a literature review, summarized in the DAR. The overall conclusion from all available information is that the risk to non target arthropods in-field is not acceptable; the in-field recovery/recolonisation needs to be further addressed. may be considered acceptable provided off field habitats are protected which require buffer zones of 10-40 m(depending on the use). This may need to be discussed at an expert meeting. In order to protect off-crop non-target arthropods buffer zones is needed (for the use in orchards 75 m is needed.).